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ABSTRACT 
Introduction: Alzheimer’s disease (AD) is a devastating neurodegenerative disease 
characterized by progressive cognitive impairment, particularly in brain regions crucial for 
learning and memory. These symptoms are caused by neuronal death resulting from two 
pathological features: extracellular senile plaques composed of aggregated amyloid-beta (Aβ) 
peptides, and intracellular neurofibrillary tangles generated by the hyperphosphorylation of tau 
protein. Although AD is a multifactorial disease, much of the AD research continues to be 
guided by the amyloid cascade hypothesis, which posits that Aβ aggregation is the key initiate 
in AD pathogenesis. Aβ is generated from the proteolytic cleavage of the amyloid precursor 
protein (APP) by β - and γ-secretase. Accordingly, research efforts to modulate APP 
processing, and better clarify the mechanisms that regulate intracellular Aβ metabolism and 
clearance during AD progression have been explored in the treatment of AD. Autophagy, a 
lysosome-based proteolytic pathway that plays a crucial role in intracellular protein quality 
control, has been implicated in both the production and clearance of Aβ peptide. Cumulative 
evidence shows that AD-related autophagic dysfunction coincides with the detection of Aβ 
within autophagic vacuoles (AVs) that accumulate within dystrophic neurites with the initial 
increase in Aβ neurotoxicity. Therefore, autophagy dysfunction may exacerbate Aβ pathology 
and further augment disease progression; however, when in this context autophagy becomes 
dysfunctional remains unclear. Moreover, although it is known that Aβ levels themselves may 
induce autophagy, how long autophagy remains upregulated and functional in this process is 
unclear. It also remains unclear whether autophagy plays a causative, or protective role in Aβ 
neurotoxicity; or whether autophagy dysfunction is a consequence of the disease process 
itself. Therefore, the aims of this study were (i) to characterize the expression profile of key 
amyloidogenic pathway proteins, both macroautophagy and chaperone-mediated autophagy 
(CMA) proteins as well as the extent of neuronal toxicity using a unique APP overexpression 
model, (ii) to dissect the interplay between proteolytic pathways and cell death markers in the 
context of APP overexpression using a proteomics approach, (iii) to assess macroautophagic 
flux in the context of APP overexpression and to unravel the extent of autophagy dysfunction, 
(iv) to assess the contribution of macroautophagy and CMA in Aβ clearance and neuronal 
toxicity by modulating each pathway, and (v) to assess the effects of prolonged intermittent 
fasting (IF) on the modulation of macroautophagy and CMA in a paraquat (PQ)-induced in vivo 
brain injury model. 
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Methods: A unique AD overexpression model, the N2a mouse neuroblastoma cell line stably 
overexpressing the human Swedish double mutation was utilized. APP overexpression was 
characterized, and the induction of macroautophagy, CMA, and apoptosis was assessed over 
time using a combination of cell viability assays, western blot analysis, fluorescence 
microscopy, transmission electron microscopy (TEM), and correlative light and electron 
microscopy techniques. Moreover, the effect of APP overexpression on a global proteome 
level was quantified using high resolution liquid-chromatography coupled to tandem mass 
spectrometry. Finally, a PQ – induced brain injury model was established and utilized to 
assess the effects of prolonged IF on macroautophagy and CMA using GFP–LC3 transgenic 
mice. Mice were injected twice weekly with 10 mg/kg PQ for a duration of 3 weeks. A prolonged 
IF protocol of 48 hrs fasting, followed by 24 hrs refeeding was implemented for a duration of 
3 weeks. Modulation of macroautophagy and CMA following chronic oxidative stress 
exposure, and prolonged IF was evaluated in selected brain regions by western blot analysis, 
fluorescence microscopy, comparative haematoxylin and eosin staining, and TEM analysis. 
 
Results: The results indicate that APP overexpression leads to prominent apoptosis induction 
after 48 hrs and activates the autophagy machinery in a time-dependent manner. To our 
surprise, macroautophagic flux analysis reveals that autophagy is upregulated upon APP 
overexpression but remains elevated in the presence of apoptosis induction. Our CMA 
analysis indicates that APP overexpression activates the CMA machinery, particularly during 
the 48 hrs time point. However, induction of apoptosis proceeded despite elevated levels of 
CMA activity. Next, our proteome analysis reveals a time-dependent increase in APP protein-
protein interaction partners over time. Cumulatively, the in vitro results suggest that the 
modulation of macroautophagy and CMA augments Aβ clearance and mitigates neuronal 
toxicity. In vivo, a significant decrease in cytochrome c, and 4HNE expression were observed 
with prolonged IF intervention in selective brain regions. These changes were associated with 
elevated levels of macroautophagy and CMA induction, as evidenced by the significant 
increase in LC3II and LAMP2A protein expression. Therefore, suggesting that protection was 
brought about by the prolonged IF intervention through the modulation of macroautophagy 
and CMA. 
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Conclusion: Our findings indicate that autophagy is upregulated in the presence of high levels 
of APP and Aβ, and to our surprise, remains upregulated even in the presence of apoptosis 
induction, suggesting an insufficient autophagy response in the mitigation of Aβ neurotoxicity. 
However, enhanced Aβ clearance was observed with a sufficiently high autophagy response 
even during 48 hrs APP overexpression, suggesting that autophagy modulation may be a 
viable treatment approach long into disease progression. These findings were also confirmed 
with prolonged IF intervention, where markers of apoptosis, and lipid peroxidation were 
notably decreased in brain regions associated with neurodegeneration. Further studies, 
specifically using in vivo APP overexpression models are warranted to further verify the clinical 
use of autophagy control. 
 




Inleiding: Alzheimer se siekte (AS) is ‘n vernietigende neuro-degeneratiewe siekte wat 
gekenmerk word deur ‘n progressiewe verlies in kognitiewe funksie in dele van die brein wat 
‘n rol speel in geheue en leervermoë. Hierdie simptome word toegeskryf aan die doodgaan 
van neurone as gevolg van twee patologiese kenmerke: ekstrasellulêre seniele plake wat 
bestaan uit geaggregeerde beta-amiloïed (Aβ) peptiede en intrasellulêre neurofibrillêre knope 
wat ontaard danksê te hiperfosforilasie van die tau proteïen. Alhoewel AS vele oorsake het, 
volg die meerderheid van huidige navorsing die amiloïed kaskade hipotese waarin Aβ 
aggregasie as die hoof oorsaak van AS beskou word. Proteolitiese skeiding van die amiloïed 
voorloper proteïen (AVP) by β - en γ-sekretase veroorsaak die produksie van Aβ. Daar is tans 
vele navorsing veldtogte geloods wat poog om AVP prosessering  te moduleer asook om die 
regulerende meganismes van intrasellulêre Aβ metabolisme en verwydering te ontbloot, met 
die hoop dat dit kan bydra tot beter behandeling van AS. Autofagie is ‘n lisosoom gebaseerde 
proteolitiese sisteem wat ‘n belangrike rol speel in die beheer van intrasellulêre proteïen 
kwaliteit en is gevind om betrokke te wees in beide die produksie en verwydering van die Aβ 
peptied. Kumulatiewe bewyse dui aan dat tydens AS verwante autofagiese disfunksie kan Aβ 
binne autofagiese vakuole (AV) gevind word en dat hierdie AV akkumuleer binne distrofiese 
neuriete tydens die aanvanklike vermeerdering in Aβ neurotoksisiteit. Daarom kan autofagiese 
disfunksie die Aβ patologie vererger en bydra tot die vorming van AS. Merendeels, alhoewel 
dit bewys is dat autofagie aangeskakel kan word namate die Aβ konsentrasie verhoog, is dit 
nog nie bekend vir hoe lank autofagie aangeskakel en funksioneel bly tydens hierdie proses 
nie. Dit is ook onduidelik of autofagie ‘n veroorsakende of beskermende rol in Aβ 
neurotoksisiteit speel en of autofagiese disfunksie nie net ‘n na gevolg van die siektetoestand 
self is nie. Dus was die doelwitte van hierdie studie om (i) ‘n proteïen uitdrukkings profiel van 
belangrike amiloïed reguleeringsproteïne te skep, (ii) die wisselwerking tussen proteolitiese 
prosesse en sel dood reguleerders in die konteks van AVP ooruitdrukking te verduidelik deur 
gebruik te maak van proteomics, (iii) die spoed van autofagie verwante proteïen degenerasie 
te assesseer in die konteks van APP ooruitdrukking asook die mate van autofagiese 
disfunksie, (iv) die bydrae van makroautofagie asook gemedieërde autofagie (GA) in Aβ 
verwydering en neuron toksisiteit te assesseer deur modulering van elke proses en (v) om die 
effek van langdurige afwisselende vas tydperke op die modulering van makroautofagie en GA 
te assesseer in ‘n paraquat (PQ)-geïnduseerde in vivo brein beskadiging model.  
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Metodes: ‘n Unieke AS ooruitdrukking model was geskep deur gebruik te maak van die N2a 
muis neuroblastoma sellyn wat ‘n dubbele Sweedse mutasie stabiel ooruitgedruk het. AVP 
ooruitdrukking was sodoende gekarakteriseer en die induksie van makroautofagie, GA en 
apoptose was met verloop van tyd geassesseer deur gebruik te maak van lewensvatbaarheid 
stoetse, Westerse blottering tegnieke, fluoressensie mikroskopie, transmissie elektron 
mikroskopie (TEM) en korrelatiewe lig en elektron mikroskopie (KLEM). Merendeels was die 
effek van AVP ooruitdrukking op globale proteoom vlakke gekwantifiseer deur gebruik te maak 
van hoë resolusie vloeistof chromatografie gekoppel aan tandem massa spektrometrie. 
Laastens, ‘n PQ geïnduseerde breinbeskadigingsmodel was opgestel en gebruik om die effek 
van langdurige afwisselende vas tydperke op makroautofagie en GA te toets in GFP-LC3 
transgeniese muise. Die muise was twee maal per week ingespuit met 10mg/kg PQ vir ‘n 
tydperk van 3 weke. Die langdurige afwisselende vas protokol was ook oor 3 weke toegepas 
en het bestaan uit 48 ure se vas, gevolg deur 24 ure van voeding. Evaluering van 
makroautofagiese en GA modulasie na blootstelling aan kroniese oksidatiewe stres en 
langdurige afwisselende vas in geselekteerde brein areas het geskied deur middel van 
Westerse blottering, fluoressensie mikroskopie, vergelykende haematoxylin en eosien 
kleuring asook TEM analise.  
 
Resultate: Die resultate dui aan dat AVP ooruitdrukking tot prominente apoptose lei na 48 
ure en dat die autofagie in ‘n tyd verwante manier aktiveer. ‘n Onverwagte bevinding was dat 
die spoed van autofagie nie net verhoog het tydens AVP ooruitdrukking nie, maar dat hierdie 
hoë vlakke behou was selfs tydens apoptose. Dit was ook gevind dat AVP ooruitdrukking GA 
reguleerders aanskakel, veral tydens die 48ste uur. Desnieteenstaande, die induksie van 
apoptose het voortgegaan ongeag die verhoogde GA aktiwiteit. Ons proteoom analise dui ook 
‘n tydafhanklike verhoging in AVP proteïen tot proteïen interaksies. Gesamentlik dui die in 
vitro resultate aan dat die modulasie van makroautofagie en GA ‘n rol speel in Aβ verwydering 
en neuron toksisiteit verlaag. In vivo was daar ‘n beduidende vermindering van sitokroom c 
en 4HNE uitdrukking was gevind tydens langdurige afwisselende vas intervensies en 
selektiewe dele van die brein. Dus dui dit aan dat hierdie vas tydperke meegebring was deur 
modulasie van beide makroautofagie en GA.  
 
Gevolgtrekkings: Ons bevindinge dui aan dat autofagie aangeskakel word in die 
aanwesigheid van hoë hoeveelhede AVP en Aβ, en merkwaardig hierdie toestand behou selfs 
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tydens apoptose aktivering, moontlik as gevolg van ‘n onvoldoende autofagiese reaksie om 
Aβ neurotoksisiteit teen te werk. Desnieteenstaande, verhoogde Aβ verwydering was gevind 
met ‘n voldoende autofagiese reaksie selfs tydens 48 ure van AVP ooruitdrukking, wat aandui 
dat autofagie modulasie ‘n lewensvatbare behandelings alternatief kan wees lank na die 
siektetoestand bevestig is. Hierdie resultate was ook bevestig deur langdurige afwisselende 
vas intervensies, waar aanduiders van apoptose en lipied peroksidasie beduidend verlaag 
was in die areas van die brein wat geassosieer word met neurodegenerasie. Verdere studies, 
spesifiek dié wat gebruik maak van in vivo AVP ooruitdrukking modelle, word dus benodig om 
die kliniese belang van autofagie regulering te bevestig. 
 




First and foremost, thank you Almighty GOD, for saying “yes” to the fulfilment of a lifelong 
dream! 
 
This thesis is the result of the cumulative effects of a phenomenal group of people, who 
generously contributed their knowledge, and experience. 
 
Words cannot express how extremely grateful and very fortunate I am to have been able to 
complete my PhD project under the supervision of Professor Ben loos. The last 3 years as 
part of the Neuro Research Group have been the most transformative years of my life, both 
scientifically and on a personal level. Thank you, Ben for all the support and encouragement, 
I know without a doubt that the successful completion of this project is in no small part due to 
you, and for this I am eternally grateful. Your work ethic is beyond commendable and I am 
immensely grateful to have had the privilege of being a student under your tutorage. Your 
patience, and constant encouragement have truly gotten me through the hardest of times, and 
because of your contribution to both my PhD and to me personally, I have developed critical 
skills that I will take with me to wherever life should take me. Above all, I wish you continued 
success being the phenomenal researcher and supervisor you are. 
 
I would also like to thank Prof. Anna-Mart Engelbrecht, for the constant words of 
encouragement and to Prof. Resia Pretorius for allowing me to make the Physiological 
Sciences Department my “home away from home”. 
 
Thank you to Stellenbosch University’s Central Analytical Facility (CAF) staff, Lize 
Engelbrecht, Dumisile Lumkwana, and Rozanne Adams for assistance with the acquisition of 
confocal micrographs. Thank you to Dr Maré Vlok for proteomic data acquisition, Nolan Muller 
for the acquisition of the TEM micrographs, Reggie Williams for assisting with the brain tissue 
sections, and Noel Markgraff for the invaluable assistance with the GFP-LC3 mice. 
 
Stellenbosch University  https://scholar.sun.ac.za
x  
Thank you to the staff members at the Department of Physiological Sciences, including Judy, 
Grazelda, Jonnifer, Annadie, Lydia and Ashwin for ensuring the labs run smoothly. 
 
I would also like to thank Chrisna, Andre, and Dumi for your contribution to a number of 
successful publications over the past 3 years. We made a phenomenal team and 
accomplished more together than I could ever have hoped to accomplish on my own. 
 
I would also like to thank the many students in Department of Physiological Sciences, 
especially the NRG group of students both past and present, for their friendships, camaraderie 
and critical discussions. I would like to extend a special thank you to Yigael for the much-
needed hugs during those tough times, and for allowing me to frequently hijack your time. To 
Jurgen, thank you for all your help, and the occasional dosage of dry humour. To Bianca, 
thank you for always being my sounding board through the tears, and the laughter, I am truly 
blessed to count you amongst my closest friends. To Andre, my gratitude for everything you 
have patiently assisted me with cannot be captured with words. I am truly in awe of your quiet 
brilliance and have no doubt that you will be great in whatever you choose to do in the future. 
To Zanobuhle, thank you for trusting me to co-supervise your Honours project, it truly was one 
of the most fulfilling experiences of my PhD journey. To Akile, for all the inspiring messages, 
thank you.  
 
I would like to thank the National Research Foundation (NRF), the Medical Research Council 
(MRC) and the Oppenheimer Trust for financial support. I would also like to thank the 
University of Stellenbosch, WhitSci- Scientific and the EMBO Conference travel grant awards 
for the opportunity provided to attend the “Autophagy: From molecular principles to human 
disease” in Cavtat-Dubrovnik, Croatia. 
 
To my family, thank you for the unwavering support, and prayers. Most importantly, I would 
like to thank my mother, who never once questioned or vetoed my never-ending study 
ambitions, I am who I am because of the sacrifices you made for me. You are the reason I 
continue to push forward, so that I may one day give you the life you deserve. This thesis is 
dedicated to you. 
 
Stellenbosch University  https://scholar.sun.ac.za
xi  
LIST OF CONFERENCE CONTRIBUTIONS AND PUBLICATIONS 
 




Claudia Ntsapi and Ben Loos. The time-dependent pro-survival role of autophagy in the face 
of amyloid beta-induced cytotoxicity in an in vitro model of Alzheimer’s disease. EMBO 
Conference on: Autophagy - From molecular principles to human disease. 24-30 September 




Claudia Ntsapi and Ben Loos. The link between autophagy dysfunction and amyloid beta-
induced neurotoxicity in an in vitro model of Alzheimer’s disease. South African Medical 
Research Council Young Researchers Forum. Parow Valley, Cape, South Africa 11-13 
October 2017. Oral presentation. 
 
Claudia Ntsapi and Ben Loos. Cells in stress/Cell death: The face of autophagy in response 
to amyloid-β induced neurotoxicity. Cell and Development Biology Mini Symposium. 22nd April 
2017. New learning Centre, Faculty of Health Sciences, University of Cape Town, Anzio Road, 
Observatory. Oral presentation. 
 
Claudia Ntsapi, and Ben Loos. Differential increase in macroautophagy and chaperone-
mediated autophagy attenuates amyloid precursor protein-induced neurotoxicity in an in vitro 
model of Alzheimer’s disease. 44thConference of the Physiology Society of Southern Africa. 
University of Cape Town, 28-31 August 2016. Poster presentation. 
 




• Claudia Ntsapi, Dumisile Lumkwana, Chrisna Swart, Andre du Toit and Ben Loos. New 
Insights into Autophagy Dysfunction Related to Amyloid Beta Toxicity and 
Neuropathology in Alzheimer's Disease. International Review of Cell and Molecular 
Biology. Volume 336, 2018. 
 
• Claudia Ntsapi, Chrisna Swart, Dumisile Lumkwana and Ben Loos. Autophagic Flux 
Failure in Neurodegeneration: Identifying the Defect and Compensating Flux Offset. 
Biochemistry, Genetics and Molecular Biology. Autophagy in Current Trends in 
Cellular Physiology and Pathology. 2016. 
 
• Claudia Ntsapi, and Ben Loos. Caloric restriction and the precision-control of 
autophagy: A strategy for delaying neurodegenerative disease progression. 
Experimental Gerontology. Volume 83. 2016. 
 
• Claudia Ntsapi, and Ben Loos. Caloric restriction regulates autophagic flux to modulate 
the proteostasis of APP in Alzheimer’s disease. Article in preparation, to be submitted 
shortly to the Journal of Molecular Neurodegeneration. 
 
• Claudia Ntsapi, and Ben Loos. Enhanced APP processing and autophagy: new 
insights into the mechanism of Aβ neurotoxicity in Alzheimer’s disease. Article in 
preparation, to be submitted shortly to the Journal of Neuroscience.  
 
• Claudia Ntsapi, and Ben Loos. Prolonged intermittent fasting stimulates 
macroautophagy and chaperone-mediated autophagy in an in vivo model of paraquat-
induced brain injury. Article in preparation, to be submitted shortly to the Journal of 
Experimental Neurobiology. 
 










LIST OF FIGURES  
LIST OF TABLES  
LIST OF ABBREVIATIONS  
 








1.2 Biology and pathophysiology of APP 8 
1.2.1 APP localization, subcellular trafficking and processing 8 
1.2.2 The role Aβ oligomers in neurotoxicity and disease propagation 12 
1.2.3 Aβ clearance systems in the brain: implications for AD progression 13 
1.3 Intracellular proteolytic systems 14 
1.3.1 The role of autophagy in stress response and neurodegeneration 15 
1.3.2 Autophagy and its machinery 16 
1.3.3 The precision control of the autophagy machinery 18 
1.3.3.1 Autophagy regulation by nutrient signalling pathways 18 
1.3.4 Chaperone-mediated autophagy: the exclusive degradative machinery 21 
1.3.4.1 CMA regulation 24 
1.4 Aging: insufficient proteostasis, or dysfunctional proteolytic 
function? 
26 
1.4.1 Autophagy declines with age 26 
1.4.2 CMA declines with age 28 
1.5  Macroautophagy, CMA and AD pathogenesis 28 
1.5.1 Autophagosome/lysosomal dysfunction in AD 28 
1.5.2 The putative role of CMA in AD 31 
1.6 Doubling up: CR impacts longevity through macroautophagy and 
CMA 
32 
1.6.1 CR and macroautophagy 32 
1.6.2 CR and CMA 34 
1.6.3 Two pathways are better than one 35 
1.6.3.1 The compensatory response to prolonged CR or starvation conditions 35 
1.6.3.2 Compensatory macroautophagy-CMA response in neurodegeneration 36 
1.7 The integration of autophagy signalling pathways during CR 38 
1.7.1 CR mimetics: targeting macroautophagy induction 42 
1.8 Treatment strategies 43 
1.8.1 CR-induced autophagy and Aβ neurotoxicity 46 
1.9 Methods for measuring macroautophagy and CMA activity 47 
1.9.1 Methods for measuring macroautophagic flux 47 
1.9.2 Methods for measuring CMA activity 52 
1.10 Thesis outline 54 
 





Reagents and consumables 
 
55 
2.1.1 Antibodies 56 
2.2 Cell culture and treatments 58 
2.2.1 Cell culture propagation 58 
2.2.2 Thawing of cryopreserved cells 59 
Stellenbosch University  https://scholar.sun.ac.za
xiv  
2.2.3 Passaging of cells 59 
2.2.4 Cryopreservation of cell lines 60 
2.3 Categorisation of N2a cell treatment groups 60 
2.3.1 Treatment groups for macroautophagy and CMA modulation 61 
2.4 Cell viability 62 
2.5 Western blot analysis of cells 62 
2.5.1 Protein extraction and cell lysis preparation 62 
2.5.2 Determination of protein concentration 63 
2.5.3 Protein separation  64 
2.5.3.1 Western blotting procedure 64 
2.5.3.2 Protein probing and signal detection 65 
2.5.3.3 Membrane stripping and re-probing 66 
2.5.3.4 Quantification of protein densitometric measurements 66 
2.6 Caspase-Glo® 3/7 Assay 67 
2.7 Immunofluorescence microscopy 67 
2.7.1 Transfection 67 
2.7.2 Cell fixation 68 
2.7.3 Confocal microscopy 69 
2.7.4 APP detection: correlative light and scanning electron microscopy 70 
2.7.4.1 Sample preparation 70 
2.7.4.2 CLEM image acquisition  70 
2.7.5 Colocalization analysis and immunofluorescence microscopy 71 
2.7.5.1 Colocalization sample preparation and imaging 73 
2.7.5.2 Quantification of colocalized proteins 73 
2.7.6 Detection of cellular ultrastructure using transmission electron 
microscopy 
74 
2.7.6.1 TEM sample preparation 74 
2.7.6.2 Processing of TEM samples 75 
2.7.6.3 TEM image acquisition 76 
2.7.6.4 TEM morphometric analysis  76 
2.8  Global proteome analysis 77 
2.8.1 Liquid chromatography-mass spectrometry-based proteome analysis 77 
2.8.2 LC–MS sample preparation 79 
2.8.2.1 In-solution protein digestion 79 
2.8.2.2 On-column desalting 80 
2.8.2.3 Liquid chromatography 80 
2.8.2.4 Mass spectrometry 81 
2.8.2.5 Data analysis 82 
2.8.2.5.1 Bioinformatics analysis: blast search 82 
2.8.2.5.2 Bioinformatics analysis: protein validation strategy 83 
2.8.2.5.3 Bioinformatics analysis: false discovery rate  83 
2.8.2.5.4 Bioinformatics analysis: protein quantification strategy 84 
2.9 Animal study: GFP-LC3 transgenic mice  
2.9.1 Experimental animals 85 
2.9.2 Experimental design 85 
2.9.2.1 Intermittent fasting treatment intervention 86 
2.9.2.2 PQ treatment protocol 87 
2.9.2.3 Animal welfare monitoring 87 
2.9.2.4 Animal sacrifice and whole brain extraction 87 
2.9.3 Tissue preparation for immunofluorescence analysis 88 
2.9.3.1 H & E staining of brain tissue  89 
2.9.3.1.1 Preparation of tissue sections for H & E staining 89 
2.9.3.1.2 H & E image acquisition 90 
2.9.4 Western blot analysis: brain tissue  90 
2.9.4.1 Sample preparation for western blot analysis 90 
Stellenbosch University  https://scholar.sun.ac.za
xv  
2.10 Statistical analyses 90 
   




3.1  Introduction to results 91 
3.2 Results  92 
3.2.1 Validation of APP overexpression model: western blot analysis of APP, 
Aβ, and LC3II in N2avec/N2awt/N2aswe cells 
92 
3.3 Time-dependent characterization of APP overexpression model 94 
3.3.1 Effect of APP overexpression on cell viability 94 
3.3.2 Western blot analysis of amyloidogenic processing in response to APP 
overexpression 
95 
3.3.3 Correlative Light and Electron Microscopy (CLEM) of APP localization in 
response to APP overexpression 
97 
3.3.4 Western blot analysis of key MA proteins in response to APP 
overexpression 
98 
3.3.5 Immunofluorescence characterization of APP, Aβ and LC3II localization 
in response to APP overexpression 
100 
3.3.6 Western blot analysis of key CMA proteins in response to APP 
overexpression 
101 
3.3.7 Immunofluorescence and colocalization analysis of CMA markers 
following APP overexpression 
102 
3.3.8 Western blot analysis of key apoptosis proteins in response to APP 
overexpression 
103 
3.3.9 Immunofluorescence and colocalization analysis following APP 
overexpression 
105 
3.4 APP and proteomics 108 
3.4.1 Assessment of N2aswe cell proteome in response to early and late APP 
overexpression 
109 
3.4.2 Volcano plot analysis of early APP proteome signature 110 
3.4.3 Volcano plot analysis of late APP proteome signature 111 
3.4.4 Volcano plot analysis of early versus late APP proteome signature 112 
3.4.5 The STRING network analysis of early APP proteome signature 114 
3.4.6 The STRING network analysis of late APP proteome signature 115 
3.4.7 The STRING network analysis of early versus late APP proteome 
signature 
116 
3.4.8 Western blot analysis of samples utilized for proteome analysis  117 
3.4.8.1 Western blot analysis of APP and Aβ expression in early versus late APP 
overexpression 
117 
3.4.8.2 Western blot analysis of LC3II and ATG5 expression in early versus late 
APP overexpression 
118 
3.4.8.3 Western blot analysis of key CMA proteins in early versus late APP 
overexpression 
119 








3.5 APP in vitro model validation – assessed by western blot analysis 122 
3.6 Time-dependent effects of APP overexpression on cell viability - 
assessed by WST-1 analysis 
123 
3.7 Time-dependent assessment of APP, Aβ, and LC3II protein expression - 
assessed by western blot and immunofluorescence analysis 
124 
Stellenbosch University  https://scholar.sun.ac.za
xvi  
3.8 Time-dependent effects of APP overexpression on the molecular 
markers MA and CMA over time – assessed by western blot and 
immunofluorescence analysis 
127 
3.9 Time-dependent effects of APP overexpression on the molecular 
markers of cell death with time – assessed by Caspase-3/7 Glo Assay 
and western blot analysis 
131 
3.10 Colocalization of APP with p62 and LAMP2A, and LAMP2A with HSC70 
– assessed by immunofluorescence analysis 
133 
3.11 APP proteome signature 135 
 





Introduction to results 
 
144 
4.2 Results 145 
4.2.1 Effect of flux modulation on amyloidogenic processing 145 
4.2.2 Effect of APP overexpression on macroautophagic flux 147 
4.2.3 Effect of flux modulation in the context of APP overexpression on CMA 
activity 
148 
4.2.4 Effect of flux modulation in the context of APP overexpression on 
apoptosis 
150 
4.2.5 Effect of APP overexpression on AV formation in N2aswe cells 152 
4.2.6 Quantification of AVs in N2aswe cells 153 
4.2.7 Effect of APP overexpression on fibrillar ultrastructure in N2aswe cells 154 
4.2.8 Effect of APP overexpression on mitochondrial ultrastructure 155 
4.2.9 Effect of APP overexpression on ferritin-like inclusions 156 
 










4.4 Effect of APP overexpression on macroautophagic flux  158 
4.5 Effect of flux modulation in the context of APP overexpression on CMA 
activity 
160 
4.6 Effect of flux modulation in the context of APP overexpression on 
apoptosis 
161 
4.7 Effect of APP overexpression on AV formation in N2aswe cells 163 
4.8 Effect of APP overexpression on fibrillar ultrastructure in N2aswe cells 165 
4.9 Effect of APP overexpression on mitochondrial ultrastructure 166 
4.10 Effect of APP overexpression on ferritin-like inclusions 166 
 





Introduction to results 
 
169 
5.2 Results 170 
5.2.1 The modulation of MA and CMA using the CRM 2DG 170 
5.2.1.1 Effect of 2DG on N2aswe cell viability during APP overexpression 170 
5.2.1.2 Effect of 2DG on amyloidogenic processing in N2aswe cells during 24 
hrs APP overexpression 
171 
5.2.1.3 Effect of 2DG on MA in N2aswe cells during 24 hrs APP overexpression 173 
5.2.1.4 Effect of 2DG on CMA in N2aswe cells during 24 hrs APP 
overexpression 
174 
5.2.1.5 Immunofluorescence tracking of CMA using the KFERQ-mCherry CMA-
specific reporter 
176 
Stellenbosch University  https://scholar.sun.ac.za
xvii  
5.2.1.6 Effect of 2DG on cell death in N2aswe cells during 24 hrs APP 
overexpression 
177 
5.2.2 The modulation of MA and CMA activity using 3MA 179 
5.2.2.1 Effect of 3MA treatment on N2aswe cell viability 179 
5.2.2.2 Effect of 3MA on MA activity in response to APP overexpression 180 
5.2.3 The modulation of MA and CMA activity using concomitant 2DG and 
3MA treatment 
182 
5.2.3.1 Effect of 12 hrs [2DG and 3MA] treatment on N2aswe cell viability during 
24 hrs APP overexpression 
182 
5.2.3.2 Effect of 12 hrs [2DG and 3MA] treatment on amyloidogenic processing 
in N2aswe cells during 24 hrs APP overexpression 
183 
5.2.3.3 Effect of 12 hrs [2DG and 3MA] treatment on MA activity in N2aswe cells 
during 24 hrs APP overexpression 
185 
5.2.3.4 Effect of 12 hrs [2DG and 3MA] treatment on CMA activity in N2aswe 
cells during 24 hrs APP overexpression 
187 
5.2.3.5 Effect of 12 hrs [2DG and 3MA] treatment on apoptosis in N2aswe cells 
during 24 hrs APP overexpression 
188 
 





The modulation of MA and CMA using the CRM 2DG 
 
190 
5.4 The modulation of MA and CMA activity using 3MA 196 




CHAPTER 6 RESULTS: IN VIVO ASSESSMENT OF THE ROLE OF MA AND 





Introduction to results 
 
205 
6.2 Results 206 
6.2.1 Effect of the treatment intervention on body weight 206 
6.2.2 Effect of the 21-day treatment intervention on overall food consumption 
and ex vivo brain weight 
207 
6.2.3 Effect of the 21-day treatment intervention on survival 208 
6.2.4 Assessment of the hippocampus region 209 
6.2.4.1 Representative H&E micrographs of the hippocampus 209 
6.2.4.2 Effect of the 21-day treatment intervention on lipid peroxidation and 
apoptosis in the hippocampus 
210 
6.2.4.3 Representative 4HNE and cytochrome c fluorescence micrographs of the 
hippocampus 
212 
6.2.4.4 Effect of the 21-day treatment intervention on MA activity in the 
hippocampus 
213 
6.2.4.5 Representative GFAP and LC3II fluorescence micrographs of the 
hippocampus 
213 
6.2.4.6 Effect of the 21-day treatment intervention on MA cargo protein 
degradation in the hippocampus 
215 
6.2.4.7 Representative p62 fluorescence micrographs of the hippocampus 216 
6.2.4.8 Effect of the 21-day treatment intervention on the expression of CMA 
exclusive protein in the hippocampus 
217 
6.2.4.9 Effect of the 21-day treatment intervention on APP expression in the 
hippocampus 
218 
6.2.5 Assessment of the cortex region 219 
6.2.5.1 Representative H & E micrographs of the cortex 219 
6.2.5.2 Effect of the 21-day treatment intervention on lipid peroxidation and 
apoptosis in the cortex 
220 
Stellenbosch University  https://scholar.sun.ac.za
xviii  
 
6.2.5.3 Representative 4HNE and cytochrome c fluorescence micrographs of the 
cortex 
222 
6.2.5.4 Effect of the 21-day treatment intervention on MA activity in the cortex 223 
6.2.5.5 Representative GFAP and LC3II fluorescence micrographs of the cortex 223 
6.2.5.6 Effect of the 21-day treatment intervention on MA cargo degradation in 
the cortex 
225 
6.2.5.7 Representative p62 fluorescence micrographs of the cortex 226 
6.2.5.8 Effect of the 21-day treatment intervention on the expression of CMA 
exclusive protein in the cortex 
227 
6.2.5.9 Effect of the 21-day treatment intervention on APP expression in the 
cortex 
228 
6.2.6 Assessment of the cerebellum region 229 
6.2.6.1 Representative H & E staining of the cerebellum 229 
6.2.6.2 Effect of the 21-day treatment intervention on lipid peroxidation and 
apoptosis in the cerebellum 
230 
6.2.6.3 Representative HNE and cytochrome c fluorescence micrographs of the 
cerebellum 
232 
6.2.6.4 Effect of the 21-day treatment intervention on MA activity in the 
cerebellum 
233 
6.2.6.5 Representative GFAP and LC3II fluorescence micrographs of the 
cerebellum 
233 
6.2.6.6 Effect of the 21-day treatment intervention on MA cargo degradation in 
the cerebellum 
235 
6.2.6.7 Representative p62 fluorescence micrographs of the cerebellum 236 
6.2.6.8 Effect of the 21-day treatment intervention on CMA exclusive protein in 
the cerebellum 
237 




CHAPTER 6 DISCUSSION: IN VIVO ASSESSMENT OF THE ROLE OF MA AND  





Physiological effects to the 21-day treatment intervention 
 
241 
6.4 Analysis of the hippocampal region 242 
6.5 Analysis of the cortex region 248 
6.6 Analysis of the cerebellum region 253 
   





























Stellenbosch University  https://scholar.sun.ac.za
xix  
LIST OF FIGURES 
 




The anatomical distribution of AD pathological changes 
 
3 
Figure 1.2 Neuropathological hallmarks of AD 3 
Figure 1.3 A hypothetical temporal model integrating AD biomarkers in 
relation to cognitive capacities, and brain structure 
5 
Figure 1.4 The amyloid cascade hypothesis (ACH) 6 
Figure 1.5 Schematic representation of amyloid precursor protein (APP) 7 
Figure 1.6 The trafficking, localization and processing of APP in cell 
vesicles 
9 
Figure 1.7 The non-amyloidogenic and amyloidogenic pathway 11 
Figure 1.8 The process of macroautophagy (MA) and the major functional 
complexes involved in its regulation during nutritional stress 
17 
Figure 1.9 Nutrient-dependent regulation of the autophagy pathway 19 
Figure 1.10 Stepwise characterisation of protein degradation through the 
chaperone-mediated autophagy (CMA) pathway 
23 
Figure 1.11 Substantial cross talk exists between (A) macroautophagy, and 
(B) chaperone-mediated autophagy (CMA), with precision 
defect localization 
37 









Quantitative morphometric analysis of TEM micrographs 
 
77 
Figure 2.2 LC-MS schematic workflow of sample preparation 78 
Figure 2.3 Representative mass spectrometry data presentation 82 







Amyloidogenic processing and MA activity in N2avec, N2awt 
and N2aswe cells in response to 24 hrs APP overexpression 
 
93 
Figure 3.2 Effect of APP overexpression on reductive capacity in N2aswe 
cells with time 
94 
Figure 3.3 Effect of APP overexpression on amyloidogenic processing in 
N2aswe cells 
96 
Figure 3.4 CLEM characterization of APP localization in response to APP 
overexpression 
97 
Figure 3.5 Effect of APP overexpression on key MA proteins in N2aswe 
cells 
98 
Figure 3.6 Immunofluorescence micrographs indicating a time-dependent 
increase in APP, Aβ, and LC3II localization in N2aswe cells in 
response to APP overexpression in time 
100 
Figure 3.7 Effect of APP overexpression on key CMA proteins in N2aswe 
cells 
101 
Figure 3.8 Immunofluorescence micrographs indicating colocalization of 
LAMP2A and HSC70 in N2aswe cells in response to APP 
overexpression 
102/3 
Figure 3.9 Effect of APP overexpression on key apoptosis proteins 104 
Figure 3.10 Immunofluorescence micrographs indicating colocalization of 
APP and p62 in N2aswe cells in response to APP 
overexpression 
106 
Stellenbosch University  https://scholar.sun.ac.za
xx  
Figure 3.11 Immunofluorescence micrographs indicating colocalization of 
APP and LAMP2A in N2aswe cells in response to APP 
overexpression 
107 
Figure 3.12 Venn diagram indicating shared (yellow), and unique proteins 
expressed in response to early and late APP overexpression in 
N2aswe cells 
109 
Figure 3.13 Volcano plot indicating changes in the level of protein 
expression in response to early APP overexpression in N2aswe 
cells 
110 
Figure 3.14 Volcano plot indicating changes in the level of protein 
expression in response to late APP overexpression in N2aswe 
cells 
111 
Figure 3.15 Volcano plot indicating changes in the level of protein 
expression between early and late APP overexpression in 
N2aswe cells 
112 
Figure 3.16 Proteome interaction network in N2aswe cells upon early APP 
overexpression 
114 
Figure 3.17 Proteome interaction network in N2aswe cells upon late APP 
overexpression 
115 
Figure 3.18 Proteome interaction network of early versus late APP 
expression in N2aswe cells 
116 
Figure 3.19 Effect of early and late APP overexpression on amyloidogenic 
processing proteins in N2aswe cells 
117 
Figure 3.20 Effect of early and late APP overexpression on key MA proteins 
in N2aswe cells 
118 
Figure 3.21 Effect of early and late APP overexpression on key CMA 
proteins in N2aswe cells 
119 













Figure 4.2 Assessment of macroautophagic flux in N2aswe cells in 
response to APP overexpression 
148 
Figure 4.3 Effect of flux modulation in the context of APP overexpression 
on CMA activity in N2aswe cells 
149 
Figure 4.4 Effect of flux modulation in the context of APP overexpression 
on apoptosis in N2aswe cell 
151 
Figure 4.5 Autophagic vacuole (AV) formation in the absence (left panel), 
and presence (right panel) of BafA1 in response to APP 
overexpression 
152 
Figure 4.6 Quantification of the number and area of AVs in response to 
APP overexpression in N2aswe cells 
153 
Figure 4.7 Fibrillar protein ultrastructure formation in the absence (left 
panel), and presence (right panel) of BafA1 in response to APP 
overexpression 
154 
Figure 4.8 Mitochondrial ultrastructure in the absence (left panel), and 
presence (right panel) of BafA1 in response to APP 
overexpression 
155 
Figure 4.9 The presence of ferritin in the absence (left panel), and 
presence (right panel) of BafA1 in response to APP 
overexpression 
156 
   






Effect of 2DG on reductive capacity in N2aswe cells reductive 
capacity in response to 24 hrs APP overexpression 
 
171 
Figure 5.2 Effect of 2DG on amyloidogenic processing in N2aswe cells in 
response to 24 hrs APP overexpression 
172 
Figure 5.3 Effect of 2DG treatment on MA activity in N2aswe cells in 
response to 24 hrs APP overexpression 
173 
Figure 5.4 Effect of 2DG on CMA activity in N2aswe cells in response to 24 
hrs APP overexpression 
175 
Figure 5.5 Immunofluorescence micrographs indicating the localization of 
the CMA reporter KFERQ-mCherry (red) in N2aswe cells in 
response to 2DG treatment and APP overexpression 
176 
Figure 5.6 Effect of 2DG on key apoptosis proteins in N2aswe cells in 
response to 24 hrs APP overexpression 
178 
Figure 5.7 The time-dependent effect of 3MA treatment on the reductive 
capacity of N2aswe cells 
179 
Figure 5.8 The time-dependent effect of 3MA treatment on MA activity in 
N2aswe cells 
181 
Figure 5.9 Effect of 12 hrs [3MA and 2DG] treatment on N2aswe cell 
viability during 24 hrs APP overexpression 
182 
Figure 5.10 Effect of 12 hrs [3MA and 2DG] treatment on amyloidogenic 
processing in N2aswe cells during 24 hrs APP overexpression 
184 
Figure 5.11 Effect of 12 hrs [3MA and 2D] treatment on key MA proteins in 
N2aswe cells during 24 hrs APP overexpression 
186 
Figure 5.12 Effect of 12 hrs [3MA and 2DG] treatment on CMA activity in 
N2aswe cells during 24 hrs APP overexpression 
187 
Figure 5.13 Effect of 12 hrs [3MA and 2DG] treatment on key apoptosis 








Body weight in response to the 21-day treatment intervention 
 
207 
Figure 6.2 (A) food consumption and (B) ex vivo brain weight in response 
to treatment intervention 
207 
Figure 6.3 Kaplan–Meier survival curves of treatment groups 208 
Figure 6.4 Representative H & E micrographs of the hippocampus in 
response to the 21-day treatment intervention 
209 
Figure 6.5 Effect of the 21-day treatment intervention on lipid peroxidation 
and apoptosis in the hippocampus 
211 
Figure 6.6 Immunofluorescence micrographs indicating 4HNE and 
cytochrome c protein expression in the hippocampus 
212 
Figure 6.7 Effect of the 21-day treatment intervention on MA activity in the 
hippocampus 
213 
Figure 6.8 Immunofluorescence micrographs indicating LC3II (green) and 
GFAP (red) expression in the hippocampus 
214 
Figure 6.9 Effect of the 21-day treatment intervention on MA cargo protein 
degradation in the hippocampus 
215 
Figure 6.10 Immunofluorescence micrographs indicating p62 signal 
(magenta) in the hippocampus 
216 
Figure 6.11 Effect of the 21-day treatment intervention on CMA activity in 
the hippocampus 
217 
Figure 6.12 Effect of the 21-day treatment intervention on APP expression in 
the hippocampus 
218 
Stellenbosch University  https://scholar.sun.ac.za
xxii  
Figure 6.13 Representative H & E micrographs of the cortex in response to 
the 21-day treatment intervention 
219 
Figure 6.14 Effect of the 21-day treatment intervention on lipid peroxidation 
and apoptosis in the cortex 
221 
Figure 6.15 Immunofluorescence micrographs indicating 4HNE and 
cytochrome c signal in the cortex 
222 
Figure 6.16 Effect of the 21-day treatment intervention on MA activity in the 
cortex 
223 
Figure 6.17 Immunofluorescence micrographs indicating LC3II (green) and 
GFAP (red) signal in the cortex 
224 
Figure 6.18 Effect of the 21-day treatment intervention on MA cargo protein 
degradation in the cortex 
225 
Figure 6.19 Immunofluorescence micrographs indicating p62 signal 
(magenta) in the cortex. 
226 
Figure 6.20 Effect of the 21-day treatment intervention on CMA activity in 
the cortex 
227 
Figure 6.21 Effect of the 21-day treatment intervention on APP expression in 
the cortex 
228 
Figure 6.22 Representative H & E micrographs of the cerebellum in 
response to a 21-day treatment intervention 
229 
Figure 6.23 Effect of the 21-day treatment intervention on lipid peroxidation 
and apoptosis in the cerebellum 
231 
Figure 6.24 Immunofluorescence micrographs indicating 4HNE and 
cytochrome c signal in the cerebellum 
232 
Figure 6.25 Effect of the 21-day treatment intervention on MA activity in the 
cerebellum 
233 
Figure 6.26 Immunofluorescence micrographs indicating LC3II (green) and 
GFAP (red) expression in the cerebellum 
234 
Figure 6.27 Effect of the 21-day treatment intervention on MA cargo protein 
degradation in the cerebellum 
235 
Figure 6.28 Immunofluorescence micrographs indicating p62 expression 
(magenta) in the cerebellum 
236 
Figure 6.29 Effect of the 21-day treatment intervention on CMA activity in 
the cerebellum 
237 













Figure B2 Mouse body condition assessment scoring chart 278 
 
Stellenbosch University  https://scholar.sun.ac.za
xxiii  
LIST OF TABLES  
  




Prerequisite criteria for a CMA substrate 
 
24 
Table 1.2  Current symptomatic treatments for AD 45 







List of reagents and consumables used in the study 
 
55 
Table 2.2 Primary antibodies 56 
Table 2.3 Secondary antibodies 57 
Table 2.4 Treatment compounds 61 
ADDENDUM A   
Table A1 Routinely used solutions 261 
Table A2 List of proteins with significantly increased expression during 24 
hrs APP overexpression relative to control 
263 
Table A3 List of proteins with significantly increased expression during 48 
hrs APP overexpression relative to control 
266 
Table A4 List of proteins with significantly increased expression levels 
between 24 hrs and 48 hrs APP overexpression 
271 
ADDENDUM B   
Table B1 Animal welfare monitoring sheet (6 mice housed per cage with a 
total of 12 mice per group) 
274 
Table B2 Description of behavioural or visible symptoms 276 
 
 
Stellenbosch University  https://scholar.sun.ac.za
xxiv  






AD Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase 
ADP Adenosine diphosphate 
AICD Amino-terminal APP intracellular domain 
AKT Gene Name (Synonymous with Protein Kinase B) 
AMPK AMP-activated protein kinase 
APLP APP-like proteins 
APOΕ Apolipoprotein E 
APP Amyloid precursor protein 
sAPPα Soluble APP generated by α‐secretase cleavage  
sAPPβ Soluble APP generated by β‐secretase cleavage 
APP‐CTFα/CTFβ APP C‐terminal fragment generated by α‐/β‐secretase cleavage 
Aβ Amyloid beta 
ATG/atg Autophagy-related genes or proteins 
ATP Adenosine triphosphate 
AVs Autophagy vacuoles 
BACE1 β-site amyloid precursor protein cleaving enzyme 1 
BA Butyric acid 
BafA1 Bafilomycin A1 
BBB Blood brain barrier 
BECN1 Beclin 1 
BSA Bovine Serum Albumin 
CMA Chaperone-mediated autophagy 
CNS Central Nervous System 
CSF Cerebrospinal fluid 
C83 83 amino-acid long Amyloid precursor protein C-terminal fragment 
C99 99 amino-acid long Amyloid precursor protein C-terminal fragment 
CTF C-terminal fragment 
CR Caloric restriction 
CRM Caloric restriction mimetic 
DAPI 4’,6‐Diamidino‐2‐phenylindole 
DMSO Dimethyl sulfoxide 
DMEM Dulbecco’s Modified Eagle’s Medium 
DNA Deoxyribonucleic acid 
EE Early endosomes 
ER Endoplasmic reticulum 
ESCRT Endosomal sorting complex required for transport 
FBS Fetal bovine serum 
FAD Familial Alzheimer’s disease 
FDA Food and drug administration 
FITC Fluorescein isothiocyanate 
GFP Green fluorescent protein 
GFAP Glial fibrillary acidic protein 
GTPase Guanosine triphosphate hydrolase 
HSC70 heat shock cognate 70 
HD Huntington’s disease 
IGF-1 Insulin-like Growth Factor-1 
IF Intermittent fasting 
LAMP2A Lysosome-associated membrane protein type 2a 
Stellenbosch University  https://scholar.sun.ac.za
xxv  
LC-MS Liquid chromatography–mass spectrometry  
MA Macroautophagy 
mRNA Messenger ribonucleic acid 
MVB Multivesicular bodies 
MAP1-LC3 Microtubule Associated Protein 1-Light Chain 3 
mTOR  Mammalian target of rapamycin  
mTORC1 Mammalian target of rapamycin complex 1 
N2a Neuroblastoma cells/cell line 
NCT Nicastrin 
NFT Neurofibrillary tangles 
n number of experiments 
PD Parkinson’s disease 
PARP Poly (ADP-ribose) polymerase 
PBS Phosphate-buffered saline 
PE Phosphatidylethanolamine 
PEN1/2 Presenilin 1 and 2 
PI3K Phosphatidylinositol 3-kinase 
PI3KC3 phosphatidylinositol-3-kinase class III 
PIP3 Phosphatidylinositol 3-phosphate 
PKB Protein kinase B 
PSM Plasma membrane 
RT Room temperature 
PTM Post-translational modification 
PQ Paraquat 
ROS Reactive oxygen species 
sAPP Soluble amyloid precursor protein 
SIRT1 Sirtuin 1 class III histone deacetylase; 
p62/SQSTM1 Sequestosome 1 
SWE Swedish 
TBST Tris Buffered Saline with Tween 20 
TGN Trans Golgi network 
UPS ubiquitin–proteasome system 
VEC Vector 
WT/wt  Wild type 
Stellenbosch University  https://scholar.sun.ac.za
xxvi  
AMINO ACID ABBREVIATIONS 
 
Amino acid 3‐letter 1‐letter 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid  Asp  D  
Cysteine  Cys  C 
Glutamine  Gln Q 
Glutamic acid  Glu  E 
Glycine  Gly  G 
Histidine  His  H 
Isoleucine  Ile  I 
Leucine  Leu  L 
Lysine  Lys  K 
Methionine  Met  M 
Phenylalanine  Phe  F 
Proline  Pro  P 
Serine  Ser  S 
Threonine  Thr  T 
Tryptophan  Trp  W 
Tyrosine  Tyr  Y 
Valine  Val  V 
Stellenbosch University  https://scholar.sun.ac.za
xxvii  


























Stellenbosch University  https://scholar.sun.ac.za
1  




Alzheimer’s disease (AD) is a neurodegenerative disease associated with aging and 
is currently the most common form of dementia, impacting more than 35 million people 
worldwide (Alzheimer’s Association, 2016). The incidence of this disease doubles 
every 5 years after 65 years of age, with the diagnosis of 1.275 new cases per year 
per 100.000 persons older than 65 years of age (Wimo et al., 2017). Paradoxically, 
AD is an unexpected consequence of increasing lifespan, which is the result of medical 
advances and research efforts that have curtailed the effects of communicable 
diseases, malnutrition and other health problems. Recent estimates indicate that by 
2050 the proportion of people aged 60 years and older will account for nearly 22% of 
the global population, with the majority living in developing countries such as sub-
Saharan Africa, where the effects of AD are further aggravated by limited medical 
resources (de Jager et al., 2017). Recent epidemiological studies have suggested that 
developed countries, perhaps due to better medical care, would have in the future a 
limited increase in AD cases, whereas developing countries are expected to be most 
significantly affected by the increasing AD epidemic (Ferri and Jacob, 2017). To date, 
66% of the global elderly population resides in developing countries, and in the 
continued absence of effective therapeutic strategies to either delay or prevent 
disease progression, 79% of the global elderly population is predicted to reside in 
developing countries by 2050 (Wimo et al., 2017). Hence, the magnitude of the AD 
crisis is set to pose an even greater burden on society and public health systems. 
 
The preclinical stage of AD is inconspicuous and there are no reliable or consistent 
symptoms which would allow for early diagnosis before the manifestation of 
irreversible cognitive deficits. This disease involves a progressive loss of synapses in 
the cerebral cortex and hippocampus leading to impaired memory and deterioration of 
cognitive functions (DeKosky and Scheff, 1990; Robinson et al., 2014). For a clinical 
diagnosis of dementia, cognitive impairment must be severe enough to compromise 
daily living activities. In the mild dementia stage, difficulties with declarative memory 
become prominent; as evidenced by increasingly frequent symptoms of depression, 
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hallucination, the increasing need for constant supervision. In the moderate dementia 
stage, cognitive function becomes more apparent, with obvious indications of cognitive 
impairments, including skewed perception and behaviour, as the patient gradually 
transitions into the late stage of disease progression, becoming completely dependent 
on caregivers (Dickerson et al., 2016, 2017). AD remains an unmet clinical challenge, 
the life expectancy of patients with a clinical diagnosis of AD is therefore significantly 
reduced. Despite the plethora of therapeutic agents currently being investigated in 
phase II and phase III clinical trials (https://clinicaltrials.gov/), currently approved 
medications, including acetylcholinesterase inhibitors (e.g. tacrine) and N-methyl-D-
aspartate (NMDA) receptor AD antagonist (memantine), only treat the disease 
symptoms without targeting the underlying causative molecular mechanism, or altering 
the natural course of the disease (Blanco-Silvente et al., 2017; Hyde et al., 2013; Tan 
et al., 2014). 
 
The anatomical distribution of pathological changes in AD, although highly selective 
for only certain brain areas, can be widespread at the end stage of the disease and 
can affect many neural systems. Neuroanatomical studies reveal prominent brain 
atrophy, particularly of the hippocampal area, temporal lobes and parieto-temporal 
cortices (Ringman, 2017). The destruction of these brain regions plays a prominent 
role in the memory deficits that herald the onset of AD and characterize the disease 
throughout its course (Fig. 1.1).  
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Figure 1.1: The anatomical distribution of AD pathological changes. Neuronal cell loss 
leads to extensive brain atrophy in the AD brain (right), compared to the healthy brain (left) 
[adapted from (Jin, 2015)].  
 
At a molecular level, AD diagnosis is based on two hallmark features (Fig. 1.2): neuritic 
plaques, which are abnormal extracellular clusters of β-amyloid peptides (Aβ), and 
intraneuronal neurofibrillary tangles (NFTs), which are somatic inclusions of 
hyperphosphorylated microtubule-associated protein tau (Bateman et al., 2012). 
Neuritic plaques play a critical role in blocking communication among nerve cells and 
disrupting processes that cells need to survive, while NFTs impair vital transport 
systems involved in the transportation of key molecules (Dickerson et al., 2016).  
 
 
Figure 1.2: Neuropathological hallmarks of AD. Microscopic view of AD brain 
demonstrating Aβ plaque deposition (arrowhead), and the presence of NFTs (arrow) (Karch 
and Goate, 2015). 
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AD is classified according to the age of onset, the aetiology, the pathophysiology, and 
the biochemical and genetic alterations associated with disease progression. Familial 
AD (FAD) is a rare (~3 to 5% of all diagnosed cases) form of dementia affecting individuals 
younger than the age 65 and is usually associated with genetic mutations (Alzheimer’s 
Association, 2016). While the overwhelming majority of AD cases are classified as late-
onset/sporadic, occurring in individuals 65 years of age and older, and is usually 
associated with multifactorial aetiology (Hondius et al., 2016). FAD cases have a 
strong genetic correlation associated with mutations in genes coding for amyloid 
precursor protein (APP; chromosome 21), presenilin 1 (PSEN1; chromosome 14) and 
presenilin 2 (PSEN2; chromosome 1), which skew the production of A𝛽, to favour 
production of the more neurotoxic A𝛽 species (Jarrett et al., 1993). In the case of 
sporadic AD, multiple genetic and environmental risk factors have been implicated, 
with the overall impairment of Aβ clearance considered to be a major contributor to 
disease progression (Mawuenyega et al., 2010). Although age is considered to be the 
principal risk factor for sporadic AD development, studies also suggest that the ε4 
allele of the ApoE gene (apolipoprotein E; chromosome 19), a lipid transport protein 
that supports brain injury repair, may contribute to the risk of AD by initiating and 
accelerating Aβ production, and deposition in the brain (Head et al., 2012; Reiman et 
al., 2009). Neurotoxic forms of Aβ have been shown to be abundant in both sporadic 
(Kuo et al., 1996) and FAD cases (Scheuner et al., 1996), suggesting that the 
accumulation of Aβ is a common pathological mechanism underlying both forms of AD, 
therefore making the balance between Aβ production and clearance crucial to 
understanding the pathogenesis of AD. 
 
Although extracellular aggregates of Aβ plaques and intraneuronal accumulations of 
NFTs define AD, it is clear that the aggregation, and conformational changes in Aβ 
play a more central role in initiating AD pathogenesis, while the contribution of NFT 
pathology has been shown to be more pronounced with late disease progression 
(Huynh and Mohan, 2017) (Fig. 1.3).  
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Figure 1.3: A hypothetical temporal model integrating AD biomarkers in relation to 
cognitive capacities, and brain structure. Elevated Aβ levels are the initial trigger in AD, 
while tau mediated neuronal injury only manifests years later in disease progression, ultimately 
leading to neuronal loss. MCI, mild cognitive impairment (Vemuri and Jack, 2010). 
 
Several hypotheses have been put forward to better understand the multifactorial 
pathophysiology of AD, including the amyloid cascade hypothesis (ACH), the 
cholinergic and tau hypothesis, as well as inflammation (Karch and Goate, 2015). 
However, the underlying molecular alterations, and their dynamic changes during 
disease progression remain unclear. The ACH has been the central dogma in AD 
pathogenesis for the past 25 years and continues to guide the development of current 
disease modifying therapeutics used in the symptomatic treatment of AD (Fig. 1.4) 
(Selkoe and Hardy, 2016). 
 




Figure 1.4: The amyloid cascade hypothesis (ACH). The ACH posits that the imbalance 
between Aβ production and clearance may be the central event in AD pathogenesis, with 
increased Aβ production in FAD and decreased Aβ clearance in sporadic AD. The common 
denominator in the pathogenesis of both AD forms is the conformational change in Aβ, 
which makes the peptide aggregate-prone. NFT formation is regarded as a downstream 
event that contributes to cognitive impairment. APP, amyloid precursor protein; PSEN1/2, 
presenilin genes 1 and 2; ApoEɛ4, apolipoprotein E ɛ4 allele. The curved blue arrow 
indicates that Aβ oligomers may directly injure the synapses and neurites of brain neurons, 
in addition to activating microglia and astrocytes (Selkoe and Hardy, 2016). 
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As the most widely accepted mechanistic hypothesis for AD, the ACH suggests that 
the accumulation of the neurotoxic Aβ isoform triggers a cascade of events leading to 
increased inflammation, tau pathology, synaptic and neuronal loss which ultimately 
culminate in disease progression (Hardy and Higgins, 1992). The basis of the ACH 
stems from the following lines of evidence: (1) the identification of Aβ as the primary 
proteinaceous constituent in neuritic plaques (Glenner and Wong, 1984); and (2), the 
identification of several FAD mutations that occur within the Aβ region of APP and have 
been reported to increase the ratio of nontoxic to neurotoxic Aβ species, increase the 
aggregation potential of the mutant neurotoxic Aβ variant to further promote the 
peptides propensity to aggregate into more complex toxic conformations, such as 
oligomeric structural formation (Giasson et al., 2003). The most notable of these 
mutations include the Swedish APP (KM670/671NL), London APP (V717I), and Indiana 
APP (V717F) which have been demonstrated to exert their pathogenic effects by 
inducing the formation of Aβ oligomers and protofibrils (Fig. 1.5) (Goate et al., 1991; 
Mullan et al., 1992). These mutations confirm the relevance of the Aβ in the 
fundamental mechanism of AD pathogenesis. Thus, intense efforts have been made 
in the search for anti - Aβ directed targets which may enhance Aβ degradation or 
prevent its aggregation.  
 
 
Figure 1.5: Schematic representation of amyloid precursor protein (APP). Positions of 
the Aβ sequence, APP transmembrane domain of (Tm), and sites of α-, β- and γ-secretase 
cleavage are illustrated with the Aβ sequence enlarged below. The constitutive proteolytic 
cleavage by α- and γ-secretases leads to the formation of the short p3 peptide and processing 
by β- and γ-secretases leads to the production of Aβ40 and Aβ42 peptides, along with a 
consecutive release of a C-terminal APP intracytoplasmic domain (AICD). Also shown are AD 
causing pathogenic mutations within APP (Kumar-Singh, 2009).
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1.2. Biology and pathophysiology of APP 
 
1.2.1. APP localization, subcellular trafficking and processing 
 
APP is the only type I transmembrane protein unequivocally linked to AD 
pathogenesis, as the unique source of Aβ neurotoxicity (Rajendran and Annaert, 2012). 
During early development, APP is highly enriched at the growth cones of developing 
neurites (O’Brien and Wong, 2011). In more mature neurons, APP localizes to focal 
adhesion sites and within pre - and postsynaptic structures of the central and 
peripheral nervous tissue, suggesting a functional role in neuritic growth and synaptic 
plasticity (Makioka et al., 2009). 
 
APP is synthesized in the endoplasmic reticulum (ER) and is transported to the plasma 
membrane (PM) via the secretory pathway. Studies suggest that APP may be 
transported through the secretory pathway in the following order: rough ER → ER-to-
Golgi transport vesicles → Golgi cisternae → secretory or transport vesicles → PM 
(Lodish et al., 2000). At the PM, APP undergoes the following: (1) proteolytic cleavage 
via α-secretases following the non-amyloidogenic (constitutive) pathway, releasing 
soluble APPα (sAPPα) in the extracellular environment (α-secretases cleavage occurs 
within the Aβ domain of APP, thus preventing Aβ generation) (Sisodia, 1992), (2) APP 
may be recycled back to the trans-Golgi network (TGN) for further packing and 
trafficking or, (3) APP may be reinternalized from the PM via endocytosis into the 
endosomal - lysosomal system pathway for proteolytic cleavage via β-secretases 
following the amyloidogenic pathway (Fig. 1. 6) (Audrain et al., 2016; O’Brien and 
Wong, 2011). APP has been shown to be cleaved by β-secretases in early endosomes 
(EEs), with the activity of these enzymes being dependent on the acidification of these 
organelles (Rajendran and Annaert, 2012; Sannerud et al., 2011). APP and β-
secretases only interact when both are endocytosed in common EEs (Sannerud et al., 
2011), subsequently β-secretases cleave APP at the N-terminus of the Aβ sequence, 
generating soluble APPβ in the endosomal lumen before being targeted for 
degradation in lysosomes (Castello and Soriano, 2014). In this regard, studies have 
shown a limited amount of Aβ immunoreactivity in lysosomes, suggesting that cells 
are able to perform rapid proteolytic digestion of this peptide under normal 
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physiological conditions (Baranello et al., 2015). In support of this notion, work by 
Zheng et al. (2006) revealed that inhibition of lysosomal enzymes further exacerbate 
Aβ accumulation within the lysosomal compartment. Moreover, Aβ has been shown to 
accumulate within lysosomes in AD model systems, where Aβ production has been 
found to promote neuronal cell death through lysosomal destabilization (Nixon et al., 




Figure 1.6: The trafficking, localization and processing of APP in cell vesicles. APP is 
transcribed in the ER, modified in the Golgi, shuttled to the cell surface and delivered to the 
plasma membrane for α-secretase mediated cleavage via the non-amyloidogenic pathway. 
Non-processed APP is internalized from the cell surface through endocytosis. From early 
endosomes, APP is transported to the late endosomes, and can be degraded via the 
autophagy pathway following the fusion of amphisomes and autophagosomes for subsequent 
degradation in autophagolysosomes. Alternatively, APP can be recycled via recycling 
endosomes and enter the cycle again. Amyloidogenic processing of internalized APP by β- 
and γ-secretases is primarily thought to occur in endosomes, and autophagosomes [adapted 
from (Nixon, 2007)]. 
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After α- and β-secretase cleavage (non-amyloidogenic versus amyloidogenic), the 
resulting membrane associated C-terminal fragments, αCTF/C83 or βCTF/C99 
respectively, are generated. Subsequently C99 and C83 are cleaved by γ-secretase 
within the transmembrane domain, resulting in the release of a nontoxic p3 fragment, 
APP intracellular domain (AICD), and Aβ species of different lengths (Fig. 1.7) 
(Sisodia and St George-Hyslop, 2002). The amyloidogenic or pathogenic pathway 
has been shown to be the more favoured pathway for APP processing in neurons, 
whereas the non-amyloidogenic pathway is predominant in all other cell types (Haass 
et al., 1992, 2012). Accordingly, β-secretase continues to be the target of intense 
therapeutic efforts, as genetic knockdown of this enzyme has been found to 
completely block Aβ generation (Cai et al., 2015; Luo et al., 2003). β-secretase is 
ubiquitously expressed, with the highest expression levels being documented in the 
brain and pancreas (Cai et al., 2001). The physiological relevance of enhanced β-
secretase expression in the pancreas remains unclear. However, APP is also 
expressed at very high levels in the brain, making this tissue one of the primary 
locations for increased Aβ generation. 
 




Figure 1.7: The non-amyloidogenic and amyloidogenic pathway. Enhanced 
amyloidogenic pathway activity increases neuronal synthesis of aggregate prone toxic Aβ 
oligomers, which in turn triggers a downstream pathogenic cascade, ultimately driving 
neurofibrillary tangle (NFT) formation and AD progression (Ntsapi et al., 2018). 
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1.2.2. The role Aβ oligomers in neurotoxicity and disease propagation 
 
Aβ is naturally present in the brain and cerebrospinal fluid (CSF) throughout life, 
indicating that its mere presence does not cause neurodegeneration (Sun et al., 2015). 
Rather, it is the dysfunctional clearance of selective Aβ isoforms, in concert with an 
elevated concentration thereof, that appears sufficient to cause both sporadic and FAD 
(Greener, 2014; Murphy and LeVine, 2010). APP cleavage by α-secretase is 
protective in the context of AD, given that the enzyme cleaves within the Aβ sequence, 
thereby preventing the production of Aβ (Marr and Masliah, 2015). In contrast, the 
activity of β-secretase is significantly elevated in both FAD and sporadic AD (Leissring, 
2014), giving rise to an admixture of Aβ peptides composed of 39–43 amino acid long 
peptides, with Aβ40 (90%) and Aβ42 (10%) being the two major Aβ species (Gouras et 
al., 2000). Although the role of Aβ40 remains unclear, studies suggests a role in the 
modulation of synaptic function (O’Brien and Wong, 2011). On the other hand, Aβ42 
has a higher tendency to self-aggregate and form higher order structures, including 
toxic Aβ dimers, trimers, and oligomers. These structures then coalesce to form Aβ 
fibrils, which is an insoluble beta-sheet conformation that eventually deposits into 
neuritic plaques (Burdick et al., 1992; Gravina et al., 1995). Prior to Aβ plaque 
deposition, Aβ42 oligomers have been shown to induce oxidative stress, promote tau 
hyperphosphorylation, and lead to synaptic and mitochondria dysfunction (Lustbader 
et al., 2004). Studies have also shown that elevated Aβ42 levels impair the functionality 
of the cells principle proteolytic system, by impeding clearance of other cytotoxic 
proteins, such as α-synuclein, through the autophagy-lysosomal pathway (Lin et al., 
2016; Silva et al., 2011). Moreover, during late disease progression, Aβ42 neuritic 
plaques have been found to activate microglia, resulting in the release of 
proinflammatory cytokines, which in turn stimulate nearby astrocytes to further 
exacerbate Aβ42 production (Heurtaux et al., 2010). In agreement, 
immunohistochemical analysis reveals significantly higher Aβ42 levels in AD brains 
compared to controls (Huynh and Mohan, 2017). Additionally, the extent of Aβ42 
deposition is much greater in AD brains, while Aβ40 shows no apparent age-dependent 
accumulation. Although many factors contribute to AD pathogenesis, the imbalance in 
Aβ production, particularly in favour of Aβ42, is increasingly being recognized as a 
common theme in both FAD and sporadic AD (Selkoe and Hardy, 2016). 
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1.2.3.  Aβ clearance systems in the brain: implications for AD progression 
 
The mechanisms of Aβ clearance and degradation include the activity of Aβ proteases, 
which are enzymes that degrade or cleave Aβ into smaller peptide fragments. Other 
proteins with a crucial role in Aβ clearance are ApoE and α2-macroglobulin (α2-M); 
which interact with transporters such as low-density lipoprotein receptor-related 
protein 1 (LRP1) receptors, very low-density lipoprotein receptor (VLDLR), and P-
glycoprotein, and localized in astrocytes on the luminal side of the cerebral 
endothelium, where they facilitate the transportation of Aβ across the blood brain 
barrier (BBB) (Deane et al., 2009; Miller et al., 2008). Genetic mutations resulting in 
loss of function of these proteins have been documented during disease progression, 
particularly in sporadic AD, where LRP1 dysfunction has been shown to result in the 
reduced efflux of Aβ from the brain, thus leading to increased Aβ accumulation (Kang 
et al., 2000; Van Uden et al., 2002). In normal brain plasma, a soluble form of LRP1 
(sLRP1) has been found to sequester approximately 70-90% of plasma Aβ peptides, 
but in AD the levels of sLRP1 and its capacity to bind Aβ are markedly reduced, thereby 
increasing the concentration of free Aβ in blood plasma (Deane et al., 2003). This in turn 
may lead to enhanced Aβ accumulation in brain, and the gradual oligomerization of 
this peptide (Kayed et al., 2003; Walsh et al., 2005). 
 
The autophagy pathway is critical for the turnover of cell organelles and degradation 
of aggregated proteins in cells under stress conditions. It has been suggested that the 
inefficient clearance of Aβ-generating autophagic vacuoles (AVs) creates conditions 
favourable for Aβ accumulation in AD, and this notion is supported by findings 
indicating that enhancing autophagy activity using rapamycin treatment (a macrolide 
compound known to induce autophagy) drastically reduces Aβ burden in vivo (Nixon, 
2007). Therefore, failure of autophagy-mediated Aβ clearance is increasingly being 
recognized as a central theme in the pathogenesis of AD (Cai et al., 2015), and 
accumulating evidence suggests that localized defects in the autophagy pathway, are 
likely to precede the neurotoxic aggregation of Aβ oligomers (Nixon and Yang, 2011; 
Zare-shahabadi et al., 2015). An understanding of autophagic function with AD 
progression, and Aβ clearance through this pathway, may reveal novel strategies to 
reduce excess Aβ deposition and mitigate AD pathogenesis. 
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1.3.  Intracellular proteolytic systems 
 
Eukaryotic cells are equipped with two major protein quality control mechanisms 
known to impact cell survival, the ubiquitin–proteasome system (UPS) and the 
autophagy-lysosome pathway. While the UPS is primarily responsible for the 
degradation of short-lived proteins, autophagy is capable of degrading a much wider 
spectrum of substrates, which on average tend to be longer-lived proteins, and often 
organized into oligomeric complexes or aggregate structures (Mizushima, 2007; 
Rubinsztein, 2006). Autophagy is particularly necessary for the clearance of 
aggregate-prone proteins that are especially detrimental to post-mitotic cells 
(Rubinsztein, 2006). The post-mitotic nature of neuronal cells is thought to further 
predispose these cells to cytotoxic protein accumulation, as these cells cannot replicate, 
making neuronal integrity more vulnerable to alterations in basal autophagy than any 
other cell types (Nikoletopoulou et al., 2015). Protein and damaged organelle 
turnover, e.g. mitochondria, and peroxisomes, is essential to maintain cellular 
homeostasis and survival. Autophagy has been implicated in various physiological 
processes, including adaptive immune responses, cellular homeostasis, 
development, differentiation, longevity, the elimination of invading pathogens, and 
intracellular protein turnover to counteract the onset of diseases characterized by the 
accumulation of protein aggregates (Mizushima and Komatsu, 2011). Although 
autophagy has previously been defined as a form of non-apoptotic, programmed cell 
death (Liu and Levine, 2015), recent findings suggest that autophagy functions 
primarily to sustain cell survival, and only localized defects in the autophagy pathway 
have been suggested to result in cell death onset (Kroemer and Levine, 2008). In 
agreement, the induction of autophagy has been shown to have compelling anti-aging 
effects, while inhibition of this process accelerates aging and compromises the 
longevity effects of caloric restriction (CR) (Rajawat et al., 2009; Rubinsztein et al., 
2015). 
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1.3.1.  The role of autophagy in stress response and neurodegeneration 
 
Autophagy is an essential pro-survival pathway induced by a variety of cellular 
stressors which have been found to contribute to the aetiology of various pathology, 
these include nutrient deprivation, growth factor withdrawal, oxidative stress, infection, 
and hypoxia (Murrow and Debnath, 2013). Although basal autophagy exists in all 
eukaryotic cells (Mizushima et al., 2008), a landmark study using a green fluorescent 
protein tagged microtubule-associated protein 1A/1B-light chain 3 (GFP-LC3) 
transgenic mouse model demonstrated that autophagy is distinctly regulated in 
neurons (Mizushima, 2004). Work by Mitra and colleagues demonstrated significant 
differences in basal autophagy between neuronal and non-neuronal cells (Mitra et al., 
2009), and pioneering loss-of function studies further support a critical role for basal 
autophagy in the brain (Hara et al., 2006; Komatsu et al., 2006, 2007a). For instance, 
tissue specific deletion of key autophagy genes in murine muscle, heart or the central 
nervous system have been shown to result in neurodegeneration, muscular atrophy, 
and cardiac hypertrophy (Hara et al., 2006; Nakai et al., 2007). Additionally, genetic 
knockout of the essential autophagy gene ATG5 in mice, has been shown to cause 
lethality soon after birth, suggesting a crucial role for autophagy during the early 
neonatal period in the maintenance of energy homeostasis (Kuma et al., 2004). 
Moreover, cells deficient in autophagy show diffuse abnormal protein accumulation 
and mitochondrial disorganization (Nishiyama et al., 2007), suggesting that autophagy 
is necessary to maintain cellular homeostasis, through the removal of protein 
aggregates and damaged organelles. In contrast, enhanced autophagy has been 
shown to extend lifespan (Rubinsztein et al., 2011). More recently, a study highlighted 
the pivotal role of dysregulated autophagy in neurodegenerative diseases, where toxic 
protein aggregates were shown to accumulate within specific types of neurons and 
lead to neuronal dysfunction and ultimately, cell death onset (Caballero and Coto-
Montes, 2012). In contrast, enhanced autophagy has been shown to improve 
clearance of aggregated proteins and reduce the symptoms of neurodegeneration in 
various animal model systems (Ravikumar et al., 2004; Spilman et al., 2010). 
Autophagy induction may therefore serve as a therapeutic target for several 
neurodegenerative diseases in which cytotoxic protein aggregation has been shown 
to be a pathological hallmark of the disease progression (Douglas and Dillin, 2010). 
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1.3.2.  Autophagy and its machinery 
 
Depending on the delivery route of the cytoplasmic material to the lysosomal lumen, 
three different autophagy pathway subtypes have been classified: (i) macroautophagy, 
or simply autophagy, (ii) microautophagy, which is further subdivided into endosomal 
microautophagy, and (iii) chaperone-mediated autophagy (CMA) (Wang and 
Mandelkow, 2012). Macroautophagy (hereafter referred to as autophagy) is the most 
extensively characterized, and quantitatively the most important proteolytic pathway, 
whereby a portion of cytoplasm targeted for degradation is first wrapped inside a 
specialized organelle, the autophagosome, which then fuses with lysosomal vesicles 
and delivers the engulfed cytoplasmic material for lysosomal degradation (Weidberg 
et al., 2011). While a continuous and dynamic process, the precision-controlled 
autophagy process is mechanistically organized into five separate steps that comprise 
(1) initiation, the formation of the phagophore structure; (2) nucleation, the expansion 
of the phagophore to engulf entire cytoplasmic regions; (3) elongation and enclosure 
of the phagophore membrane to form the autophagosome; (4) maturation, the fusion 
of the mature autophagosome with the lysosome to form the 
autolysosome/autophagolysosome, and (5) degradation of luminal contents, with the 
resultant biomolecules being released back into the cytosol for reuse by the cell 
(Galluzzi et al., 2017) (Fig. 1.8). 




Figure 1.8: The process of macroautophagy (MA) and the major functional complexes involved in its regulation during nutritional 
stress. Distinctly localized autophagy defects have been shown to result in autophagic flux changes during the progression of Alzheimer's disease 
(AD), Parkinson's disease (PD), and Huntington's disease (HD). The multistep pathway of macroautophagy forms an energetic feedback loop 
from energetic sensing to cargo degradation and amino acid release. The rate of flow through this pathway is termed autophagic/macroautophagic 
flux and contributes to proteostasis, quality control and metabolite substrate generation (Ntsapi and Loos, 2016). 
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1.3.3. The precision control of the autophagy machinery 
 
Given the important roles played by the autophagy pathway, it is not surprising that this 
process requires to be finely regulated to avoid both excessive, and insufficient activity. 
Over 50 years have passed since Nobel laureate Christian de Duve first coined the 
term autophagy, or “self-eating’, through identification of the lysosome (Deter and de 
Duve, 1967). Years later, pioneering genetic studies in yeast by Nobel laureate, 
Yoshinori Ohsumi ushered in the era of molecular autophagy research, allowing for 
the identification of several ATG genes, i.e. ATG1-ATG35, conserved from yeast to 
mammals, with ATG or atg referring to “autophagy related” (Ohsumi, 1997, 2014). 
Each step in the autophagy process is mediated by the tight regulation of several 
indispensable ATG proteins. 
 
1.3.3.1. Autophagy regulation by nutrient signalling pathways 
 
The regulation of autophagy tightly interconnects multiple nutrient sensing pathways, 
to ensure that during conditions of nutrient deprivation, or nutrient excess, cellular 
homeostasis can still be maintained. Starvation is the classic stimulus for autophagy, 
allowing cells to respond to nutrient scarcity through increased allocation of amino 
acids from cytoplasmic material sequestered as autophagic cargo (Hosokawa et al., 
2009). The classical pathway regulating mammalian autophagy involves the 
serine/threonine kinase, mammalian target of rapamycin (mTOR), that receives and 
merges input from various signalling pathways, such as adenosine monophosphate-
activated protein kinase (AMPK), phosphatidylinositol 3-kinases (PI3K), and the 
serine/threonine kinase Akt (also known as protein kinase B or PKB), to trigger or halt 
the synthesis of proteins in response to a shift in nutrient availability and energy status 
(Kim and Guan, 2015). mTOR forms two functionally distinct complexes in mammals, 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), distinguished by their 
partner proteins and differing sensitivities to rapamycin. Autophagy is negatively 
regulated by mTORC1 (Fig. 1.9) (Guertin and Sabatini, 2007; Noda and Ohsumi, 
1998), while mTORC2 is implicated in the regulation of CMA in response to nutrient 
starvation (Arias et al., 2015; Ebner et al., 2017). 




Figure 1.9: Nutrient-dependent regulation of the autophagy pathway. A. Under conditions of 
nutrient excess, mTORC1 binds the Ulk1 kinase complex and inhibits autophagy by 
phosphorylating ULK1 and Atg13. B. When cells are starved or depleted of energy, mTORC1 
dissociates from the complex, ULK1 autophosphorylation increases and the kinase phosphorylates 
Atg13 and FIP200, resulting in autophagy induction [adapted from (Ntsapi and Loos, 2016)]. 
 
In brief, during conditions of nutrient availability, activated mTORC1 is sequestered 
into a complex with the Unc-51 Like Autophagy Activating Kinase 1 (ULK1), consisting 
of Atg13, and focal adhesion kinase family interacting protein of 200 kDa (FIP200), 
and phosphorylates Atg13 and ULK1, thereby inhibiting the initiation of autophagy 
(Ganley et al., 2009; Mercer et al., 2009). During conditions of nutrient starvation, 
amino acid deprivation, growth factor withdrawal, or treatment with rapamycin, 
mTORC1 dissociates from the ULK1 complex, which frees ULK1 to auto-
phosphorylate, and trans- phosphorylate its binding partners Atg13 and FIP200 to 
induce autophagy (Fig. 1.9) (Jung et al., 2010). Subsequently, activated ULK1 
phosphorylates and activates the Beclin1-vacuolar protein sorting 34 (VPS34) 
complex, which contains Beclin1 (BECN1), VPS34, and Atg14L (Itakura et al., 2012). 
The activated Beclin1 complex functions as a class III phosphatidylinositol 3-kinase 
(PI3KCIII), to produce phosphatidylinositol 3-phosphate (PI3P), which in turn 
provides a platform to recruit PI3P-binding proteins during the nucleation process 
(Kim et al., 2011; Sarkar, 2013). The PI3P-binding proteins label and recruit binding 
proteins, termed WD repeat domain phosphoinositide interacting (WIPI) and double 
FYVE domain-containing protein 1 (DFCP1), which serve as a docking platform (Neer 
et al., 1994). Atg14L targets the Beclin1/PI3KCIII complex to the specialized 
subdomain of the ER, called the omegasome, which consequently triggers phagophore 
formation (Matsunaga et al., 2010). Although the Golgi apparatus, mitochondria and 
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PM may also act as membrane sources for phagophore formation under certain 
conditions (Axe et al., 2008; Mizushima et al., 2011), a growing number of studies have 
revealed that phagophores locate between two cisterns of rough ER in starved cells 
(Hayashi-Nishino et al., 2009). In support of this finding, the omegasome marker 
protein DFCP1 has also been reported to be localized within delicate membrane 
tubules extending from the ER, thus making the ER the most likely membrane source 
for the phagophore formation (Uemura et al., 2014). Two ubiquitin-like conjugation 
systems are involved in the elongation and expansion of the phagophore membrane. 
Firstly, Atg12 is conjugated to Atg5, which then interacts with Atg16L to form the 
Atg12-Atg5-Atg16L complex, which is necessary for autophagosome formation 
(Mizushima et al., 2003). This is followed by the conjugation of LC3 to the lipid 
phosphatidylethanolamine (PE). LC3 is cleaved at its C-terminus by Atg4 to form the 
cytosolic LC3I, which is conjugated with PE to generate LC3II (Tanida et al., 2004). 
LC3II specifically associates with both the internal and external surfaces of the 
autophagosome membrane, where it plays a role in selecting cargo for degradation 
(Tanida et al., 2002). The synthesis and processing of LC3 is increased in response 
to autophagy induction, making it a key readout of autophagosome abundance 
present in cells (Kuma et al., 2007; Tanida et al., 2004). However, it must be noted 
that the appearance of LC3II represents the abundance of autophagosomes rather 
than a true reflection of the dynamic nature of the autophagy process. Autophagic 
activity can be affected by either the formation, or the degradation of selective 
structures; hence, the concept of “autophagic/macroautophagic flux” was coined to 
represent the sum total of autophagy, from the induction to autophagosome formation, 
to subsequent degradation thereof (Klionsky et al., 2016; Loos et al., 2014). To assess 
flux, the conversion of LC3I to LC3II is measured using a turnover assay involving 
autophagy inhibitors. Following their formation, autophagosomes undergo a 
maturation process that may include fusion with endosomal and lysosomal vesicles 
(Eskelinen, 2005). Studies show that undisturbed macroautophagic flux requires a 
tight cooperation between the endosomal compartments, including early and late 
endosomal sorting, and autophagosomes (Eskelinen, 2005). For example, before 
fusing with lysosomes to form autophagolysosomes, autophagosomes can also 
directly fuse with early and/or late endosomes to form hybrid structures called 
amphisomes, which then fuse with lysosomes, to form autophagolysosomes in which 
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cytosolic contents are degraded (Gutierrez et al., 2004; Saftig et al., 2008). Fusion of 
autophagosomes, or amphisomes with lysosomes is mediated by Rab7 and the 
lysosomal transmembrane protein LAMP2 (Filimonenko et al., 2010). Degradation 
products, such as amino acids, are released back into the cytoplasm to replenish 
cellular energy reserves, and to sustain growth during starvation conditions (Mindell, 
2012). mTORC1 signalling is reactivated in response to prolonged starvation, as 
increased mTORC1 activity functions as a negative feedback mechanism to avoid 
excessive autophagy induction. Subsequently, the lysosomal pool is renewed through 
a process called autophagic lysosome reformation (ALR), to maintain lysosome 
homeostasis at the terminal stage of autophagy (Chen and Yu, 2017; Yu et al., 2010). 
 
While starvation-induced autophagy leads to the indiscriminate engulfment and 
degradation of cytoplasmic material for anabolic reactions, selective autophagy 
accepts preferentially ubiquitinylated cargo. A number of autophagy receptors, such 
as scaffold protein sequestosome 1 (SQSTM1/p62) (Pankiv et al., 2007), and p62-
related proteins such as Neighbor of BRCA1 gene 1 (NBR1), and Optineurin are 
involved in selective autophagy degradation (Birgisdottir et al., 2013). These receptor 
proteins share similar domain architecture containing an N-terminal Phox/Bem1p (PB1) 
domain which plays a critical role in mediating protein–protein interactions, a LC3-
interacting region (LIR) domain for direct incorporation of cargo into autophagosomes, 
and a C-terminal ubiquitin binding domain (UBD) for the selective targeting of 
ubiquitinated proteins (Stolz et al., 2014; Zaffagnini and Martens, 2016). 
 
1.3.4. Chaperone-mediated autophagy: the exclusive degradative machinery 
 
In sharp contrast to the above pathway, CMA involves the selective recognition and 
unfolding of substrate proteins bearing a KFERQ amino acid motif by a complex of 
cytosolic chaperones, with heat shock cognate chaperone of 70 kDa (HSC70) being 
the most prominent. This substrate/chaperone complex is targeted to the lysosomal 
membrane for docking at the cytosolic tail of CMA-specific lysosome-associated 
membrane protein type-2A (LAMP2A), and then translocated across the lysosomal 
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membrane for subsequent degradation (Kaushik and Cuervo, 2012). The KFERQ 
targeting motif is found in nearly 30% of all cytosolic proteins (Dice, 1990). However, 
even more proteins could potentially be degraded via CMA, as proteins that do not 
carry the KFERQ motif can also be degraded via CMA after posttranslational 
modifications, e.g. phosphorylation or acetylation (Dice, 2007). Although the presence 
of the KFERQ motif is a requirement for all CMA substrates, validation of a protein as 
a CMA substrate requires more than the mere identification of the KFERQ targeting 
motif, as this motif has also been shown to be utilized for targeting of proteins to late 
endosomes for endosomal microautophagy (Sahu et al., 2011). A set of criteria (Table 
1.1) must be met to validate that a protein is in fact a CMA substrate; but ultimately, it 
is recommended that the best way to confirm that a protein is a CMA substrate is to 
reproduce its binding and translocation across the membrane of isolated 
lysosomes(Arias, 2017; Kaushik and Cuervo, 2018). 
 
Protein degradation via CMA is characterized by four distinct stages (Fig. 1.10): (1) 
substrate proteins bearing the KFERQ motif are recognized by HSC70, and 
translocated to the lysosomal surface; (2) the HSC70-substrate complex binds to the 
CMA specific substrate receptor, LAMP2A, leading to its multimerization; (3) the 
substrate protein unfolds and is translocated across the lysosomal membrane aided by 
a luminal form of HSC70 (lys-HSC70); and (4) degradation of substrate proteins by 
lysosomal hydrolases (Kaushik and Cuervo, 2018). Importantly, CMA is maximally 
activated in response to nutritional stress, oxidative stress and hypoxia, while its 
activity has been shown to decline with age (Bejarano and Cuervo, 2010). 
 




Figure 1.10: Stepwise characterisation of protein degradation through the chaperone-
mediated autophagy (CMA) pathway. The sequential steps involved in the preferential 
degradation of substrate proteins via CMA are as follows: (1) recognition of substrate proteins 
by HSC70; (2) binding of the substrate–chaperone complex to LAMP2A; (3) unfolding of the 
substrate-chaperone complex; (4) LAMP2A multimerization resulting in substrate 
translocation across the lysosomal membrane for subsequent degradation. With disease 
progression, LAMP2A levels are diminished at the lysosomal membrane, and increasing levels 
of selective mutated proteins, such as mutant tau protein in AD, inhibit LAMP2A receptor 
function and thereby impair CMA activity. Abbreviations: CMA, chaperone-mediated 
autophagy; HSC70/Hsc70, heat shock cognate protein of 70 kDa; LAMP2A, lysosome-
associated membrane protein type 2A [adapted from (Ntsapi and Loos, 2016)]. 
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Table 1.1. Prerequisite criteria for a CMA substrate. 
Requirements Validation assays References 
KFERQ motif bearing 
proteins. 
Sequence analysis. (Dice, 1990) 
CMA-targeting motif that is 
accessible for chaperone 
binding. 
A decrease in substrate 
levels upon LAMP2A 
overexpression. 
(Kaushik and Cuervo, 
2012) 
Association with CMA-active 
lysosomes (positive for 




(Terlecky and Dice, 
1993) 
Long half-life (> 10 hrs to 
several days). 
Metabolic labelling and 
immunoprecipitation. 
(Cuervo et al., 2004) 
Substrate protein must 
increase with CMA blockage 




(Cuervo et al., 1995a) 
Must be compatible for 
binding with cytosolic 
HSC70. 
Co-immunoprecipitation 
using cytosol fractions. 
(Cuervo et al., 1998) 
Interaction with LAMP2A 
through its cytosolic tail. 
Co-immunoprecipitation 
using isolated lysosome 
fractions. 
(Cuervo et al., 2004) 
ATP- and HSC70-dependent 
translocation into isolated 
lysosomes. 
In vitro binding and uptake 
by immunoblotting. 
Degradation by intact 
lysosomes 
(Cuervo et al., 1995a) 
 
1.3.4.1. CMA regulation 
 
Pioneering studies, mostly through the work of the laboratories of Erwin Knecht, Fred 
Dice and, more recently, Ana Maria Cuervo led to the discovery of the CMA pathway, 
as well as the elucidation of the molecular mechanisms underlying this process. 
Although multiple factors may regulate the assembly and disassembly of the HSC70-
substrate complex, the rate of CMA depends largely on the levels of LAMP2A at the 
lysosomal membrane (Arias, 2017; Kaushik and Cuervo, 2018). Although the 
signalling pathways which regulate starvation-induced CMA activation have not been 
fully clarified, recent findings have revealed a putative CMA regulatory axis comprised 
of the Pleckstrin homology (PH) domain and leucine-rich repeat protein phosphatase 
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1 (PHLPP1), mTORC2 and their common downstream target Akt 
(mTORC2/PHLPP1/Akt) (Arias et al., 2015). The mTORC2/PHLPP1/Akt axis has been 
shown to modulate basal CMA activity in response to starvation, or during nutrient 
limitation. Using isolated lysosomes in vitro, Arias and colleagues observed that 
signalling through mTORC2 under basal conditions was relatively lower than 
constitutive CMA activity in most cells. The cause of this repressed CMA activity was 
associated with the phosphorylation of lysosome associated Akt by mTORC2. This 
kinase transiently repressed CMA activation by negatively regulating the assembly of 
LAMP2A into the CMA translocation complex (Arias et al., 2015). However, following 
enhanced CMA activity in response to starvation-conditions, the transient inhibition by 
mTORC2/Akt was released, and phosphatase PHLPP1 (that dephosphorylates and 
inactivates Akt) and the GTPase Rac1 (that stabilizes PHLPP1 at the lysosomal 
membrane) was recruited to CMA-active lysosomes where it altered the kinetics of 
assembly and disassembly of the CMA translocation complex (Arias et al., 2015).  
 
Microautophagy is the least characterized autophagic pathway, involving the 
engulfment of cytosolic material through the formation of multivesicular bodies (MVBs) 
which are either degraded in late endosomes, or upon their fusion with lysosomes 
(Mukherjee et al., 2016).  
 
Autophagy forms the primary focus of this review discussion, given that this pathway 
is distinctively associated with Aβ toxicity, and autophagic dysfunction has been shown 
to be extensively impaired during AD progression (Boland et al., 2008; Nixon et al., 
2005). Moreover, given the association of autophagy as part of a compensatory cell 
survival response with CMA (Kaushik et al., 2008; Massey et al., 2006a), the role of 
CMA will also be shortly discussed where appropriate. Notably, autophagy is 
henceforth referred to as macroautophagy, to better distinguish between the two 
autophagic pathways. 
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1.4.  Aging: insufficient proteostasis, or dysfunctional proteolytic function? 
 
1.4.1. Macroautophagy declines with age 
 
Advancing age is a major risk factor for AD, and macroautophagy is thought to dictate 
normal and pathological aging through its intricate regulation of toxic protein 
accumulation (Rubinsztein et al., 2011). Age is a cumulative process characterized by 
the accumulation of detrimental molecular, cellular and functional changes in various 
organisms (Rubinsztein et al., 2011). Age is associated with a gradual deterioration in 
cellular fitness and viability which is thought to begin when the rate of cell damage 
exceeds the rate of continual repair and protein turnover (Kaushik and Cuervo, 2015). 
Dysfunction of macroautophagy has been shown to increase with aging (Rubinsztein 
et al., 2011), contributing both directly and indirectly to cellular damage, through the 
accumulation of toxic protein aggregates as seem in neurodegenerative diseases such 
as AD, Parkinson’s disease (PD), and Huntington’s disease (HD), thus compounding 
the overall functional decline associated with aging. These diseases are characterized 
by the formation, and deleterious aggregation of selective protein deposits which are 
composed of ubiquitin conjugates, suggesting a failure in the principal protein 
degradation machinery (Nixon, 2013). Constitutive macroautophagy activity is 
essential for neuronal homeostasis; thus, malfunction in the quality control function of 
this process results in the cytotoxic build-up of defective proteins and organelles 
(Caballero and Coto-Montes, 2012).  
 
The notion that functional macroautophagy increases longevity is well illustrated by 
experiments in which the induction of macroautophagy by either pharmacological 
methods, such as the administration of rapamycin (which is the best characterized 
pharmacological inducer of macroautophagy), or CR (which is best characterized 
physiological inducer of macroautophagy), has been found to extend the lifespan of 
the nematode Caenorhabditis elegans (C. elegans) only when the autophagic 
machinery was intact (Jia and Levine, 2007; Mariño et al., 2014). Indeed, 
macroautophagy mediated protein clearance becomes increasingly impaired with age 
(Martinez-Vicente et al., 2005; Ward, 2002), as evidenced by a decrease in 
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autophagosome formation with age (Taneike et al., 2010; Terman, 1995). Moreover, 
macroautophagy has been found to be transcriptionally down-regulated during normal 
aging in the human brain (Lipinski et al., 2010). Declining autophagic function with age 
has been shown to result from the following factors: (1) impaired autophagosome-
lysosome fusion, (2) variable autophagic response to insulin and glucagon levels; and 
(3) insufficient turnover of damaged mitochondria (Donati, 2006; Donati et al., 2013). 
Using liver from aging rodents, impaired lysosomal hydrolase activity was revealed to 
be the cause of impaired autophagosome-lysosome fusion, and reduced AV 
clearance (Vittorini et al., 1999). This defect was attributed to a change in lysosomal 
pH, and the accumulation of lipofuscin (an age-associated pigment that accumulates 
in the lysosomal compartment of post-mitotic cells) (Brunk and Terman, 2002). The 
first experimental study examining the role of ATG protein in lifespan regulation was 
performed using C. elegans (Meléndez et al., 2003), where inhibition of Tor kinase 
(whose activity inhibits macroautophagy) was found to double the lifespan of this 
nematode, thus supporting the notion that macroautophagy dysfunction may induce 
premature aging (Vellai, 2009; Vellai et al., 2003). Knockdown of Beclin1 by RNA 
interference (RNAi) has been shown to shorten the lifespan of wildtype nematodes 
(Meléndez et al., 2003). Results in aged Drosophila melanogaster (D. melanogaster) 
brains demonstrate that enhanced ATG8 expression in the nervous system extends 
the average adult lifespan by 56%, promotes resistance to oxidative stress, and 
prevents the accumulation of ubiquitinated proteins in the brain (Simonsen et al., 2008; 
Vellai, 2009). These findings indicate that genetic or age-dependent suppression of 
macroautophagy is closely associated with the increased manifestation of cellular 
damage and reduced lifespan, while enhancing macroautophagic activity has been 
shown to reverse these effects, promote longevity, and is confer protection in various 
animal models of neurodegeneration (Hara et al., 2006; Ravikumar et al., 2004). 
Therefore, diminishing macroautophagic activity with age may contribute to the age-
dependent development of chronic neurodegenerative diseases, suggesting that 
upregulation of the macroautophagy pathway may be beneficial in maintaining neuronal 
function with age. 
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1.4.2.  CMA declines with age 
 
A decrease in the lysosomal levels of LAMP2A has been shown to be the primary 
cause of diminishing CMA activity with age (Cuervo and Dice, 2000a, 2000b). Although 
the synthesis and lysosomal targeting of LAMP2A has been found to remain consistent 
during middle age, at advanced age, LAMP2A levels have been found to be drastically 
reduced (Cuervo and Dice, 2000b). Consequently, the binding and translocation of 
CMA substrates into the lysosome is progressively compromised with age 
(Bandyopadhyay and Cuervo, 2008). Indeed, the stability and expression of LAMP2A 
at the lysosomal membrane has been shown to be significantly reduced in aged rats, 
compared to their younger counterparts (Kiffin et al., 2007). Compelling evidence of 
the detrimental role of reduced LAMP2A levels with age was demonstrated using aged 
transgenic mouse models in which CMA function was preserved by exogenously 
expressing an extra copy of LAMP2A in the liver (Zhang and Cuervo, 2008). The 
restoration of CMA activity resulted in improved cellular homeostasis, enhanced stress 
resistance, and led to an overall improvement in liver function comparable to that 
observed in younger mouse models (Zhang and Cuervo, 2008). Although further 
studies are required to elucidate the mechanisms underlying these altered LAMP2A 
dynamics with age, ongoing studies support the notion that primary changes in the 
lipid composition of the lysosomal membrane with age may contribute to the LAMP2A 
alterations (Koga and Cuervo, 2011). 
 
1.5. Macroautophagy, CMA and AD pathogenesis 
 
1.5.1. Autophagosome/lysosomal dysfunction in AD 
 
Although extracellular Aβ plaques and intraneuronal NFTs are the defining hallmarks 
of AD neuropathology, a growing body of literature suggests that localized deficits in 
the macroautophagy pathway are likely to precede the formation of these pathological 
features (Nixon and Yang, 2011; Zare-shahabadi et al., 2015). The extensive 
involvement of macroautophagy in AD pathology was first demonstrated in an electron 
microscopy-based study of the AD brain, where prominent accumulation of immature 
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AVs was observed in dystrophic neurites, suggesting that the transport of these AVs 
and their fusion with lysosomes may be impaired (Nixon et al., 2005). In a separate 
study, Yu et al. (2004) revealed that purified AVs found in the AD brain were a major 
reservoir of intracellular Aβ production, and other AD-associated proteins including 
full-length APP, sAPPβ, and the γ-secretase complex subunits presenilin 1 (PS1) and 
nicastrin, suggesting that AVs may serve as Aβ production sites. Lysosomal 
intracellular aspartyl proteases, cathepsin D and E, have been found to influence Aβ 
peptide generation within the macroautophagy machinery as these proteases exhibit 
both β- and γ-secretase-like activity (Ingegni et al., 2003; Mo et al., 2014). Accordingly, 
macroautophagy has been shown to facilitate the degradation of APP, and Aβ (Tian 
et al., 2014b; Zhou et al., 2011a), whereas inhibition of cathepsin activity has been 
shown to result in a rapid and pronounced build-up of these proteins (Bahr et al., 1994; 
Butler et al., 2011). The deletion of cathepsin B, a lysosomal cysteine protease that 
primarily degrades the aggregation-prone Aβ42 species, has been shown to result in 
increased Aβ42 levels and robust Aβ plaque deposition in an APP mouse model 
(Mueller-Steiner et al., 2006). The underlying mechanism of Aβ accumulation and 
neuronal cell death in AD is thought to, at least in part, result from a combination of 
increased autophagic induction, impaired clearance of Aβ-containing AVs, and 
defective lysosomal proteolysis (Boland et al., 2008; Lee et al., 2010, 2011a). The role 
of macroautophagy in the secretion of Aβ is further supported by recent findings in 
which the measurement of extracellular Aβ in macroautophagy-deficient mice 
revealed that the Aβ secretion was reduced by 90%, while restoration of 
macroautophagy enhanced Aβ secretion to control conditions (Nilsson and Saido, 
2014). In separate work, Nilsson et al. (2015) revealed that the secretion of Aβ was 
significantly reduced in ATG7 knockdown mice, and this reduction was accompanied 
by the profound intracellular accumulation of Aβ. The macroautophagy inducer 
trehalose (a natural disaccharide that block glucose transporters), was shown to 
rescue the AD-like phenotype in APP/PS1 transgenic mice. In this sense, trehalose 
treatment significantly improved cognitive function; and more notably, Aβ deposits 
were significantly reduced in the hippocampus region following macroautophagy pathway 
induction (Rami, 2009). This suggests that insufficient macroautophagic activity can be 
reversed through pharmacological stimulation to promote Aβ degradation, translating 
to cell protection. Indeed, several studies have shown that rapamycin reduces the 
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accumulation of Aβ fibrillar aggregates approximately 40 to 50% in AD mouse models 
(Yu et al., 2005). Using an AD mouse model overexpressing Aβ, Pickford et al. (2008) 
revealed that BECN1 haploinsufficiency reduced macroautophagic activity and 
exacerbated AD pathology, as evidenced by increased Aβ deposition and 
neurodegeneration. Morphological evidence from Yu et al. (2004) demonstrates that 
APP and Aβ peptide are colocalized with LC3ll-positive autophagosomes, showing 
greater colocalization of Aβ with AVs. Intervention strategies targeting 
macroautophagy induction have been shown to enhance the clearance of Aβ and APP-
derived fragments in vitro and in vivo models of AD (Caccamo et al., 2010, 2011; 
Majumder et al., 2011). The degradation of extracellular Aβ through microglia has 
been shown to involve at the first step endocytosis; once Aβ peptide is in the cytosol, 
it is then recognized by LC3II via optineurin, which has been shown to promote Aβ 
degradation through the autophagic pathway (Du et al., 2013). These results provide 
compelling evidence for the efficacy of macroautophagy induction in AD model 
systems. On the other hand, Aβ has also been shown to regulate macroautophagic 
activity. For example, Aβ40 has been found to induce macroautophagy in endothelial 
cells and impair neurovascular regeneration (Hayashi et al., 2009). Taken together, it 
is evident that enhancing autophagic degradation ameliorates Aβ neurotoxicity and, 
in some cases, even prevents cytotoxicity and cognitive decline in vivo (Yang et al., 
2011a). To date, rapamycin remains the most widely used pharmaceutical inducer of 
macroautophagy (Miller et al., 2014; Wu et al., 2013a). However, the side effects of 
rapamycin make it unsuitable for clinical use due to the side-effects associated with 
long-term usage. Primary amongst these are the immune suppressive effects, and 
metabolic defects including hyperglycaemia, hyperlipidaemia, insulin resistance and 
increased incidence of type 2 diabetes (Fischer et al., 2015; Salmon, 2015). In healthy 
rodents, dose-dependent rapamycin treatment has been shown to impair glucose 
homeostasis (Miller et al., 2014). Hence, physiological induction of macroautophagy 
may represent a more practical strategy for the enhancement of Aβ degradation. 
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1.5.2.  The putative role of CMA in AD 
 
Similar to macroautophagy, CMA has been found to play an important role in both the 
formation of tau protein NFT formation and, to a lesser extent, Aβ aggregate formation 
(Koga and Cuervo, 2011). The role of CMA in AD pathogenesis, although poorly 
understood, is thought to modulate the extent of NFT formation resulting from the 
aggregation of mutant tau tangles (Wang et al., 2009). Tau protein contains two CMA-
targeting motifs, thus making it amiable for efficient degradation via the CMA pathway 
(Wang et al., 2009), or as recently shown, endosomal microautophagy (Tekirdag and 
Cuervo, 2018). In contrast, mutant tau protein has been shown to be partially 
internalized once bound to LAMP2A, and while the portion of the protein that enters 
the lysosomal lumen is enzymatically cleaved, the portion at the lysosomal membrane 
has been shown to form smaller tau fragments that oligomerize directly at the 
lysosomal surface, thereby disrupting the integrity of the lysosomal membrane and 
blocking LAMP2A receptor (Fig. 1.10). Indeed, studies using an inducible neuronal 
tauopathy model have shown that mutant tau protein fragmentation is initiated in the 
cytosol and is completed at the lysosomal surface upon binding to LAMP2A (Wang et 
al., 2009). Although the mechanism of tau mediated CMA blockage is not fully 
understood, inefficient translocation of mutant tau fragments across the lysosomal 
membrane has been shown to promote the formation of tau oligomers at the lysosomal 
surface, and these oligomers are then thought to act as precursors of aggregation 
(Wang et al., 2009), thereby blocking CMA activity. In the case of APP, a direct 
connection with CMA is not easily inferred, as membrane proteins have generally not 
been shown to be amenable to CMA degradation (Koga and Cuervo, 2011). However, 
the cytoplasmic tail of APP, has recently been discovered to bear a CMA-targeting motif 
which is recognized by HSC70 (Park et al., 2016). It is thus conceivable that CMA, or 
endosomal microautophagy, could aid in APP clearance under basal conditions, and 
that alteration of either of these pathways may impair APP clearance and contribute to 
Aβ toxicity. Interestingly, deletion of APP’s KFERQ motif has not been found to abolish 
its interaction with HSC70 (Park et al., 2016), suggesting that the KFERQ motif may 
not be crucial for CMA degradation in this context. However, further studies are 
warranted to better unravel the putative role of CMA in APP processing. 
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Given the increasing evidence in support of the essential role of macroautophagy in 
the generation, secretion and clearance of Aβ, modulators of macroautophagy offer 
great potential for the treatment of AD. To this end, a number of macroautophagy 
modulators have been demonstrated to have positive effects in various AD animal 
models, but adverse effects in patients (Ross et al., 2015; Salmon, 2015). This 
scenario makes it clear that non-pharmaceutical interventions, such as CR, that can 
robustly modulate macroautophagy, positively impact lifespan in various organisms, 
and consistently favour neuronal protection in neurodegeneration, may hold 
therapeutic promise. 
 
1.6. Doubling up: CR impacts longevity through macroautophagy and CMA  
 
1.6.1.  CR and macroautophagy 
 
CR, also called the “longevity diet” refers to the restriction of energy (food) intake, 
beginning early or in mid-life and sustained over the life span, without causing 
malnutrition (Bales and Kraus, 2013). CR is to date been shown to be the most robust 
physiological inducer of the macroautophagy pathway, to confer neuroprotection with 
increasing age in diverse species, ranging from yeast to mammals (Fontana et al., 
2010). Increased generation of ROS has been postulated to be one of the major 
hallmarks of increasing age, and CR has been found to reduce the levels of oxidative 
stress in mammals (Sohal and Forster, 2014). Similarly, rodents subjected to CR show 
a decreased incidence of age-associated mitochondrial dysfunction, and oxidative 
damage resulting from increased oxidative stress (Forster et al., 2000; Sohal and 
Weindruch, 1996). The compelling role for CR in delaying the onset of age-
associated pathologies appears to have emerged in the early 20th century (Osborne 
et al., 1917), when McCay and colleagues published the first manuscript on the 
beneficial effects of CR on life extension in rats (McCay et al., 1989). Since then, CR-
induced life extension has been documented in species from the following kingdoms: 
Animalia (mammals), Protista (single-celled eukaryotes), and fungi (fungus and 
related organisms) (Lee and Longo, 2016; Li et al., 2017a). CR enhances 
macroautophagic activity to promote the rapid turnover of macromolecules and 
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organelles in aging mice kidneys. This enhanced macroautophagic activity under CR 
conditions suggests a protective role for macroautophagy pathway induction with age. 
In the kingdom of Animalia, the anti-aging benefits of CR have been extensively studied 
in mice, hamsters, dogs (Masoro, 2006, 2009); and more recently in long-lived non-
human primates, the rhesus monkey (Colman et al., 2014; Mattison et al., 2017). The 
rhesus monkey serves as an ideal model for human physiology as it shares 
approximately 93% sequence identity with the human genome (Gradnigo et al., 2016), 
as well as numerous aspects related to endocrinology, anatomy, neurology, 
immunology, and behaviour (Zimin et al., 2014). Accordingly, a plethora of data 
supporting the role of CR in improving health has been generated using the rhesus 
monkey as an experimental model over the past 20 years. The first report on increased 
lifespan emanated from work by Bodkin and colleagues where a 2.6-fold increased 
risk of death was reported in control animals compared with animals subjected to CR 
(Bodkin et al., 2003). In agreement, work by Colman and colleagues reported a 2.9-
fold increased risk of disease and 3.0-fold increased risk death for control animals 
compared with CR animals (Colman et al., 2009). In a more recent study, these 
researchers further cemented the role of CR in longevity, reporting a significant 
improvement in age-related pathology and overall survival in rhesus monkeys on a 
long-term (~30%) CR diet since young adulthood (Colman et al., 2014). If, and to what 
extent the health benefits of CR can be translated to human ageing remains to be 
determined, although there is evidence to suggest that CR provides at least some 
benefits to humans consistent with delayed aging (Lefevre et al., 2009). Although 
compelling data from in vivo animal models clearly support the view that CR dietary 
regimes decrease the incidence of various diseases, including AD and PD (Lee and 
Longo, 2016; Mattison et al., 2017). The absence of adequate information on the 
effects of CR in humans reflects the difficulties involved in conducting long-term CR 
studies, including ethical and methodologic considerations. However, there are a 
limited number of ongoing clinical trials funded by the National Institute of Aging, to 
bring about insight into the question of whether the observed health benefits of CR in 
nonhuman primates can be translated to humans. One of these trials, entitled the 
Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy 
(CALERIE), is evaluating the effects of a 2-year long CR regimen (25% less calories 
than controls) in healthy, non-obese individuals. Preliminary data of this study 
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indicates that similar metabolic and endocrine changes previously observed in rodents 
and rhesus monkeys subjected to CR, are also evident in humans (Heilbronn et al., 
2006; Redman and Ravussin, 2009). The biological outcomes of CR include, but are 
not be limited to, the reduction and clearance of damaged protein, and the decrease in 
chronic inflammation associated with increased circulating free fatty acids, cytokines, 
and chemokines (Balasubramanian et al., 2017; Li et al., 2017a). A more recent report 
stemming from a 2-year randomized controlled trial in non-obese humans subjected 
to CR, provided the first evidence that sustained CR is both feasible and without 
adverse effects on quality of life (Ravussin et al., 2015). The feasibility, safety, and 
effects of sustained CR can be better elucidated from epidemiological and cross-
sectional observations in longer-lived humans, i.e. centenarians, and individuals who 
self-impose CR. Perhaps the most compelling epidemiological support in favour of the 
anti-aging effects of CR in humans is represented by the population of Okinawa 
(Japan) where the mean number of centenarians is generally 4 to 5 times that of most 
industrialized countries (Suzuki et al., 2001; Willcox et al., 2007, 2009). Here, it was 
revealed that these individuals had undergone a mild form of prolonged CR (~20% 
CR) for about half their adult lives (Willcox et al., 2009). The composition of a 
traditional Okinawan diet was shown to be similar to a Mediterranean diet, which is 
known to be beneficial to human health with age (Rosenbaum et al., 2010; Willcox et 
al., 2009). Indeed, elderly Okinawans have been found to have the lowest mortality 
emanating from age-related diseases (Rosenbaum et al., 2010; Willcox et al., 2009). 
Although these reports have provided valuable insight regarding the translatability CR-
induced benefits to humans, studies of longer duration are required to better 
understand the causative factors in age-related disease susceptibility, and to quantify 
the impact of CR in attenuating the deleterious effects associated with advanced age 
in humans. 
 
1.6.2. CR and CMA 
 
Activation of CMA in response to CR is associated with higher levels HSC70 and 
LAMP2A at the lysosomal membrane (Agarraberes et al., 1997; Cuervo et al., 1995a). 
Studies have shown a drastic increase in the percentage of HSC70-containing 
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lysosomes from 40% under basal conditions, to 80% under conditions of prolonged 
starvation or mild oxidative stress in liver (Cuervo et al., 1995a, 1997). In rat liver, CMA 
activity has been found to plateau after 36 hrs of CR, remaining active for 72 hrs 
(Cuervo et al., 1995a). Although basal level of CMA activity can be detected in most 
cell types, maximal activation of this pathway has been demonstrated during 
prolonged starvation in vivo (Cuervo et al., 1995), or serum removal in vitro (Dice, 
1987). While the initial cellular response to starvation has been shown to be the 
activation of macroautophagy, CMA is induced much later (Cuervo et al., 1995a). 
However, for reasons yet unknown, the time course activation of CMA in response to 
starvation is tissue and cell type specific (Wing et al., 1991). The effects CR on lifespan 
have been extensively documented by Nikolai et al. (2015), but the key effectors of 
CR-activated pathways remain largely unknown. Further research is warranted in this 
regard. 
 
1.6.3. Two pathways are better than one 
 
1.6.3.1.  The compensatory response to prolonged CR or starvation conditions 
 
The macroautophagic pathway is extensively interconnected through various 
crosstalk mechanisms which facilitate controlled and well-balanced cellular responses 
to specific stress signals. For example, crosstalk exists between macroautophagy and 
apoptosis (Delgado et al., 2014), macroautophagy and the UPS (Zhan et al., 2016), 
and macroautophagy and CMA (Kaushik et al., 2008; Massey et al., 2006b). The focus 
of this section is on the latter, as there is evidence for a clearly dynamic and temporal 
balance between the two processes (Wu et al., 2015a). Under physiological 
conditions, macroautophagy and CMA both occur at basal levels, but can be 
maximally induced when cells are subjected to starvation conditions (Boya et al., 
2013). Under these conditions, macroautophagy has been found to be rapidly 
upregulated as early as 30 minutes following nutrient deprivation and reaches a 
plateau of maximal activation around 4 to 6 hrs post-starvation (Backer and Dice, 1986; 
Massey et al., 2006b). However, macroautophagy is progressively downregulated 
thereafter, and CMA is consequently upregulated in response to prolonged starvation 
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following 10 hrs onwards (Arias et al., 2015). It has been proposed that differences in 
the levels and time frames of activation may be due to CMA's higher selectivity, which 
enables this pathway to tightly control the choice of proteins degraded (Kaushik and 
Cuervo, 2018). Moreover, maintaining high levels of the less selective 
macroautophagic pathway could quickly tip towards pathologically enhanced activity, 
and become detrimental to cell survival (Kiffin et al., 2004; Zhang and Cuervo, 2008). 
Compensatory activation of macroautophagy has been shown to confer protection in 
CMA-defective cells by maintaining basal levels of protein degradation (Massey et al., 
2006b). Consistent with these findings, further studies by Massey et al. (2008) 
demonstrated that CMA inactivation, mediated through RNAi against LAMP2A, 
increased macroautophagy levels in vitro. However, macroautophagy could only 
partially compensate for CMA function, suggesting that the continuous activation of 
macroautophagy could be detrimental to cell viability (Massey et al., 2008). Therefore, 
there is a need to identify the conditions when this compensatory macroautophagy-
CMA activation can maintain cellular viability, and for how long. Additionally, whether 
neuronal protection can be conferred through the compensatory activation of 
macroautophagy-CMA in neurodegenerative diseases remains unknown.  
 
1.6.3.2.  Compensatory macroautophagy-CMA response in neurodegeneration 
 
Individual proteins were previously thought to follow a particular autophagic pathway 
for their degradation. However, it is now known that macroautophagy and CMA can 
simultaneously, or in a compensatory fashion dynamically contribute to protein 
degradation, depending on the cellular conditions and presence of specific aggregate-











Figure 1.11: Substantial crosstalk exists between (A) macroautophagy, and (B) 
chaperone-mediated autophagy (CMA), with precision defect localization. This calls for 
the need to precisely map and quantify both macroautophagic and CMA fluxes, to correct 
localized impairments in either pathway, and re-establish proteostasis [adapted from (Ntsapi 
et al., 2016)]. 
 
This demands for a crosstalk-based assessment that is inclusive in assessing both 
macroautophagy and CMA fluxes. For example, in an in vitro model of taupathology, 
mutant tau protein was shown to impair CMA function by blocking the LAMP2A 
receptor (Wang et al., 2010). However, CMA impairment was alleviated through the 
compensatory upregulation of macroautophagy which attenuated the aggregation of 
tau fragments, thus providing compelling evidence of a functional interplay between 
macroautophagy and CMA in neurodegeneration (Wang et al., 2010). Using a PC12 
cell model, CMA blockage by mutant α- synuclein, implicated in PD neuropathology, 
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was shown to be partially alleviated by macroautophagy upregulation (Cuervo et al., 
2004). Similar findings were reported in cortical neurons and differentiated SHSY5Y 
cells, where CMA activity was found to be ameliorated by increased levels of 
macroautophagic activity (Xilouri et al., 2009). Further evidence for the interaction of 
both autophagic pathways in the degradation of wildtype α-synuclein was observed 
through the simultaneous inhibition of macroautophagy and CMA which resulted in α-
synuclein accumulation (Vogiatzi et al., 2008; Webb et al., 2003). These results 
suggest that both pathways are important for the degradation of wildtype α-synuclein. 
Importantly, this compensatory upregulation has been found to be compromised with 
age (Schneider et al., 2015). Therefore, it is crucial to fully elucidate the molecular 
machinery that enables macroautophagy-CMA compensatory mechanisms. The 
relationship between macroautophagy and various neurodegenerative diseases has 
been extensively documented in literature (Nixon et al., 2008). Only recently; however, 
it became clear that defined localized defects are present in the onset of AD, PD and 
HD. These defects are defined as: 1) insufficient macroautophagy induction, 2) 
impaired lysosomal hydrolase activity, and 3) macroautophagic dysfunction related to 
dysregulated excessive activation (Cherra and Chu, 2008). Knowing the location of the 
autophagic pathway impairment in each disease is important when designing 
appropriate strategies to overcome the defect. This requires careful dissection of the 
macroautophagy and CMA pathway under physiological conditions, and their 
dysfunction in the context of the protein species driving various pathology. 
 
1.7. The integration of macroautophagy signalling pathways during CR 
 
The physiological changes induced by CR have been extensively characterized with 
the hope of better understanding the basis of the beneficial effects of CR. However, 
have not been clearly defined. This disparity in knowledge is due to, at least in part, 
the complexity of these mechanisms, and the fact that multiple regulatory pathways 
are likely activated to mediate the full range of CR benefits (Masoro, 2009). The 
consensus is that the beneficial effects of CR on longevity are associated with nutrient-
triggered signalling cascades, including the insulin/insulin-like growth factor-1 (IGF1) 
signalling, and the mTORC1 pathway (Balasubramanian et al., 2017). The 
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convergence of CR-triggered pathways on macroautophagy has attracted increased 
attention, as CR is a robust inducer of this process (Bergamini and Gori, 2013). In this 
regard, three highly conserved nutrient and energy sensing signalling pathways are 
thought to converge on mTOR to regulate the lifespan of many species (Rabinowitz 
and White, 2010; Zoncu et al., 2011). The integral role of the Insulin-
IGF1/PI3K/Akt/mTORC1 signalling pathways in CR- mediated longevity is 
underscored by the following lines of evidence: (1) prolonged lifespan has been 
described in response to the Akt deletion in yeast (Fontana et al., 2010), (2) mTORC1 
inhibition results in overall health improvement in yeast, flies, worms and mice 
(Kaeberlein et al., 2005); and (3), genetic manipulation of daf-2 (encoding an insulin 
receptor-like protein) demonstrated that reduced Insulin-IGF1 signalling could 
increase lifespan in invertebrate models (Anisimov and Bartke, 2013). Briefly, under 
nutrient rich conditions, such as excess amino acids, Insulin/IGF1 activates the 
PI3K/Akt signalling pathway, Akt then phosphorylates the tuberous sclerosis complex 
(TSC) and thereby inhibits TSCs GTPase activity. TSC in turn activates Rheb and 
mTORC1, thereby inhibiting macroautophagy induction (Inoki et al., 2002, 2003). 
Inhibition of Insulin-IGF1/PI3K/Akt/mTORC1 pathway during CR plays a central role 
in the induction of macroautophagy, which has been shown to lead to lifespan 
extension in various organisms (Feng, 2010). Apart from decreased signalling through 
the Insulin-IGF1/PI3K/Akt/mTORC1 pathway, the increased signalling through the 
AMPK/SIRT1-FOXO (1/3) pathway has also been shown to be an integral effector of 
CRs beneficial effects (Fig 1.12). Sirtuin 1 (SIRT1, silent information regulator 2 Sir2 
homolog), and AMPK are well established sensors of cellular energy status (Gomes 
et al., 2013). Notably, due to their cross-activation, AMPK and SIRT1 are targets of 
common activators and produce overlapping outcomes, one of which is the stimulation 
of peroxisome proliferator- activated receptor γ co-activator α (PGC1 α), which 
regulates mitochondrial biogenesis and energy expenditure (Brenmoehl and Hoeflich, 
2013). SIRT1 is an evolutionally conserved nicotine amide (NAD+)-dependent 
deacetylase whose transgenic overexpression has been found to prolong lifespan in 
C. elegans, and D. melanogaster (Rogina and Helfand, 2004). SIRT1 can be activated 
by CR, through fluctuations in the NAD+/NADH concentration, or through activators 
such as CR mimetic resveratrol (Nisoli et al., 2005). When nutrients, especially 
glucose, decrease because of CR, NAD+ accumulates and SIRT1 is activated and 
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directly induces macroautophagy, or indirectly activates macroautophagy through 
deacetylation of Forkhead box class O (FoxO) family members 1 and 3, which in turn 
coordinate the induction of macroautophagy (López-Lluch and Navas, 2016). SIRT1 
deacetylates FOXO1 and FOXO3, which are required for the transcriptional activation 
of genes that are involved in autophagosome formation, such as PIK3C3, ATG12, 
ATG4L, BECLIN1, and ULK1 and through direct protein-protein interaction with Atg7 
(Bánréti et al., 2013; Eisenberg et al., 2009). This interplay between protein acetylation 
and deacetylation appears to underlie the role of SIRT1 in CR. 
 
AMPK is also integral to CR’s longevity benefits, as this kinase is activated in response 
to decreased energy or glucose levels, which are consequences of CR (Kahn et al., 
2005). Under CR conditions, AMPK initiates the signalling cascade that stimulates the 
processes to generate ATP through mTORC1 inhibition and subsequent 
macroautophagy induction through phosphorylation of the ULK1 complex as 
previously described (Alers et al., 2012; Kim et al., 2011). Evidence in support of this 
role has been extensively provided using C. elegans, where nematodes 
overexpressing AMPK (aak-2) were found to live longer compared to controls (Greer 
et al., 2007; Schulz et al., 2007). Additionally, glucose restriction increased aak-2 
activity, further prolonging lifespan, thus suggesting that the benefits of CR were 
dependent on aak-2 in the nematode model (Schulz et al., 2007). Based on these and 
other findings, it is plausible to conclude that macroautophagy is universally required 
for the benefits of CR. 
 




Figure 1.12: Potential role of macroautophagy in caloric restriction (CR)-mediated 
longevity. CR causes reduced levels of insulin, IGF and amino acids, and increased levels 
of NAD+ and AMP as a result of diminished energy production and decreased nutrient 
availability. These changes result in the inhibition of the insulin-IGF1/PI3K/AKT/mTOR 
pathway, and activation of the AMPK/SIRT1-FOXO (1/3) pathway. As a consequence of 
diminished mTORC1 activity, protein translation, and overall cell growth would be limited and 
the dynamics of decreased mTORC1 would favour increased macroautophagy to sustain cell 
survival translating in neuronal protection, and ultimately, longevity. TSC, Tuberous sclerosis 
complex [adapted from (Schultz and Sinclair, 2016)].  
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1.7.1.  CR mimetics: targeting macroautophagy induction 
 
Studies of CR in rhesus monkeys have reported beneficial effects of CR on health and 
aging. Specifically, prolonged CR (approximately 30% CR) since young adulthood has 
been found to extend lifespan in rhesus monkeys, which exhibited overall improved 
health; lower incidence of neurodegeneration, cardiovascular disease, type 2 diabetes 
mellitus, and cancer (Colman et al., 2012, 2014). However, recent findings have 
demonstrated that although some of the beneficial effects of CR persist for 2 weeks 
after subsequent ad libitum refeeding in mice, the entirety of CR-mediated effects is 
reversed within 6 months of re-feeding (Giller et al., 2013). This finding suggests that 
long term CR is necessary to continuously maintain its beneficial effects, and that the 
magnitude of maximal lifespan extension is determined by the degree, duration and 
age at which this regime is initiated (Rosenbaum et al., 2010). An alternative approach 
to long-term CR is intermittent fasting (IF) (Goodrick et al., 1990), a dietary regimen 
that alternates between 24 hrs ad libitum food consumption, with 24 hrs of total or 
partial CR (Varady and Hellerstein, 2007). Indeed, studies have shown that IF can 
increase lifespan to an extent similar to that of CR, even when there is little or no overall 
decrease in calorie intake (Bhutani et al., 2010). Although the health and longevity 
benefits of a CR regimen are numerous, it is not without its potential adverse effects 
(Redman and Ravussin, 2011). These include lowered body temperature (Soare et 
al., 2011), slowed wound healing (Hunt et al., 2012), a reduction in resting energy 
expenditure (Blanc et al., 2003), hypotension (Cava and Fontana, 2013), and 
indications of osteoporosis in post-menopausal women (Michaëlsson et al., 1996). 
Nevertheless, emerging evidence indicates that dietary therapies, in which the 
nutritional composition of the restricted diet is carefully monitored, can be safely 
executed in children and adults, and are effective in the attenuation of a variety of 
neurodegenerative diseases (Cervenka et al., 2013). Moreover, there is considerable 
evidence suggesting the role of CR in ‘therapeutic fasting’ to improve general health, 
manage a broad range of chronic diseases, and delay the onset of age associated 
pathologies (Balasubramanian et al., 2017; Lee and Longo, 2016). For these reasons, 
increasing interest is now being shown to determine the efficacy of natural or 
pharmacological alternatives to classical CR, such as the use of CR mimetics (CRM). 
These are compounds that mimic the biochemical and functional effects of CR. These 
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compounds mimic the biological effects of a rigorous CR regimen by reproducing CR-
like beneficial effects on mortality and age-related ailments through the activation of 
selective stress responsive pathways, while circumventing the need to drastically 
reduce food and calorie intake (Mariño et al., 2014; Roth and Ingram, 2015). Such 
compounds, including resveratrol SIRT1 supplementation, 2-deoxyglucose, and 
metformin (Lee and Min, 2013; Selman, 2014), may be of more practical use in humans 
as the implementation of long-term CR regimes may be difficult for most to maintain. It is 
expected that IF regimens or the use of CRM can trigger similar biological pathways 
as CR, and thereby impact the clearance of aggregate toxic protein species in 
neurodegenerative diseases such as AD, PD and HD. 
 
1.8. Treatment strategies 
 
To date, only four compounds have been approved by the FDA for the symptomatic 
treatment of AD (Table 1.2). While these compounds have been shown to improve the 
disease symptoms and may positively impact on the rate of cognitive decline, they do 
not reverse neuronal damage, or prevent cognitive decline in AD (Berk and Sabbagh, 
2013). Hence, a large body of evidence supporting the ACH has led to robust efforts 
dedicated to the development of disease-modifying strategies that either disrupt 
aggregation, promote removal or prevent formation of Aβ (Gao et al., 2016; Sanabria-
Castro et al., 2017). To this end, the feasibility β-secretase inhibitors has been 
considered to be an important therapeutic target. The β-secretase enzyme complex 
participates in the initial stages of the amyloidogenic pathway, and its inhibition has 
been shown to reduce Aβ levels, preventing the accumulation of βCTFs which contain 
the entire Aβ domain and serve as the final substrate for Aβ production (Citron, 2004). 
Indeed, several pharmaceutical inhibitors of this enzyme, such as MK- 8931 (clinical 
trial ID# NCT01739348), E2609 (clinical trial ID# NCT01600859), and LY2886721 
(clinical trial ID# NCT01807026 and NCT01561430) have all shown efficacy in 
reducing Aβ production by 80–90% in the CSF in humans (Folch et al., 2016, 2017). 
Towards the end of 2012, Merck initiated the phase II/III studies of MK-8931 for the 
treatment of AD (Dobrowolska et al., 2014). The safety and efficacy of MK-8931 
versus a placebo was determined in patients with mild and moderate AD, and 
published findings thus far indicate that this drug reduced Aβ40 and Aβ42 CSF levels 
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up to 84%, and was well tolerated by patients (Dobrowolska et al., 2014), but further 
clinical validation of MK-8931 efficacy is still required. One notable challenge that 
continues to impact several β-secretase inhibitors during clinical trials has been their 
propensity to induce off-target toxicity (Vassar, 2014). This is likely due to the role of 
β-secretase in a number of functions including myelination, synaptic plasticity, axon 
targeting, maintaining spine density, neurogenesis, as well as processing of non-APP 
substrates such as neuregulin-1 (Hu et al., 2013; Vassar, 2014). Moreover, findings 
suggest that the use of β-secretase inhibitors may be better suited early in disease 
onset, before the deposition of Aβ plaques, as inhibition of enzyme has been found to 
have no impact on already existing Aβ aggregates (Menting and Claassen, 2014). 
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Table 1.2: Current symptomatic treatments for AD. 
 
Drug AD stages Target            Mechanism of action Side effects 
Donepezil Mild to severe Cholinesterase Prevents acetylcholine  Nausea, diarrhoea, muscle 
  Inhibitor breakdown  cramps, fatigue, weight 
   in the brain loss 
Galantamine® Mild to Cholinesterase Prevents acetylcholine  Nausea, diarrhoea, 
 moderate Inhibitor breakdown  decreased appetite 
   and  
   stimulates nicotinic  
   receptors to release  
   more in the brain  
Memantine Moderate to NMDA receptor Blocks the toxic Dizziness, headache, 
 severe Antagonist effects associated diarrhoea, constipation, 
   with excess confusion 
   glutamate, and  
   regulates glutamate  
   activation  
Rivastigmine Mild to Cholinesterase Prevents acetylcholine  Nausea, diarrhoea, weight 
 moderate Inhibitor breakdown  loss, decreased appetite, 
   in the brain muscle weakness 
[adapted from (Folch et al., 2017) 
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1.8.1. CR-induced macroautophagy and Aβ neurotoxicity 
 
The neurotoxic accumulation of Aβ peptides and subsequent deposition into plaques 
has been shown to be the result of an imbalance between Aβ production and clearance. 
Thus, pharmaceutical targeting of Aβ production through modulation of the 
amyloidogenic pathway has been the overarching focus of AD research efforts for 
more than two decades (Li et al., 2013). However, the failure rate of these 
amyloidocentric agents since 2002, excluding agents currently in Phase 3, is 99.6% 
(Cummings and Fox, 2017). It has been suggested that use of anti-Aβ agents may be 
optimized by intervening earlier in the disease process before neurodegeneration 
begins (Aisen et al., 2013; Vellas et al., 2012). Alternatively, identifying new disease 
pathways more amenable to pharmacologic or physiological manipulation, may 
increase the likelihood of developing effective AD therapies in the future. Increasing 
evidence has demonstrated the neuroprotective role of macroautophagy in mediating 
the degradation of aggregated proteins implicated in AD pathology (Baranello et al., 
2015; Folch et al., 2017). Thus, macroautophagy is thought to be a potential 
therapeutic target to mitigate the effects of Aβ aggregation in neurons, and alleviate 
neurotoxicity (Rubinsztein et al., 2015). Accordingly, targeting Aβ degradation, 
through enhanced macroautophagic activity, instead of targeting its production via the 
amyloidogenic pathway may represent a more viable disease-modifying strategy. 
Indeed, inhibition of macroautophagy activity through Beclin1 deletion has been 
shown to increase Aβ accumulation, extracellular Aβ deposition, and 
neurodegeneration in mice (Pickford et al., 2008). In contrast, enhanced Aβ clearance 
has been observed in response to resveratrol treatment, which has been shown to 
impact Aβ levels through macroautophagy induction in vitro (Marambaud et al., 2005). 
Importantly, studies reveal that the underlying mechanism of CRM-induced 
macroautophagy is mediated, at least in part, through inhibition of the insulin-
IGF1/PI3K/AKT/mTOR pathway, and activation of the AMPK/SIRT1-FOXO (1/3) 
pathway (Heras-Sandoval et al., 2014), the same pathways previously implicated in 
the macroautophagy mediated longevity benefits of CR. 
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1.9. Methods for measuring macroautophagy and CMA activity 
 
1.9.1.  Methods for measuring macroautophagic flux  
 
Taking the above information into account, it becomes clear that the ability to measure 
the macroautophagy process accurately is a critical to understand the degree of 
macroautophagy dysfunction in neurodegeneration. Methodologies used to quantify 
macroautophagy in both in vitro and in vivo experimental systems are continuously 
being developed given the intense medical interest in the role of macroautophagy in 
various diseases. Macroautophagy maintains a basal flux of substrates to lysosomes 
that accelerates during stress or starvation; thus, analysing static levels of 
autophagosome markers does not provide information on macroautophagy activity. In 
contrast, measuring macroautophagic flux that reveals the net amount of substrate 
delivered to lysosomes per unit time, provides information to what extent 
macroautophagy is active or inhibited (Loos et al., 2014). Recent developments 
focusing on molecular tools that measure macroautophagic flux are continually being 
updated, suggesting new ideas for linking proteostasis and the loss thereof with cell 
death onset (Klionsky et al., 2016; Loos et al., 2014). Updated overviews on how to 
more precisely measure the macroautophagic flux in vitro and in vivo have been 
extensively described (Klionsky et al., 2016; Yoshii and Mizushima, 2017). Here, we 
only shortly summarize the markers and inhibitors that are most commonly used for 
fundamental macroautophagic flux measurements (Table 1.3). 
 
Measurement of macroautophagic flux depends on the ability to distinguish between 
autophagosome formation and the completion of macroautophagy through lysosome 
fusion and degradation. To distinguish between these processes, one can block either 
the synthesis or degradation of autophagosomes using common autophagic inhibitors, 
such as bafilomycin A1, hydroxychloroquine and NH4Cl, all of which alter lysosomal 
pH, thereby blocking autophagosome-lysosome fusion, resulting in the accumulation 
of autophagosomes which are unable to fuse with lysosomes. Other lysosomal 
inhibitors include leupeptin, pepstatin A, and E64d, which can be used in combination 
to inhibit lysosomal proteases for longer periods of time (Yang et al., 2013). The 
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lipidation of LC3 can be demonstrated by western blot analysis, upon an increase in 
autophagosomes, the LC3 band will shift from LC3I (18kDa) to LC3II (16kDa) on SDS-
PAGE (Tanida et al., 2005). Compounds such as 3-methyl adenine (3MA), 
Wortmannin and LY294002 can inhibit autophagosome synthesis through inhibition of 
the PI3KC3 complex, which activates the macroautophagy machinery (Pasquier, 
2016). In this scenario, if LC3 is still lipidated by the experimental condition in the 
presence of these inhibitors, this would imply that autophagosome-lysosomal fusion 
is impaired, as inhibition of synthesis should result in a decrease in 
LC3II/autophagosome formation (Mizushima and Yoshimori, 2007). Caution should 
however be applied when using 3MA, as it has a time-dependent dual effect on 
macroautophagy, whereby class 1 PI3K, a kinase which triggers mTORC1 signalling, 
is persistently blocked while 3MA’s inhibition of class III PI3K is transient (Wu et al., 
2010). Levels of p62 can also be used as an indirect measure of functional 
macroautophagy since p62 accumulates when macroautophagy is defective. 
However, macroautophagy-independent regulation of p62 makes this a less robust 
readout of macroautophagic flux (Barth et al., 2010). In addition to measuring 
macroautophagic flux by western blot analysis, it is recommended to routinely perform 
intracellular staining for endogenous LC3. In unstressed cells, LC3 is expressed 
ubiquitously and is detected in a diffuse pattern in the cytoplasm of cells by 
immunofluorescence. As a result of elevated macroautophagy, this staining pattern 
changes from largely diffuse to predominantly punctate structures (Mizushima, 2004). 
Quantification of LC3- positive puncta is thus also used to measure increases in 
macroautophagy flux when experiments are performed in the presence and absence 
of bafilomycin A1 or hydroxychloroquine. Co-staining with other antibodies can also 
be performed to determine whether a putative macroautophagic substrate colocalizes 
with LC3-positive autophagosomes to examine the maturation state of 
autophagosomes in cells. For example, LC3 can be co-stained with LAMP2A to 
examine when autophagosomes overlap with lysosomes as a measure of functional 
macroautophagy. Similar approaches can be utilized to examine the fusion process 
of endosomes, e.g. using Rab5, or Rab7 as endosomal markers, with LC3-positive 
autophagosomes to characterize pathways that interact with macroautophagy. 
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Expression of exogenously introduced green fluorescent protein (GFP)-fused LC3 
provides a convenient method for measuring macroautophagy both qualitatively and 
quantitatively by measuring the punctate green fluorescence structures in stably 
transfected cells (Loos et al., 2014; Sharifi et al., 2015), and in transgenic mice 
expressing GFP–LC3 under the constitutive CAG promoter to aid macroautophagy 
studies in vivo (Mizushima, 2004). In transfected cells, GFP-LC3 is expressed as 
punctate signals, observed by fluorescence microscopy as ring-shaped structures or 
dots. It should however be noted that while GFP is a stably folded protein in the cytosol 
and lumen of early autophagosomes, its fluorescence is quenched by the low pH inside 
the lysosome and LC3 degradation inside autophagolysosomes. To overcome this 
limitation, Kaizuka et al. (2016) recently developed a fluorescence probe, GFP-LC3-
RFP-LC3ΔG, to directly demonstrate macroautophagic flux without being combined 
with lysosomal inhibitors. When expressed in transfected cells the probe is cleaved 
into a degradable/quenchable part, i.e.GFP-LC3, and stable/cytosolic part, i.e. RFP-
LC3ΔG. The latter serves as an internal control and a decrease of the GFP: RFP ratio 
indicates the occurrence of macroautophagy flux (Kaizuka et al., 2016). The 
degradation of GFP-LC3 can also be used to measure the cumulative effect of basal 
macroautophagy. Using the transgenic GFP–LC3 mouse model, occurrence of 
macroautophagy can be directly monitored by creating tissue cryosections and 
analysing these by fluorescence microscopy. Overexpression of GFP-LC3 is found in 
all tissues where the level of GFP-LC3 is comparable to the endogenous LC3 
expression (Alirezaei et al., 2010), with low expression thereof suggesting a rapid 
turnover of autophagosomes (Boland et al., 2008). However, caution should be taken 
when interpreting the GFP signal, because GFP-LC3 overexpression can generate 
protein aggregates, and cells possess autofluorescent punctate structures such as 
lipofuscin that are also detectable in the green spectrum. To avoid these artefacts, 
GFP-LC3 transgenic mice cryosections are compared with non-transgenic control 
littermates, with GFP fluorescence only detected using FITC filter sets (Mizushima, 
2009). A list of other transgenic mice models has been described for more targeted 
macroautophagy flux measurement in vivo (Moulis and Vindis, 2017). 
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Aside from measuring LC3II and p62 using biochemical methods, macroautophagy 
can also be semi-quantitatively analysed using transmission electron microscopy 
(TEM). TEM facilitates the numerical quantification of the number of autophagosomes 
formed and measures the surface area of each autophagolysosome structure 
(Eskelinen and Kovács, 2011). These structures, including the sequestration of 
specific substrates by autophagosomes, such as mitochondria, and AVs structures, 
can be distinctly analysed and quantified for macroautophagic flux if cells are 
incubated with lysosomal inhibitors (Eskelinen et al., 2011). Upon macroautophagy 
induction, the number of degradative compartments increases and the quantification of 
the number of autophagolysosomes, lysosomes and amphisomes per cell section, 
provides a simple morphological readout (Klionsky et al., 2016). However, it can be 
difficult to distinguish between autophagolysosomes, lysosomes and amphisomes, 
and the consensus in such cases is to classify all these organelles together, as AVs 
structures (Klionsky et al., 2016). It is thus critical that more than one experimental 
approach is used in parallel to obtain a firm conclusion whether there is a change in 
macroautophagic flux. Moreover, the choice of experimental model system is key for 
the achievement of a successful outcome, as different mammalian cell lines and 
tissues exhibit varying degrees of basal macroautophagy and show distinct capacities 
to increase their rates of macroautophagic flux in response to various stressors 
(Mizushima, 2010). 
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Table 1.3: Current methods for monitoring macroautophagic flux. 
 
 Expected Results 









IHC → ↑ ↓ ↑ 
LC3II level WB → ↑ ↓ ↑ 
Morphology AP/AL detection TEM AP → AP ↑ AP ↓ AP ↑ 






LC3II turnover WB → ↑ ↓ ↓ 
p62 level IHC/WB → ↓ ↑ ↑ 
mCherry-GFP-
LC3 
IHC/FM Red → Red ↑ Red ↓ Red ↓ 
Yellow → Yellow ↑ Yellow ↓ Yellow ↑ 
mCherry-GFP-LC3, tandem fusion of LC3 to the acid-insensitive mCherry (Red) and the acid-sensitive GFP (Green). At first, both GFP and 
mCherry are detected in autophagosomes, which appear as yellow puncta. Once autophagosomes fuse with lysosomes, the green 
fluorescence is quenched because of the degradation of GFP by acid lysosomal proteases, resulting in LC3 emitting only red fluorescence. 
The dynamic switch from yellow to red fluorescence indicates a functional macroautophagic flux. AP, autophagosome; AL, autolysosome; 
IHC, immunohistochemistry; FM, flow cytometry; TEM, transmission electron microscopy; WB, western blotting. Inhibition of synthesis refers 
to early step macroautophagy suppression, and inhibition of degradation refers to late step macroautophagy suppression. ↑ indicate an 
increase, ↓indicates a decrease, → indicates no change [adapted from (Zhang et al., 2013)]. 
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1.9.2.  Methods for measuring CMA activity 
 
Most cells have a basal level of CMA activity, and cellular stressors such as oxidative 
stress (Kiffin et al., 2004), lipotoxicity (Rodriguez-Navarro et al., 2012), nutrient-
limitation (Cuervo et al., 1995a), and proteotoxicity (Koga et al., 2011a) have been 
shown to upregulate CMA. The connection between CMA and different human 
diseases has seen a growing interest to finely quantify CMA flux in different model 
systems and manipulate its activity for therapeutic purposes. For example, reduced 
CMA activity has been described in several age-related neurodegenerative diseases 
(Cuervo and Dice, 2000a), diet-induced obesity (Rodriguez-Navarro et al., 2012), and 
diabetes (Sooparb et al., 2004). In contrast abnormal upregulation of CMA activity is 
common in many types of cancer (Kon et al., 2011). However, unlike macroautophagic 
flux measurement, the study of CMA flux measurement is still in its infancy, and most 
of the current assays have been developed and optimized by Cuervo and colleagues 
(Arias, 2017; Kaushik and Cuervo, 2018). Commonly used assays include the 
following: (1) steady-state readout of CMA using western blot and 
immunofluorescence analysis to assess the expression and distribution of key CMA 
proteins, using antibodies that can specifically recognize the cytosolic tail of LAMP2A, 
and lysosomal-HSC70 (Agarraberes et al., 1997). CMA activity can also be tracked 
over time using photoconvertible fluorescent reporters, including photoswitchable 
KFERQ-ps-CFP reporter in which fluorescence switches from CFP to GFP upon 
exposure to 405nm light, and the photoactivatable KFERQ-PA-mCherry1 reporter 
which becomes fluorescent upon exposure to 405nm light (Koga et al., 2011b). 
Changes in the number of fluorescent puncta per cell represent a readout of CMA 
activation and may vary depending on the cell type and their level of basal CMA 
activity. CMA can finely be measured when working with isolated lysosomes from cells 
or tissues, in the presence and absence of inhibitors of lysosomal proteases such as 
leupeptin (Schneider et al., 2014). CMA-substrate flux can be quantified using [14C]-
radiolabelled CMA substrates, e.g. GAPDH, or even a pool of long-lived radiolabelled 
cytosolic proteins (common CMA substrates) which can be incubated with purified 
isolated lysosomes, and their association and degradation in the lysosome can be 
monitored by free [14C]-radiolabelled amino acids released in the incubation media as 
proteolysis occurs (Terlecky et al., 1992). By comparing degradation of these 
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substrates, it is possible to distinguish substrate uptake and degradation through CMA 
pathway induction (Cuervo et al., 1997). However, such assays are both labour and 
resource intensive and require a high level of expertise as a large number of cultured 
cells or tissue is required to isolate and purify a sufficient number of CMA-active 
lysosomes (lysosomes containing both LAMP2A and HSC70). 
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1.10.  Thesis outline 
 
Although much has been learnt about the role of macroautophagy dysfunction in AD, 
the relationship between APP pathology and macroautophagy remains unclear. In 
particular, how macroautophagy activity changes in the disease progression, and 
whether both macroautophagy and CMA are equally implicated, remains unknown. 
 
Using an in vitro and in vivo model of AD, the overarching aims of this project are 
therefore: 
 
i. To characterize the expression profile of key proteins in amyloidogenesis, 
macroautophagy, CMA, and proteins implicated in the execution of apoptosis 
using a unique APP overexpression model system. 
ii. To characterise the impact of early and late APP overexpression on the proteome. 
iii. To assess macroautophagic flux in the context of APP overexpression and to 
unravel the extent of macroautophagy dysfunction with disease progression. 
iv. To assess the contribution of macroautophagy and CMA in Aβ clearance and 
neuronal toxicity by modulating each pathway. 
v. To assess the effects of intermittent fasting on the modulation of 
macroautophagy and CMA activity in a paraquat-induced in vivo brain injury 
model. 
 
It is hypothesized that increased Aβ production, as a consequence of APP 
overexpression, will decrease macroautophagy activity and cell viability over time. 
Conversely, implementation of CR will induce a compensatory macroautophagy-CMA 
response which mitigates Aβ neurotoxicity, translating to neuronal protection. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1.  Reagents and consumables 
 
Nunc ™ Lab-Tek™ II Chamber Slide™ 8-chamber dishes (#154534) were purchased 
from ThermoFisher Scientific (TFS). Sterile T175 (175 cm2, #431080), T75 (75 cm2, 
#708003), and T25 (25 cm2, #707003) cell culture flasks were purchased from 
Whitehead Scientific (Winelands, Stikland). Tissue culture falcon tubes, including 15 
ml (#50015) and 50 ml (#50050), and cell culture plates (96 (#30096), 48 (#30048), 24 
(#30024), 6 (#30006) well – plates; flat and round bottom) were all purchased from 
Bio-Smart Scientific (Edgemead, Cape Town). Sterile serological pipettes, including 5 
ml (#326001), 10 ml (#327001) and 25 ml (#328001) were purchased from B&M 
Scientific (Parow, Cape Town). Pipette tips and Eppendorf tubes were also purchased 
from B&M Scientific. Other consumables are listed in Table 2.1, and the formulations 
of routinely used solutions is described in Table A.1. 
Table 2.1. List of reagents and consumables used in the study. 
Reagents/products Company Catnr# 
APS Sigma Aldrich A3678-25G 
Bromophenol Blue Sigma Aldrich SAAR1437500CB 
2-Mercaptoethanol Sigma Aldrich M6250 
n-Pentane Merck 1.07177.1000 
Potassium chloride Merck SAAR5042020EM 
Sodium hydroxide Sigma Aldrich S5881-500G 
Sodium chloride Merck 1.06404 
SDS Sigma Aldrich L3771 
Temed Merck 1.10732.0100 
TGX Stain-Free™ Fast Cast™ 
Acrylamide Kit, 12% 
Bio-Rad Laboratories 1610185 
Trans-Blot® Turbo Midi PVDF Transfer 
Packs 
Bio-Rad Laboratories 1704157 
Clarity™ ECL Western Blotting 
Substrate 
Bio-Rad Laboratories 1705061 
Triton X-100 Sigma Aldrich T8787 
Glycerol Merck SAAR2676520 
Hoechst 33342 Stain solution Sigma Aldrich H6024 
Mounting media Diagnostech S302380 
Spar Fat Free Long-Life Milk Local Spar - 
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Running buffer Bio-Rad 161-0772 
Prestained Protein Ladder Biocom Biotech PM007-0500 
cOmplete™ Protease Inhibitor Sigma Aldrich 11873580001 
NP40 Sigma Aldrich 74385-1L 
NaF Merck 193270 
Na3VO4 Sigma Aldrich S6508 
PMSF Sigma Aldrich 93482-50ml -F 
Tween-20 Sigma Aldrich P1379 
BSA Sigma Aldrich 10735078001 
Cell scrapers Whitehead Scientific 710001 
Microscope slides Sigma Aldrich BR474701 
Coverslips Sigma Aldrich Z692263 
Cryovials Scientific Group 430658 
DMSO Whitehead Scientific D2650 
Opti-MEM Reduced Serum Media ThermoFisher Scientific 31985047 
DMEM LifeTechnolgies 41965-062 
Fetal Bovine Serum (FBS) Biocom Biotech FBS-G1-12A 
PenStrep LifeTechnolgies 15140-122 
Trypsin-EDTA LifeTechnolgies 25200072 




A list of primary antibodies used for western blotting, and immunofluorescence 
analysis is presented in Table 2.2. All primary antibodies were purchased either from 
Cell Signalling Technology Inc. (Danvers, Massachusetts), or Abcam Inc. (Pretoria, 
South Africa). All primary antibodies were used at a 1:1000 dilution in a 5% BSA in 1x 
TBS-T solution, and 1:200 dilution in a 5% BSA in 1x PBS‐T solution for western blot 
and immunofluorescence analysis, respectively. 
 
Table 2.2. Primary antibodies. 
Antibody Company/Catnr# Host species Size (kDa) 
APP (NAB228) Cell Signalling #2450 Mouse monoclonal IgG2a 100-140 
APP Cell signalling #2452 Rabbit polyclonal IgG 100-140 
Amyloid beta (Aβ) Cell signalling #2454 Rabbit polyclonal IgG 5 
LC3B Cell Signalling #2775 Rabbit polyclonal IgG 16, 18 
SQSTM1/p62 Abcam #ab155686 Rabbit polyclonal IgG 62 
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Lamp2a CMA selective Abcam #ab18528 Rabbit polyclonal IgG 140 
HSC70 CMA selective Abcam #ab2788 Mouse monoclonal IgM 70 
Cleaved-PARP Asp 214 Cell Signalling #9541 Rabbit polyclonal IgG 89 
Total Capase-3 (Asp175) Cell Signalling #9661 Rabbit polyclonal IgG 35 
Ubiquitin (P4D1) Cell Signalling #3936 Mouse monoclonal IgG1 40-200 
4-hydroxy-2-nonenal Abcam #ab46545 Rabbit polyclonal IgG 52-76 
cytochrome c (136F3) Cell Signalling #4280 Rabbit polyclonal IgG 14 
 
A list of Horse Radish Peroxidase (HRP)- and Fluorophore-conjugated secondary 
antibodies used for western blotting, and immunofluorescence analysis, respectively, 
is presented in Table 2.3. HRP, and Fluorophore-conjugated secondary antibodies 
were purchased from Cell Signalling and ThermoFisher Scientific (Pittsburgh, 
Pennsylvania), respectively. 
 
Table 2.3. Secondary antibodies. 
HRP‐conjugated 
Antibody Company/Catnr# Western Blotting dilution 
Anti‐mouse IgG Cell Signalling # CST7076S 1:10 000 in 1x TBS-T 
Anti‐rabbit IgG Cell Signalling # CST7074S 1:10 000 in 1x TBS-T 
Fluorophore‐conjugated 




Alexa 568 ThermoFisher Scientific # 
A-10042 
1:200 in 5% BSA 
Donkey anti-Goat 
FITC 
Alexa 647 ThermoFisher Scientific # 
A-21447 





ThermoFisher Scientific # 
A-21295 
1:200 in 5% BSA 
Donkey anti-Mouse 
FITC 
Alexa 568 ThermoFisher Scientific #A-
10037 
1:200 in 5% BSA 
Donkey anti-Rabbit 
FITC 
Alexa 488 ThermoFisher Scientific #F-
2761 
1:200 in 5% BSA 
Routinely used fluorophores for immunofluorescence labelling 
Fluorophore Dye Absorbance wavelength Emission wavelength Visible colour 
Alexa Fluor 488 494 517 Green 
Alexa Fluor 568 578 603 Red 
Alexa Fluor 594 590 617 Red 
Alexa Fluor 647 650 670 Red 
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2.2. Cell culture and treatments 
 
2.2.1. Cell culture propagation 
 
Three stably transfected mouse neuroblastoma cell lines, N2a wild-type cells stably 
transfected with the wild-type human APP695 plasmid (N2awt/APPwt); Swedish 
mutant form of the APP695 plasmid (N2aswe/APPswe); and N2a cells transfected with 
an empty vector-(N2avec/APPvec) (Sisodia et al., 1990), were kindly provided by 
Professor Sangram Sisodia (Department of Neurobiology, University of Chicago, 
USA). The generation of these cell lines has been extensively described by Lo et al. 
(1994). Briefly, the APPwt plasmid was generated by subcloning a DNA fragment 
encoding wild-type human APP695 with a carboxyl (COOH)-terminal epitope tag of 12 
amino acids from the c-Myc oncoprotein at the COOH terminus of APP downstream of 
a cytomegalovirus (CMV) promoter in plasmid pCB6 (ATCC, #37274). The N2aswe 
plasmid was generated by subcloning a DNA fragment encoding Myc epitope- tagged 
human APP695 containing the Swedish Familial AD-specific amino acid substitutions 
(K595N→M596L) downstream of a butyrate-inducible CMV in pCB6 for finer 
transcriptional control of the APP transgene induction. The pCB6 vector contains a 
gene encoding resistance to the neomycin analogue, stable pAPPwt and pAPPswe 
transfectants were therefore selected in medium containing 0.4 mg/ml G418 (Chen 
and Okayama, 1987). 
 
The N2aswe cell line has been extensively used in the characterization of various 
disease pathology related to Aβ neurotoxicity, revealing valuable clues towards the 
elucidation of AD-related neuropathogenesis (Lee et al., 2015; Salto et al., 2015; 
Schlachetzki et al., 2013). In accordance with the manufacturer's instructions, these 
cells were optimally cultured in growth media containing an equal volume of 
Dulbecco’s modified Eagle’s medium (DMEM, Gibco®) and OptiMEM Reduced Serum 
Media (Gibco®) supplemented with 5% fetal bovine serum (FBS, Gibco®), and 1% 
Penicillin-Streptomycin (solution stabilized with 10,000 U penicillin, and 10 mg 
streptomycin/ml; PenStrep). To induce the butyrate-inducible CMV promoter-driven 
APP transgene expression, N2aswe cells were treated with 1 mM to 10 mM butyric 
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acid (sodium salt, BA), with 5 mM BA showing a significant increase in APP expression 
following 12 and 24 hr treatment with minimal cytotoxic effects (Lo et al., 1994, 1995; 
Ramalho et al., 2006). Experiments were performed at a cell passage of 6 to 12. 
 
2.2.2. Thawing of cryopreserved cells 
 
Cryovials containing ~1x106 N2a cells were rapidly thawed in 37°C pre-warmed water, 
and the cell suspension was gently added to 12 ml pre-warmed growth media in a T75 
cell culture flask which was stored in a humidified incubator with 5% CO2 at 37°C. After 
2 hrs, the growth media was aspirated to remove dimethyl sulfoxide (DMSO) from the 
media, as DMSO is toxic to growing cells. The adhering cells were then replenished 
with 12 ml pre-warmed growth prior to being placed in the incubator under the 
described conditions. Cells were passaged twice weekly through trypsinization with 
0.25% Trypsin-EDTA (Gibco®) at a 1:5 ratio in a T75 flask, or once weekly at a 1:20 
ratio in a T25 flask. 
 
2.2.3.  Passaging of cells 
 
For passaging of cells grown in T75 flasks, growth media was aspirated from the flask 
and the cell monolayer was briefly rinsed with 5 ml pre-warmed 1x phosphate buffered 
saline (PBS) (ADDENDUM A Table A.1) to remove residual media. Subsequently, 
cells were briefly detached by adding 4 ml pre-warmed 0.25% Trypsin-EDTA to the 
flask, which was then allowed to incubate for ~5 min at 37°C with gentle agitation. Cells 
were then visualized under an Olympus CKX41 light microscope (Olympus) to ensure 
visible cell detachment from the flask surface area. The trypsin reaction was 
immediately neutralized by adding pre-warmed growth media to the dissociated cells 
(2x the volume relative to trypsin used), and this cell suspension was then transferred 
to a 15 ml falcon tube, which was then spun in a centrifuge for 5 min at 1500 RPM at 
room temperature (RT). The cell supernatant was removed, and the pellet was 
resuspended in 1 ml pre-warmed growth media and the cells were counted using a 
Neubauer-improved haemocytometer coverslip (Sigma Aldrich) with 0.1 mm sample 
depth. The Neubauer chamber was prepared by placing a sterile coverslip in the 
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middle of the chamber. A 10 µl volume of homogenous cell suspension was 
transferred to the edge of the Neubauer counting chamber, and this suspension was 
then drawn by capillary action under the cover slip. The chamber was then placed 
under the Olympus CKX4 inverted light microscope, and cells were individually counted 
in all 4 quadrants using the 40x objective lens. The volume of cells was determined 
using the following calculation: cells/ml = (number of cells counted/4) x dilution factor 
x 104 
After counting, cells were seeded at the desired volume into appropriate pre-labelled 
experimental plates and/or flasks containing pre-warmed growth media. Throughout 
this study, cells were cultured in a humidified incubator, with a CO2 concentration held 
at 5%, and a temperature of 37◦C. 
 
2.2.4.  Cryopreservation of cell lines 
 
Cryopreservation of cells was routinely performed to ensure long term maintenance of 
N2a cell lines. Confluent cells were detached from the culture plate/flask following the 
procedure for cell passaging. After centrifugation, the cell pellet was resuspended in a 
predetermined volume of pre- chilled, freshly prepared freezing mixture consisting of 
90% fetal bovine serum (FBS), 10% DMSO (Sigma Aldrich). A volume of 1 ml cell 
suspension, containing 1x106 cells, was transferred into a pre-labelled 1.2 ml cryovial 
using a sterile pipette tip (P1000 micropipette). These cryovials were stored at -80°C 
overnight to for allow slow cooling and avoid crystal formation. The following day, the 
cryovials were transferred to a liquid nitrogen tank for long-term storage. 
 
2.3.  Categorisation of N2a cell treatment groups 
 
N2avec cells were used to validate the level of APP expression, expected for the 
N2awt cells, and the N2aswe APP overexpression model. N2awt cells were used as 
a control for N2aswe cells in selective experiments. Given that the N2awt Myc 
expression vector is not driven by the butyric acid (BA)-inducible CMV promoter, 
N2aswe BA untreated cells, i.e. control, was thought to be a more appropriate control 
for the BA induced N2aswe-myc expression vector as performed previously by others 
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(Sinha et al., 1999; Yan et al., 2012). Pure BA is a carboxylic acid, shown to play 
several beneficial roles in the treatment of gastrointestinal infections (den Besten et 
al., 2013). Sigma Aldrich supplies pure BA for research purposes owing to its 
stimulatory effects on CMV driven transgene expression, as shown for the N2aswe 
Myc expression vector following BA treatment (Lo et al., 1994, 1995). For experimental 
purposes, cells were passaged when ~80% confluent as described in section 2.2.3. 
After counting, 5x105 N2aswe and N2awt cells were seeded into pre-labelled T75 
flasks, or culture plates and allowed to adhere overnight. 
 
2.3.1.  Treatment groups for macroautophagy and CMA modulation 
 
Cells were treated with the following treatment compounds in accordance with the 
study aims. 
 
Table 2.4. Treatment compounds. 
Treatment compounds Company Catnr# Working concentration 
Butyric acid (BA) Sigma Aldrich B103500 5 mM 
2-Deoxy-D-glucose (2DG) Sigma Aldrich 407248 5 mM 
3-Methyladenine (3MA) Sigma Aldrich M9281 5 mM 
Bafilomycin A1 (BafA1) Lkt® Laboratories B0025 400 nM 
 
Treatment groups were defined as follows: 
1. Control 
2. 12, 24, 36, or 48 hrs BA treated groups 
3. 6 or 12 hrs 2-DG treated groups 
4. 6, 12, 18, 24, or 30 hrs 3MA treated groups 
5. 2 hrs BafA1 treated group 
 
Combination groups were selected as described in appropriate results chapter. 
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2.4.  Cell viability 
 
A ready-to-use cell proliferation reagent (#11644807001), containing WST-1 {4- [3-(4- 
iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate} and an 
electronic coupling reagent, diluted in phosphate buffered saline (Roche Diagnostics) 
was used to measure cell viability. This calorimetric assay is based on the cleavage 
of the tetrazolium salt WST-1 (slightly red) to formazan (dark red) by various 
mitochondrial dehydrogenase enzyme. An increase in metabolically healthy cells is 
accompanied by increased absorbance signal detected at the wavelength of 450 nm, 
while a decrease in signal can indicate a decrease in metabolically healthy cells in 
response to the cytotoxic effects of treatment compounds. To perform WST-1 assays, 
2x105 N2aswe and N2awt cells were seeded into 48-well plates containing 200 ul pre-
warmed growth media and allowed to adhere overnight. Culture media was aspirated 
the following day, and cells were treated as described in section 2.3.1. Following 
completion of the various treatment protocols, 10 µl pre-warmed WST-1 reagent was 
added directly to each 200 µl test-compound containing well, and the cells were 
incubated at a temperature of 37◦C for 2 hrs. Subsequently, the culture plates were 
gently shaken for ~5 min and the colorimetric readings were recorded using the EL800 
universal microplate reader (BioTek Instruments Inc), at a wavelength of 595 nm. The 
calorimetric readings were then exported using the KC Junior software (Bio-Tek 
Instruments Inc.). The treated versus untreated control readings were subtracted from 
the background control. The results were expressed as a percentage of the optical 
density of treated versus untreated controls. The optical density values corresponding 
to the control cells were recorded as 100%. 
 
2.5.  Western blot analysis of cells 
 
2.5.1. Protein extraction and cell lysis preparation 
 
After completion of the appropriate incubation period, growth media was aspirated 
from T75 culture flasks and cells were harvested by trypsinization method as previously 
described. Resuspended cells were transferred to 15 ml tubes and centrifuged at 1500 
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RPM for 5 min at room temperature (RT). After centrifugation, the 15 ml tubes were 
placed on ice, the supernatant was removed, and the cell pellet was resuspended in 
500 µl cold 1x PBS. The cell suspension was then transferred to pre-chilled 1.5 ml 
Eppendorf tubes and centrifuged at 1500 revolutions per minute (RPM) for 5 min at 4°C. 
The cell pellet was washed in 1x cold PBS and centrifuged 3x prior to being 
resuspended in pre-chilled radio immunoprecipitation assay (RIPA) buffer 
supplemented with phosphatase inhibitors (ADDENDUM A Table A.1), and EDTA-
free protease inhibitors (1x Complete protease inhibitor mixture, Sigma-Aldrich) (as 
per manufacturers protocol). Depending on the size of the cell pellet, 50-200 µl cold 
RIPA lysis buffer was added, and the cells were gently resuspended in this buffer to 
achieve a homogenous suspension of cells and lysis buffer. The cell suspension was 
then allowed to incubate for 15 min on ice. The cell suspension was sonicated on ice 
at an amplitude of 5 for 2-3 sec bursts followed by a 30 min cooling interval. To pellet 
the cell debris, cell lysates were centrifuged at 8000 RPM for 10 min at 4°C. The 
supernatant containing total protein lysates was then collected and transferred to a 
fresh pre-chilled microcentrifuge tube and stored at -80°C for future utilization. 
 
2.5.2. Determination of protein concentration 
 
Stored at -80oC, cell lysates were placed on ice to slowly thaw. For measuring cell 
concentration, the lysates were diluted 1:10 in distilled water (dH2O) to avoid the 
sample being too concentrated for accurate measurement. To determine protein 
concentration, each sample was gently vortexed, and the concentration was 
determined using the Direct Detect™ system (EMD Millipore). This is an infrared (IR)-
based spectrometry system used to determine the quantity of protein (0.25–5 mg/ml), 
and lipid content present in biological samples based on their separable IR spectra 
(Strug et al., 2014). The IR - based spectrometer employs an innovative hydrophilic 
polytetrafluoroethylene (PTFE) membrane card technology that is transparent in most 
of the infrared spectral region. The protein concentration is determined by loading 2 µl 
of cell lysate solution and blank buffer solution, which is usually fully supplemented 
RIPA lysis buffer, directly onto a blank PTFE card according to manufacturer’s 
protocol. Briefly, the card content is measured by inserting the card into the sampling 
accessory slot of the Direct Detect™ spectrometry system. The instrument then dries 
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the loaded sample card and proceeds to measure each sample for its respective lipid, 
detergent and protein concentration. The results of these measurements are then 
graphically represented using the Direct Detect Data Export Software™. 
 
2.5.3.  Protein separation  
 
During western blotting, proteins are immobilized on a membrane and labelled by 
complexing with primary antibodies followed by incubation with horseradish 
peroxidase conjugated secondary antibodies. To this end, proteins were fractionated 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE; Mini-
PROTEAN® Tetra cell, Bio-Rad) at a voltage of 100-120 V and current of 200 mA 
(Bio-Rad Power Pac 1000) until the migration front reached the bottom of the gel. 
Resolved proteins were then electro-transferred onto polyvinylidene fluoride 
membrane (PVDF; Immobilon, Millipore, USA) using a horizontal semi-dry 
electrotransfer system (Bio-Rad Trans-blot® SD, USA) at voltage of 15 V and constant 
current of 0.5 A (Bio-Rad Power Pac 1000). Alternatively, a vertical wet transfer system 
(Mini- Trans blot cell, Italy) was used when electrotransfer was performed using a 
voltage of 200 V and constant current of 200 mA (Bio-Rad Power Pac™ HC). Briefly, 
after determining the exact concentration of each lysate sample, a cell lysate volume 
containing 50 μg/ul of protein was diluted in Laemaelli’s loading buffer (ADDENDUM 
A Table A.1) at a ratio of 2:1. The addition of the anionic detergent sodium dodecyl 
sulphate (SDS) in Laemaelli’s loading buffer causes denaturation of the tertiary 
structure of the protein, hence, all the proteins become negatively charged by their 
attachment to the SDS anions. Glycerol is added to the loading buffer to increase the 
density of the sample to be loaded, thereby maintaining the sample at the bottom of 
the well, restricting overflow and uneven gel loading. Bromophenol blue is added to the 
loading buffer to enable visualization of the migrating proteins and the separation 
progress. 
 
2.5.3.1. Western blotting procedure 
 
After brief vortexing, cell lysates were boiled for 5 min at 95oC and resolved using a 
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12% TGX Stain-Free Fast Cast SDS–PAGE gel (Bio-Rad). After polymerization, the 
fast cast gels were placed in a Mini-PROTEAN Tetra System (Bio-Rad Laboratories 
Inc., USA) and filled with running buffer (ADDENDUM A Table A.1). The first lane 
position on each gel was loaded with 4 µl of BLUeye® Prestained Protein Ladder 
(Biocom Biotech) to aid with molecular weight determination for specific protein bands. 
The second lane was loaded with a control sample, and subsequent lanes contained 
samples from treated groups. Proteins were separated for 10 mins at 100 V, followed 
by 1 hr at 120 V until the Laemaelli’s loading buffer reached the bottom of the gel. 
 
2.5.3.2.  Protein probing and signal detection 
 
Following protein separation, the SDS–PAGE gel was carefully removed from the 
electrophoresis chamber and placed on the ChemiDoc™ Imaging System (Bio-Rad 
Laboratories Inc., USA) for stain-free gel activation. Subsequently, resolved proteins 
were electro-transferred onto PVDF membranes using the semi-dry electrotransfer system 
for 7 mins at voltage of 15 V and constant current of 0.5 A. The membrane was then 
visualized using the ChemiDoc™ Imaging System to ensure proper electrotransfer, and 
thereafter soaked in methanol for 60 secs to allow the membrane to tightly interact 
with the transferred proteins. After washing the membrane 3x in 1x TBS-T 
(ADDENDUM A Table A.1) for 5 min, the membrane was blocked in 5% fat-free milk 
in 1x TBS-T to prevent nonspecific antibody binding, blocking was performed with 
gentle agitation for 1 hr at RT. Following the 1 hr blocking period, the membrane was 
then washed 3x in 1x TBS-T for 5 min, followed by overnight incubation on a rotor at 
4oC in a 1:1000 dilution of various primary antibodies made up in a 5% BSA/1x TBS-
T solution. The following day, the membranes were washed 3x with 1x TBS-T for 5 
mins each, followed by 1 hr incubation with a HRP-conjugated secondary antibody in 
a 1:10 000 1x TBS-T solution gentle rotation at RT. After incubation in secondary 
antibody, the membranes were then washed 3x with 1x TBS-T for 5 mins, and 
thereafter exposed to Enhanced chemiluminescence Clarity™ Western ECL 
Substrate Chemiluminescence Reagents (Bio-Rad Laboratories Inc) utilizing the Bio-
Rad ChemiDoc™ imaging system to activate the protein signal. In the 
chemiluminescence reaction, HRP catalyses the oxidation of luminol to a light emitting 
reagent, which releases light during its decay. Since the oxidation of luminol is 
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catalysed by HRP, which is complexed with the membrane bound protein of interest, 
the amount and location of light that HRP catalyses the emission of is directly 
correlated with the location and amount of the protein on the membrane. In accordance 
with the manufacturers protocol, an equal volume of ECL solution A and B were 
prepared away from light, and thoroughly mixed together. A volume of 200 µl of the ECL 
mixture was evenly added onto the membrane, and the proteins of interest were 
visualized using the Bio-Rad ChemiDoc™ imaging software.  
 
2.5.3.3.  Membrane stripping and re-probing 
 
Membranes were generally probed for several proteins at a time by incubating the 
membrane in stripping buffer (ADDENDUM A Table A.1) for 30 min followed by a 
wash step of 5 min in 1x TBS-T with gentle agitation, to remove bound antibodies. The 
membranes were then blocked in 3% fat milk/1x TBS-T buffer for 1hr at RT. The 
membrane was then washed 3x with 1x TBS-T for 5 mins each and probed for different 
target proteins as previously described. 
 
2.5.3.4.  Quantification of protein densitometric measurements 
 
To control for protein loading, all blots were probed for the representative β-actin 
protein. The images were refined in terms of their display using the Image Lab™ 
Software (version 4.0 build 17). Target protein bands were quantified and normalized 
to their respective β-actin loading control using Image J v1.43 (NIH) software 
(http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-
image-j/). The intensity values (measured in arbitrary units (A.U) of various proteins of 
interest were expressed as a ratio of the intensity value of their respective β-actin 
loading control, and these values were then exported to Microsoft Excel software for 
further processing, prior to statistical analysis with the appropriate tests. A minimum 
of three independent experiments were performed. 
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2.6.  Caspase-Glo® 3/7 Assay 
 
The Caspase 3/7 Assay is a sensitive, luminescent assay that qualitatively measures 
the activity of caspase 3 and 7 in response to various stressors. Caspase-3 and 
caspase 7 are activated universally to coordinate the execution of apoptosis by 
cleaving multiple structural and repair proteins and are therefore primarily responsible 
for the majority of proteolytic reactions that take place during apoptosis (Brentnall et 
al., 2013). The Caspase 3/7 assay is based on the reaction of a caspase substrate 
that is conjugated with an enzyme luciferase. Caspase substrate lyses and enters the 
cell to interact with caspase 3/7, which causes the cleavage and activation of luciferase 
enzyme, resulting in the emission of light, which is then measured in relative light units 
(RLU) using a luminometer. 
 
To measure caspase-3 and 7 activities in response to APP overexpression over time, 
15,000 N2aswe cells were seeded into 96-well luminometer plates and allowed to 
adhere overnight. The following day, cells were treated with 5 mM BA to induce APP 
transgene overexpression for 12, 24, 36, or 48 hrs. Following completion of the 
treatment protocol, an equal volume of Caspase-Glo® 3/7 reagent was added to the 
media in each well (70 µl), and cells were incubated for 3 hrs at 37°C due to RT 
fluctuations. Luminescence was measured using the GloMax® 96 Microplate 
Luminometer (Promega), and the luminescence values were recorded using the 
GloMax® software (Promega) using optimised pre- installed settings for the Caspase-
Glo® 3/7 Assay. Caspase 3/7 activity was reported as a mean of RLU by subtracting 
the blank (measured luminescence) from the corresponding sample luminescence 
value. 
 




2DG was used to elucidate its effects in AD-related Aβ-pathology, using N2aswe cells, 
to assess chaperone-mediated autophagic activity. To this end, N2aswe cells were 
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transiently transfected with the KFERQ-mCherry plasmid. The KFERQ-mCherry 
plasmid is a CMA reporter which preferentially recruits CMA substrates to the 
lysosomal membrane for subsequent degradation via this pathway (Koga et al., 
2011b). The plasmid was a kind gift from Professor Ana Maria Cuervo (Department of 
Developmental and Molecular Biology, Albert Einstein College of Medicine, NY). 
N2aswe ells were transfected using the Lipofectamine 3000 Transfection Reagent 
(Invitrogen, #L3000008) according to manufactures instructions. Briefly, N2aswe cells 
were seeded into 6-well plates at a high density of 8x105 and allowed to adhere 
overnight. The following day cells were transfected at a confluency of ~90% to ensure 
a high transfection efficiency. A total of 1.5 µg plasmid DNA was transfected per well 
at a ratio of 1:3 to Lipofectamine™ 3000 transfection reagent, prepared in 200 µl 
OptiMEM reduced serum media. Diluted pDNA: lipofectamine 300 reagent complexes 
were incubated for 15 to 20 min at RT, and subsequently added to each well in a 
dropwise manner. The transfection efficiency was determined through live-cell imaging 
of the KFERQ-mCherry construct using the 40x objective lens on the Olympus Cell® 
system attached to an Ix 81 Inverted fluorescence microscope, equipped with a F-
view-II cooled CCD camera (Soft Imaging Systems). When the cells were determined 
to have ~50% transfection efficiency, cells were treated with BA and 2DG combination 
treatment, or BA only as previously described, and allowed to incubate for 12, 24, and 
48 hrs under these treatment conditions. After completion of the treatment protocol, 
transfected cells were imaged per group at a 100x magnification. Three excitation 
filters were used to capture images: the TxRed excitation filter was used to capture 
images of lysosomal puncta and the DAPI excitation filter for the acquisition of nuclei. 
Images were processed, and the background was subtracted using the Olympus Cell® 
software (Hamburg, Germany), and presented in a maximum intensity projection. 
 
2.7.2. Cell fixation 
 
N2aswe cells were seeded at a density of 3x104 into 6-well plates containing round 
22x22 mm coverslips (No 1.5H High precision cover slips, Zeiss, #474030-9020-000) 
and 2 ml growth media and allowed to adhere at a temperature of 37°C, and a 5% 
CO2 concentration. Following BA treatment for 12, 24, or 48 hrs, with untreated cells 
serving as the control, the media was aspirated, and the cells were fixed for 10 min in 
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a 1:1 ratio of 4% paraformaldehyde (PFA) (w/v): Opti-MEM/DMEM (Sigma Aldrich, 
#158127) and incubated at 37°C for 15 min to maintain cell integrity. The fixative 
solution was then aspirated, and the coverslips were washed 3x for 5 min with cold 1x 
PBS-T, after which cells were permeabilized by adding 0.2% Triton-X-100 and 
incubation for 2 min at RT. The coverslips were then washed 3x for 5 min with cold 1x 
PBS-T, and cells were incubated for 30 min a blocking buffer solution, containing 5% 
donkey serum (Sigma Aldrich, #D9663) in 1x PBS-T. After blocking, coverslips were 
washed 3x for 5 min with cold 1x PBS-T, before incubation in various primary 
antibodies, which were diluted in 5% BSA/1x PBS-T (see Table 2.2 for list of 
antibodies). Each coverslip was incubated with 50 µl primary antibody solution 
overnight at 4°C. The following day the coverslips were washed 3x for 5 min with cold 
1x PBS-T, and incubated in fluorophore-conjugated secondary antibodies against the 
appropriate species (see Table 2.3 for list of antibodies) for 50 min. Following this, a 
50 µl volume of Hoechst 33342 nuclear dye (diluted 1:200 in 1x PBS-T) was added to 
the coverslips for 10 min. Coverslips were then washed 3x for 5 min with 1x PBS-T, 
and mounted in an inverted manner onto microscope slides containing Dako® 
fluorescent mounting media (Diagnostech), sealed with clear nail varnish and left to 
dry for 60 min at RT protected from light. Slides were wrapped in foil paper to prevent 
bleaching of fluorescent molecules and stored at -20°C until further analysis. 
 
2.7.3. Confocal microscopy 
 
Cells were imaged at the Central Analytical Facility (CAF, Stellenbosch University) 
with a laser scanning confocal microscope, LSM780 ELYRA PS1 confocal microscope 
(Carl Zeiss, Germany) using the 60x oil immersion objective lens. Hoechst was excited 
with the 405 nm laser, with the MBS405 beam splitter and detection in the range 415-
499 nm, and the appropriate lasers, primarily 488 and 561, were used to excite the 
corresponding fluorophore-conjugated proteins of interest. Images were acquired with 
the Zen Imaging software, and further processed using the Zeiss Zen Lite Black Edition 
Imaging Software v.2.3 (Carl Zeiss, Germany). Cells incubated without primary 
antibody served as negative controls. 
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2.7.4. APP localization: correlative light and scanning electron microscopy 
 
Correlative light and electron microscopy (CLEM) is a microscopy technique that 
combines the capabilities of two typically separate microscopy platforms: fluorescently 
labelled proteins localized by fluorescence microscopy (FM), and the visualization of 
subcellular ultrastructure by electron microscopy (EM). While FM enables the user to 
retrieve information from fluorescently labelled structures, EM provides detailed 
information about the biological ultrastructure (Russell et al., 2017). By combining 
these two techniques, CLEM makes it possible to image dynamic biological events for 
structural analysis at high resolution. EM micrographs were acquired using a scanning 
electron microscope (SEM), which uses a focused electron beam to form an image 
with information pertaining to the surface topography and composition, captured at a 
high imaging magnification and resolution. 
 
2.7.4.1. Sample preparation 
 
A total of 3x104 N2aswe cells were seeded into 6-well plates containing round 22x22 
mm coverslips, grown overnight and treated for 12, 24, or 48 hrs BA, including an 
untreated control. Upon completion of the treatment protocol, coverslips were 
prepared for confocal microscopy analysis as previously described. Notably, for this 
experiment, cells in each experimental group were only incubated in APP (#2452) 
primary antibody overnight at 4°C, and its corresponding secondary antibody, Alexa 
Fluor 488 Donkey anti-rabbit for 50 min, followed by 10 min Hoechst staining. 
Coverslips were then rinsed and immersed in 1x PBS-T overnight in a 6-well plate 
prior to CLEM/SEM analysis. 
 
2.7.4.2. CLEM image acquisition  
 
Each cover slip was separately placed in the CLEM sample holder for Life Science 
Cover Glass (Zeiss, Germany) to be imaged. Confocal imaging was performed as 
previously described in section 2.7.3. The marker coordinates of the sample holder 
were saved using the Shuttle and Find mode of ZEN 2012 software using transmitted 
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light with the 10x objective. After calibration, a 3 x 3 tile scan of the area of interest 
was imaged using the EC “Plan-Neofluar”10x/0.3 objective, followed by a 1x image of 
identified regions with the same objective. This was then followed by Z-stack imaging 
with both the LD “Plan-Nuofluar” 40x/0.6 Corr M27 objective and the LCI “Plan-
Apochromat”63x/1.4 Oil DIC M27 objective. For all samples, the 488 nm Argon laser 
was used for excitation of Alexa Fluor 488, with the MBS488 beam splitter and 
emission was detected with the GaAsP detector in the range 499- 588 nm. Hoechst 
was excited with the 405 nm laser, with the MBS405 beam splitter and detection in the 
range 415-499 nm. 
 
After confocal imaging, each sample was washed with dH2O, without removing it from 
the sample holder. The assembly was coated with a thin (~5 nm thick) layer of carbon 
prior to analysis, using a Quorum Q150T coater by performing carbon rod evaporation. 
Once the samples were coated, the coating cannot be removed without damaging the 
sample, therefore electron analysis must succeed fluorescence analysis as coating 
diminishes the fluorescent signals. Secondary electron (SE2) In Lens micrographs 
were acquired using a Field Emission Gun Scanning Electron Microscope (FEG-SEM) 
and SmartSEM® software (Zeiss MERLIN, Germany) at the Electron Microbeam Unit 
(CAF). First the coordinates of the sample holder were saved again in ZEN 2012 
Imaging Software (Carl Zeiss, Germany), after which the areas of interest were 
automatically located by the Shuttle and Find mode. The precision of superposition of 
the FM images on the SEM micrographs is important for accurately localizing the 
labelled proteins within the SEM micrographs. Beam conditions during the analysis on 
the Zeiss MERLIN were 5 kV accelerating voltage, with a working distance of 9.1 mm 
and a beam current of 250 pA. Final images were acquired with the Zeiss SmartSEM® 
software. 
 
2.7.5. Colocalization analysis and immunofluorescence microscopy 
 
Colocalization analysis is typically used to determine if two different proteins of interest 
cluster to the same subcellular location. The quantification of colocalization between 
two fluorescence channels is performed on a pixel by pixel basis which can be split into 
two categories: (1) co-occurrence and (2), correlation (Adler and Parmryd, 2010). The 
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former measure, quantifies the presence of both fluorophores in individual pixels, while 
the latter quantifies the extent overlap between the signals from each fluorophore 
(Adler and Parmryd, 2010). Two measures of correlation are used to quantify the 
degree of colocalization between fluorophores, the Pearson correlation coefficient 
(PCC) and the Mander’s overlap coefficient (MOC) (Manders et al., 1993). The 
formulae for the PCC and MOC, respectively, are presented below for a quantification 
of two fluorophore channels. 
 
PCC =
∑ (Ch1iCh1avg) ∗ (Ch2iCh2avg)𝑖
√∑ (Ch1iCh1avg)2𝑖 ∗ ∑ (Ch2iCh2avg)2𝑖
 
 
Ch1i and Ch2i refer to the pixel intensity values of two different colour channels of the 
same image, and Ch1avg and Ch2avg indicate the mean intensities of the colour 
channels across the entire image. The PCC values range from 1 to -1, with the former 
indicating perfect correlation, the latter indicating a negative correlation, i.e. every pixel 
that contains green does not contain red and vice versa, and a PCC value of 0, 
signifying the total absence of a relationship (Adler et al., 2008). 
 
MOC =
∑ 𝐶ℎ1𝑖 ∗ 𝐶ℎ2𝑖𝑖
√∑ (𝐶ℎ1𝑖)2𝑖 ∗ ∑ (𝐶ℎ2𝑖)2𝑖
 
 
The MOC provides a highly sensitive measure of co-occurrence and correlation 
(Zinchuk and Grossenbacher-Zinchuk, 2009). MOC values range from 0 to 1, with the 
former corresponding to non-overlapping images, i.e. no overlap of pixels from either 
of two or more channels, while the latter signifies 100% colocalization between all 
pixels. The Mander’s colocalization coefficients (MCC), M1 and M2 metrices are an 
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Pixels Ch1.coloc is the intensity of the fluorophore 1 in pixels where fluorophore 2 is 
present. Similarly, pixels Ch2.coloc is the intensity of the fluorophore 2 in pixels where 
fluorophore 1 is present. Pixels Ch1.total, and Ch2.total represent the ratio of the 
"summed intensities of pixels from each co-localizing fluorophore for which the 
intensity is above zero". 
 
Although the PCC and MOC coefficients are mathematically similar, differing only in the 
use of either the absolute intensities (MOC), or the deviation from the mean (PCC), 
MOC is more widely used, partly due to its interpretative ease, while the negative 
values generated using the PCC may be difficult to interpret when the degree of 
overlap is being measured (Churchman and Spudich, 2012). A threshold value for 
each channel is also required to define the cut-off value for colocalization. 
 
2.7.5.1.  Colocalization sample preparation and imaging 
 
For colocalization analysis, N2aswe cells adherent coverslips were treated with BA 
and prepared for microscopy analysis as previously described. To avoid bleed-
through, i.e. when the red fluorochrome emits into the green channel and/or the green 
fluorochrome emits into the red channel, fluorophore-linked secondary antibodies that 
do not have cross-reactivity, and with well- separated excitation and narrow band 
emission spectra were selected for dual channel colocalization. Single stained controls 
were used for evaluating any bleed-through and unstained negative controls were used 
to determine the degree of background autofluorescence. Dual-stained images were 
obtained using the LSM780 ELYRA PS1 confocal microscope (Zeiss, Germany) oil 
immersion 100x objective lens. 
 
2.7.5.2.  Quantification of colocalized proteins 
 
Quantitative analysis of colocalization was performed on randomly selected images 
using the Zeiss Zen Lite Black Edition Software v.2.3. To improve the quality of images 
before analysis of colocalization, deconvolution methods, filtering, and background 
noise was reduced using the Zeiss Software Colocalization threshold and 
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Colocalization Test plug-ins, prior to overlap quantification. For each image, the region 
of interest (ROI) was selected using the Overlay tool, thereby reducing the number of 
pixels outside the region of colocalization to improve the accuracy of colocalization 
measurements. Every pixel in the image was plotted in a scatterplot diagram based 
on its intensity level from each channel. The colour in the scatterplot represents the 
number of pixels that are plotted in that region. Using the Colocalization test plug-ins, 
four software quadrants were designated for each image, with only quadrants 1 and 2 
being selected for colocalization analysis. Colocalized pixels were viewed by selecting 
quadrant 3 and setting to white for easier visualization of the pixels exhibiting 
colocalization. The Zeiss Software then automatically generates a table with denoting 
different measurements extrapolated from the scatterplot. These measurements 
include values signifying the PCC, MOC, and MCC for each selected ROI. To identify 
statistically significant differences in colocalization of BA treated groups relative to a 
control sample, the colocalization coefficients were exported into an appropriate 
statistical program for further quantification. 
 
2.7.6. Detection of cellular ultrastructure using transmission electron 
microscopy 
 
In transmission electron microscopy (TEM), electrons are transmitted through a 
plastic-embedded specimen, allowing for the resolution and visualization of 
ultrastructural detail not possible via confocal microscopy. Accordingly, TEM is a widely 
utilized approach when investigating the changes in cellular morphology in response 
to various treatment conditions. 
 
2.7.6.1. TEM sample preparation 
 
A total of 5x106 N2aswe and N2awt cells were seeded into T75 flasks in duplicate. 
Cells were grown to approximately 90% confluency prior to being treated as follows: 
control, control + BafA1, 12 hrs BA, 12 hrs BA + BafA1, 24 hrs BA, 24 hrs BA + BafA1, 
48 hrs BA, or 48 hrs BA + BafA1. Following treatment, 4 ml trypsin was added to each 
flask and incubated for 5 min prior to being supplemented with 8 ml media and 
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transferred into 15 ml falcon tubes. Tubes were centrifuged at 1500 RPM for 5 min at 
RT, the supernatant was removed, and the remaining cell pellet was resuspended in 
pre-warmed 1x PBS to remove residual trypsin and media. Cells were rinsed twice with 
1x PBS with repeat of the centrifugation step. Primary fixation was performed by 
resuspending the cell pellet in 1 ml pre-warmed 2.5% glutaraldehyde. The cell 
suspension was then transferred to new 15 ml falcon tubes and centrifuged as before, 
but for an additional 10 min to ensure tight pellet formation. The fixative solution was 
carefully removed, and the pellet was resuspended in 1 ml fresh fixative solution and 
stored overnight at 4°C to slow down autolytic processes and reduce cell shrinkage. 
TEM processing of samples was performed by Stellenbosch University’s National 
Health Laboratory Services at Tygerberg Medical Campus. 
 
2.7.6.2.  Processing of TEM samples 
 
Briefly, the primary fixative solution was carefully aspirated, and the cells were washed 
3x in 0.1 M sodium phosphate buffer for 5 min, with centrifugation at 1500 RPM 
between each successive wash step. The cells were then washed 5x in dH20 to remove 
residual phosphate ions, and post-fixed with 1% osmium tetroxide in 0.1 M sodium 
phosphate buffer at 4°C for 1 hr. Subsequently, cell samples were washed 5x in dH20, 
transferred to an automated tissue processer, where they immersed in a sequence of 
dehydration solutions as described below: 
 
i. 10% uranyl acetate for 15min 
ii. 30% Ethanol for 10 min 
iii. 50% Ethanol for 10 min 
iv. 70% Ethanol for 10 min 
v. 90% Ethanol for 10 min 
vi. 95% Ethanol for 10 min 
vii. 100% Ethanol for 10 min 
viii. 100% Ethanol for 10 min 
 
Following dehydration, the cells were infiltrated by progressive incubations with ethanol 
and Spurr’s resin (Low viscosity embedding kit, Electron Microscopy Sciences) at a 
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ratio of 1:1 for 90 min, followed by incubation with 100% Spurr’s resin. After 120 min 
infiltration in Spurr’s resin, the cell samples were embedded and polymerized in 100% 
Spurr’s resin using the BEEM® Embedding Capsules (Electron Microscopy Sciences) 
by heating for 72 hrs in a 60°C oven. Subsequently, the BEEM® Embedding Capsules 
were removed from the hardened resin block and dipped into liquid nitrogen, where 
the difference in the shrinkage of the resin and the capsule allowed for separation of 
the capsule from the resin, thereby leaving the cells attached to the resin. The resin-
embedded samples were then trimmed and sectioned with a Leica EM UC7 
ultramicrotome (Leica Microsystems, Wetzlar, Germany) to obtain 200 nm thick 
sections. These sections were then fully stretched through exposure to chloroform 
vapor prior to being placed onto 200 mesh copper grids (G200-Cu, Electron 
Microscopy Sciences). 
 
2.7.6.3.  TEM image acquisition 
 
Images were examined using the JEOL JEM 1011 transmission electron microscope 
(JEOL, Inc., Peabody, MA) operated at 100 kV, and the iTEM Olympus Soft Imaging 
Solutions’ imaging platform. Ten to thirty random areas were selected from each 
treatment group and captured at magnifications of 1000×, 2000×, 3000 and 5000×, as 
8-bit grey-level images at a minimum TIFF resolution of 300 pixels/inch required for 
RGB images (24-bit with 8-bits for each of the red, green and blue channels). 
 
2.7.6.4.  TEM morphometric analysis  
 
Quantitative morphometric analysis of TEM micrographs was performed as described 
by Asikainen et al. (2014), using the semi-automatic open source image processing 
program, ImageJ v1.41 (Schneider et al., 2012), as illustrated in Fig. 2.1. Briefly, an 
automated image grayscale binarization tool, “thresholding", in ImageJ was used to 
process TIFF images into black-and-white image maps as follows: 
Image>adjust>threshold. Accordingly, pixels with grey levels falling under a specified 
threshold were turned into black pixels, and those with grey levels above the specified 
threshold were turned into white pixels, thereby separating the structures of interest 
from the background. After thresholding, the images were segmented using the 
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“watershed analysis plug-in” as follows: process>binary>watershed. The number of 
structures, i.e. autophagic vacuoles (AVs), and the area measurements thereof were 
calculated using the “Particle analysis plug-in” as follows: analyse>analyse Particles, 
and the “Wand Auto measure tool” was used to select individual AVs to obtain the area 
measurements (in μm2), and to quantify the number of AVs present per cell analysed. 
The data was then exported to Statistica® 13 software for statistical analysis. 
 
 
Figure 2.1: Quantitative morphometric analysis of TEM micrographs. A. 
Representative micrograph of an N2aswe cell captured at low magnification. B. 
Particle outline and segmentation of vacuolar bodies. C, D. Setting of threshold range 
to distinguish vacuolar bodies apart from the background. E, F. Automated estimation 
of the surface area (µm2) using the empirical parameters (spherical body estimate, 
density of the body radii, recognition threshold, and calculation range). 
 
2.8. Global proteome analysis 
 
2.8.1. Liquid chromatography-mass spectrometry-based proteome analysis 
 
Liquid chromatography coupled with mass spectrometry (LC-MS) based proteomics 
consists of two powerful separation techniques that allow the sample (s) of interest in 
highly complex mixtures to be isolated and interrogated for their global proteolytic 
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profile (Mesaros and Blair, 2016). LC-MS is a robust technique that combines the dual 
selectivity, and physical separation capabilities of liquid chromatography with the mass 
analysis capabilities of mass spectrometry. The basic LC-MS processes is performed 
as follows: (1) introduction of sample onto a mass spectrometry device for subsequent 
vaporization, (2) ionization; sample components are ionized by an electron ionization 
source which exposes the analyte, under a vacuum, to a stream of electrons produced 
from a heated filament to create ions, (3) analyser sorting; the ions are sorted in an 
analyser according to their m/z ratios through the use of electromagnetic fields, (4) 
detector; the ions are then passed through a detector in which the ion flux is converted 
into electrical current and (5) data conversion; the magnitude of the ion/electrical 
signals is converted into a mass spectrum (Chatfield and Fitzgerald, 2004). A 
schematic workflow of LC-MS experiment is illustrated in Fig. 2.2. 
 
 
Figure 2.2: LC-MS schematic workflow of sample preparation. Proteins can be extracted 
from any biological source, e.g. whole tissues, cells, or body fluids. Peptides are separated 
by liquid chromatography systems to reduce the complexity of the sample. MS analysis is 
performed by selecting individual peptides, which are then fragmented by collisions, 
generating tandem mass spectra (MS/MS) containing peptide sequence information. In the 
final step, organism-specific databases are searched to identify proteins from the peptide 
sequence information (Hosp and Mann, 2017). 
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2.8.2.  LC–MS sample preparation 
 
N2aswe and N2awt cells were seeded in T75 flasks at a density of 5x106 cells per 
flask in triplicate, allowed to adhere overnight, and then treated with BA. The former 
cell line consisted of a control, 24 hrs BA, and 48 hrs BA treatment group. The latter 
cell line only consisted of a control and 48 hrs BA treated group. Following treatment, 
cellular protein extraction was carried out according to standard procedures as 
previously described. After centrifugation of the cell lysates at 8000 RPM for 30 min at 
4°C, protein concentrations were determined as previously described, and the 
supernatant was stored at -80°C for a maximum of 1 week prior to LC-MS analysis. 
Using a minimal concentration of 70 μg/µl, LC-MS was performed at the CAF 
Proteomics Unit (Stellenbosch University) using the Thermo Scientific™ UltiMate™ 
3000 Rapid Separation systems for high-performance liquid chromatography (HPLC) 
separations, linked to the Thermo Scientific Orbitrap Fusion™ mass spectrometer. 
LC-MS was performed as follows: 
 
2.8.2.1.  In-solution protein digestion 
 
In-solution digestion was performed to yield shorter peptides with suitable m/z range 
for MS analysis, as most MS systems require that the analysed particle is not too large 
and contains adequate number of charges. Several different enzymes, were used for 
protein digestion. Samples were reduced by adding 50 mM tris carboxyethyl 
phosphine (TCEP; Fluka) in 100 mM triethylammonium bicarbonate (TEAB) [final 
concentration 5 mM (tris(2-carboxyethyl)phosphine) (TCEP)] for 30 min at 37°C. 
Following reduction, cysteine residues were modified to methylthio using 200mM 
methane methylthiosulphonate (MMTS; Sigma Aldrich) in 100 mM TEAB (final 
concentration 20 mM) for 30 min at 37°C. After modification, the samples were diluted 
to 98 µl with 100 mM TEAB. To allow the identification of peptides participating in 
sulphur bridges, proteins were digested by adding 5 µl trypsin (Promega) (1 µg/µl) to 
the samples, which were then allowed to incubate for 18 hrs at 37°C. Trypsin adds a 
secondary ionization site at the C-terminus of peptides, thereby increasing the 
coverage of MS fragmentation (Olsen et al., 2004). The samples were then dried down 
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and resuspended in 100 µl 2% acetonitrile (Fluka): water; 0.1% formic acid (formic 
acid; Sigma Aldrich). 
 
2.8.2.2. On-column desalting 
 
Given that the mixture of peptides generated by an enzymatic digest can vary in 
complexity, LC based separation of peptides is required to reduce the complexity of 
the analyte before entering the MS instrument. Hence, residual digest reagents were 
removed using an in-house manufactured C18 stage tip (Empore Octadecyl C18 
extraction discs; Supelco). A total of 20 µl of the sample analyte was loaded onto the 
stage tip after activating the C18 membrane with 30 µl methanol (Sigma Aldrich) and 
equilibrating with 30 µl 2% acetonitrile: water; 0.05% trifluoroacetic acid (TFA). The bound 
sample was then washed with 30 µl 2% acetonitrile: water; 0.1% formic acid (FA), 
before elution with 30 µl 50% acetonitrile: water; 0.1% FA. The eluate was evaporated 
to dryness, and the dried peptides were dissolved in 20 µl 2% acetonitrile: water; 0.1% 
FA for LC-MS analysis. 
 
2.8.2.3. Liquid chromatography 
 
LC nano-LC-MS was performed on a Dionex™ Ultimate 3000 RSLCnano system 
(Ultimate 3000, Thermo Scientific) equipped with a 0.5 cm x 300 µm C18 trap column 
and a 35 cm x75 µm in-house manufactured C18 (Luna C18, 3.6 µm; Phenomenex) 
analytical column. The following solvent system was employed for loading: 2% 
acetonitrile: water; 0.1% FA; solvent A: 2% acetonitrile: water; 0.1% FA and solvent 
B: 100% acetonitrile: water. Samples were loaded onto the trap column using loading 
solvent at a flow rate of 15 nl/min from a temperature controlled autosampler set at 
70C. Loading was performed for 5 min before the sample was eluted onto the 
analytical column. Flow rate was set to 500 nl/min and the gradient was generated 
as follows: 2.0% - 10% B over 5 min; 5%-25% B from 5-50 min using Chromeleon 
non-linear gradient 6 (Chromeleon™ Chromatography Data System), 25%-45% from 
50-65 min, using Chromeleon non-linear gradient 6. Chromatography was performed 
at 50°C and the outflow delivered to the mass spectrometer through a stainless steel 





2.8.2.4. Mass spectrometry 
 
Mass spectrometry (MS) was performed using a Thermo Scientific Fusion mass 
spectrometer equipped with a Nanospray Flex ionization source. The sample was 
introduced through the stainless steel nano-bore emitter. Data was collected in 
positive mode using the Nanospray Flex (Thermo Scientific) nano-ESI source with 
spray voltage set to 2 kV and ion transfer capillary set to 275°C. Spectra were internally 
calibrated using polysiloxane ions at m/z = 445.12003 and 371.10024. MS1 scans 
were recorded in the Orbitrap mass analyser set to 12 000 resolutions over the scan 
range m/z = 350-1650 with a maximum injection time of 40 ms, or until adaptive gain 
control (AGC) target of 3e5 was reached. Generated MS data was acquired in profile 
mode (Fig. 2.3). MS2 acquisitions were performed using monoisotopic precursor 
selection for ion with charges +2 to +6 with error tolerance set to ± 0.02 ppm. 
Precursor ions were excluded from fragmentation once for a period of 30 sec. 
Precursor ions were selected for fragmentation in HCD mode using the quadrupole 
mass analyser with HCD energy set to 32.5%. Fragment ions were detected in the 
orbitrap mass analyser set to 15 000 resolutions. The AGC target was set to 1e4 and 
the maximum injection time to 45 ms. The data was acquired in centroid mode. MS 
data is usually presented as either profile or centroid mode (Fig. 2.3. In profile mode, 
a peak is represented by a collection of signals over several scans, while centroid 
mode displays the peaks as discrete m/z value weighted by the intensity, thereby 
generating a significantly smaller file size for faster processing (Murray et al., 2013). 
 




Figure 2.3: Representative mass spectrometry data presentation (Dutta et al., 2015). 
 
2.8.2.5.  Data analysis 
 
The raw files generated by the mass spectrometer were imported into Proteome 
Discoverer™ v1.4 (Thermo Scientific) and processed using the SequestHT algorithm 
included in Proteome Discoverer. Data analysis was structured to allow for methylthio 
as fixed modification as well as NQ deamidation (NQ), oxidation (M). Precursor 
tolerance was set to 10 ppm and fragment ion tolerance to 0.02 Da. The database 
used was the murine taxonomy database, obtained from UniProt 
(http://www.uniprot.org/) with the FASTA sequence for amyloid beta A4 P05067 
downloaded from the UniProt Knowledgebase, UniProtKB/Swiss-Prot. The results 
files were important into Scaffold v1.4.7.5 (http://www.proteomesoftware.com) 
(Proteome Software Inc., Portland, OR) and identified peptides validated using 
Sequest and X! Tandem (http://thegpm.org/TANDEM/index.html ) search algorithms 
included in Scaffold. Peptide and Protein validation were performed using the Peptide 
and Protein Prophet algorithms, which automatically validate peptides assignments to 
MS/MS spectra. 
 
2.8.2.5.1.  Bioinformatics analysis: blast search  
 
The basic local alignment search tool (BLAST) was used to compare sequences of 
Stellenbosch University  https://scholar.sun.ac.za
83 
 
interest against various gene and genome databases, such as the Ensemble 
Genomes Release 36 (as of May 2017) (http://www.ensembl.org/index.html ), which 
includes the new, updated Mus musculus genome assemblies and gene annotation, 
including updated variation data and comparative genomics analyses from the 
European Nucleotide Archive (http://www.ebi.ac.uk/ena) and NCBI's reference 
sequence (RefSeq) database (http://www.ncbi.nlm.nih.gov/RefSeq/). 
 
2.8.2.5.2.  Bioinformatics analysis: protein validation strategy 
 
The proteins expressed in the different treatment groups were differentiated using 
spectral counting, which represents the total number of spectra (peak areas in label 
free proteomics) identified for a protein satisfying a specified quality threshold 
(Lundgren et al., 2010; Milac et al., 2012). The data was first normalized prior to 
standard statistical analyses, using a mathematical normalization technique referred 
to as the normalized spectral abundance factor (NSAF). Changes in protein 
expression were compared using t‐tests. Post hoc analyses were performed with the 
Benjamini and Hochberg false discovery rate correction. All values were expressed as 
the mean ± SEM. Significance was accepted at p<0.05. 
 
2.8.2.5.3.  Bioinformatics analysis: false discovery rate  
 
The false discovery rate (FDR) test is the most widely accepted LC-MS proteomic 
validation approach, ensuring the accurate and precise estimation of both protein 
identifications and quantifications (Colquhoun, 2014; Yang et al., 2016). Using this 
approach, decoy/false versions of the murine taxonomy database was constructed by 
reversing each protein sequence from the normal murine databases (He et al., 2015). 
This strategy is based on the premise that decoy protein sequences added to the 
search space would correspond with incorrect search results that might otherwise be 
deemed to be correct. With this knowledge, it is possible to estimate how many 
incorrect results are in a final data set and design a filtering criterion that sensitively 
separates the data set into correct and incorrect identifications using the decoy hits as 
a guide. 
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2.8.2.5.4.  Bioinformatics analysis: protein quantification strategy 
 
Peptide hits were accepted if they could be established at greater than 95% probability 
by the Scaffold Local FDR algorithm. Protein hits were accepted if they could be 
established at greater than 99.0% probability and contained at least two identified 
peptides. Protein probabilities were assigned by the Protein Prophet algorithm 
(Serang and Noble, 2012). Proteins sharing significant peptide evidence were grouped 
into clusters. Proteins found to be statically different were automatically marked for 
fold change calculations. These proteins were then further analysed using the 
STRING v10 functional protein association networks database (https://string-db.org/).  
The basic interaction unit in STRING is the functional association, i.e. a specific and 
productive functional relationship between two proteins. Interactions are derived from 
multiple sources including: (i) known experimental interactions, (ii) pathway 
knowledge from curated databases, (iii) automated text-mining which is applied to 
uncover statistical links between proteins, based on Medline abstracts and a large 
collection of full-text articles, (iv) de novo interactions which are predicted by a number 
of algorithms using genomic information and co-expression analysis (Chiva and 
Sabidó, 2017; Mei, 2018). All sources of protein-protein interactions are benchmarked 
and calibrated against previous knowledge, using the high-level functional groupings 
provided by the Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway maps 
(Szklarczyk et al., 2015). 
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2.9.  Animal study: GFP-LC3 transgenic mice 
 
2.9.1. Experimental animals 
 
The generation of green fluorescent protein (GFP)–LC3 expressing transgenic 
C57BL/6 mice (GFP-LC3) has been extensively described (Mizushima, 2004, 2009b). 
The expression of the green fluorescent protein (GFP)-linked microtubule-associated 
protein 1 light chain 3 alpha (LC3) protein is the most widely used marker for 
autophagosome formation, used in this context, to analyse autophagy in whole animals 
(Mizushima, 2009b). A GFP-LC3 mouse breeding pair was purchased from the RIKEN 
Bio‐ Resource Centre in Japan (http://www.brc.riken.jp/lab/animal/en/dist.shtml 
#BRC00806). The mice were acclimatized for one week prior to experimentation and 
maintained at constant ambient temperature (21 ± 1°C) with 12 hrs light/dark cycle 
and humidity (55 ± 9%) at the Stellenbosch University’s animal breeding facility. During 
this period, mice were provided with water and standard chow ad libitum. All 
procedures were carried out in accordance with the recommendations set forth in the 
South African national standard for the care and use of laboratory animals for scientific 
purpose (ISBN 978-0-626-22296-3, SANS 10386:2008) as outlined in the 8th Edition 
of the South African Veterinary Foundation (http://www.savf.org.za/). All experiments 
were performed following the protocols approved by Stellenbosch University’s Ethical 
Committee guidelines (ethics approval no. SU- ACUD16-00175). Expression of the 
GFP-LC3 marker in the whole animal was confirmed using 360 nm goggle instrument 
in the dark. Green fluorescence could typically be seen on the snout, ears and tail. 
 
2.9.2. Experimental design 
 
A total of 48 GFP-LC3 mice were randomly y assigned into 4 groups of 12, as 
illustrated in Fig. 2.4. Group 1, control group, had ad libitum access to a standard 
chow diet, group 2 was subjected to 48 hrs intermittent fasting (IF), group 3 was 
subjected to a two-weekly intraperitoneal (i.p.) injection with nonselective herbicide, 
paraquat (PQ) (Ali et al., 1996; Chen et al., 2012) to mimic the elevated oxidative 
stress condition observed in the brains of AD patients, and group 4 was the 
combination treatment group, subjected to 48 hrs alternate day IF, and twice-weekly 
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PQ i.p. injection. All groups had ad libitum access to fresh water throughout the study. 
 
 
Figure 2.4: In vivo study design. (1) Control group, (2) PQ exposed group, (3) 48 hrs IF 
group, and (4) [(48 hrs IF) + PQ] group.  
 
2.9.2.1.  Intermittent fasting treatment intervention 
 
To investigate the effects of IF on the functionality of macroautophagy and CMA in the 
event of increased ROS in vulnerable neuronal populations from selective brain 
regions which are crucial to sustained cognition function, eight-week-old male GFP-
LC3 mice were deprived of the standard chow diet for 48 hrs, i.e. from 10:00 am on day 
1 until 10:00 am on day 3. The mice were then permitted to 24 hrs ad libitum access 
to standard chow following the 48 hrs IF period. 
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2.9.2.2.  PQ treatment protocol 
 
To investigate the effects of PQ in selective brain regions, GFP-LC3 mice were treated 
with either saline or PQ using a well-established PQ-induced brain injury protocol 
(Chen et al., 2012). PQ (Sigma-Aldrich, #36541) was reconstituted in sterile saline 
solution and administered at a dosage of 10 mg/kg for 3 weeks (60 mg/kg total in 6 
injections). Mice were weighed immediately prior to PQ administration by i.p. injection 
using a 26 g needle twice weekly. Control mice were i.p. injected with saline using the 
same volume as that in the PQ exposed and [(48 hrs IF) + PQ] groups. 
 
2.9.2.3.  Animal welfare monitoring 
 
Each animal was closely monitored daily, including weekends, and various 
observations were recorded [ADDENDUM B (Table B1-B2)].  
 
2.9.2.4.  Animal sacrifice and whole brain extraction 
 
Two mice per group were sequentially euthanized by cervical dislocation from 10 am 
to 10 pm. Whole brain tissue was carefully excised by inserting sterile surgical scissors 
and cutting first laterally and then anteriorly through each skull, and then cutting toward 
the midline. The skull was carefully lifted upward and peeled back to expose the 
hindbrain. The intact brain was extracted using curved forceps, and subsequently 
placed on a pre-chilled petri dish filled covered with wet filter paper. Whole brain 
tissues were then rapidly sectioned into two equal parts by cutting in the sagittal plane 
using a surgical scalpel. One part, was rapidly dissected into the cortex, cerebellum, 
and the hippocampus using a dissecting microscope, transferred to a pre-labelled  
2 ml Eppendorf tube, snap-frozen in liquid nitrogen, and stored at -80°C for western 
blotting analysis. The second part, to be used for immunofluorescence analysis, was 
completely immersed in isopentane at -30°C for less than 5 secs to preserve the shape 
of the brain, transferred to a pre-labelled 2 ml Eppendorf tube and snap-frozen in liquid 
nitrogen within 30 secs to avoid expansion or cracking. 
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2.9.3. Tissue preparation for immunofluorescence analysis 
 
After snap freezing, the second part of the whole brain section was secured to a 
cryostat pedestal using Jung Tissue Freezing Medium™ (Leica Microsystems). The 
brain cryomold was left to equilibrate in the Leica CM1100 cryostat (Leica-
Microsystems) at -20°C for ~10 to 15 min to prevent cracking of the tissue block wile 
sectioning. Subsequently, three 5-15 µm thick tissue sections were sectioned using 
the freezing microtome, the tissue sections were then allowed to attach onto glass 
microscope slides by air drying for 30 min at RT. Using a hydrophobic barrier pen 
(Dako), tissue sections were outlined on the microscope slide to ensure optimal 
coverage of the reagents followed by fixation with 4% PFA for 15 min. The slides were 
then washed 3x with 1x PBS-T for 5 mins each, and permeabilized using 0.2% Triton 
X-100 for 2 min at RT. Non-specific binding between the primary antibodies and the 
tissue was prevented by incubating slides in blocking buffer (5% donkey serum in 1x 
PBS-T) for 60 min. Subsequently, slides were incubated with various primary and 
secondary antibodies as previously described. Immunofluorescent images of each 
brain section were acquired using the LSM780 Confocal microscope (Carl Zeiss, 
Germany) with a 10x and 40x objective lens. 
 
To determine the extent of brain tissue damage caused by an inflammatory stress 
response to the treatment intervention, blocked tissue sections were probed for Alexa 
Fluor conjugated glial fibrillary acidic protein (GFAP, Table 2.3) for 4 hrs at 4oC. GFAP 
is highly expressed in numerous cell types of the central nervous system, particularly 
in astrocytes where GFAP is generally highly expressed in response to brain injury 
(Kamphuis et al., 2012; Li et al., 2017b). PQ is a prolific inducer of oxidative stress; 
therefore, blocked tissue sections were also probed for 4-hydroxynonenal (4HNE, 
Table 2.3). It is well recognized that excessive production of reactive oxygen species 
(ROS) can lead to oxidative stress and tissue damage (Flora, 2007; Sinclair et al., 
1990). ROS reacts with many cellular components including lipids, which can initiate 
lipid peroxidation (Bergamini et al., 2004). One of the products of lipid peroxidation, 
4HNE, is a relatively abundant reactive aldehyde derived from the peroxidation of 
omega-6-polyunsaturated fatty acids (Poli et al., 2008), and is formed in biological 
tissues under physiological and pathological conditions (Maniti et al., 2015). Its 
Stellenbosch University  https://scholar.sun.ac.za
89 
 
concentration increases with oxidative stress and induces deleterious modifications of 
proteins and membranes (Majima et al., 2002). Moreover, elevated 4HNE expression 
has been identified in the plasma and brain of AD patients (Ma et al., 2018; 
Markesbery and Lovell, 1998), and in colocalization with Aβ deposits (Huang et al., 
2016). To assess the effects of increased oxidation on 4HNE production, blocked 
tissue sections were incubated in 4HNE primary antibody overnight at 4°C and 
prepared for confocal microscopy analysis as described previously. 
 
2.9.3.1.  H & E staining of brain tissue 
 
As previously described, H & E stains were used the detailed assessment of cellular 
structures including the cytoplasm, nuclei and selective extracellular components. 
 
2.9.3.1.1.  Preparation of tissue sections for H & E staining 
 
Stored at -80°C, 5 to 15 µm tissue sections were air dried for ~15-20 min to remove 
moisture, and processed as follows: 
 
1. Tissue sections were stained with filtered 0.1% Mayer’s Haematoxylin (Sigma; 
MHS-16) for 10 min in a 50 ml conical tube.  
2. Using a Coplin jar, tissue sections were rinsed in cool running dH2O for 5 min. 
3. Tissue sections were dipped in 0.5% Eosin (1.5 g dissolved in 300 ml of 95% EtOH) 
12x. 
4. Tissue sections were dipped in dH2O until the eosin stopped streaking. 
5. Tissue sections were dipped in 50% EtOH 10x. 
6. Tissue sections were dipped in 70% EtOH 10x. 
7. Staining was equilibrated in 95% EtOH for 30 secs followed by equilibration in 
100% EtOH for 1 min. 
8. Tissue sections were then dipped in Xylene 5x, and the slide was gently wiped off 
using a Kim wipe before using Cytoseal XYL (Stephens Scientific; cat# 8312-4) to 
mount the coverslip, which was then allowed to dry at RT for 1 hr prior to confocal 
microscopy imaging.  
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2.9.3.1.2.  H & E image acquisition 
 
H & E stained sections were imaged using the Nikon Eclipse E400 phase contrast 
microscope (Nikon, USA) equipped with a RT Colour Spot Camera (Diagnostics 
Instruments Inc., USA). Spot Analysis v4.0.9 software (Diagnostics Instruments Inc., 
USA) was employed for optimization of image quality and image acquisition. 
 
2.9.4. Western blot analysis: brain tissue  
 
2.9.4.1. Sample preparation for western blot analysis 
 
Frozen brain tissue sections including the cerebellum, cortex and hippocampus 
region, were dissected into smaller pieces using aseptically treated surgical scissors 
while on ice. For a ~10 mg piece of brain tissue, 500 µl ice cold RIPA buffer 
supplemented with protease and phosphatase inhibitors was added to the Eppendorf 
tube and the tissue was rapidly homogenized by sonication on ice, using 3 bursts of 5 
secs in the Kine Matica Polytron PT2100 homogenizer (ThermoFisher Scientific). The 
tissue homogenates were t briefly allowed to settle on ice before being centrifuged at 
8000 RPM for 10 min at 4oC. The supernatant was then aspirated from the pellet and 
transferred to a new pre-chilled Eppendorf tube. After using the Direct Detect™ System 
(EMD Millipore) to determine the protein concentration of each sample, tissue lysates were 
prepared for SDS gel loading, and assessed for various proteins according to previously 
described standard procedures. 
 
2.10. Statistical analyses 
 
All statistical analysis was performed in Statistica 64 v.13 (Dell Inc.). All data sets were 
assessed for normality and the appropriate tests were performed, including paired 
Student’s t-tests, one-and two-way ANOVA with Fisher’s least significance difference 
test as post hoc test. Bonferroni correction for multiple comparisons was applied 
where appropriate. Mean values ± standard error of the mean (SEM) are reported. 
Results were considered statistically significant when p<0.05. 
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CHAPTER 3 RESULTS. IN VITRO CHRACTERISATION OF APP 
OVEREXPRESSION MODEL 
 
3.1. Introduction to results 
 
Neurotoxic deposition of Aβ peptides, owing to increased APP cleavage or decreased 
Aβ degradation, has been shown to be an early event in AD progression (Selkoe and 
Hardy, 2016). Elevated Aβ levels have been found in cells from both patients with pre-
symptomatic and clinical AD (Citron et al., 1994; Selkoe, 2001), supporting the notion 
that Aβ overproduction may occur many years prior to the onset of clinical symptoms. 
Increased Aβ levels have been shown to correlate with the level of cognitive decline 
observed in AD patients, supporting the hypothesis that failure to regulate the 
production and clearance of Aβ, leads to neurotoxicity and contributes to AD 
pathogenesis (Bharadwaj et al., 2009). Moreover, studies comparing Aβ levels in 
young (3 months old) and old (12 to 15 months old) mice found that the half-life of Aβ 
within the brain interstitial fluid is doubled in older animals (Herukka et al., 2015). This 
data indicates that AD progression may be primarily associated with diminished Aβ 
clearance from the brain, in part, due to a diminished protein clearance capacity, with 
age. In order to assess the role of macroautophagy (MA) and CMA in this context, 
mouse neuroblastoma (N2a) cells stably expressing: (i) the APP Swedish double 
mutation K670N/M671L shown to augment Aβ production (N2aswe); (ii) human wild-
type APP695 (N2awt); and (iii) N2a cells transfected with an empty vector (N2avec) 
were utilized as a means to mimic in vitro APP processing that may be associated with 
that observed in the human condition in AD. N2aswe cells were incubated in BA-
containing medium for 12, 24, 36, and 48 hrs to simulate the effects of early and late 
amyloidogenesis. Notably, BA treatment is specific for the induction APP transgene 
CMV promoter (Lo et al., 1994). To rule out the potential influence of BA treatment on 
the APP expression levels observed in N2awt, and N2avec cells, these cells were 
treated with BA to validate the null-effect of this compound. 
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3.2. Results  
 
3.2.1. Validation of APP overexpression model: western blot analysis of APP, Aβ, and 
LC3II in N2avec/N2awt/N2aswe cells 
 
As shown in Fig. 3.1.A, APP protein expression is significantly increased in the 24 hrs 
BA treated N2aswe cells [1.65 ± 0.05 (p<0.05)] compared to control N2aswe cells 
[1.16 ± 0.08]. Similarly, APP expression is significantly increased in the 24 hrs BA 
treated N2awt cells [1.11 ± 0.07 (p<0.05)] compared to control N2awt cells [0.76 ± 
0.1], with no difference in APP expression in the 24 hrs BA treated N2avec cells [0.14 
± 0.03] compared to control N2avec cells [0.11 ± 0.003] (Fig. 3.1.B). 
 
Figure 3.1.C reveals that Aβ protein expression is significantly increased in the 24 hrs 
BA treated N2aswe cells [0.19 ± 0.02 (p<0.05)] compared to control N2aswe cells 
[0.32 ± 0.03]. No significant difference in Aβ expression is indicated in the 24 hrs BA 
treated N2awt cells [0.15 ± 0.02] compared to control N2awt cells [0.14 ± 0.03], or in 
the 24 hrs BA treated N2avec cells [0.04 ± 0.0] compared to control N2avec cells [0.04 
± 0.0] (Fig. 3.1.D). 
 
As shown in Fig. 3.1.E, LC3II protein expression is significantly increased in the 24 
hrs BA treated N2aswe cells [1.38 ± 0.14 (p<0.05)] compared to control N2aswe cells 
[0.8 ± 0.14]. No significant difference in LC3II expression is indicated in the 24 hrs BA 
treated N2awt cells [0.39 ± 0.1] compared to control N2awt cells [0.36 ± 0.06], or in 
the 24 hrs BA treated N2avec cells [0.15 ± 0.1] compared to control N2avec cells [0.15 
± 0.0] (Fig. 3.1.F). 
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Figure 3.1: Amyloidogenic processing and MA activity in N2avec, N2awt and N2aswe 
cells in response to 24 hrs APP overexpression. Representative western blot and 
densitometric analysis for (A, B) APP, (C, D) Aβ, and (E, F) LC3II protein expression is shown. 
Data expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni correction, 
*p<0.05 vs. cell line specific control, n = 6, arbitrary units (a.u). 
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3.3. Time-dependent characterization of APP overexpression model 
 
3.3.1. Effect of APP overexpression on cell viability 
 
In order to assess the effects of BA treatment on cell viability, the WST-1 tetrazolium 
reduction assay was utilized. The results indicate that viability (indicated by the WST-
1 tetrazolium product that is directly proportional to the number of viable cells) 
measured in N2aswe cells is significantly decreased in the 24 hrs BA treated group 
[0.065 ± 0.005 (p<0.05)], 48 hrs BA treated group [0.046 ± 0.002 (p<0.05)], 72 hrs BA 
treated group [0.036 ± 0.002 (p<0.05)], 96 hrs BA treated group [0.016 ± 0.004 
(p<0.05)], 120 hrs BA treated group [0.009 ± 0.002 (p<0.05)], and 144 hrs BA treated 
group [0.006 ± 0.002 (p<0.05)] compared to control cells [0.087 ± 0.002] (Fig. 3.2). BA 
treatment time points of 12, 24, 36, and 48 hrs BA exposure were selected for 
subsequent experiments.  
 
 
Figure 3.2: Effect of APP overexpression on reductive capacity in N2aswe cells. Data 
expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni correction, *p<0.05 
vs. control. 
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3.3.2. Western blot analysis of amyloidogenic processing in response to APP 
overexpression 
 
APP protein expression is significantly increased in the 12 hrs BA treated group [1.69 
± 0.12 (p<0.05)], 24 hrs BA treated group [2.79 ± 0.13 (p<0.05)], 36 hrs BA treated 
group [3.17 ± 0.24 (p<0.05)], and 48 hrs BA treated group [4.32 ± 0.14 (p<0.05)] 
compared to control cells [0.31 ± 0.03]. Additionally, APP expression is significantly 
increased in the 48 hrs BA treated group compared to the 24 hrs BA treated group 
and 36 hrs BA treated group (Fig. 3.3.B). 
 
As shown in Fig. 3.3.C, β-secretase protein expression is significantly increased in the 
24 hrs BA treated group [2.23 ± 0.33 (p<0.05)], 36 hrs BA treated group [3.51 ± 0.18 
(p<0.05)], and 48 hrs BA treated group [4.04 ± 0.19 (p<0.05)] compared to control cells 
[0.5 ± 0.12], with no significant difference in the 12 hrs BA treated group [1.35 ± 0.17] 
compared to control cells. Additionally, β-secretase expression is significantly 
increased in both the 36 hrs BA treated group and 48 hrs BA treated group compared 
to the 24 hrs BA treated group (Fig. 3.3.D). 
 
Figure 3.3.E reveals that Aβ protein expression is significantly increased in the 24 hrs 
BA treated group [1.25 ± 0.07 (p<0.05)], 36 hrs BA treated group [1.33 ± 0.08 
(p<0.05)], and 48 hrs BA treated group [1.52 ± 0.12 (p<0.05)] compared to control cells 
[0.04 ± 0.01], with no significant difference in the 12 hrs BA treated group [0.08 ± 0.01] 
compared to control cells (Fig. 3.3.F). 
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Figure 3.3: Effect of APP overexpression on amyloidogenic processing in N2aswe cells. 
Representative western blot and densitometric analysis for (A, B) APP, (C, D) β-secretase, 
and (E, F) Aβ protein expression is shown. Data expressed as mean ± SEM, statistical 
analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, 
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3.3.3. Correlative Light and Electron Microscopy (CLEM) of APP localization in 
response to APP overexpression 
 
CLEM analysis indicates that APP positive membrane structures (green) are 
increasing shed in a time-dependent manner into the extracellular environment in 
response to increasing APP expression (Fig. 3.4). 
 
Figure 3.4: CLEM characterization of APP localization in response to APP 
overexpression. Left panel. Scanning electron microscopy (SEM) micrographs indicating 
surface topography and composition. Middle panel. Light microscopy (LM) micrographs 
indicating the localization of APP (green). Right panel. CLEM micrographs of APP 
localization at different time points. Nuclei are counterstained with Hoechst 33342 (blue). SEM 
and CLEM scale bars indicate 20 μm, LM scale bars indicate 5 μm. Arrowheads indicate APP 
membrane shedding. 
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3.3.4. Western blot analysis of key macroautophagy (MA) proteins in response to APP 
overexpression 
 
As shown in Fig 3.5.A, LC3II protein expression is significantly increased in the 24 hrs 
BA treated group [2.77 ± 0.28 (p<0.05)], 36 hrs BA treated group [4.73 ± 0.42 
(p<0.05)], and 48 hrs BA treated group [6.17 ± 0.53 (p<0.05)] compared to control cells 
[0.09 ± 0.0]. Moreover, LC3II expression is further enhanced in the 36 hrs BA treated 
group, and 48 hrs BA treated group compared to the 24 hrs BA treated group (Fig. 
3.5.B). 
Figure. 3.5.C reveals that MA cargo protein p62, is significantly increased in the 12 
hrs BA treated group [2.79 ± 0.22 (p<0.05)], and the 24 hrs BA treated group [2.58 ± 
0.28 (p<0.05)] compared to both the control cells [0.62 ± 0.12] and 48 hrs BA treated 
group [6.17 ± 0.53] (Fig. 3.5.D). 













Figure 3.5: Effect of APP overexpression on key MA proteins in N2aswe cells. 
Representative western blot and densitometric analysis for (A, B) LC3II, and (C, D) p62 protein 
expression is shown. Data expressed as mean ± SEM, statistical analysis: ANOVA and 
Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3, arbitrary units (a.u). 
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APP localizes in distinct protein clusters that increase in abundance over time. 
Similarly, Aβ is indicated as cytoplasmic clusters that increase in abundance, 
particularly in the 24 hrs BA treated group and 48 hrs BA treated group. Similarly, 
LC3II positive structures are most abundant in the 24 hrs BA treated group, and the 
48 hrs BA treated group (Fig. 3.6). These data suggest a concomitant increase in MA 
activity with increasing APP and Aβ protein expression, particularly at later time-points. 
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3.3.5. Immunofluorescence characterization of APP, Aβ and LC3II localization in response to APP overexpression 
 
Figure 3.6: Immunofluorescence micrographs indicating a time-dependent increase in APP, Aβ, and LC3II localization in N2aswe cells 
in response to APP overexpression in time. Representative micrographs of APP (green), Aβ (yellow), and LC3II (red) are displayed. Nuclei 
are counterstained with Hoechst 33342 (blue). Scale bars indicate 5μm. Individual cells are demarcated. 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
101 
 
3.3.6. Western blot analysis of key chaperone-mediated autophagy (CMA) proteins in 
response to APP overexpression 
 
As shown in Fig. 3.7.A, LAMP2A protein expression is significantly increased in the 
36 hrs BA treated group [2.46 ± 0.19 (p<0.05)], and the 48 hrs BA treated group [3.06 
± 0.24 (p<0.05)] compared to control cells [1.17 ± 0.08]. Additionally, LAMP2A 
expression is significantly increased in the 48 hrs BA treated group compared to the 
24 hrs BA treated group (Fig. 3.7.B).  
No significant difference in HSC70 protein expression following BA treatment is 
indicated for all the treatment groups (Fig. 3.7.D). 
 














Figure 3.7: Effect of APP overexpression on key CMA proteins in N2aswe cells. 
Representative western blot and densitometric analysis for (A, B) LAMP2A, and (C, D) HSC70 
protein expression is shown. Data expressed as mean ± SEM, statistical analysis: ANOVA 
and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3, arbitrary units 
(a.u). 
Stellenbosch University  https://scholar.sun.ac.za
102 
 
3.3.7. Immunofluorescence and colocalization analysis of CMA markers following APP 
overexpression 
 
Colocalization of HSC70 with LAMP2A is often used to identify the subset of CMA 
active lysosomes, with the level of colocalization being used as a reliable steady-state 
indication of the CMA status (Kiffin et al., 2004). Colocalization analysis of key CMA 
proteins LAMP2A/HSC70 was performed (Fig. 3.8.A). A significant increase in 
LAMP2A/HSC70 colocalization is indicated in the 12 hrs BA treated group [0.32 ± 0.02 
(p<0.05)], 24 hrs BA treated group [0.47 ± 0.02 (p<0.05)], and in the 48 hrs BA treated 
group [0.56 ± 0.03 (p<0.05)] compared to control cells [0.23 ± 0.0]. Colocalization is 
significantly increased in the 48 hrs BA treated group compared to the 24 hrs BA 









Figure 3.8: Immunofluorescence micrographs indicating colocalization of LAMP2A and 
HSC70 in N2aswe cells in response to APP overexpression. A. Colocalization of LAMP2A 
(cyan) and HSC70 (green) puncta. B. Colocalization is quantified using Mander’s Overlap 
Coefficient (MOC). Data expressed as mean ± SEM, statistical analysis: ANOVA and 
Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3, a total of 18 cells 
were analysed, scale bar indicates 5 μm. 
 
3.3.8. Western blot and Caspase-Glo analysis of both expression and activity of key 
apoptosis proteins in response to APP overexpression 
 
A luminescent assay was utilized to measure the activity of caspase-3 and caspase-
7, proteases involved in the execution of apoptosis. The results indicate a significant 
increase in caspase 3/7 activity in the 24 hrs BA treated group [154.4 ± 10.9 (p<0.05)], 
36 hrs BA treated group [168.4 ± 15.0 (p<0.05)], and 48 hrs BA treated group [208.0 
± 17.6 (p<0.05)] compared to control cells [100.0 ± 0.0]. Additionally, the activity of 
caspase 3/7 is significantly increased in the 48 hrs BA treated group compared to the 
24 hrs BA treated group (Fig. 3.9.A).  
 
Cleaved-PARP expression is significantly increased in the 24 hrs BA treated group 
[1.49 ± 0.24 (p<0.05)], 36 hrs BA treated group [2.61 ± 0.17 (p<0.05)], and 48 hrs BA 
treated group [2.76 ± 0.24 (p<0.05)] compared to control cells [0.04 ± 0.0]. Cleaved-
PARP expression remains significantly increased in the 36 hrs BA treated group and 
the 48 hrs BA treated group compared to the 24 hrs BA treated group (Fig. 3.9.C). 
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Total Caspase-3 protein expression is significantly increased in the 36 hrs BA treated 
group [1.46 ± 0.12 (p<0.05)], and in the 48 hrs BA treated group [1.45 ± 0.1 (p<0.05)] 
compared to control cells [0.59 ± 0.14] (Fig. 3.9.E).  
A. 
 

















Figure 3.9: Effect of APP overexpression on key apoptosis proteins. A. Caspase-3/7 
activity in response to APP overexpression. The luminescnt intensity produced is directly 
proportional to caspase 3/7 activity. Values are expressed as a percentage of the control 
(100%) in relative luminescence units (RLU). B. Representative western blot and 
densitometric analysis for (B, C) cleaved-PARP, and (D, E) Total Caspase-3 protein 
expression is shown. Data expressed as mean ± SEM, statistical analysis: ANOVA and 
Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3, arbitrary units (a.u). 
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3.3.9. Immunofluorescence and colocalization analysis following APP overexpression 
 
The cytosolic cargo p62 binds directly to LC3 for co-degradation by MA (Pankiv et al., 
2007), and is often used to assess protein turnover through MA. In order to assess the 
role of APP as a proteinaceous MA cargo, APP/p62 colocalization analysis was 
performed (Fig. 3.10.A). A significant increase in APP/p62 colocalization is indicated 
in the 24 hrs BA treated group [0.63 ± 0.04 (p<0.05)], and 48 hrs BA treated group 
[0.64 ± 0.04 (p<0.05)] compared to control cells [0.43 ± 0.03] (Fig. 3.10.B). 
 
Studies indicate that LAMP2A antibodies that specifically recognize the amino acid 
residues that constitute the cytosolic tail of LAMP2A are specific for LAMP2A levels 
present at the lysosomal membrane, which are limiting on substrate binding and 
degradation through CMA (Cuervo and Dice, 1996; Kaushik and Cuervo, 2012). In 
order to assess the role of APP as a proteinaceous CMA cargo, APP/LAMP2A 
colocalization was performed (Fig. 3.11.A). A significant decrease in APP/LAMP2A 
colocalization is indicated in the 12 hrs BA treated group [0.59 ± 0.02 (p<0.05)], 24 hrs 
BA treated group [0.69 ± 0.03 (p<0.05)], and in the 48 hrs BA treated group [0.57 ± 
0.03 (p<0.05)] compared to control cells [0.41 ± 0.02]. Moreover, APP/LAMP2A 
colocalization is significantly decreased in the 48 hrs BA treated group compared to 
the 24 hrs BA treated group (Fig. 3.11.B).  
 







Figure 3.10: Immunofluorescence micrographs indicating colocalization of APP and 
p62 in N2aswe cells in response to APP overexpression. A. Colocalization of APP (green) 
and p62 (red). B. Colocalization is quantified using Mander’s Overlap Coefficient (MOC). Data 
expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni correction, *p<0.05 
vs. control, n = 3, a total of 18 cells were analysed, scale bar indicates 5 μm. 
 







Figure 3.11: Immunofluorescence micrographs indicating colocalization of APP and 
LAMP2A in N2aswe cells in response to APP overexpression. A. Colocalization of APP 
(green) and LAMP2A (red) puncta. B. Colocalization is quantified using Mander’s Overlap 
Coefficient (MOC). Data expressed as mean ± SEM, statistical analysis: ANOVA and 
Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3, a total of 18 cells 
were analysed, scale bar indicates 5 μm. 
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3.4. APP and proteomics 
 
Having determined whether or not MA and CMA are both implicated during APP 
overexpression, next the proteome signature profile of N2aswe cells was 
characterised to assess the effects of APP overexpression on the global proteome. A 
LC‐MS based quantitative proteomics approach was utilized to perform a 
comprehensive large‐scale assessment of protein abundance following APP 
overexpression. Notably, 24 hrs BA treatment and 48 hrs BA treatment is hereafter 
referred to as early and late APP overexpression. 
Venn diagrams, graphs represented as either overlapping or non-overlapping circles, 
were employed to depict how groups of proteins relate to each other in response to 
early, and late APP overexpression. As shown in Fig. 3.12, the Venn diagram 
indicates that the largest set of proteins are shared and unique in response to early 
APP overexpression compared to control cells (Fig. 3.12.A). Further analysis was 
performed using volcano plots, scatter-plots with the − log10 (p-value) from the t-test as 
shown on the y-axis, and log2 fold change as shown on the x-axis. As shown in Fig. 3.13, 
preliminary analysis reveals that MA associated protein BECN1, CMA associated 
protein HSP7c, and apoptosis associated protein CASP3 are upregulated upon early 
APP overexpression, indicated as a 1.6 FC compared to control. Preliminary analysis 
of Fig. 3.14 reveals that MA associated protein BECN1, endocytosis protein RAB7a, 
and amyloidogenic protein APBA1 are upregulated upon late APP overexpression, 
indicated as a 3.0 FC compared to control. Lastly, preliminary analysis between early 
and late APP overexpression reveals that CMA protein HSP7c, anti-apoptotic protein 
BCL6 are upregulated, with APP overexpression indicated as a 2.28 FC when late 
APP overexpression is compared to early APP overexpression (Fig. 3.15).  
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Figure 3.12: Venn diagram indicating shared (yellow), and unique proteins expressed 
in response to early and late APP overexpression in N2aswe cells. A. Shared and unique 
proteins expressed between the control and early APP overexpressing group. B. Shared and 
unique proteins expressed between the control and late APP overexpressing group. C. Shared 
and unique proteins expressed between the early and late APP overexpressing group. D. The 
total number of shared and unique proteins expressed between the control, early APP 
overexpressing group, and late APP overexpressing group. 
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3.4.2. Volcano plot analysis of early APP proteome signature 
 
 
Figure 3.13: Volcano plot indicating changes in the level of protein expression in response to early APP overexpression in N2aswe 
cells. Differentially expressed proteins are displayed, red dashed line demarcates proteins with a 2.0-fold increase and above (p<0.05). Each 
protein is represented as a dot and is mapped according to its fold change, represented as the − log10 (p-value) from the t-test as shown on the 
y-axis, and log2 fold change as shown on the x-axis. 
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3.4.3. Volcano plot analysis of late APP proteome signature 
 
 
Figure 3.14: Volcano plot indicating changes in the level of protein expression in response to late APP overexpression in N2aswe cells. 
Differentially expressed proteins are displayed, red dashed line demarcates proteins with a 2.0-fold increase and above (p<0.05). Each protein 
is represented as a dot and is mapped according to its fold change, represented as the − log10 (p-value) from the t-test as shown on the y-axis, 
and log2 fold change as shown on the x-axis. 
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3.4.4. Volcano plot analysis of early versus late APP proteome signature 
 
 
Figure 3.15: Volcano plot indicating changes in the level of protein expression between early and late APP overexpression in N2aswe 
cells. Differentially expressed proteins are displayed, red dashed line demarcates proteins with a 2.0-fold increase and above (p<0.05). Each 
protein is represented as a dot and is mapped according to its fold change, represented as the − log10 (p-value) from the t-test as shown on the 
y-axis, and log2 fold change as shown on the x-axis. 
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To provide a critical assessment of the protein–protein interactions, including direct 
(physical) and indirect (functional) associations in response to APP overexpression, 
the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database 
which displays functional associations between proteins on a global scale was 
employed. As shown in Fig. 3.16, the STRING analysis reveals a preliminary direct 
functional association between early APP overexpression and the following key 
proteins: MA protein BECN1, lysosomal membrane protein LAMP1, apoptosis protein 
CASP3, oxidative stress protein CAT, glycolytic and CMA cargo protein GAPDH, and 
APP cleaving enzyme BACE1, when control cells are set as the reference group. 
 
Figure 3.17 reveals a preliminary direct functional association between late APP 
overexpression and the following key proteins: amyloidogenic protein APBA, and APP 
cleaving enzyme BACE1, apoptosis protein CASP3, glycolytic and CMA cargo protein 
GAPDH, and the major blood plasma protein ALB, when control cells are set as the 
reference group. 
 
When the formed protein–protein interactions between early versus late APP 
overexpression was assessed, the STRING analysis reveals a preliminary direct 
functional association between the following key proteins: lysosomal aspartyl protease 
CATD, APP cleaving enzyme BACE1, and glycolytic and CMA cargo protein GAPDH 
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3.4.5. The STRING network analysis of early APP proteome signature 
 
 
Figure 3.16: Proteome interaction network in N2aswe cells upon early APP 
overexpression. The STRING proteome network indicates direct protein-protein interactions 
between proteins with similar coloured nodes. The thicker the connecting line, the greater the 
strength of evidence for direct association. Red encircled indicates APP; black encircled nodes 
represent proteins of interest. 
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3.4.6. The STRING network analysis of late APP proteome signature 
 
Figure 3.17: Proteome interaction network in N2aswe cells upon late APP 
overexpression. The STRING proteome network indicates direct protein-protein interactions 
between proteins with similar coloured nodes. The thicker the connecting line, the greater the 
strength of evidence for direct association. Red encircled node indicates APP; black encircled 
nodes represent proteins of interest. 
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3.4.7. The STRING network analysis of early versus late APP proteome signature 
 
 
Figure 3.18: Proteome interaction network of early versus late APP expression in 
N2aswe cells. The STRING proteome network indicates direct protein-protein interactions 
between proteins with similar coloured nodes. The thicker the connecting line, the greater the 
strength of evidence for direct association. Red encircled node indicates APP; black encircled 
nodes represent proteins of interest. 
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3.4.8. Western blot analysis of samples utilized for proteome analysis  
 
3.4.8.1. Western blot analysis of APP and Aβ expression in early versus late APP 
overexpression 
 
APP protein expression is significantly increased in the 24 hrs BA treated group [1.85 
± 0.17 (p<0.05)], and in the 48 hrs BA treated group [2.03 ± 0.12 (p<0.05)] compared 
to control cells [0.19 ± 0.05] (Fig. 3.19.B). 
 
Similarly, Aβ protein expression is significantly increased in the 24 hrs BA treated 
group [0.09 ± 0.005 (p<0.05)], and in the 48 hrs BA treated group [0.13 ± 0.01 (p<0.05)] 
compared to control cells [0.01 ± 0.003] (Fig. 3.19.C). 
A. 
 











Figure 3.19: Effect of early and late APP overexpression on amyloidogenic processing 
proteins in N2aswe cells. Representative western blot and densitometric analysis for (A, B) 
APP, and (A, C) Aβ protein expression is shown. Data expressed as mean ± SEM, statistical 
analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, n = 3, arbitrary units (a.u). 
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3.4.8.2. Western blot analysis of LC3II and ATG5 expression in early versus late 
APP overexpression 
 
As shown in Fig. 3.20.A, LC3II protein expression is significantly increased in the 24 
hrs BA treated group [1.31 ± 0.08 (p<0.05)], and the 48 hrs BA treated group [2.08 ± 
0.06 (p<0.05)] compared to control cells [0.57 ± 0.05]. Moreover, 48 hrs BA treatment 
led to a significant increase in LC3II protein levels compared to 24 hrs BA treatment 
(Fig. 3.20.B). 
 
ATG protein expression is significantly increased in the 24 hrs BA treated group [1.35 
± 0.08 (p<0.05)], and the 48 hrs BA treated group [1.58 ± 0.05 (p<0.05)] compared to 













Figure 3.20: Effect of early and late APP overexpression on key MA proteins in N2aswe 
cells. Representative western blot and densitometric analysis for (A, B) LC3II, and (A, C) 
ATG5 protein expression is shown. Data expressed as mean ± SEM, statistical analysis: 
ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3, arbitrary 
units (a.u). 
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3.4.8.3. Western blot analysis of key CMA proteins in early versus late APP 
overexpression 
 
As shown in Fig. 3.21.A, LAMP2A protein expression is significantly increased in the 
48 hrs BA treated group [0.55 ± 0.03 (p<0.05)] compared to control cells [0.37 ± 0.01], 
with no significant difference indicated in the 24 hrs BA treated group [0.42 ± 0.03] 
compared to control cells. Moreover, 48 hrs BA treatment led to a significant increase 
in LAMP2A expression compared to 24 hrs BA treatment (Fig. 3.21.B). 
 
No significant differences in HSC70 protein expression are indicated in the 24 hrs BA 
treated group [1.04 ± 0.05], or the 48 hrs BA treated group [1.11 ± 0.1] compared to 











Figure 3.21: Effect of early and late APP overexpression on key CMA proteins in N2aswe 
cells. Representative western blot and densitometric analysis for (A, B) LAMP2A, and (A, C) 
HSC70 protein expression is shown. Data expressed as mean ± SEM, statistical analysis: 
ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3, arbitrary 
units (a.u). 
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3.4.8.4. Western blot analysis of cytochrome c expression in early versus late APP 
overexpression 
 
As shown in Fig. 3.22.A, cytochrome c expression is significantly increased in the 48 
hrs BA treated group [0.96 ± 0.06 (p<0.05)] compared to control cells [0.29 ± 0.05], 
with no significant difference indicated in the 24 hrs BA treated group [0.48 ± 0.03] 
compared to control cells. Moreover, 48 hrs BA treatment led to a significant increase 
















Figure 3.22: Effect of early and late APP overexpression on apoptosis in N2aswe cells. 
Representative western blot and densitometric analysis for (A, B) cytochrome c protein 
expression is shown. Data expressed as mean ± SEM, statistical analysis: ANOVA and 
Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3, arbitrary units (a.u). 
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CHAPTER 3 DISCUSSION: IN VITRO CHRACTERISATION OF APP 
OVEREXPRESSION MODEL 
 
Despite the significant advancement in our understanding of the mechanisms that 
contribute to AD progression, the aetiology of this complex disease remains unclear. 
The prevailing dogma provides compelling support for the prominent role of increased 
Aβ generation and/or accumulation in AD pathogenesis (Selkoe and Hardy, 2016). 
Moreover, as evidenced in initial studies by Glenner and Wong (1984), Aβ is present 
in its soluble form in the healthy brain, while only found in its aggregated form in the 
AD brain. Two primary mechanisms have been implicated in the clearance of Aβ 
peptides: firstly, degradation facilitated by various Aβ-degrading proteases, including 
β-secretase and cathepsin D (Saido and Leissring, 2012), and secondly, Aβ-laden 
autophagosomes have been shown to accumulate in dystrophic neurites (i.e. main 
constituents of neuritic plaques in AD), due to impaired MA function (Nixon et al., 2005; 
Yu et al., 2005). The is especially prevalent in the brains of AD patients, as evidenced 
by the accumulation of intracellular Aβ with neuronal degeneration in AD (Nilsson and 
Saido, 2014; Nilsson et al., 2013). Although the link between MA dysfunction and Aβ 
generation and/or clearance is increasingly being recognized as a unifying theme in 
AD pathology (Nixon, 2007; Nixon and Yang, 2011), the changes in macroautophagic 
activity during AD progression are poorly understood. In particular, the relationship 
between MA activity and Aβ clearance remains unclear, and to what extent a failing 
macroautophagic activity or increased proteotoxicity contributes to neuronal cell 
death. 
 
We demonstrate a clear relationship between increased APP overexpression with 
concomitant Aβ generation, resulting in increased neurotoxicity with time (Fig. 3.3). In 
line with these findings, several studies have shown that increased APP expression is 
proportionately associated with increased Aβ generation and may contribute to 
neurotoxicity through activation of the apoptotic pathway in both sporadic and FAD 
patients (Matsui et al., 2007; Wu et al., 2015). We also demonstrate that MA activity 
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is increased, even with APP overexpression at later time points (Fig. 3.5). Conversely, 
work by Nixon et al. (2005) indicates that MA is dysregulated in AD brains, and others 
have shown that the end stage of autophagosomal clearance is impaired in AD mouse 
models (Cataldo et al., 1991; Yang et al., 2011a).  
 
3.5. APP in vitro model validation – assessed by western blot analysis 
 
The mouse N2aswe cell line is one of the most frequently utilized in vitro AD models, 
and its use has advanced the understanding of both AD pathology and 
neurodegeneration over the past decades (Netzer et al., 2017; Thinakaran et al., 
1996). One of the most important lessons learned from genetic cases of AD, is that 
the neuropathology of FAD is very similar to sporadic AD, most notably, that Aβ 
deposition is also the primary event in sporadic AD (Shepherd et al., 2009). Moreover, 
the changes in biomarker expression observed in sporadic and FAD cases appears 
similar in many, but not all cases, thus making the N2aswe cell model informative for 
both disease subtypes (Dorszewska et al., 2016). Using western blot analysis, our 
results consistently demonstrate a marked increase in APP expression, with 
subsequent Aβ expression following the induction of APP overexpression in the 24 hrs 
BA treated N2aswe cells compared to the untreated N2aswe cells (Fig. 3.1.B,D). 
Although the level of APP expression is also significantly increased in the 24 hrs BA 
treated N2awt cells compared to the untreated N2awt cells (Fig. 3.1.B), no differences 
in Aβ expression are demonstrated (Fig. 3.1.D). In line with these findings, Netzer et 
al., (2017) demonstrate that the ratio of Aβ42/Aβ40, i.e. increased production of the 
more toxic Aβ42 relative to Aβ40, is enhanced following APP overexpression in 5 hrs 
BA treated N2aswe cells compared to both the untreated N2aswe cells and 5 hrs BA 
treated N2a 695 cells (same as N2awt cells) using an enzyme-linked immunosorbent 
assay (ELISA). Similarly, Lo et al. (1994) revealed that relative to the steady-state 
levels of APP and Aβ in N2aswe cells, the levels of these proteins were significantly 
diminished following 3 hrs BA treatment, demonstrated using surface biotinylation and 
release approaches. Importantly, our results indicate that the level of MA activity is 
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notably increased upon APP overexpression in the 24 hrs BA treated N2aswe cells 
compared to untreated N2aswe cells, while no differences are observed in the N2awt 
cells (Fig. 3.1.F). Consistent with these findings, others have shown that MA is a key 
regulator of Aβ generation and clearance (Nilsson and Saido, 2014), thus reinforcing 
the significance of APP, Aβ and the MA pathway in the pathophysiology of AD 
(Colacurcio and Nixon, 2016). Our results validate the use of the N2aswe cell line in 
this context, as evidenced by the profound increase in APP expression and Aβ 
generation, which is consistent with the cell line specifications outlined by Lo et al. 
(1994). Moreover, indications of markedly increased MA activity in the BA treated 
N2aswe cells suggests that the MA machinery is engaged during APP overexpression 
and requires further investigation to determine how functional the MA system remains 
in this context. The validity of our results was further confirmed by our comparison of 
the levels of APP, Aβ, and LC3II in the 24 hrs BA treated N2avec cells. As expected, 
the expression of these proteins was consistently negligible in the N2avec cells 
compared to the 24 hrs BA treated N2aswe cells (Fig. 3.1.B,D,F).  
 
3.6. Time-dependent effects of APP overexpression on cell viability - assessed by 
WST-1 analysis 
 
The importance of APP in AD pathogenesis relates to its role in the increased 
generation of toxic Aβ (Butterfield, 2002; Chen et al., 2000). However, when this 
toxicity becomes detectable, and what levels APP expression causes the loss of cell 
viability is less clear. The results of the WST-1 assay indicate that the cytotoxic effects 
of APP overexpression are time-dependent, with a profound decrease in cell viability 
revealed as early as 24 hrs BA treatment (Fig. 3.2). In agreement, initial in vitro studies 
by Yankner et al. (1989) demonstrates that increased Aβ production is acutely toxic, 
resulting in complete cell death within 24 hrs of APP overexpression in APPswe 
transfected PC12, and fibroblast (NIH 3T3) cells. More recent studies have also shown 
that the effects of increased APP expression as early as 24 hrs, results in the 
augmentation of neuronal cell death by favouring increased Aβ production in human 
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neuroblastoma medium spiny neuronal cells (MSN) (Quiroz-Baez et al., 2009) and 
APPswe transfected PC12 cells (Tong et al., 2005). Therefore, therapeutic 
interventions that mitigate APP overexpression with disease progression may 
translate in neuronal protection. 
 
3.7. Time-dependent assessment of APP, Aβ, and LC3II protein expression - 
assessed by western blot and immunofluorescence analysis 
 
Based on our WST-1 results (Fig. 3.2), it was concluded that BA treatment time points 
of 12, 24, 36, and 48 hrs would be most suitable to assess the progression of mild to 
more sever cell injury for subsequent experimental in N2aswe cells. 
 
Studies reveal that APP is continuously produced in large quantities in neurons, and 
rapidly metabolized to Aβ in the brain (Bateman et al., 2006; Lee et al., 2008b). Under 
physiological conditions, the amyloidogenic and non-amyloidogenic pathway are 
thought to exist in dynamic equilibrium in all cells (Haass et al., 1992; Mohamed and 
Posse de Chaves, 2011). Conversely, robust correlation has been demonstrated 
between the altered processing of APP, the increased production Aβ, and the extent 
of synaptic loss and cognitive decline in AD (Lue et al., 1999; McLean et al., 1999), 
suggesting that amyloidogenic processing is favoured in AD. It is however less clear, 
to what extent the MA machinery would be engaged during APP overexpression over 
time. To this end, the extent of amyloidogenic processing in N2aswe cells was 
assessed by western blot analysis. Our results reveal no APP, β-secretase, or Aβ 
expression under control conditions (Fig. 3.3). The results indicate a significant time-
dependent increase in APP levels as early as 12 hrs BA exposure, with APP 
expression further increasing upon 24, 36, and 48 hrs APP overexpression compared 
to control cells (Fig. 3.3.B). Moreover, our results indicate a similar pattern in β-
secretase levels, with its expression being significantly indicted upon 12 hrs BA 
exposure, and further increasing upon 24, 36, and 48 APP overexpression compared 
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to control cells (Fig. 3.3.D), indicating the very close relation between APP levels and 
β-secretase activity. In line with these findings, others have shown that the Swedish 
APP mutation, causes increased proteolysis of APP by β-secretase to generate 
elevated levels of total Aβ or Aβ42, as this mutation clusters near the β-secretase 
cleavage site (Di Fede et al., 2009; Kuhn et al., 2010). The levels of Aβ expression is 
significantly enhanced already at 24 hrs APP overexpression, and is further increased 
upon 36, and 48 hrs APP overexpression compared to control cells, while no 
expression is observed upon 12 hrs BA exposure (Fig. 3.3.F). This observation 
suggests that even though APP levels are already significantly elevated upon 12 hrs, 
a time-dependent effect is required for enhanced APP availability to translate into the 
generation of enhanced Aβ levels. To this effect, MRI-based studies in AD patients 
suggests that either Aβ continues to be  sufficiently cleared, or not sufficiently 
generated early in disease progression (Butterfield, 2002; Holtzman et al., 2011). 
Alternatively, as suggested by Walsh and Selkoe (2007), the total levels of Aβ may 
only be detected when the abundance of Aβ42 is elevated above a certain threshold, 
and the abundance of Aβ40 is severely decreased. Although speculative, our results 
may suggest that the ratio of Aβ42 to Aβ40 is gradually elevated with time, and only 
becomes apparent upon 24 hrs APP overexpression and onward. In line with this idea, 
in vivo microdialysis (measurement of the levels of Aβ in the extracellular interstitial 
fluid (ISF) of the brain) comparing Aβ clearance in young (3 months old) and old (12 
to 15 months old) APP mouse models, demonstrated that the half-life of Aβ within the 
ISF is doubled in older animals, even when Aβ production is prevented (Cirrito et al., 
2003; Wildsmith et al., 2013), suggesting impaired/reduced Aβ clearance with age as 
also revealed by microdialysis analysis of ISF of the human brain (Mawuenyega et al., 
2010; Ramanathan et al., 2015). Interestingly, work by Yan et al. (2009) reveals that 
a small reduction in Aβ production is sufficient to reduce Aβ load in 6-month-old, but 
not in 10-month-old mice, suggesting that the brain's ability to clear Aβ diminishes with 
age/time, and that APP and Aβ homeostasis may be impacted by both production and 
clearance mechanisms. Overall, our results demonstrate a significant increase in β-
secretase only after 24 hrs (Fig. 3.3.D), supporting the notion that sufficient APP levels 
are required to enhance Aβ levels. Indeed, studies have shown a reduction in the rate 
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of APP turnover with increasing APP overexpression (Wu et al., 2015), and a decrease 
in α-secretase processing of APP in AD patients, i.e. the enzyme that cleaves APP 
inside the Aβ sequence, further augmenting Aβ production (Yan and Vassar, 2014). 
Therefore, strategies to either decrease β-secretase activity, or increase Aβ clearance 
prior to cell death onset, i.e. early disease stages, may be effective in AD treatment. 
 
The combination of light microscopy with electron microscopy, i.e. CLEM, affords the 
dual advantages of fluorescent imaging with the high-resolution of electron 
microscopy. APP fluorescence intensity APP is increased upon 12, 24, and 48 hrs 
APP overexpression compared to control cells, and APP increasingly also localizes in 
extracellular regions (Fig. 3.4). CLEM analysis reveals, that indeed, membrane 
structures visible in the SEM micrograph, are APP positive, indicating active shedding 
of APP positive membrane structures which is further increased upon 24 hrs and 48 
hrs BA exposure. In line with these observations, the cell membrane is thought to be 
the first site where the amyloidogenic cascade is initiated (Peters et al., 2009). 
Although the mechanism through which this cascade is initiated remains unclear, 
findings by Yanagisawa (2007) demonstrate that Aβ reduces membrane fluidity in 
PC12 cells and alters the localization of receptors within the plasma membrane. Peters 
and colleagues demonstrated that Aβ stimulates its own production through a positive 
feedback mechanism that enhances amyloidogenic processing of APP by complexing 
with GM-1 ganglioside to reduce membrane fluidity (Peters et al., 2009). Indeed, our 
western blot findings of elevated APP, and Aβ expression with time (Fig. 3.3) may 
support the notion of changing membrane dynamics since APP-positive membrane 
structures are being released into the extracellular space (Fig. 3.4). These findings 
provide new insights into the mechanism of APP release and subsequent Aβ 
generation. 
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3.8. Time-dependent effects of APP overexpression on the molecular markers MA 
and CMA over time – assessed by western blot and immunofluorescence analysis 
 
Neurotoxic accumulation of Aβ in the brain is hypothesized to result from an imbalance 
in Aβ production and clearance (Musiek and Holtzman, 2015). Indeed, impaired Aβ 
clearance mechanisms, rather than its overproduction, have been shown to contribute 
to the pathological accumulation of cerebral Aβ as evidenced in sporadic AD cases 
(Mawuenyega et al., 2010), while increased β-secretase activity is reported to increase 
Aβ load in FAD patients (Holsinger et al., 2002; Li et al., 2004a), thereby impacting the 
capacity of Aβ clearance mechanisms. However, the interplay between MA activity in 
the process of APP overexpression is not clear. Our western blot analysis reveals a 
significant increase in LC3II protein expression upon 24, 36, and 48 hrs APP 
overexpression compared to control cells (Fig. 3.5.B), suggesting either an increase 
in autophagosome synthesis, or a decrease in autophagosome clearance. When 
assessing the MA cargo receptor p62, it becomes clear that MA activity may indeed 
be increased as p62 expression is comparable to control cells in the process of 36, 
and 48 hrs APP overexpression, suggesting p62 turnover is maintained even with late 
APP overexpression (Fig. 3.5.D). However, the expression of p62 is significantly 
increased upon 24 hrs APP overexpression compared to the control cells. This 
increase may be reflective of a temporary cargo increase, which is being cleared 
through the enhanced MA activity as evidenced by the significant decrease in p62 
levels upon 48 hrs APP overexpression compared to 24 hrs APP overexpression. This 
pattern is not mirrored by the Aβ cargo (Fig. 3.3.F), which could be due to the 
continuous overexpression of APP (Fig. 3.3.B). Based on the p62 expression profile, 
our data suggest that even during the process of the late APP overexpression, there 
is no MA failure per se, but rather a mismatch between macroautophagic activity and 
toxic protein cargo aggregation. In line with these findings, MA has been shown to be 
the ‘first-line of defence’ in an orchestrated stress-induced response which allows cells 
to remove damaged organelles, misfolded proteins, and aggregate-prone proteins 
such as Aβ in AD (Kroemer et al., 2010; Ravanan et al., 2017). Further support by Li 
et al. (2012), following the incubation of mouse neuroblastoma N2a cells and primary 
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cortical neurons obtained from 17-day-old embryos of wild-type C57BL/6 mice in 
exogenous Aβ42, reveals a concentration-dependent increase in the production of 
lysosomal system components is observed, while dysfunction of MA leads to the 
accumulation of Aβ. Although However, others suggest that protein variants shown to 
contribute to the pathogenesis of neurodegenerative disorders may fail to undergo 
degradation by MA and accumulate intracellularly resulting in cell toxicity and often 
cell death (Menzies et al., 2015; Nixon, 2013), consistent with our results, Nixon (2007) 
suggests that the combination of increased MA induction and defective clearance of 
Aβ-laden AVs may create conditions favourable for Aβ accumulation in AD. It is 
possible, that abnormal APP expression may constitute a cellular stress, the cell may 
therefore upregulate MA as a pro-survival stress response in an effort to mitigate the 
cytotoxic effects of increased Aβ production. Our model system allowed us to more 
finely dissect this relationship, by controlling the level of APP from non-toxic to toxic 
conditions, potentially better resolving the relationship between macroautophagic 
activity and toxicity onset with Aβ cargo generation. These findings provide rationale 
for the use of therapeutic strategies which enhance MA clearance, particularly with 
late disease progression, and may therefore have potential implications for clinical 
application. 
 
Our immunofluorescence analysis reveals an increase in APP, Aβ, and LC3II 
localization in distinct protein clusters that increase in abundance over time (Fig. 3.6). 
These clusters are particularly abundant upon 24 hrs, and 48 hrs APP overexpression, 
which is consistent with our western blot data demonstrating a significant increase in 
APP (Fig. 3.3.B), Aβ (Fig. 3.3.F), and LC3II (Fig. 3.5.B) protein expression at these 
time points. In line with our findings, the link between aberrant APP processing, Aβ 
generation, and impaired MA in AD has been extensively documented by others using 
western blot analysis, and pulse chase experiments (Li et al., 2012; Nixon, 2007). 
These data also highlight the clear relationship between MA machinery and Aβ cargo. 
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Under stress conditions, the selective removal of proteins by CMA also contributes to 
protein degradation, and recycling of amino acids. Due to its cross talk with MA under 
selective stress conditions (Kaushik and Cuervo, 2009; Massey et al., 2006c), it is 
important to determine the status of CMA, as APP overexpression and increased Aβ 
production constitutes a cellular stress which may necessitate a switch between these 
pathways. Although it is known that CMA is usually a late response that follows MA 
induction under nutrient, ER, or oxidative stress conditions (Gan et al., 2017; Ravanan 
et al., 2017), to what extent the CMA pathway engages under APP overexpression, 
remains however unclear. Hence, we performed western blot analysis to assess the 
effects of APP overexpression on the molecular markers of CMA activity, i.e. LAMP2A 
and HSC70, the abundance of which correlates well with an increase in CMA activity 
(Fig. 3.7). To our surprise, the results indicate a significant increase in LAMP2A 
protein expression in the process of 36 hrs, and 48 hrs APP overexpression compared 
to control cells, and is further increased upon 48 hrs compared to 24 hrs APP 
overexpression (Fig. 3.7.B). Studies indicate that the levels of LAMP2A at the 
lysosomal membrane is limiting for CMA activity in lysosomal fractions isolated from 
mouse fibroblasts cells (NIH 3T3) (Bandyopadhyay et al., 2008), and dopaminergic 
neurons cells derived from the substantia nigra of transgenic mouse embryos (SN4741 
cells) (Li et al., 2017c; Rodriguez-Losada et al., 2017). Here we demonstrate that CMA 
activity is increased in the process of late APP overexpression, possibly as a 
complementary pathway to MA as the cells attempt to accelerate APP clearance. In 
support of this notion, recent work by Park et al. (2016) discovered the presence of a 
KFERQ-like targeting sequence in APP, a characteristic that makes APP correct for 
degradation via CMA. However, most recent data by Tekirdag and Cuervo (2018) 
suggests that the presence of a KFERQ-like motif is necessary, but not sufficient to 
classify a protein as bona fide CMA substrate, as the same targeting sequence can 
also be used to target cytosolic proteins to late endosomes for degradation via the 
endosomal microautophagic pathway (Sahu et al., 2011). To our surprise, no 
difference in HSC70 protein expression is indicated with APP overexpression overtime 
(Fig. 3.7.D). It could be that a lysosomal fraction analysis is required, in order to finely 
interrogate the role of CMA in this context, since it has been shown that isolated 
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lysosomal fractions contain comparatively more CMA-active lysosomes than cellular 
lysates (Arias, 2017; Patel and Cuervo, 2015). It is plausible that additional pathways, 
such as endosomal microautophagy, may also play a role in this context. This notion 
may be addressed in the future. Our LAMP2A data suggest that a change in the CMA-
specific lysosomal pool size may be induced indicating that CMA is indeed induced, 
particularly at later time points in APP overexpression (Fig. 3.7.B). In line with our 
finding, Xiao et al. (2014) demonstrated that the expression of transcription factor EB 
(TFEB), a master regulator of lysosomal pathways, enhanced Aβ uptake and its 
lysosomal degradation to reduce Aβ levels in astrocytes. More recently, the authors 
reported a reduction in APP and Aβ levels in the brain ISF of aged APP/PS1 mice 
following the induction of CMV promoter-driven TFEB. These findings were further 
validated in vitro where TFEB transfection in N2a cells stably expressing APP695, 
enhanced lysosome biogenesis, reduced APP levels, and attenuated Aβ generation 
(Xiao et al., 2015). Our findings thus raise the possibility that a change in the lysosomal 
pool, as evidenced by enhanced LAMP2A protein levels (Fig. 3.7.B), may impact 
lysosomal degradative pathways to promote APP/Aβ clearance. 
 
Our western blot data are supported by the immunofluorescence analysis, where we 
show significant colocalization of LAMP2A with HSC70 following 12 hrs APP 
overexpression onwards (Fig. 3.8). This colocalization is further enhanced at 48 hrs 
compared to 24 hrs APP overexpression, suggesting that CMA activity is more 
pronounced at these later time points. These findings provide new insights into the 
mechanism of both MA and CMA recruitment. In line with our findings, cellular toxicity 
resulting from the accumulation of altered proteins (or proteotoxicity) has been shown 
to modulate CMA activity, as evidenced in mouse fibroblasts, PD, and HD-affected 
neuronal cells expressing mutant α-synuclein (Vogiatzi et al., 2008), huntingtin protein 
(htt) aggregates (Sarkar et al., 2009), ataxin-7, the protein bearing the polyQ stretch 
in spinocerebellar ataxia 7 (Duncan et al., 2010). Moreover, work by Bandyopadhyay 
et al. (2010) demonstrates that CMA is maximally activated under prolonged stress 
conditions, e.g. 48 hrs nutrient deprivation, as evidenced by increased colocalization 
of bona fide CMA substrates such as nuclear factor of kappa light polypeptide gene 
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enhancer in β-cells inhibitor, α (IκBα) and RNase with LAMP2A in isolated lysosomes 
from rat liver and mouse fibroblasts. In our study context, increased APP 
overexpression constitutes a cellular stress condition, these findings provide novel 
insights, that also upon APP–induced proteotoxicity, CMA activity is engaged, and 
highly active at later time points, even though neuronal toxicity is already detectable. 
 
3.9. Time-dependent effects of APP overexpression on the molecular markers of cell 
death with time – assessed by Caspase-3/7 Glo Assay and western blot analysis 
 
While Aβ has been shown to enhance endothelial cell survival in nanomolar 
concentrations, only becoming toxic in the micromolar range (Cantara et al., 2005), it 
remains unclear at what stage/time point in APP processing Aβ becomes toxic in 
neuronal cells. Accordingly, the Caspase-3/7 Glo assay was utilized to assess the 
time-dependent effects of APP overexpression on cell death, as evidenced by the 
activity levels of apoptotic executioner caspase proteins, caspase-3 and caspase-7, 
the activation of which is a consistent feature in AD brains (Smale et al., 1995; Su et 
al., 1994). The results indicate a time-dependent increase in caspase 3 and 7 activity 
following 24, 36 and 48 hrs APP overexpression compared to control cells, with the 
activity levels rising further significantly at 48 hrs compared to 24 hrs APP 
overexpression (Fig. 3.9.A). Of note, our data reveals that caspase activity becomes 
significant at the same time points where Aβ levels become significantly enhanced 
(Fig. 3.3.F). In line with our findings, previous reports indicate that APP 
overexpression may impact caspase activity, as APP has been shown to be a caspase 
substrate and caspase cleavage of APP has been shown to promote the production 
of C-terminal APP fragments in the brain of AD patients (Gervais et al., 1999; Lu et 
al., 2000). Caspase-3 is a key cell death protease involved in apoptotic cell death 
(Porter and Jänicke, 1999), and mediates the cleavage of several key proteins 
including DNA repair enzyme, poly (ADP-ribose) polymerase (PARP) (Brentnall et al., 
2013). Under physiological conditions, the primary function of PARP repair DNA 
damage, while the 89 kD cleaved-PARP fragment reveals greatly reduced DNA 
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binding capacity (Soldani and Scovassi, 2002). Consistent with enhanced caspase 
activity at these time points, our results indicate a significant increase in cleaved-PARP 
protein expression following 24, 36 and 48 hrs APP overexpression compared to 
control cells, and PARP cleavage is further enhanced in during 36 hrs and 48 hrs APP 
overexpression compared to 24 hrs APP overexpression (Fig. 3.9.B). These data 
suggest that apoptosis is not only activated, but fact executed as early as 24 hrs APP 
overexpression. Moreover, the activation of executioner caspases 3 and 7, has been 
shown to result in the irreversible proteolysis of PARP, leading to inevitable cell death, 
as evidenced in multiple cell lines, including HeLa cells, 3T3 fibroblasts, and various 
in vivo systems, including neuronal cells of C. elegans, and mammalian cardiac 
myocytes and neurons (Brentnall et al., 2013; Tang et al., 2012, 2013). In line with 
these findings, others have echoed the sentiment that PARP cleavage is the ‘point of 
no return’ because it typically leads to cell death (Loos and Engelbrecht, 2009; Tait 
and Green, 2013). Thus, our findings indicate that the induction of apoptosis is 
inevitable as early as 24 hrs APP overexpression. In agreement, earlier work by 
Mattson et al. (2001) demonstrated that enhanced APP processing leads to decreased 
levels of neuroprotective sAPPα in the cellular microenvironment, making cells more 
susceptible to cell death onset. We further assessed Total Caspase-3 activity using 
western blot analysis, and the results indicate a significant increase in Total Caspase-
3 protein expression upon 36 hrs, and 48 hrs APP overexpression compared to control 
cells (Fig. 3.9.E). Consistent with increased caspase activity in the process of 
enhanced APP expression, others have shown that APP is also a substrate for 
caspase-3 cleavage (LeBlanc et al., 1999; Lu et al., 2000), suggesting that increased 
caspase activity may exacerbate amyloidogenic processing. In line with this sentiment, 
Tesco et al. (2003) demonstrate that caspase-3 activation increases the production of 
total Aβ and Aβ42 in Chinese hamster ovary (CHO) cell lines stably transfected with 
APP751. Similarly, in vivo work by Zhao et al. (2003) has demonstrates that caspase-
mediated proteolysis of APP may contribute to neurodegeneration in AD. Conversely, 
western blotting and RT-PCR analysis reveals that caspase-3 inhibition decreases 
ischemia-induced Aβ production by reducing APP proteolysis and β-secretase mRNA 
and protein levels (Xiong et al., 2008). These findings provide new insights into the 
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potential link between apoptosis and amyloidogenic processing and may offer insights 
into the mechanisms involved in the cells life and death decisions. Importantly, our 
findings suggest N2aswe cells undergo apoptosis (Fig. 3.9), even with the 
upregulation of MA early in the process of APP overexpression (Fig. 3.5), and the 
induction of CMA later in the process (Fig. 3.7-3.8), suggesting that the cells are 
unable to counteract the sustained additional stress emanating from increased APP 
and Aβ levels (Fig. 3.3). Overall, these findings suggest that a delicate equilibrium in 
APP processing and Aβ production/clearance may exists within cells where sustained 
APP processing can induce cell death onset through increased Aβ production. They 
also point towards the interplay between caspase-mediated APP cleavage, apoptosis 
induction, and the time-dependent upregulation of  both MA and CMA in the process 
of enhanced APP/Aβ levels. This interplay warrants further investigation to better 
exploit mechanisms of cell protection in the future. 
 
3.10. Colocalization of APP with p62 and LAMP2A, and LAMP2A with HSC70 – 
assessed by immunofluorescence analysis 
 
Studies by Nilsson and Saido have not only demonstrated a role for MA in Aβ 
metabolism (Nilsson and Saido, 2014), but have also indicated increased Aβ 
accumulation in MA-deficient mice (Nilsson and Saido, 2014; Nilsson et al., 2015), 
suggesting a duel role for MA in Aβ production and clearance. However, when APP 
becomes cargo in the process of APP overexpression is less understood. Hence, 
colocalization analysis was performed to assess the interaction of p62 with APP over 
time. p62 is a receptor protein involved in cargo recruitment to the autophagosome 
and is in part degraded through MA (Salminen et al., 2012), therefore, p62 serves as 
a critical marker protein to indicate cargo degradation. Our findings reveal significantly 
increased APP/p62 colocalization in the process of 24 hrs and 48 hrs APP 
overexpression compared to control cells (Fig. 3.10). The increased colocalization 
observed during 24 hrs APP overexpression is consistent with our western blot data 
showing increased p62 (Fig. 3.5.D), and APP protein expression (Fig. 3.3.B), which 
Stellenbosch University  https://scholar.sun.ac.za
134 
 
are both enhanced at the 48-hr time point. These findings suggest that APP could be 
sequestered as MA proteinaceous cargo. In line with our findings, previous work by 
Yu et al. (2004) in an AD mouse model of amyloidosis demonstrates that AVs are 
enriched in both APP and Aβ, and Pickford et al. (2008) revealed increased Aβ load 
in in affected brain regions of patients AD, and following the deletion of MA-induction 
protein, BECN1, in APP mice. More recently, Caccamo et al. (2017) showed that 
removing the LIR domain of p62, which facilitates p62-mediated selective MA, in 7PA2 
cells, or blocking MA though 14 hrs 3MA treatment in p62 infected neuronal cells from 
APP/PS1 mice, was sufficient to prevent APP/Aβ clearance through MA. Further 
supporting the notion that APP is indeed being cleared, and not only engulfed into 
autophagosomes, our colocalization analysis of APP with LAMP2A, indicates that APP 
is indeed reaching the lysosome (Fig. 3.11.A). A time-dependent increase in 
APP/LAMP2A colocalization is observed compared to control cells, reaching 
significance already at 12 hrs APP overexpression, suggesting that APP cargo has 
been delivered to the lysosome already at this time point (Fig. 3.11.B). In line with our 
data, previous work by Park et al. (2016) reveals increased colocalization LAMP2A 
and APP in SH-SY5Y neuronal cells transfected with wild-type APP, while KFERQ-
deficient cells did not. These results provide new insights, that also during increased 
APP, at a time where toxicity is already indicated, APP increasingly colocalizes with 
LAMP2A (Fig. 3.11.B). To our surprise, APP/LAMP2A colocalization is reduced at the 
48-hr compared to the 24-hr time point, which may be explained, at least in part, by 
the fact that CMA activity was assessed in whole lysates instead of isolated lysosomes 
shown to be enriched in CMA-positive lysosomes (Arias, 2017). Significant 
colocalization late in APP overexpression suggests that the lysosomes at a late time 
point are composited of a higher percentage of CMA positive lysosomes, over the 
entire lysosome pool size. This may warrant further investigation, especially since 
novel techniques have been recently developed to isolate lysosomes (Abu-Remaileh 
et al., 2017). 
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3.11. APP proteome signature 
 
Despite the prevalence of shared pathology, and overlap in molecular machinery, 
characterisation of the proteome network linking lysosomal systems, including MA, 
CMA, and endocytosis, with the UPS and apoptosis and the dynamics of these 
systems with AD progression are incompletely understood. Here we report a large-
scale quantitative LC-MS proteomic dataset following APP overexpression in N2aswe 
cells. To this end, the global proteome signature of early (24 hrs) versus and late (48 
hrs) APP overexpression was profiled. This is, to the best of our knowledge, the first 
global proteome analysis of APP overexpression in an in vitro model of AD. The major 
advantage of LC-MS‐based proteomics over western blot, or immunofluorescence 
analysis is the quantity of proteins identified and the specificity of algorithms utilized in 
the automated quantification of protein datasets (Chiva and Sabidó, 2017). 
Surprisingly, the Venn diagram analysis indicates that the largest quantity of shared 
and unique proteins is expressed in response to early APP overexpression compared 
to control cells (Fig. 3.12.A), while Fig 3.12 B, C reveal less unique proteins between 
early versus late APP overexpression, and late APP overexpression versus control 
conditions, respectively. These results could suggest the robust engagement of 
pathways early in APP overexpression, while this response gradually decreases with 
increasing APP overexpression. In line with this notion, Seyfried et al. (2017) 
demonstrate a transient, concerted upregulation of a protein network prior to symptom 
onset, with key upregulated proteins linked to inflammatory responses, activation of 
astrocytes and microglia prior to cognitive decline in glial cells of asymptomatic and 
AD patients. In addition, large-scale transcriptome studies in the CA1 field of the 
hippocampus of individuals with advanced AD and non-demented controls reveals the 
modulation of pathways consistent with early microglial activation, production of 
energy, cytoskeletal dynamics, synaptic transmission, and apoptosis early in disease 
progression (Miller et al., 2013). Using an isobaric tag for relative and absolute 
quantitation (iTRAQ)-based two-dimensional LC coupled with tandem mass 
spectrometry (2D-LC-MS/MS), Manavalan et al. (2013) identified 950 proteins in the 
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hippocampus, cortex, and cerebellum of AD brains, most of which were implicated in 
in molecular transport, nervous system development, synaptic plasticity and 
apoptosis. Following Ingenuity Pathway Analysis (IPA)-based network analysis, 
Manavalan et al. (2013) suggested reduced UPS activity as one of the causative 
factors of sporadic AD (early stage). While these studies have generated significant 
knowledge regarding proteomic changes early in AD pathogenesis, there is a clear 
lack of quantitative proteomic studies designed specifically to identify APP and/or 
autophagy-related proteomic changes throughout AD pathogenesis. Given 
suggestions of apoptosis induction early in disease progression (Manavalan et al., 
2013; Miller et al., 2013; Wood, 2017), the APP early proteome response (Fig. 3.12) 
may indicate enhanced proteomic upregulation already early APP overexpression. 
Our volcano plot analysis reveals that APP expression is significantly higher during 
late APP expression compared to control cells (Fig. 3.14, 3.0 FC), and between 24 
hrs and 48 hrs APP overexpression (Fig. 3.15, 2.3 FC), which is consistent with our 
western blot data of the cell lysates utilized for proteome analysis (Fig. 3.19.B). To our 
surprise, the volcano plots reveal that MA protein BECN1 is significantly expressed 
during both early (Fig. 3.13, 2.81 FC) and late (Fig. 3.14, 2.75) APP overexpression, 
suggesting that BECN1 expression is maintained during APP overexpression, even at 
the late time point. BECN1, is an important protein that regulates the initiation of 
autophagosome formation. Our findings are contrast to a previous study by Pickford 
et al. (2008) which demonstrates that BECN1 is significantly reduced in brain tissue 
from the midfrontal cortex grey matter of moderate (mean age, 85.1 ± 2.7 years) to 
severe AD patients (mean age, 81.6 ± 4.2 years). In addition, these findings were 
confirmed cortical cells from aged APP transgenic mice leading to Aβ accumulation 
and neurodegeneration (Pickford et al., 2008). These findings were further confirmed 
by Jaeger et al. (2010) who showed a significant decline of BECN1 expression in 
cortical neurons from the mid-frontal tissue of confirmed AD patients. These data shed 
particularly new light into the relationship between APP and BECN1, suggesting a role 
for MA in the regulation of APP processing, and more studies are needed in this 
regard. In further support of our volcano plot data (Fig. 3.13-14), our western blot data 
also indicates significantly increased LC3ll and ATG5 protein levels in the cell lysates 
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utilized for proteome analysis (Fig. 3.20), suggesting that MA activity is sustained early 
and late in APP overexpression. ATG5 forms part of the ATG12-ATG5-ATG16L 
complex, one of the two ubiquitin-like conjugation systems involved in the early stages 
of autophagosome formation. Studies by Kuma et al. (2004) highlight the importance 
of this protein, showing that ATG5-knockout mice die at the neonatal stage, while 
overexpression of ATG5 in mice has been shown to induce MA and extend lifespan 
(Pyo et al., 2013). In line with our findings, microarray-based proteomics analysis 
carried out in DU145, MCF7, HT29 cells exposed to different durations of hypoxia 
reveals enhanced LC3II and ATG5 levels (Rouschop et al., 2010). Further work by 
Jaeger et al., (2010) also reveals significantly increased LC3II levels in AD brain 
tissue, with reduced BECN1 levels thought to inhibit the degradation rate of 
autophagosomes in this context, while ATG5 levels were not significantly changed. 
Contrary to our findings, Qiu et al. (2016) demonstrate reduced LC3II levels in the 
frontal cortex of AD post-mortem tissues of various Braak stages (Braak stages III, IV, 
V, VI), indicating MA impairment may be an early event in AD. Moreover, microarray 
data of the hippocampus and entorhinal cortex tissue from late-onset AD patients 
(mean age, 79.9 ± 6.9 years) reveal that ATG5 is downregulated in AD progression, 
and at the transcriptional level during ageing in healthy humans [young (≤40 y old) and 
old (≥70 y old)] (Lipinski et al., 2010). Recent work by Cavieres et al. (2015) found that 
depletion of ATG5 enhanced the accumulation of APP even in the presence of 
tetrahydrohyperforin (IDN5706), a compound previously shown to promote the 
degradation of APP/Aβ via MA in an ATG5-dependent manner (Inestrosa et al., 2011). 
These findings suggest that ATG5-dependent MA induction may impact Aβ 
metabolism, however, further studies are needed. Our volcano plot analysis indicates 
that HSP7c (also called HSC70) protein expression is significantly indicated only upon 
early APP overexpression (Fig. 3.13), suggesting that CMA may be induced as early 
as 24 hrs. In line with these findings, Cuervo et al. (1995) demonstrate that CMA is 
unregulated as early as 12 hrs following starvation in rat liver cells and remains active 
as long as starvation persists. Others have also shown that CMA activity is promoted 
in response to increased proteotoxicity, as evidenced in vivo for mutant tau and α-
synuclein (Chesser et al., 2013; Vogiatzi et al., 2008), however, it was not specified at 
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which time point in proteotoxicity CMA was induced. To our surprise, our western blot 
data reveals no significant difference in CMA activity at the 24-hr time point, instead, 
CMA activity is significantly induced only upon 48 hrs APP overexpression, i.e. 
enhanced LAMP2A, while HSC70 expression remains unchanged (Fig. 3.21.B,C). 
These findings are in contrast with previous data revealing that enhanced HSC70 and 
LAMP2A protein levels as early as 20 hrs in lysosomes isolated from the liver of rats 
starved for 20-88 hrs in the presence or absence of the protease inhibitor, leupeptin 
(Cuervo et al., 2000). These findings may be better aligned in the future using CMA-
positive lysosomes isolated from APP overexpression N2aswe cells. 
 
During early APP overexpression (Fig. 3.13), our volcano plot indicates increased 
caspase-3 (indicated as CASP3) levels, while no expression is revealed upon late APP 
overexpression (Fig. 3.14). Caspase-3 is a principal effector caspase that is critically 
involved in the progression of apoptosis and the appearance of hallmark 
morphological changes such as nuclear fragmentation (Brentnall et al., 2013). Our 
volcano plot finding is in contradiction with earlier caspase-3/7 Glo analysis which 
indicates a caspase 3/7 activation from 24 hrs onwards (Fig. 3.9). Similarly, others 
have demonstrated increased levels of caspase-3 immunoreactivity in AD 
hippocampal neurons of various Braak stages, where caspase-3 exhibits a high 
degree of colocalization with Aβ deposits and NFT (Louneva et al., 2008; Su et al., 
2001). Moreover, in situ immunohistochemistry and western blot analysis 
demonstrates that both caspase-3 and APP are increased in AD hippocampal and 
frontal cortex tissue [Braak stage IV-VI] compared to aged-matched control cases 
(Zhao et al., 2003). The detection of increased caspase-3 activity with APP expression 
supports the hypothesis that caspases contribute to amyloidogenic processes, and my 
thus contribute to AD neurodegeneration. To further address the role of apoptosis, 
western blot analysis of cytochrome c expression was performed. Cytochrome c is a 
mitochondrial protein with a dual role in respiration and apoptosis. Under physiological 
conditions, cytochrome c functions as a ROS scavenger and participates in the 
mitochondrial electron transport chain, thus playing an essential role in efficient ATP 
generation process (Hüttemann et al., 2011). Robust cytochrome c expression is 
indicated upon 48 hrs APP overexpression, with no difference upon 24 hrs APP 
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overexpression (Fig. 3.22.B). In line with our findings, in situ hybridization, 
immunocytochemistry analysis reveals a significant increase in cytochrome c levels in 
hippocampal, cortex, and cerebellum tissues obtained from AD patients at autopsy 
(mean age, 85 ± 4.2 years) (Hirai et al., 2001). Others have shown rapid cell death 
associated with decreased ATP production and the release of several apoptotic 
proteins, including cytochrome c, which triggered the caspase cascade leading to 
apoptosis in Jurkat T cells treated with ATP-synthase inhibitor or mitochondrial 
uncoupler (Aronis et al., 2003). Increased cytochrome c release has been shown to 
exacerbate the bioenergetic defect observed in platelet mitochondria and hippocampi 
and cortex tissue sections from AD patients [Braak stage IV (mean age, 65.2 ± 8.5 
years)] compared to age-matched control subjects (Bosetti et al., 2002). These data 
suggest a role of mitochondrial bioenergetics in the pathogenesis of AD, mitochondrial 
isolation from N2aswe cells may shed insight into oxidative phosphorylation 
(OXPHOS) function and ATP production in the process of APP overexpression. The 
volcano plot analysis representing protein expression between early and late APP 
overexpression reveals increased expression of APP, HSP7c, and anti-apoptotic 
protein BCL6 in addition to other proteins (Fig. 3.15). BCL6 has been called a “master 
regulator” of germinal centre formation and is thought to repress the transcription of 
hundreds of proteins, including those implicated in apoptosis (Basso et al., 2012). It is 
plausible that BCL6 may indicate a failed rescue attempt, as our data suggest a clear 
role for apoptosis machinery engagement after the 24-hr time point as evidenced by 
enhanced Aβ expression (Fig. 3.3) and caspase activation (Fig. 3.9). In fact, previous 
work by Kurosu et al. (2003) revealed that BCL6 overexpression significantly inhibited 
apoptosis and the increase in ROS levels in lymphoma cell lines following treatment 
with etoposide, a chemotherapeutic compound used for the treatments of various 
types of cancer, by enhancing the antioxidant defence systems. BCL6 has also been 
shown to be a repressor of the integral membrane 2B gene (ITM2B) (Del Campo et 
al., 2014). ITM2B is abundantly distributed in the hippocampus and cerebellum 
compared to the cortex . This protein has been found to bind to APP and inhibits its 
processing (Fotinopoulou et al., 2005; Matsuda et al., 2005, 2011), leading to a 
reduction Aβ production in N2a, HEK293, and HEK293T cells stably expressing APP-
751(Fotinopoulou et al., 2005), with a 3-fold increase in ITM2B found in AD 
hippocampus in early pathologic stages (Braak-III) (Del Campo et al., 2014), 
suggesting that BCL6 may have a role in AD progression. Overall, our findings raise 
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the possibility that key proteins involved in cellular stress mechanisms are upregulated 
during early and late APP overexpression. These include enhanced expression of APP 
Binding Family A Member 1 (APBA1) a protein that facilitates APP accumulation in the 
trans-Golgi network, ras-related protein, Rab7, which has a role in the late endocytic 
pathway and lysosome biogenesis. Indeed, electron microscopy studies by Jäger et 
al. (2004) found that Rab7 participated in the final maturation of late AVs and was 
highly colocalised with LC3II and late endosomal and lysosomal markers in HeLa and 
MEF cells following 1-4 hrs starvation. More recently, Rab7 has been suggested to 
regulate MA activity through its interaction with ATG4B (Kjos et al., 2017). In U2OS 
cells co‐transfected with GFP‐ATG4B and mCherry‐Rab7 and starved for 2 hrs, 
live‐cell imaging of indicates increased ATG4B colocalization with Rab7. 
Furthermore, TEM analysis revealed that Rab7 knockdown increased the size of AVs, 
with western blot analysis showing a substantial increase in LC3II levels in Rab7b‐
knockdown cells compared to control cells following macroautophagic flux 
assessment, i.e. cells were starved for 2 hrs in in the absence and presence of 
lysosomal acidification inhibitor bafilomycin A1 (Kjos et al., 2017). Overall, our findings 
suggest that MA activity is enhanced early in APP overexpression and remains 
enhanced as indicated by sustained BECN1 expression. Moreover, APP 
overexpression elicits transient and temporal engagement of CMA and the endolytic 
pathway machinery the in response to enhanced proteotoxicity, as evidenced by 
increased expression of oxidative stress and apoptosis markers (ADDENDUM A 
Table A2-A4).  
 
To gain further understanding of the protein networks involved in the context of APP 
overexpression, STRING database analysis was employed. This open-source 
database contains information on protein–protein interactions derived from the 
analyses of co-expressed proteins, high-throughput experimental data, database 
mining, and computational predictions (Rezadoost et al., 2016). STRING network 
analysis employs a scoring framework based on benchmarks of the various types of 
associations against a common reference set to produce a single confidence score 
per prediction (Szklarczyk et al., 2015). The STRING network analysis reveals a time-
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dependent increase in the complexity and abundance of APP-associated protein-
protein interactions in response to early (Fig. 3.16) and late (Fig. 3.17) APP 
overexpression. Notably, direct protein-protein interactions are consistently indicated 
between APP, BACE1 (also known as β-secretase), CASP3, and GAPDH during both 
early and late APP overexpression. Although reports have shown the upregulation of 
APP, BACE1, CASP3, as well as BECN1, the role of GAPDH is less understood. 
GAPDH is an abundantly expressed enzyme known for its role in glucose metabolism. 
Additionally, GAPDH is also a CMA substrate (Cuervo et al., 2000), and has been 
found to interact with disease-associated proteins such as Aβ (Sunaga et al., 1995), 
implicating this protein in neurodegeneration. Our STRING protein-protein network 
between early and late APP overexpression indicates that APP is also strongly 
associated with GAPDH (Fig. 3.18). In line with our findings, a large-scale single-
nucleotide polymorphism (SNP)-based association studies suggest that the GAPDH 
gene (GAPD) may be a risk factor for late-onset AD (Li et al., 2004b; Lin et al., 2006), 
showing increased colocalization with such as Aβ plaques extracted from AD cortical 
tissue (Sunaga et al., 1995). Hence, our data suggest that APP overexpression 
contributes to an enhanced glycolytic pathway activity, possibly as a cellular attempt 
to meet the increasing energetic demands following the upregulation of energy 
intensive proteolytic pathways such as MA, CMA, and the UPS during APP 
overexpression. In contrast with our findings, a three-year longitudinal study reveals 
that brain glucose metabolism was pathologically reduced in the temporal lobes of 
FAD patients before the clinical onset of symptoms became obvious (Wahlund et al., 
1999), suggesting that glycolysis may be impaired early in AD development. In support 
of this data, brain imaging study by Rapoport (1999) indicates that glucose metabolism 
is significantly reduced in severe AD patients compared to mildly demented patients, 
as well as age-matched controls. These analyses, in addition to others, serve to 
emphasize the critical role GAPDH plays in AD, however, more studies are required 
to further unravel the role of GAPDH in Aβ pathology, and AD pathogenesis. Although 
not indicated when comparing early and late APP overexpression to control cells, 
strong interaction between APP and cathepsin D (CasD) is indicated between early 
and late APP overexpression (Fig. 3.18). Our data, suggest that CasD expression in 
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N2aswe cells may form part of the APP proteome signature of AD. CasD is a 
lysosomal enzyme whose primary function is to degrade proteins through lysosomal 
proteolysis. In line with our findings, other studies indicate that CasD mRNA levels and 
enzyme activity are upregulated in blood lymphocytes of AD patients (Bai et al., 2014), 
and this protease is present in Aβ plaques, and may have a role in APP processing 
and Aβ clearance in vitro (Leissring and Turner, 2013; Tian et al., 2014). Indeed, 
several studies have reported dysfunction in the MA-lysosomal system at several 
stages of AD pathology (Cataldo et al., 1991, 1996; Nixon and Cataldo, 2006). 
Therefore, lysosomal proteases may have a role in neurodegeneration, as they play a 
dual role in APP processing within autophagosomal/endosomal vesicles and their 
dysregulation has been shown to contribute to the overall lysosomal pathology in 
numerous diseases, including AD. In fact, studies by Nixon et al. (2000, 2005) reveals 
that both immature AVs and hydrolase-containing lysosomes accumulate in dystrophic 
neurites, suggesting that fusion between these structures is inefficient. Morphometric 
analyses of post-mortem AD brain tissue (62-78 years) by Cataldo et al. (1996), 
reveals a 2 to 8 increase in CasD-positive vacuolar structures in 80–93% of all 
hippocampal, and pyramidal cells compared to age-matched controls, suggesting that 
MA activity and/or endocytosis are robustly activated. Conversely, Koike et al. (2005) 
demonstrate that AVs structures accumulate in neurons and dystrophic neurites of 
CasD-deficient mice, while enhancing neuronal cathepsin activity significantly reduced 
Aβ levels, mitigated AV pathology, and improved cognitive function in APP mice 
(Gowrishankar et al., 2015; Wang et al., 2012; Yang et al., 2011a, 2011b). These 
reports all support our data, which suggest an interplay between MA, endocytosis and 
the APP system.  
 
Notably our data also suggests an interplay between MA, and the UPS system, 
particularly late in APP overexpression (Fig. 3.17), as evidenced by the cluster of 
UPS-related proteins at this time point (ADDENDUM A Table A3). In line with our 
findings, studies have suggested that the UPS may contribute to AD pathogenesis 
(Hong et al., 2014; Upadhya and Hegde, 2007). In fact, recent studies reveal that de-
ubiquitinating enzymes, play a pivotal role in Aβ clearance. For example, enhanced 
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proteasomal degradation of β-secretase and γ-secretase components has been 
shown to result in reduced Aβ accumulation in HEK-293T, and cortical neuronal cells 
(Hong et al., 2014; Williamson et al., 2017). In support of these findings, Keller and 
colleagues, demonstrated a significant decrease in UPS activity in the hippocampal 
gyrus (48%), superior and middle temporal gyri (38%), and inferior parietal lobule 
(28%) of AD patients (mean age 77.9 ± 3.3 years), while no significant changes in 
proteasome activity was observed in less vulnerable brain regions, such as the 
cerebellum (Keller et al., 2000). In line with our findings, these studies indicate a 
possible role for the UPS during APP overexpression. However, future studies are 
needed to investigate the mechanism underlying the interplay between 
macroautophagic activity, APP/Aβ and the UPS in AD pathology. 
 
LC-MS proteomics is extensively used to facilitate the high-throughput detection and 
quantification of thousands of proteins in numerous AD clinical samples (Panis et al., 
2014; Ping et al., 2018). Of the two prevalent strategies used for protein-based 
quantitation, either label-free or differential labelling-based approaches, the former is 
favoured for quantitative proteomic studies (Théron et al., 2014). Hence, we employed 
a label-free LC-MS approach to characterise the APP proteome signatures early and 
late in APP overexpression. However, this approach has several limitations, including 
dependence on accurate mass measurements and reproducible peptide retention 
times by liquid chromatography (LC), which if not tightly controlled can introduce bias 
in peptide ion intensities and ultimately contribute to a higher number of missing values 
and increased variance of lower abundant proteins (Di Luca et al., 2015; Karpievitch 
et al., 2012). Accordingly, the expression of key amyloidogenic (APP, Aβ), MA (LC3II, 
ATG5), CMA (LAMP2A, HSC70), and apoptotic (cytochrome c) molecular markers 
proteins was further assessed by western blot analysis using the remaining cell lysates 
utilized in LC-MS proteome analysis. 
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CHAPTER 4 RESULTS: APP AND MACROAUTOPHAGIC FLUX ASSESSMENT 
 
4.1. Introduction to results 
 
Autophagic/macroautophagic flux refers to the dynamic balance between AV 
formation and clearance with the term flux referring to the rate of flow along the MA 
pathway (Klionsky et al., 2016; Loos et al., 2014). Impaired macroautophagic flux, as 
evidenced by the abnormal accumulation of AV, including autophagosomes or 
autolysosomes, in affected neurons of the brain is prominently observed at several 
stages in AD progression (Nixon and Yang, 2012). However, it is unclear whether 
accumulated AV reflect an increase in macroautophagic flux, as an increased 
autophagosome number can indicate macroautophagy induction or failed 
autophagosome fusion (Lee et al., 2010, 2011b). While LC3 levels serve as a read-
out of AV number at specific time points, they do not provide information about MA 
activity per se, as AV numbers can also be increased by blocking MA in later stages 
of the process (Klionsky et al., 2016). Macroautophagic flux is a more reliable indicator 
of MA activity and can be determined by comparing the numbers of AV in control 
conditions and after blocking the final steps of the process, e.g., after lysosomal 
inactivation. Hence, the aim of this chapter was to assess the effects of APP 
overexpression on flux, i.e. (i) MA and CMA activity, (ii) protein clearance, and (iii) 
neuronal protection. To this end, BA (5 mM) treated N2aswe cells were treated in the 
presence and absence of BafA1. Subsequently, western blot analysis for relevant 
protein levels, and TEM was conducted. 
 





In order to assess whether macroautophagic flux is still functional under APP 
overexpression, and whether flux may increase in time, N2aswe cells were treated 
with saturating concentrations of BafA1 (Loos et al., 2014). Briefly, western blot 
analysis was performed using 400 nM BafA1 for a treatment duration of 2 hrs 
(indicated as +), and 5 mM BA for a treatment duration of 24 hrs. 
 
4.2.1. Effect of flux modulation on amyloidogenic processing  
 
As shown in Fig. 4.1.A, APP protein expression is significantly increased in the 24 hrs 
BA treated group (+) [0.89 ± 0.02 (p<0.05)] compared to the 24 hrs BA treated group 
(-) [0.64 ± 0.06], and in the 48 hrs BA treated group (+) [1.09 ± 0.03 (p<0.05)] compared 
to the 48 hrs BA treated group (-) [0.85 ± 0.02]. More importantly, a significant increase 
in APP expression is indicated in the 24 hrs BA treated group (+) and the 48 hrs BA 
treated group (+) compared to the 12 hrs BA treated group (+), and in the 48 hrs BA 
treated group (+) compared the 24 hrs BA treated group (+) (Fig. 4.1.B). 
 
Figure 4.1.C reveals that β-secretase protein expression is significantly increased in 
the 24 hrs BA treated group (+) [0.77 ± 0.03 (p<0.05)] compared to the 24 hrs BA 
treated group (-) [0.47 ± 0.029], and in the 48 hrs BA treated group (+) [1.08 ± 0.12 
(p<0.05)] compared to the 48 hrs BA treated group (-) [0.77 ± 0.08]. Moreover, β-
secretase expression is significantly increased in the 24 hrs BA treated group (+) and 
the 48 hrs BA treated group (+) compared to the 12 hrs BA treated group (+), and in 
the 48 hrs BA treated group (+) compared the 24 hrs BA treated group (+) (Fig. 4.1.D). 
 
Similarly in Fig. 4.1.E, Aβ protein expression is significantly increased in the 24 hrs 
BA treated group (+) [0.77 ± 0.03 (p<0.05)] compared to the 24 hrs BA treated group 
(-) [0.57 ± 0.06], and in the 48 hrs BA (+) [1.0 ± 0.04 (p<0.05)] compared to the 48 hrs 
BA treated group (-) [0.84 ± 0.007]. Aβ expression is also significantly increased in the 
24 hrs BA treated group (+) and the 48 hrs BA treated group (+) compared to the 12 
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hrs BA treated group (+), and in the 24 hrs BA treated group (+) compared to the 48 
hrs BA treated group (+) (Fig. 4.1.F). 
 






















Figure 4.1: Effect of flux modulation on amyloidogenic processing in N2aswe cells. 
Representative western blot and densitometric analysis for (A, B) APP, (C, D) β-secretase, 
and (E, F) Aβ protein expression is shown. Data expressed as mean ± SEM, statistical 
analysis: ANOVA and Bonferroni correction, *p<0.05 vs. time-specific control (-), #p<0.05 vs 
12 hrs BA (+), $p<0.05 vs 24 hrs BA (+), n = 3, arbitrary units (a.u). 
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4.2.2. Effect of APP overexpression on macroautophagic flux  
 
In order to assess the impact of APP overexpression on macroautophagic flux in time, 
western blot analysis of key MA proteins was performed.  
 
As shown in Fig. 4.2.A, LC3II protein expression is significantly increased in control 
(+) [1.44 ± 0.17 (p<0.05)] compared to control (-) [0.28 ± 0.09], in the 12 hrs BA treated 
group (+) [2.38 ± 0.21 (p<0.05)] compared to the 12 hrs BA treated group (-) [1.09 ± 
0.29], in the 24 hrs BA treated group (+) [3.58 ± 0.26 (p<0.05)] compared to the 24 hrs 
BA treated group (-) [2.19 ± 0.23], and in the 48 hrs BA treated group (+) [5.24 ± 0.31 
(p<0.05)] compared to the 48 hrs BA treated group (-) [3.72 ± 0.32]. Moreover, a 
significant increase in LC3II expression is observed in the 24 hrs treated group (+) and 
the 48 hrs BA treated group (+) compared to the12 hrs BA treated group (+), and in 
the 48 hrs BA treated group (+) compared the 24 hrs BA treated group (+) (Fig. 4.2.B), 
suggesting an increase in macroautophagic flux. 
 
Figure 4.2.C reveals that p62 protein expression is significantly increased in the 24 
hrs BA treated group (+) [4.47 ± 0.18 (p<0.05)] compared to the 24 hrs BA treated 
group (-) [2.96 ± 0.37], and in the 48 hrs BA treated group (+) [5.33 ± 0.4 (p<0.05)] 
compared to the 48 hrs BA treated groups (-) [3.46 ± 0.27]. Moreover, a significant 
increase in p62 expression is observed in the 24 hrs BA treated group (+) and the 48 
hrs BA treated group (+) compared to the 12 hrs BA treated group (+) (Fig. 4.2.D), 
suggesting a decrease in cargo degradation with increasing flux, and APP 
overexpression. 
 

























Figure 4.2: Assessment of macroautophagic flux in N2aswe cells in response to APP 
overexpression. Representative western blot and densitometric analysis for (B, C) LC3II (low 
and high exposure), and (D, E) p62 protein expression is shown. Data expressed as mean ± 
SEM, statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. time-specific control 
(-), #p<0.05 vs 12 hrs BA (+), $p<0.05 vs 24 hrs BA (+), n = 3, arbitrary units (a.u). 
 
 
4.2.3. Effect of flux modulation in the context of APP overexpression on CMA activity 
 
In order to assess whether inhibition of cargo degradation through MA affects CMA 
activity over time, western blot analysis of key CMA proteins was performed.  
 
As shown in Fig. 4.3.A, LAMP2A protein expression is significantly increased in the 
24 hrs BA treated group (+) [1.19 ± 0.07 (p<0.05)] compared to the 24 hrs BA treated 
group (-) [0.84 ± 0.09], and in the 48 hrs BA (+) treated group [1.31 ± 0.06 (p<0.05)] 
compared to the 48 hrs BA treated group (-) [0.95 ± 0.05]. Moreover, LAMP2A 
expression is significantly increased in the 24 hrs BA treated group (+) and the 48 hrs 
BA treated group (+) compared to the 12 hrs BA treated group (+) [0.59 ± 0.05] (Fig. 
4.3.B), suggesting an increase in CMA activity. 
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Figure 4.3.C indicates that HSC70 expression is significantly increased in the 24 hrs 
BA treated group (+) [2.49 ± 0.12 (p<0.05)], and the 48 hrs BA treated group [2.72 ± 














Figure 4.3: Effect of flux modulation in the context of APP overexpression on CMA 
activity in N2aswe cells. Representative western blot and densitometric analysis for (A, B) 
LAMP2A, and (A, C) HSC70 protein expression is shown. Data expressed as mean ± SEM, 
statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. time-specific control (-), 
#p<0.05 vs 12 hrs BA (+), n = 3, arbitrary units (a.u). 
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4.2.4. Effect of flux modulation in the context of APP overexpression on apoptosis 
 
In order to assess whether inhibition of MA cargo degradation in the context of APP 
overexpression impacts apoptosis in time, western blot analysis of key apoptotic 
proteins was performed. 
 
As shown in Fig. 4.4.A, there is no significant difference in Total Caspase-3 protein 
expression under similar treatment conditions in the absence and presence of BafA1. 
In contrast, a significant increase in Total Caspase-3 is observed in the 24 hrs BA 
treated group (+) and the 48 hrs BA treated group (+) compared to the 12 hrs BA 
treated group (+) (Fig. 4.4. B). 
 
Figure 4.4.C reveals that cleaved-PARP protein expression is significantly increased 
in the 24 hrs BA treated group (+) [2.48 ± 0.14 (p<0.05)] compared to the 24 hrs BA 
treated group (-) [1.71 ± 0.25], and in the 48 hrs BA treated group (+) [3.17 ± 0.13 
(p<0.05)] compared to the 48 hrs BA treated group (-) [2.38 ± 0.22]. Additionally, a 
significant increase in cleaved-PARP expression is observed in the 24 hrs BA treated 
group (+) and the 48 hrs BA treated group (+) compared to the 12 hrs BA treated group 
(+) (Fig. 4.4.D). 
 
 

























Figure 4.4: Effect of flux modulation in the context of APP overexpression on apoptosis 
in N2aswe cells. Representative western blot and densitometric analysis for (A, B) Total 
Caspase-3, and (C, D) cleaved-PARP protein expression is shown. Data expressed as mean 
± SEM, statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. time-specific 
control (-), #p<0.05 vs 12 hrs BA (+), n = 3, arbitrary units (a.u). 
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4.2.5. Effect of APP overexpression on AV formation in N2aswe cells 
 
TEM analysis reveals increased abundance of AVs in a time-dependent manner upon 
BA exposure (Fig. 4.5 A, C, E, G). Moreover, AV formation is further increased in 
abundance and complexity upon BafA1 treatment (Fig. 4.5 B, D, F, H). These 
observations suggest that AV clearance is increasingly impeded in response APP 
overexpression, and further exacerbated in response to BafA1 treatment.  
 
 
Figure 4.5: Autophagic vacuole (AV) formation in the absence (left panel), and presence 
(right panel) of BafA1 in response to APP overexpression. Lower magnification 
micrographs (left of each panel) indicate general cellular ultrastructure; higher magnification 
micrographs (right of each panel) reveal the presence of AV structures. Nucleus = N, scale 
bar A-H = 5000 nm, higher magnification micrographs = 2000 nm, arrowheads indicate AV 
structures. 
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4.2.6. Quantification of AVs in N2aswe cells 
 
Image J automatic particle counting plug-in was used to quantify the number and area 
of AVs. The results indicate a significant increase in the number of AVs per cell in the 
control (+) [44.6 ± 4.08 (p<0.05)] compared to the control (-) [19.68 ± 0.99], in the 12 
hrs BA treated group (+) [59.65 ± 5.17 (p<0.05)] compared to the 12 hrs BA treated 
group (-) [35.11 ± 4.2], in the 24 hrs BA treated group (+) [80.63 ± 2.85 (p<0.05)] 
compared to the 24 hrs BA treated group (-) [58.03 ± 4.78], and in the 48 hrs BA 
treated group (+) [122.4 ± 3.08 (p<0.05)] compared to the 48 hrs BA treated group (-) 
[95.13 ± 4.93]. Moreover, a significant increase in AVs is observed in both the 24 hrs 
BA treated group (+) and the 48 hrs BA (+) treated group compared to the 12 hrs BA 
treated group (+), and in the 48 hrs BA treated group (+) compared to the 24 hrs BA 
treated group (+) (Fig. 4.6.A). 
 
Automated analysis of each AV reveals a significant increase in AV surface area per 
cell in the control (+) [45.19 ± 4.35 (p<0.05)] compared to the control (-) [21.33 ± 3.46], 
in the 12 hrs BA treated group (+) [58.18 ± 4.49 (p<0.05)] compared to the 12 hrs BA 
(-) [32.76 ± 3.0], in the 24 hrs BA treated group (+) [79.84 ± 4.7 (p<0.05)] compared to 
24 hrs BA treated group (-) [54.16 ± 7.47], with no significant difference between the 
48 hrs BA treated group (+) and the 48 hrs BA treated group (-) (Fig. 4.6.B). 
 









Figure 4.6: Quantification of the number and area of AVs in response to APP 
overexpression in N2aswe cells. A. Number of AVs per cell. B. Average area of AVs per 
cell. Data expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni correction, 
*p<0.05 vs. time-specific control (-), #p<0.05 vs 12 hrs BA (+), $p<0.05 vs 24 hrs BA (+). A 
total of 40 cells were analysed, n = 2. 
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4.2.7. Effect of APP overexpression on fibrillar ultrastructure in N2aswe cells 
 
Figure 4.7 A, C, E, G reveals fibrillar protein ultrastructure formation which increases 
in size upon BA exposure, and the abundance and size of these electron dense 
structures is further increased upon BafA1 treatment (Fig. 4.7 B, D, F, H), suggesting 
that APP overexpression impacts the formation and length of these structures, while 
BafA1 treatment impacts the abundance and length. 
 
 
Figure 4.7: Fibrillar protein ultrastructure formation in the absence (left panel), and 
presence (right panel) of BafA1 in response to APP overexpression. Lower magnification 
micrographs (left of each panel) indicate general cellular ultrastructure; higher magnification 
micrographs (right of each panel) reveal the presence of fibrillar structures. Nucleus = N, 
scale bar A-H = 5000 nm, higher magnification micrographs = 2000 nm, arrowheads indicate 
fibrillar structures. 
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4.2.8. Effect of APP overexpression on mitochondrial ultrastructure 
 
As revealed in Fig. 4.8 A, C, E, G, mitochondrial organelle accumulation is increased 
in abundance upon BA exposure, and is further increased in abundance upon BafA1 
treatment (Fig. 4.8 B, D, F, H), suggesting that APP overexpression increasingly 




Figure 4.8: Mitochondrial ultrastructure in the absence (left panel), and presence (right 
panel) of BafA1 in response to APP overexpression. Lower magnification micrographs 
(left of each panel) indicate general cellular ultrastructure; higher magnification micrographs 
(right of each panel) reveal mitochondrial structures. Nucleus = N, scale bar A-H = 5000 nm, 
higher magnification micrographs = 2000 nm, arrowheads indicate mitochondrial structures. 
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4.2.9. Effect of APP overexpression on ferritin-like inclusions 
 
TEM analysis reveals increased abundance of ferritin-like inclusions upon 24 hrs BA 
exposure and 48 hrs BA exposure (Fig. 4.9 A, C, E, G), and these inclusions are 
further increased in abundance upon BafA1 treatment (Fig. 4.9 B, D, F, H). Notably, 
these inclusions are absent in the control and 12 hrs BA exposed group, but are 
revealed in these groups upon BafA1 treatment, suggesting that clearance is impacted 
upon late APP overexpression and further impacted upon BafA1 treatment, even as 




Figure 4.9: The presence of ferritin in the absence (left panel), and presence (right 
panel) of BafA1 in response to APP overexpression. Lower magnification micrographs 
(left of each panel) indicate general cellular ultrastructure; higher magnification micrographs 
(right of each panel) reveal a time-dependent accumulation black inclusion bodies, most 
likely ferritin. Nucleus = N, scale bar A-H = 5000 nm, higher magnification micrographs = 2000 
nm, arrowheads indicate electron dense inclusion bodies. 
 
Stellenbosch University  https://scholar.sun.ac.za
157 
 
CHAPTER 4 DISCUSSION: APP AND MACROAUTOPHAGIC FLUX 
 
The role of MA dysfunction in neurodegeneration has received considerable attention 
in the last years. However, it remains largely unclear, whether MA dysfunction 
manifests with high macroautophagic activity or whether degradation of proteins 
completely fails. One of the challenges in this context is to accurately assess 
macroautophagic flux. To this end, macroautophagic flux was assessed in the context 
of APP overexpression by inhibiting autophagosome/lysosome fusion while observing 
the accumulation of autophagosomes or LC3II protein levels. 
 
4.3. Effect of flux modulation on amyloidogenic processing with APP overexpression 
 
To assess whether APP, β-secretase, and Aβ turnover is impacted by the blockade of 
MA’s degradative capacity over time, western blot analysis was performed in the 
absence and presence of BafA1 treatment (Fig. 4.1). The results indicate a time-
dependent increase in APP (Fig. 4.1.B), β-secretase (Fig. 4.1.D), and Aβ (Fig. 4.1.F) 
protein levels following 24 hrs and 48 hrs APP overexpression in the presence of 
BafA1 treatment compared to control cells. This data strongly suggests that (a), the 
macroautophagic pathway is still functional, since APP is increased in the presence of 
BafA1 at each time point, and (b) that the macroautophagic pathway is unable to clear 
the highly abundant APP protein, since it is continuously increasing. This result 
strongly suggests that the MA machinery, although dysfunctional in the context of 
coping with toxic protein aggregates, is, per se still functional and clears toxic protein. 
The line with our findings, others have shown that MA contributes to Aβ pathology. In 
a study by Nilsson et al. (2013), significantly decreased Aβ plaque load was reported 
in MA-deficient mice, and these findings were confirmed in MA-deficient 
cortical/hippocampal neurons in which Aβ was significantly reduced. Conversely, 
ATG7 lentivirus supplementation restored the level of Aβ released to that of MA-
competent neurons (Nilsson and Saido, 2014; Nilsson et al., 2013). More recently, 
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confocal microscopy analysis by Barbero-Camps et al. (2018) revealed higher 
presence of Aβ and autophagosomes (LC3B puncta) in the hippocampus from 7-
month-old APP mice. These data support our findings that MA influences APP/Aβ 
accumulation by regulating the clearance of these proteins. In line our findings of 
significantly enhanced β-secretase (Fig. 4.1.D), Cai et al. (2015) demonstrated that 
both MA inhibitor (24 hrs 3MA treatment) and inducer (24 hrs serum starvation) Aβ 
production and accumulation by enhancing the activity of β-, and γ-secretases in SH-
SY5Y cells. Our data also suggests that MA activity effects β-secretase and turnover 
since BafA1 treatment enhances its abundance, suggesting that β-secretase itself is 
also targeted to the MA machinery. These findings are supported by previous data 
showing enhanced the retention of β-secretase with AVs of cortical neurons isolated 
from APP mice, thereby leading to enhanced β-secretase cleavage of APP within 
these vesicles (Feng et al., 2016). Moreover, studies by Fukumoto et al. (2002, 2004) 
reveal that the levels of Aβ, and β-secretase activity are elevated with age in AD 
patient brains, rhesus monkeys, and in APP transgenic mice.  
 
Overall, our data reveals a time-dependent increase of APP, β-secretase, and toxic 
Aβ protein cargo, which is further enhanced following the blockage of autophagosome 
degradation (Fig. 4.1), raising the possibility that MA activity is not sufficient to meet 
the increased cargo. Therefore, MA enhancing drugs could promote the clearance of 
these proteins with disease progression and may represent a viable therapeutic 
strategy in the amelioration of Aβ neurotoxicity in AD. To our knowledge, this is novel 
and critical insights into the role of MA in Aβ induced toxicity.  
 
4.4. Effect of APP overexpression on macroautophagic flux  
 
To our surprise, our data reveals that autophagosome abundance is significantly 
increased (LC3II protein levels), however, macroautophagic flux remains unchanged, 
yet functional, even at the 48-hr time point (Fig. 4.2.B). However, despite a functional 
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macroautophagic activity, p62 levels increase, suggesting the mismatch between 
overall protein clearance and macroautophagic activity (Fig. 4.2.D). This data 
contrasts previous findings indicating that macroautophagic flux is reduced in brain 
tissue from AD patients, and in vivo AD models (Colacurcio and Nixon, 2016; Nixon 
and Yang, 2011). Our results clearly indicate that MA remains functional, albeit unable 
to clear APP, Aβ and β-secretase sufficiently. In line with our findings, a study by Bordi 
et al. (2016), which assessed the entire MA process in CA1 pyramidal neurons from 
early and late-stage AD patients, revealed that MA is upregulated early and 
progressively throughout the disease course. Consistent with our data, 
macroautophagy flux did not decrease, instead, becoming progressively impeded due 
to insufficient substrate clearance, as reflected by autolysosomal accumulation p62 
and expansion of autolysosomal size and total area. It is reasonable to propose that 
the upregulation of MA activity may be an initial neuroprotective to increasing 
proteotoxicity, which is maintained with increasing APP, and Aβ expression, but is 
insufficient to maintain substrate turnover. In contrast with our findings, accumulation 
of Aβ-laden autophagosomes have been reported in AD brain tissue and in vivo 
models of AD with AD progression (Nilsson et al., 2013; Nixon, 2007; Yu et al., 2004, 
2005). These findings not only suggest that the end stage of autophagosomal 
clearance is impaired, but also, that impaired MA may be implicated in the mechanism 
of Aβ toxicity as suggested by Nixon (2007). To our knowledge, our results indicate 
for the first time, that macroautophagic flux remains functional in APP overexpressing 
N2aswe cells, and in fact, is significantly upregulated even as the clearance of MA 
cargo is progressively reduced. This novel observation indicates that MA activity can 
still be modulated even at late time points, as macroautophagic flux is maintained with 
increasing Aβ neurotoxicity. However, further studies are needed to comprehensively 
evaluate the entire MA process, specifically in vulnerable neuronal cell populations, 
from early to late stages in AD progression compared to controls. In addition, a 
component of model system utilization may also contribute to the variability in findings. 
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4.5. Effect of flux modulation in the context of APP overexpression on CMA activity 
 
Autophagic pathways are closely interconnected (Park and Cuervo, 2013), and 
although MA and CMA are preferentially activated in a time- and stimuli-specific 
manner, most cells activate MA in response to CMA blockage and vice versa (Kaushik 
and Cuervo, 2018). The interplay between MA and CMA activity during the 
progression of AD is not well understood. Hence, in order to determine whether CMA 
is induced as a compensatory response to the inhibition of autophagosome- 
degradation, western blot analysis was performed to assess LAMP2A and HSC70 
protein levels in the context of APP overexpression in the presence and absence of 
BafA1 treatment (Fig. 4.3.A). While LAMP2A protein expression is significantly at the 
24-hr and 48-hr time points compared to the time-specific control cells following BafA1 
treatment (Fig. 4.3.B), no significant difference in HSC70 levels is observed at these 
time points (Fig. 4.3.C). However, HSC70 expression is significantly enhanced during 
24 hrs and 48 hrs APP overexpression compared to 12-hrs APP overexpression 
following BafA1 treatment. These data indicate that CMA activity remains relatively 
unchanged early in APP overexpression, however, it is enhanced upon impairment of 
MA’s degradative capacity, as revealed following BafA1 treatment during 24 hrs and 
48 hrs APP overexpression. These findings are supported by previous reports that 
have shown that increased LAMP2A and HSC70 protein levels serve as preliminary 
indicators of increased CMA activity (Arias, 2017). Although there are discrepancies 
in HSC70 expression, it may be that the cell lysates utilized in this analysis contained 
a lower lysosomal fraction of HSC70, however, this does not infer a reduction in CMA 
capacity as LAMP2A levels at the lysosomal membrane have been shown to be rate-
limiting step for CMA activity in lysosomes isolated from rat liver with age (Cuervo et 
al., 1995b, 1997). Moreover, a study by Xilouri et al. ( 2013) found that overexpression 
of LAMP2A alone was sufficient to enhance CMA activity and reduce the levels of 
mutant α-synuclein in rat cortical neurons in vitro, SH-SY5Y cells, and dopaminergic 
neurons in vivo, thereby mitigating α-synuclein-induced proteotoxicity. Our data 
indicates sequential activation in CMA activity at the later time points (Fig. 4.3.B), 
which is maintained with MA activity at these time points (Fig. 4.2.B), following 
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significantly APP and Aβ expression (Fig. 4.1). Our data suggests that the activity of 
both pathways remain functional but are not sufficient for Aβ clearance. In contrast 
with our findings, previous studies by Wang and colleagues in a cell model of 
tauopathy demonstrate that of mutated tau protein is incompletely digested by the 
CMA pathway, leading to tau aggregation (Wang et al., 2009). At the same time, MA 
activity was enhanced and able to clear these CMA-related tau aggregates, 
suggesting the functional interplay between MA and CMA in the context of mutant tau 
proteotoxicity (Wang et al., 2009, 2010). Our data therefore suggests that 
compensatory CMA induction, while beneficial in certain contexts such as tau (Wang 
et al., 2009) and mutant α-synuclein-mediated blockage of CMA function (Cuervo et 
al., 2004), is not sufficient to compensate for the MA activity in the context of APP 
overexpression over time. These data provide new insights into CMA activity following 
inhibition of autophagosome degradation in this context, however, further studies are 
warranted to determine whether Aβ toxicity is further augmented when both MA and 
CMA function is inhibited.  
 
4.6. Effect of flux modulation in the context of APP overexpression on apoptosis 
 
Massive neuronal cell death due to apoptosis is a common characteristic in 
neurodegeneration and has been extensively characterised in the brains of AD 
patients (Obulesu and Lakshmi, 2014; Shimohama, 2000). However, the role of MA in 
impacting apoptosis onset in the face of Aβ-induced toxicity in the context of APP 
overexpression remains unclear. Hence, western blot analysis of key apoptosis 
molecular markers was assessed in the absence and presence of BafA1 during APP 
overexpression (Fig. 4.4). Our results indicate a similar trend in Total Caspase-3 and 
cleaved-PARP expression, with the level of both proteins being significantly increased 
during 24 hrs, and 48 hrs APP overexpression in the presence of BafA1 compared to 
12 hrs APP overexpression in the presence of BafA1 (Fig. 4.4.B,D). More importantly, 
the induction of apoptosis is only revealed in response to MA dysfunction, as indicated 
by the enhanced cleavage of PARP protein during 24 hrs and 48 hrs APP 
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overexpression in the presence of BafA1 compared to the time-specific control cells 
(Fig. 4.4.D). These results indicate that the blockage of autophagosome degradation 
impacts cell viability in favour of cell death onset during APP overexpression at later 
time points, and therefore highlight the protective role of MA in the context of Aβ-
induced toxicity. In line with these findings, studies of MA-deficient mice reveal 
enhanced neuronal cell death and the accumulation of cytoplasmic proteins (Komatsu 
et al., 2006, 2007b; Liang et al., 2010). Others have shown that impaired 
autophagosome degradation augments the aggregation of Aβ oligomers and 
promotes cytochrome c release in APP mice with age, thereby triggering activation of 
the caspase cascade and favour cell death onset (Hashimoto et al., 2003; Sasaguri et 
al., 2017). Similarly, a study by Lustbader et al. (2004) suggests that APP 
overexpression may impact cell viability as evidenced by increased ROS levels, cell 
death onset, and impaired cognitive function in the brains of AD patients and AD 
mouse models in response to increased Aβ proteotoxicity. Our data reveals that the 
expression of Total Caspase-3 and cleaved-PARP is augmented following APP 
overexpression with impaired MA function at the same time points that Aβ protein 
levels are enhanced (Fig. 4.1.F). These results suggest a direct link between cell 
death onset, APP overexpression/Aβ toxicity and impaired macroautophagic activity. 
In accord, other studies have demonstrated that APP overexpression increases the 
susceptibility of APPswe transfected PC12 cells to oxidative stress, resulting in the 
rapid onset of caspase-3 dependent cell death (Eckert et al., 2001; Marques et al., 
2003). Additionally, Eckert et al. (2001) also revealed that following treatment with 
caspase-3 inhibitors, cell death onset was significantly attenuated in these transfected 
PC12 cells, thereby reinforcing the important role of caspase-3 dependent apoptotic 
induction during APP overexpression. Others have also demonstrated the efficient 
cleavage APP by caspase-3 during apoptosis, as evidenced by elevated Aβ 
production following increased caspase activity. This finding suggests that APP may 
be a substrate for caspase-3 cleavage. In fact, caspase-3 has been found to be highly 
colocalised with Aβ in senile plaques of dying neurons in the brains AD patients 
(Gervais et al., 1999). Findings by Nilsson and colleagues also indicate a link between 
impaired MA function, Aβ accumulation, and apoptosis. Using MA-deficient APP mice, 
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the authors found enhanced cell death onset coupled to increased caspase-3 
activation compared to MA-deficient mice without Aβ amyloidosis (Nilsson et al., 
2013). In agreement with our data, these findings indicate that MA dysfunction may 
further augment Aβ accumulation, therefore demonstrating that MA acts as a pro-
survival mechanism in the context of APP overexpression. However, further 
investigations are warranted to fully clarify the implications of such a connection.  
 
4.7. Effect of APP overexpression on AV formation in N2aswe cells 
 
Given the intense interest in the molecular and cellular underpinnings of the MA 
pathway, transmission electron microscopy (TEM) analysis continues to play a central 
role in the field of MA research since autophagosomes were first identified and 
described in 1950s by Christian de Duve using this technique (Deter et al., 1967). 
Owing to its capacity to generate high resolution cellular ultrastructural information, 
TEM facilitates the direct count of autophagosomes and autolysosomes (Klionsky et 
al., 2016; Shibutani and Yoshimori, 2014). In most scenarios, cell analysis using 
conventional TEM in the presence and absence of lysosomal inhibitors such as BafA1, 
is sufficient to discern whether there are changes in macroautophagic flux in response 
to various treatment conditions (Eskelinen et al., 2011). Upon MA induction, the 
accumulation of degradative structures increases, and the number of autolysosomes, 
lysosomes and amphisomes per cell section can thus be quantified to provide simple 
morphological read out of macroautophagic flux (Klionsky et al., 2016). However, 
given the difficulty that may arise when distinguishing between autolysosomes, 
lysosomes, and amphisomes, these structures are generally classified as AVs 
(Eskelinen, 2008).  
 
In order to determine to what extent impaired autophagosome degradation contributes 
to the accumulation of AVs on an ultrastructural level, as well as other aspects of 
cellular injury, such as mitochondrial damage, N2aswe cells were incubated in the 
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presence and absence of BafA1 during APP overexpression over time. Figure 4.5 
(left panel) reveals that the clearance of AVs is increasingly reduced in response to 
APP overexpression, particularly at the 24-hr and 48-hr time point, suggesting that 
APP overexpressing may reduce MA’s clearance capacity at later time points. 
Moreover, and most importantly, the abundance of AVs is further enhanced upon 
BafA1 treatment [Fig. 4.5 (right panel)]. These observations reveal that MA is 
continuously induced as early as 12 hrs and as late as 48 hrs APP overexpression, 
consistent with our western blot data (Fig. 4.2.B). Our findings are supported in an 
electron-microscopy based study by Nixon et al. (2005), which reveals the striking 
accumulation of AVs in neocortical biopsies from AD brains, while this pathology was 
reportedly uncommon in control patients. Studies by Boland et al. (2008) also confirm 
that MA is constitutively active and highly efficient in healthy neurons, while impaired 
macroautophagic clearance accounts for the extensive AVs pathology observed with 
AD progression. More recent studies demonstrate that not only is the retrograde 
transport and maturation of AVs to lysosomes impaired in AD, but most importantly, 
that the accumulation of Aβ oligomers within these AVs further augment 
macroautophagic stress and exacerbate disease progression in the brains of AD 
patient brains, and in APP mice with age (Sanchez-Varo et al., 2012; Tammineni et 
al., 2017).  
 
Next, we quantified the abundance of AVs in response to APP overexpression and in 
the absence and presence of BafA1 treatment. A significant time-dependent increase 
in the total number of AVs counted per cell is indicated (Fig. 4.6.A). Notably, the 
increase in AVs is further enhanced in the 24-hr versus 12-hr BA treated group upon 
BafA1 treatment, and the 48-hr compared to the 24 hr BA treated group upon BafA1 
treatment. These data suggest that the level of MA activity during APP overexpression 
at these time points is not sufficient to clear the accumulating AVs. Further analysis 
reveals a significant increase in AVs surface area in response to APP overexpression 
over time, with the exception of the 48-hr BA treated group in the presence of BafA1 
(Fig. 4.6.B). The surface area is further enhanced in the 48-hr BA treated group 
compared to both the 12-hr and 24-hr BA treated group upon BafA1 treatment, 
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suggesting that amount/volume of cytoplasmic contents engulfed within these vesicles 
may be increased with increasing MA activity and APP overexpression. In line with our 
finding, Nixon et al. (2005) previously highlighted the massive accumulation of AVs in 
‘swollen’ neurites as a unique feature of AD pathology, suggesting that the enhanced 
engulfment of cytoplasmic contents within these vesicles may account for their swollen 
morphology. These data support our findings which indicate that targeting late steps 
in the MA pathway may aid in the maturation Aβ-laden AVs to lysosomes, and the 
subsequent degradation of vesicles, thereby attenuating proteotoxicity. Moreover, our 
findings suggest that therapeutic intervention, by modulating MA activity, is possible 
throughout the disease progression. 
 
4.8. Effect of APP overexpression on fibrillar ultrastructure in N2aswe cells 
 
Other ultrastructural structures are also revealed in the N2aswe cells TEM 
micrographs. These include the formation of fibrillar protein structures, which we 
suspect may be Aβ fibrils (Fig. 4.7). A time-dependent increase in the extension/length 
of these structures is observed with APP overexpression [Fig. 4.7 (left panel)]. 
Moreover, the abundance of these structures is further enhanced upon BafA1 
treatment with APP overexpression over time [Fig. 4.8.B (right panel)]. These 
observations suggest that MA impacts the clearance of these fibrillar structures. In line 
with our observations, Gremer et al. (2017) described similar structures using cryo–
electron microscopy (cryo-EM) to reconstruct the atomic model Aβ(1–42) fibril, as 
twisted filaments which became progressively intertwined with increasing abundance. 
Our TEM observations suggests that these fibrillar structures may be potential 
proteinaceous cargo for MA as a notable increase in the length and distribution of 
these structures is observed with impaired autophagosome degradation, particularly 
in response to 24 hrs and 48 hrs APP overexpression. However, we cannot 
conclusively identify the observed structures as Aβ fibrils using conventional TEM 
analyses. Hence, future work through CLEM can be suggested.  
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4.9. Effect of APP overexpression on mitochondrial ultrastructure 
 
In addition to the accumulation of AVs, our TEM analysis revealed the sequestration 
of specific cargo, particularly upon BafA1 treatment. A distinct increase in 
mitochondrial organelle clusters is revealed in response to APP overexpression over 
time [Fig. 4.8 (left panel)]. Mitochondrial abundance is further enhanced upon BafA1 
treatment [(Fig. 4.8 (right panel)]. Most notably, the accumulation of these organelles 
is more pronounced following 24 hrs and 48 hrs APP overexpression upon BafA1 
treatment, suggesting that mitochondrial turnover is reduced at later time points, 
consistent with reduced mitophagy, i.e. selective mitochondrial degradation by MA. In 
line with our findings, impaired MA function has been shown to exacerbate 
mitochondrial dysfunction and accumulation of damaged mitochondria with age 
(Edens et al., 2016; Sebastián et al., 2016). A recent study by Song et al. (2018) 
suggests that impaired autophagosome degradation with concomitant mitophagy 
dysfunction may be the primary cause of neuronal cell damage during chronic hypoxia. 
Conversely, rapamycin treatment in vivo (García-Prat et al., 2016), and moderate 
exercise in the elderly (Moreira et al., 2017) has been shown to impact major cellular 
pathways involved in the mitochondrial quality and quantity control, such as MA. 
Accordingly, therapeutic strategies targeting MA induction with age holds great 
promise for delaying AD progression. 
 
4.10. Effect of APP overexpression on ferritin-like inclusions 
 
Interestingly, ferritin-like inclusion structures were observed upon closer inspection of 
the TEM micrographs (Fig. 4.9). Ferritin is a cytosolic protein that stores excess iron 
in a redox inactive form, thereby protecting cells from iron toxicity (Asano et al., 2011; 
Koperdanova and Cullis, 2015). In line with our findings, cconventional electron 
microscopy analysis by Kishi-Itakura et al. (2014) revealed similar structures, 
described as ferritin clusters, in the AVs of MA-deficient MEF cells under starvation 
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conditions. The accumulation of these inclusions is observed in response to 24 hrs 
and 48 hrs APP overexpression [Fig. 4.9 (left panel)], and further increased in 
abundance upon BafA1 treatment with APP overexpression [Fig. 4.9 (left panel)], 
suggesting that ferritin may proteinaceous cargo for MA. In line with our findings, 
studies indicate that ferritin degradation occurs by two routes, MA and the UPS 
(Domenico et al., 2010). In agreement, Ma et al. (2017) reported that ferritin is partially 
dependent upon MA degradation, and Asano et al. (2011) revealed that the acidic 
environment of the lysosome was crucial for iron extraction from ferritin and utilization 
by cells. Given that BafA1 treatment inhibits the acidification of lysosomes, it not only 
impairs autophagosome-lysosome fusion but also the degradation of ferritin within 
lysosomes. In line with our findings, Ott et al. (2016) reveal that CMA plays a negligible 
role in ferritin degradation, while this protein was found to colocalise with LC3 following 
inhibition autophagosome degradation, indicating that MA plays a pivotal role in ferritin 
clearance. Our findings also raise the possibility that ferritin aggregation may be 
implicated in APP overexpression [Fig. 4.9 (left panel)]. In fact, MRI evaluation of 
brain iron in neocortical neurons revealed significantly higher iron stores in AD patients 
compared normal subjects (Bartzokis et al., 1994). Our findings are further supported 
by western blot analysis shown by Rogers et al. (2002) which reveals that when 
cellular iron levels are high, APP processing and ferritin levels are increased. Our 
findings provide new insights into the mechanism Aβ proteotoxicity, linking iron 
accumulation to enhanced APP overexpression. However, whether ferroptosis, APP 
and MA are linked is unclear in this context. 
 
Overall, our data reveal that MA activity is not impaired during APP overexpression, 
but rather a mismatch between MA activity and protein aggregation. APP 
overexpression increased the APP cytosolic pool, which in turn induced a concomitant 
increase in β-secretase activity to favour Aβ production, and the interaction between 
APP/β-secretase was further enhanced upon BafA1 treatment, favouring Aβ 
generation/accumulation. In response to increased APP and Aβ protein cargo with 
time, macroautophagic flux was maintained, while LC3 abundance and 
autophagosome pool size increased. Although MA remained functional, CMA activity 
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was induced late in APP overexpression, but both pathways proved insufficient to clear 
Aβ load or prevent cell death onset. Future examination of brain tissue from of AD 
patients or APP overexpressing mice at various Braak stages may yield a better 
understanding of the modulation of autophagic pathways. 
 
Our findings highlight that the modulation of MA throughout AD progression may be 
fundamental to the preservation of cell survival. However, multiple obstacles, including 
the lengthy period required for promising drugs to pass clinical trials, have hampered 
the implementation of disease-modifying treatment strategies targeting MA in the 
management of neurodegenerative disease on a clinical level. Recent systemic 
reviews highlight the urgent need for the implementation of lifestyle-based 
interventions which may be safely and immediately executed to halt disease 
progression (Metaxakis et al., 2018; O’Flanagan et al., 2017). To this end, recent 
translational studies have tested the therapeutic potential of CR, and CR mimetic 
drugs as adjuvant therapies in neurodegeneration.  
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CHAPTER 5 RESULTS: THE EFFECTS OF MA AND CMA MODULATION  
 
5.1. Introduction to results 
 
The imbalance between protein synthesis and degradation contributes to the 
accumulation of proteinaceous inclusions characteristic of several neurodegenerative 
diseases, as evidenced by the accumulation of Aβ in AD (Nixon, 2013). Compelling 
evidence demonstrates that increased Aβ-induced neurotoxicity, together with 
impaired protein degradation may be a key factor in AD pathogenesis (Hardy and 
Selkoe, 2002). Although the modulation of Aβ clearance following rapamycin 
treatment has been found to be neuroprotective, the side-effects of long-term 
rapamycin treatment make this compound unattractive for clinical use in pre-
symptomatic patients who may require long-term therapy (Salmon, 2015). Hence, the 
use of non-pharmaceutical interventions that impact both MA and CMA activity may 
present a more practical approach for clinical use. One such example is CR, i.e. 
reduced intake of nutrients without causing malnutrition. CR is to date the most 
successful intervention shown to delay the onset of age associated pathologies, 
including AD (Balasubramanian et al., 2017). Several pharmaceutical drugs and 
naturally occurring compounds in food (nutraceuticals) have been found to mimic the 
beneficial effects of CR both in vitro and in vivo (Ito et al., 2016; Roth and Ingram, 
2015), and these may be used as alternatives to a practically challenging CR dietary 
regime in humans.  
 
The aims of this chapter were to assess (i) the effects of 2DG treatment on MA and 
CMA, and (ii) the contribution of MA and CMA modulation to protein clearance, and 
neuronal protection. To this end, the effects of 2DG, were assessed in BA (5 mM) 
treated N2aswe cells. To fully assess the contribution of each pathway to neuronal 
protection, N2aswe cells were treated with the most widely used MA inhibitor, 3-
methyladenine (3MA). 
 





5.2.1. The modulation of MA and CMA using the CRM 2DG 
 
In order to create an environment of caloric restriction, the caloric restriction mimetic 
2DG was employed. Modulation of MA and CMA was assessed using 5 mM 2DG for 
a duration of 6 and 12 hrs, APP overexpression was induced for 24 hrs (BA, 5 mM). 
 
5.2.1.1. Effect of 2DG on N2aswe cell viability during APP overexpression 
 
WST-1 results indicate a significant increase in reductive capacity in the 6 hrs 2DG 
treated group [0.12 ± 0.004 (p<0.05)], and the 12 hrs 2DG treated group [0.14 ± 0.005 
(p<0.05)] compared to control cells [0.1 ± 0.0] and the 24 hrs BA treated group [0.08 
± 0.008], with a significant decrease in the 24 hrs BA treated group [0.08 ± 0.008 
(p<0.05)] compared to control cells. No significant difference is indicated in the 6 hrs 
2DG + 24 hrs BA treated group [0.09 ± 0.004], and the 12 hrs 2DG + 24 hrs BA treated 
group [0.1 ± 0.014] compared to control cells, however, and most importantly, 
reductive capacity is significantly increased in the 12 hrs 2DG + 24 hrs BA treated 
group [0.1 ± 0.014 (p<0.05)] compared to the 24 hrs BA treated group [0.08 ± 0.008] 
(Fig. 5.1).  
 




Figure 5.1: Effect of 2DG on reductive capacity in N2aswe cells in response to 24 hrs 
APP overexpression. Data expressed as mean ± SEM, statistical analysis: ANOVA and 
Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs 24 hrs BA, n = 3. 
 
5.2.1.2. Effect of 2DG on amyloidogenic processing in N2aswe cells during 24 hrs APP 
overexpression 
 
The results indicate no reducing effect of 2DG on APP overexpression. In brief, APP 
protein expression is significantly increased in the 24 hrs BA treated group [0.98 ± 
0.07 (p<0.05)], 6 hrs 2DG treated group [0.85 ± 0.08 (p<0.05)], 6 hrs 2DG + 24 hrs BA 
treated group [0.89 ± 0.08 (p<0.05)], and in the 12 hrs 2DG + 24 hrs BA treated group 
[0.93 ± 0.07 (p<0.05)] compared to control cells [0.39 ± 0.07], with no significant 
difference indicated in the 12 hrs 2DG treated group [0.7 ± 0.04] compared to control 
cells (Fig. 5.2.B).  
 
Figure 5.2.A reveals that Aβ protein expression is significantly decreased in the 6 hrs 
2DG + 24 hrs BA treated group [0.068 ± 0.012 (p<0.05)], and the 12 hrs 2DG + 24 hrs 
BA treated group [0.15 ± 0.027 (p<0.05)] compared to the 24 hrs BA treated group 
[0.28 ± 0.014], while Aβ expression is significantly increased in the 12 hrs 2DG + 24 
hrs BA treated group compared to control cells [0.063 ± 0.014]. Similarly, Aβ 
expression is significantly increased in the 24 hrs BA treated group [0.28 ± 0.014 
(p<0.05)], 6 hrs 2DG treated group [0.25 ± 0.014 (p<0.05)], and the 12 hrs 2DG treated 
group [0.235 ± 0.009 (p<0.05)] compared to control cells [0.063 ± 0.014] (Fig. 5.2.C).  








B.                                                                      C. 
 
     
 
Figure 5.2: Effect of 2DG on amyloidogenic processing in N2aswe cells in response to 
24 hrs APP overexpression. Representative western blot and densitometric analysis for (A, 
B) APP, and (A, C) Aβ protein expression is shown. Data expressed as mean ± SEM, 
statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, # p<0.05 vs 24 hrs 
BA, n = 3, arbitrary units (a.u). 
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5.2.1.3. Effect of 2DG on MA in N2aswe cells during 24 hrs APP overexpression 
 
LC3II protein expression is significantly increased in the 24 hrs BA treated group [1.57 
± 0.096 (p<0.05)], 6 hrs 2DG treated group [1.68 ± 0.083 (p<0.05)], 12 hrs 2DG treated 
group [1.73 ± 0.11 (p<0.05)], 6 hrs 2DG + 24 hrs BA treated group [1.64 ± 0.08 
(p<0.05)], and in the 12 hrs 2DG + 24 hrs BA treated group [1.59 ± 0.17 (p<0.05)] 
compared to control cells [0.82 ± 0.1] (Fig. 5.3.B).  
 
Figure 5.3.C reveals no significant difference in p62 protein expression for any of the 




B.                                                                    C. 
           
Figure 5.3: Effect of 2DG treatment on MA activity in N2aswe cells in response to 24 hrs 
APP overexpression. Representative western blot and densitometric analysis for (A, B) 
LC3II, and (A, C) p62 protein expression is shown. Data expressed as mean ± SEM, statistical 
analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, # p<0.05 vs 24 hrs BA, n = 
3, arbitrary units (a.u). 
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5.2.1.4. Effect of 2DG on CMA in N2aswe cells during 24 hrs APP overexpression 
 
Western blot analysis of key CMA proteins (Fig. 5.4.A) reveals that LAMP2A protein 
expression is significantly increased in the 24 hrs BA treated group [1.49 ± 0.15 
(p<0.05)], 12 hrs 2DG treated group [1.57 ± 0.07 (p<0.05)], 6 hrs 2DG + 24 hrs BA 
treated group [1.57 ± 0.08 (p<0.05)], and in the 12 hrs 2DG + 24 hrs BA treated group 
[1.63 ± 0.06 (p<0.05)] compared to control cells [0.97 ± 0.09], with LAMP2A expression 
significantly decreased only in the 6 hrs 2DG treated group [1.201 ± 0.05 (p<0.05)] 
compared to the 24 hrs BA treated group [1.49 ± 0.15] (Fig. 5.4.B).  
 
No significant difference in HSC70 protein expression is indicated for any of the BA, 
2DG, or BA/2DG treated groups compared to control cells (Fig. 5.4.C). 
 
The expression of CMA cargo Tau, is significantly decreased in the 6 hrs 2DG + 24 
hrs BA treated group [0.84 ± 0.04 (p<0.05)], and in the 12 hrs 2DG + 24 hrs BA treated 
group [0.78 ± 0.06 (p<0.05)] compared to control cells [1.35 ± 0.09] and the 24 hrs BA 
treated group [1.32 ± 0.05], with no significant difference indicated in the 6 hrs 2DG 
treated group [1.08 ± 0.09] and the 12 hrs 2DG treated group [0.99 ± 0.12] (Fig. 5.4.D). 
 






B.                                                                        C. 
           
D. 
 
Figure 5.4: Effect of 2DG on CMA activity in N2aswe cells in response to 24 hrs APP 
overexpression. Representative western blot and densitometric analysis for (A, B) LAMP2A, 
(A, C) HSC70, and (A, D) Tau protein expression is shown. Data expressed as mean ± SEM, 
statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, # p<0.05 vs 24 hrs 
BA, n = 3, arbitrary units (a.u). 
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5.2.1.5. Immunofluorescence tracking of CMA using the KFERQ-mCherry CMA-
specific reporter 
 
In order to assess the effect of 2DG on CMA activity during increasing APP 
overexpression, the KFERQ-mCherry CMA probe was used to monitor CMA activity. 
The probe binds to CMA-active lysosomes, and a change in the KFERQ-mCherry-
lysosomal binding signal intensity, or number of fluorescent puncta per cell in response 
to incubation with the probe is indicative of CMA activation (Koga et al., 2011b). As 
shown in Fig. 5.5, the signal intensity of the KFERQ-mCherry reporter (red) becomes 
stronger, and less diffuse in the 24 hrs BA + 12 hrs 2DG treated group and the 48 hrs 
BA + 12 hrs 2DG treated group compared to the respective controls.  
 
 
Figure 5.5: Immunofluorescence micrographs indicating the localization of the CMA 
reporter KFERQ-mCherry (red) in N2aswe cells in response to 2DG treatment and APP 
overexpression. Nuclei are counterstained with Hoechst 33342; scale bar indicates 5 μm. 
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5.2.1.6. Effect of 2DG on cell death in N2aswe cells during 24 hrs APP overexpression 
 
As indicated in Fig. 5.6.A, Total Caspase-3 protein expression is significantly 
increased in the 24 hrs BA treated group [1.84 ± 0.14 (p<0.05)], 6 hrs 2DG treated 
group [1.48 ± 0.15 (p<0.05)], and the 12 hrs 2DG treated group [1.79 ± 0.05 (p<0.05)] 
compared to control cells [0.47± 0.08], but significantly decreased in the 6 hrs 2DG + 
24 hrs BA treated group [0.97 ± 0.19 (p<0.05)], and the 12 hrs 2DG + 24 hrs BA treated 
group [0.7 ± 0.09 (p<0.05)] compared to the 24 hrs BA treated group [1.84 ± 0.14] 
(Fig. 5.6.B), suggesting protection upon 2DG exposure during APP overexpression. 
 
Cleaved-PARP expression is significantly increased in the 24 hrs BA treated group 
[0.79 ± 0.03 (p<0.05)], 6 hrs 2DG treated group [0.72 ± 0.02 (p<0.05)], 12 hrs 2DG 
treated group [0.7 ± 0.04 (p<0.05)], and the 12 hrs 2DG + 24 hrs BA treated group 
[0.79 ± 0.05 (p<0.05)] compared to control cells [0.39 ± 0.07], but is significantly 
decreased only in the 6 hrs 2DG + 24 hrs BA treated group [0.5 ± 0.05 (p<0.05)] 
compared to the 24 hrs BA treated group [0.79 ± 0.03] (Fig. 5.6.C). 
 







B.                                                          C. 
 
Figure 5.6: Effect of 2DG on key apoptosis proteins in N2aswe cells in response to 24 
hrs APP overexpression. Representative western blot and densitometric analysis for (A, B) 
Total Caspase-3, and (A, C) cleaved-PARP protein expression is shown. Data expressed as 
mean ± SEM, statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, # 
p<0.05 vs 24 hrs BA, n = 3, arbitrary units (a.u). 
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5.2.2. The modulation of MA and CMA activity using 3MA 
 
In order to further interrogate the role of MA in the observed response, 3MA was 
utilized. 3MA is the most widely inhibitor of MA induction, which modulates 
autophagosome synthesis through inhibition of the class III phosphatidylinositol 3-
kinase (PtdIns3K) (Wu et al., 2010). A 3MA concentration of 5 mM was utilized 
(Heckmann et al., 2013). 
 
5.2.2.1. Effect of 3MA treatment on N2aswe cell viability  
 
In order to determine the amount of time required to completely inhibit MA induction, 
five 3MA treatment time points were assessed. As shown in Fig. 5.7, reductive 
capacity is significantly decreased in the 6 hrs 3MA treated group [0.077 ± 0.002 
(p<0.05)], 12 hrs 3MA treated group [0.046 ± 0.003 (p<0.05)], and the 18 hrs 3MA 
treated group [0.067 ± 0.003 (p<0.05)] compared to control cells [0.092 ± 0.007]. No 
significant difference is indicated in the 24 hrs 3MA treated group [0.097 ± 0.007], and 









Figure 5.7: The time-dependent effect of 3MA treatment on the reductive capacity of 
N2aswe cells. Data expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni 
correction, *p<0.05 vs. control, n = 3. 
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5.2.2.2. Effect of 3MA on MA activity in response to APP overexpression 
 
Western blot analysis assessing the effect of 3MA on LC3II, and p62 protein 
expression was performed (Fig. 5.8.A). A significant decrease in LC3II protein 
expression is indicated following 6 hrs 3MA exposure [0.018 ± 0.0 (p<0.05)], 12 hrs 
3MA exposure [0.018 ± 0.0 (p<0.05)], and 18 hrs 3MA exposure [0.73 ± 0.07 (p<0.05)] 
compared to control cells [1.09 ± 0.04], with a significant increase following 30 hrs 
3MA exposure [1.43 ± 0.08 (p<0.05)] compared to control cells (Fig. 5.8.B).  
 
MA cargo protein p62, is significantly increased following 12 hrs 3MA exposure [2.11 
± 0.12 (p<0.05)] compared to control cells [1.26 ± 0.07], with no significant difference 
following 6 hrs 3MA exposure [1.77 ± 0.05], 18 hrs 3MA exposure [1.53 ± 0.13], 24 hrs 
3MA exposure [1.34 ± 0.08)] and 30 hrs 3MA exposure [1.33 ± 0.14)] compared to 
control cells (Fig. 5.8.C). These data highlight the complete loss of protein clearance 
upon 12 hrs 3MA exposure. 
 







B                                                                    C. 
     
 
Figure 5.8: The time-dependent effect of 3MA treatment on MA activity in N2aswe cells. 
Representative western blot and densitometric analysis for (A, B) LCII, and (A, C) p62 protein 
expression is shown. Data expressed as mean ± SEM, statistical analysis: ANOVA and 
Bonferroni correction, *p<0.05 vs. control, n = 3, arbitrary units (a.u). 
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5.2.3. The modulation of MA and CMA activity using concomitant 2DG and 3MA 
treatment 
 
In order to assess the contribution of MA in 2DG mediated cytoprotection (Fig. 5.2), 
concomitant 3MA treatment was performed. Modulation of MA and CMA activity was 
performed using 5 mM 2DG and 3MA both for a duration of 12 hrs, APP 
overexpression was induced for 24 hrs (BA, 5 mM). 
 
5.2.3.1. Effect of 12 hrs [2DG and 3MA] treatment on N2aswe cell viability during 24 
hrs APP overexpression 
 
The results indicate that reductive capacity is significantly decreased in the 24 hrs BA 
treated group [0.06 ± 0.005 (p<0.05)], and the 12 hrs 3MA treated group [0.056 ± 0.003 
(p<0.05)] compared to control cells [0.092 ± 0.001], while reductive capacity is 
significantly increased in the 12 hrs 2DG treated group [0.097 ± 0.006 (p<0.05)], 24 
hrs BA + 12 hrs 2DG treated group [0.086 ± 0.003 (p<0.05)], and the 24 hrs BA + 12 
hrs (3MA +2DG) treated group [0.098 ± 0.003 (p<0.05)] compared to the 24 hrs BA 











Figure 5.9: Effect of 12 hrs [3MA and 2DG] treatment on N2aswe cell viability during 24 
hrs APP overexpression. Data expressed as mean ± SEM, statistical analysis: ANOVA and 
Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3. 
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5.2.3.2. Effect of 12 hrs [2DG and 3MA] treatment on amyloidogenic processing in 
N2aswe cells during 24 hrs APP overexpression 
 
APP protein expression is significantly increased in the 24 hrs BA treated group [1.52 
± 0.09 (p<0.05)], 12 hrs 3MA treated group [1.67 ± 0.09 (p<0.05)], 24 hrs BA + 12 hrs 
3MA treated group [1.76 ± 0.07 (p<0.05)], and the 24 hrs BA + 12 hrs (3MA +2DG) 
treated group [1.62 ± 0.09 (p<0.05)] compared to control cells [0.7 ± 0.08], with APP 
expression significantly increased in the 24 hrs BA + 12 hrs (3MA +2DG) treated group 
compared to the 24 hrs BA + 12 hrs 2DG treated group [1.13 ± 0.08]. In contrast, APP 
expression is significantly decreased in the 12 hrs 2DG treated group [1.08 ± 0.04 
(p<0.05)], and the 24 hrs BA + 12 hrs 2DG treated group [1.13 ± 0.08 (p<0.05)] 
compared to the 24 hrs BA treated group [1.52 ± 0.09] (Fig. 5.10.B).  
 
Figure 5.10.C indicates that β-secretase protein expression is significantly increased 
in the 12 hrs 3MA treated group [2.51 ± 0.29 (p<0.05)], 24 hrs BA + 12 hrs 3MA treated 
group [2.24 ± 0.16 (p<0.05)], 12 hrs 2DG treated group [1.92 ± 0.14 (p<0.05)], 24 hrs 
BA + 12 hrs 2DG treated group [2.19 ± 0.17 (p<0.05)], and the 24 hrs BA + 12 hrs 
(3MA +2DG) treated group [2.75 ± 0.3 (p<0.05)] compared to control cells [0.79 ± 0.1], 
with β-secretase expression also significantly increased in the 12 hrs 3MA treated 
group, 24 hrs BA + 12 hrs 3MA treated group, and the 24 hrs BA + 12 hrs (3MA +2DG) 
treated group compared to the 24 hrs BA treated group [1.09 ± 0.13] (Fig. 5.10.D). 
 
As revealed in Fig. 5.10.E, Aβ protein expression is significantly increased in the 12 
hrs 3MA treated group [0.05 ± 0.006 (p<0.05)], 24 hrs BA + 12 hrs 3MA treated group 
[0.06 ± 0.004 (p<0.05)], and the 24 hrs BA + 12 hrs (3MA +2DG) treated group [0.05 
± 0.004 (p<0.05)] compared to control cells [0.02 ± 0.002], and the 24 hrs BA treated 
group [0.02 ± 0.003]. Moreover, Aβ expression is significantly increased in the 24 hrs 
BA + 12 hrs (3MA +2DG) treated group compared to the 24 hrs BA + 12 hrs 2DG 
treated group [0.03 ± 0.004] (Fig. 5.10.F). 
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Figure 5.10: Effect of 12 hrs [3MA and 2DG] treatment on amyloidogenic processing in 
N2aswe cells during 24 hrs APP overexpression. Representative western blot and 
densitometric analysis for (A, B) APP, (C, D) β-secretase, and (E, F) Aβ protein expression is 
shown. Data expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni 
correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, $p<0.05 vs. 24 hrs BA + 12 hrs 2DG, 
n = 3, arbitrary units (a.u). 
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5.2.3.3. Effect of 12 hrs [2DG and 3MA] treatment on MA activity in N2aswe cells 
during 24 hrs APP overexpression 
 
Figure 5.11.A indicates that LC3II protein expression is significantly increased in the 
24 hrs BA treated group [1.18 ± 0.12 (p<0.05)], 12 hrs 3MA treated group [0.7 ± 0.12 
(p<0.05)], 24 hrs BA + 12 hrs 3MA treated group [0.94 ± 0.08 (p<0.05)], 12 hrs 2DG 
treated group [1.64 ± 0.06 (p<0.05)], 24 hrs BA + 12 hrs 2DG treated group [1.83 ± 
0.08 (p<0.05)], and the 24 hrs BA + 12 hrs (3MA +2DG) treated group [1.52 ± 0.15 
(p<0.05)] compared to control cells [0.05 ± 0.008]. Notably, LC3II expression is 
significantly increased only in the 24 hrs BA + 12 hrs 2DG treated group compared to 
the 24 hrs BA treated group (Fig. 5.11.B). 
 
As shown in Fig. 5.11.C, p62 protein expression is significantly increased in the 12 hrs 
3MA treated group [1.39 ± 0.04 (p<0.05)], 24 hrs BA + 12 hrs 3MA treated group [1.27 
± 0.04 (p<0.05)], 24 hrs BA + 12 hrs 2DG treated group [1.16 ± 0.09 (p<0.05)], and 
the 24 hrs BA + 12 hrs (3MA +2DG) treated group [1.46 ± 0.07 (p<0.05)] compared to 
the control cells [0.68 ± 0.1] and the 24 hrs BA treated group [0.75 ± 0.07] (Fig. 5.11.D). 
 




























Figure 5.11: Effect of 12 hrs [3MA and 2D] treatment on key MA proteins in N2aswe cells 
during 24 hrs APP overexpression. Representative western blot and densitometric analysis 
for (A, B) LCII, and (C, D) p62 protein expression is shown. Data expressed as mean ± SEM, 
statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs 
BA, n = 3, arbitrary units (a.u). 
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5.2.3.4. Effect of 12 hrs [2DG and 3MA] treatment on CMA activity in N2aswe cells 
during 24 hrs APP overexpression 
 
No significant difference in LAMP2A protein expression is indicated in all the treatment 
groups (Fig. 5.12.B). 
 
Similarly, no significant difference in HSC70 protein expression is revealed in all 
groups (Fig. 5.12.D), suggesting that 2DG may not have a role in CMA activity during 
APP overexpression. 























Figure 5.12: Effect of 12 hrs [3MA and 2DG] treatment on CMA activity in N2aswe cells 
during 24 hrs APP overexpression. Representative western blot and densitometric analysis 
for (A, B) LAMP2A, and (C, D) HSC70 protein expression is shown. Data expressed as mean 
± SEM, statistical analysis: ANOVA and Bonferroni correction, n = 3, arbitrary units (a.u). 
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5.2.3.5. Effect of 12 hrs [2DG and 3MA] treatment on apoptosis in N2aswe cells during 
24 hrs APP overexpression 
 
As shown in Fig. 5.14.A, Total Caspase-3 protein expression is significantly increased 
in the 24 hrs BA treated group [0.21 ± 0.007 (p<0.05)], 12 hrs 3MA treated group [0.3 
± 0.009 (p<0.05)], 24 hrs BA + 12 hrs 3MA treated group [0.29 ± 0.009 (p<0.05)], 12 
hrs 2DG treated group [0.24 ± 0.02 (p<0.05)], 24 hrs BA + 12 hrs 2DG treated group 
[0.22 ± 0.02 (p<0.05)], and in the 24 hrs BA + 12 hrs (3MA +2DG) treated group [0.22 
± 0.01 (p<0.05)] compared to control cells [0.045 ± 0.02]. Importantly, Total Caspase-
3 expression is significantly increased only in the 12 hrs 3MA treated group compared 
to the 24 hrs BA treated group (Fig. 5.13.B), suggesting that complete inhibition of MA 
impacts apoptosis.  
 
Similarly, Fig. 5.13.C reveals a significant increase in cleaved-PARP protein 
expression in all groups compared to the control. Briefly, a significant increase is 
indicated in the 24 hrs BA treated group [0.479 ± 0.02 (p<0.05)], 12 hrs 3MA treated 
group [0.51 ± 0.05 (p<0.05)], 24 hrs BA + 12 hrs 3MA treated group [0.56 ± 0.05 
(p<0.05)], 12 hrs 2DG treated group [0.52 ± 0.02 (p<0.05)], 24 hrs BA + 12 hrs 2DG 
treated group [0.54 ± 0.02 (p<0.05)], and in the 24 hrs BA + 12 hrs (3MA +2DG) treated 
group [0.59 ± 0.06 (p<0.05)] compared to control cells [0.04 ± 0.003] (Fig. 5.13.D). 
 


































Figure 5.13: Effect of 12 hrs [3MA and 2DG] treatment on key apoptosis proteins in 
N2aswe cells during 24 hrs APP overexpression. Representative western blot and 
densitometric analysis for (A, B) Total Caspase-3, and (C, D) cleaved-PARP protein 
expression is shown. Data expressed as mean ± SEM, statistical analysis: ANOVA and 
Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 24 hrs BA, n = 3, arbitrary units (a.u). 
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CHAPTER 5 DISCUSSION. THE EFFECTS OF MA AND CMA MODULATION  
 
AD requires precise diagnosis and treatment, preferably before the first 
pathophysiological symptoms manifest. The accumulation of Aβ aggregates in the 
brain is thought to trigger neuronal damage and synaptic dysfunction. Hence, the 
removal and/or inhibition of the formation of these aggregates is proposed to be a 
potential therapeutic approach in the mitigation of AD progression. Efforts in aetiology-
based treatment are currently underway in clinical trials, as well as adjuvant therapies 
such as physical activity, reduced caloric diets, and cognitive stimulation (Nelson and 
Tabet, 2015; Scheltens et al., 2016). The MA and CMA pathways are crucial 
mechanisms through which cells degrades aggregate-prone proteins, such as Aβ. 
However, the relationship between enhanced MA and/or CMA activity and ability to 
clear protein aggregates is not very clear. Hence, we assessed the role of glucose 
analogue 2-deoxy-D-glucose (2DG), a CR mimic (CRM), in the context of enhanced 
Aβ toxicity and its ability to control MA or CMA activity.  
 
5.3. The modulation of MA and CMA using the CRM 2DG 
 
CR is a dietary intervention shown to promote mammalian cell survival in vitro and in 
vivo (Liang et al., 2018; Mattison et al., 2017). The effects of CRM 2DG on cell viability, 
as measured by the WST-1 tetrazolium conversion assay, was assessed in response 
to 24 hrs APP overexpression. Our findings reveal a significant increase in the 
reductive capacity of N2aswe cells upon 6 hrs and 12 hrs 2DG treatment compared to 
control cells (Fig. 5.1). Moreover, and most importantly, the reductive capacity was 
significantly increased in the aforementioned treatment groups and the [24 hrs BA + 
12 hrs 2DG] treated group compared to the 24 hrs BA treated group. These results 
indicate that while 24 hrs APP overexpression decreases cell viability, 12 hrs 
concomitant treatment with 2DG tips the balance in favour of cell survival. In line with 
our findings, 2DG treatment was found to protects neurons in co-culture with 
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astrocytes and microglia, by causing microglial loss through ATP depletion, thereby 
protecting neurons (Vilalta and Brown, 2014). 2DG treatment has also been shown to 
prevent neurodegeneration in the brains of triple-transgenic AD mouse model. Six-
month-old mice fed a diet supplemented with 2DG for 7 weeks exhibited a significant 
reduction in both APP and Aβ oligomers, with a parallel decrease in γ-secretase 
expression, and a significant increase in α-secretase expression (Yao et al., 2011), 
suggesting that 2DG induced a shift towards the nonamyloidogenic pathway. 
Additionally, mitochondrial bioenergetic capacity was maintained with reduced 
oxidative stress levels in mice fed the 2DG diet compared to those fed a regular diet 
(Yao et al., 2011). In support of our findings of a neuroprotective role following 2DG 
treatment with concomitant APP overexpression (Fig. 5.1), these studies suggest that 
2DG may be used as a disease-modifying intervention to mitigate Aβ load, 
neurodegeneration and delay the onset of bioenergetic deficits associated with AD 
progression.  
 
Western blot analysis was performed to assess the effects of 2DG treatment on 
amyloidogenic pathway during 24 hrs APP (Fig. 5.2.A). Our results indicate that APP 
protein expression is comparable to control cells upon 12 hrs 2DG treatment, however, 
a significant increase in APP is observed upon [24 hrs BA + 12 hrs 2DG] treatment 
compared to control cells (Fig. 5.2.B). These data suggest that 2DG treatment 
attenuates APP overexpression. To our surprise, Aβ expression is significantly 
increased upon 12 hrs 2DG treatment (Fig. 5.2.C), suggesting that 2DG does not 
sufficient promote Aβ clearance. Moreover, Aβ is significantly decreased upon [24 hrs 
BA + 6 hrs 2DG] and [24 hrs BA + 12 hrs 2DG] treatment compared to the 24 hrs BA 
treated group (Fig. 5.2.C), which is contrast with the increased APP levels observed 
in these treatment groups (Fig. 5.2.B). Although these findings suggest that 2DG 
treatment may not impact APP expression in this context, they also suggest that 2DG 
treatment modulates Aβ levels in favour of enhanced clearance during 24 hrs APP 
overexpression. These data are supported in a recent study by Chakraborty (2017), 
which demonstrated that nutrient starvation significantly decreased the level of Aβ, 
and amyloid precursor protein intracellular domain (AICD) without affecting APP 
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transcription in SH-SY5Y neuroblastoma cells overexpressing the APP London 
mutation. In line with our findings (Fig. 5.2.C), in a study by Yao et al. (2011) 2DG 
induced a shift towards the nonamyloidogenic pathway, reducing both APP and Aβ 
protein levels in AD mouse models. The neuroprotective effects of CR regimes have 
also been extended to in vivo settings where sustained CR in AD mice has been shown 
to reduce Aβ neuropathology compared to ad libitum fed mice (Mouton et al., 2009; 
Patel et al., 2005). In agreement, Wang et al. (2005) also demonstrated that CR 
reduced Aβ production and Aβ neuritic plaque deposition in AD mouse models. 
Overall, our findings of reduced Aβ production/accumulation suggests that 2DG 
treatment may confer a neuroprotective effect, in favour of the nonamyloidogenic 
pathway.  
 
In order to assess effects of 2DG treatment on key of MA molecular markers during 
24 hrs APP overexpression, western blot analysis was performed to examine LC3II 
and p62 protein levels (Fig. 5.3.A). Our results indicate a significant increase in LC3II 
levels following 6 hrs, and 12 hrs 2DG treatment only, and upon 6 hrs and 12 hrs 2DG 
treatment with 24 hrs APP overexpression compared to control cells (Fig. 5.3.B). 
These data suggest that 2DG increases LC3II levels and autophagosome abundance 
even during APP overexpression. In line with these findings, western blot analysis 
revealed LC3II levels in neuronal SK-N-SH cells treated with 2DG for 16 hrs (Nijholt 
et al., 2011). MacCallum and colleagues have also shown that LC3II levels are 
markedly increased in kidneys harvested from CR rates, while decreased those 
subjected to a high calorie diet (MacCallum et al., 2013).In a study by Ramírez-
Peinado et al. (2013), alveolar Rh4 cells treated with 2DG for 3, 6, 18, and 24 hrs in 
the absence or presence of 20 nM BafA1 for 3 hrs, was found to induce 
macroautophagic flux. Similarly, Ferreira-Marques et al. (2016) reported a significant 
increase in LC3II expression in response to CR in the presence of chloroquine 
treatment compared to cells under CR treatment conditions in the absence of 
chloroquine treatment. Consistent with our data, these studies support the view that 
MA protects cells from glucose deprivation, and my attenuate proteotoxicity following 
2DG treatment. To our surprise, no significant changes in p62 protein levels are 
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indicated (Fig. 5.3.C), despite the significant increase in MA induction. These findings 
are in contrast with previous studies that have shown a concomitant increase in LC3II 
levels with decreased p62 levels in rat cortical neurons, with the level of p62 being 
significantly higher under CR conditions in the presence of chloroquine, than under 
CR conditions in the absence of chloroquine (Ferreira-Marques et al., 2016). It was 
previously established in the current study that macroautophagic flux was maintained 
with increasing APP overexpression (Fig. 4.2.B), while the autophagosome pool size, 
as indicated by increased LC3II expression, increased in a time-dependent manner. It 
is therefore possible that lysosomal degradation of p62 may be affected by APP 
overexpression. However, this possibility can only be determined if autophagosome 
degradation is inhibited in this context. 
 
In order to determine assess the effects of 2DG treatment CMA during APP 
overexpression, western blot analysis of LAMP2A, HSC70, and CMA cargo protein 
Tau was performed (Fig. 5.4.A). The results indicate that LAMP2A levels are 
significantly reduced in the 6 hrs 2DG treatment group compared to the 24 hrs BA, but 
still comparable to the control cells. For all the other treatment groups, LAMP2A levels 
are significantly increased compared to control cells (Fig. 5.4.B). Conversely, HSC70 
levels are not significantly changed for all the treatment groups compared to control 
cells (Fig. 5.4.C). Assessment of Tau levels reveals a significant decrease in both the 
[6 hrs 2DG + 24 hrs BA] and [12 hrs 2DG + 24 hrs BA] treatment groups compared to 
the control cells and the 24 hrs BA treated group (Fig. 5.4.D). Although HSC70 
remains relatively unchanged, the increased LAMP2A and decreased Tau protein 
levels suggests that under conditions of glucose deprivation and 24 hrs APP 
overexpression, CMA activity is increased to favour protein clearance since Tau 
protein is efficiently cleared following 2DG/BA combination treatment. In line with our 
findings, others have shown that CMA is induced in higher organisms following 
glucose or amino acid deprivation in vitro (Cuervo et al., 1995b, 1997). Indeed, a study 
by Finn and Dice (2005) indicate that isolated lysosomes from fibroblast cells 
maintained in serum-free media demonstrate an increased ability to degrade CMA 
substrates GAPDH, and RNaseA. In support of these findings, Li et al. (2014) showed 
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sequential activation of MA and CMA in response to serum deprivation and arsenic 
exposure in Raji cells.  
 
We further confirmed the contribution of CMA to protein turnover following 2DG 
treatment during 24 hrs APP overexpression by transfecting N2aswe cells with the 
CMA-fluorescent reporter (KFERQ-mCherry), which allows for fluorescence 
microscopy-based visualization of CMA activity as a change in the distribution of the 
fluorescent reporter from the cytosol (diffuse fluorescent puncta pattern) to the 
lysosomal membrane (punctate fluorescent pattern). Our immunofluorescence 
analysis reveals that the KFERQ-mCherry reporter is increasingly localised to the 
lysosomal membrane following [24 hrs BA + 12 hrs 2DG] treatment, and further 
enhanced in the [12 hrs 2DG + 48hrs BA] treatment compared to their respective 
control groups (Fig. 5.5). These observations suggest that glucose deprivation further 
induces CMA activity in the presence of APP overexpression. In line with these 
findings, Koga et al. (2011) revealed that the fluorescence pattern of the KFERQ-PS-
CFP2 reporter transfected in mouse fibroblasts cells changed with increasing CMA 
activity 16 hrs serum starvation. Mukherjee and colleagues confirmed that the change 
in the distribution of the CMA reporter was due to enhanced CMA induction and is 
temporally distinct from MA activity in which 1 hr CR was sufficient for induction, while 
no punctate structures were formed under fed conditions, and that 1 - 4 hrs of 
starvation was not sufficient to detect the CMA reporter (Mukherjee et al., 2016). 
Instead, puncta formation required at least 12 hrs starvation, with puncta formation 
being highly pronounced following 25 hrs starvation, suggesting that puncta formation 
associated with the KFERQ-mCherry reporter is kinetically distinct for CMA following 
prolonged starvation (Mukherjee et al., 2016). In accord, our data strongly indicates 
that the increased localization of the KFERQ-mCherry reporter with lysosomes is 
indicative of robust CMA induction, particularly following 48 hrs APP overexpression 
with 12 hrs 2DG treatment (Fig. 5.5). Taken together, our data clearly suggests that 
the enhancement of CMA activity may contribute to the preservation of the cellular 
energetic status following glucose deprivation.  
Stellenbosch University  https://scholar.sun.ac.za
195 
 
The effects of 2DG modulation on cell death onset during 24 hrs APP overexpression 
were assessed using western blot analysis of apoptosis markers Total Caspase-3 and 
cPARP (Fig. 5.6.A). Our results indicate a significant increase in Total Caspase-3 
expression in the 24 hrs BA, 6 hrs 2DG, and 12 hrs 2DG treatment groups (Fig. 5.6.B). 
More importantly, a significant decrease in Total Caspase-3 expression is indicated in 
the 6 hrs sand 24 hrs BA + 12 hrs 2DG treatment group, consistent with the reduced 
induction of apoptosis in these treatment groups. In support of our findings, Duan and 
Mattson (1999) revealed that 2DG treatment can mimic the beneficial effects of CR 
regimes on neurodegeneration. In this study, 2DG supplementation to ad libitum fed 
mice ameliorated the loss of dopaminergic neurons, improved deficits in cognitive 
function and preserved mitochondrial function following exposure to 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced oxidative stress. Consistent Total 
Caspase-3 activation, our results indicate a significant increase in cPARP expression 
in the 24 hrs BA, 6 hrs 2DG, and 12 hrs 2DG treated group compared to control cells 
(Fig.5.6.C). To our surprise, cPARP expression is also significantly enhanced in the 
[12 hrs 2DG + 24 hrs BA] treatment group compared to control cells, while Total 
Caspase-3 activity in this group is comparable to the control cells (Fig. 5.6.B). This 
data suggests a mismatch between caspase activity and PARP cleavage in this 
context. It is possible that PARP may be cleaved by other proteases other than Total 
Caspase-3. In support of this notion, findings by Gobeil et al. (2001) reveal that 
cathepsins B and G can also cleaved PARP in an in vitro. Notably, PARP cleavage is 
significantly reduced in the [6 hrs 2DG + 24 hrs BA] treated group compared to the 24 
hrs BA treated group, consistent with the reduced Total Caspase-3 levels in this group 
(Fig. 5.6.B). These findings suggest that 2DG confers neuronal protection during 24 
hrs APP overexpression in this group. Indeed, we previously reported the amelioration 
of Aβ levels, with this protein being significantly reduced in the [6 hrs and 12 hrs + 24 
hrs BA] treatment groups (Fig. 5.2.C), the same groups in which apoptosis induction 
is significantly reduced, translating to cell protection. In line with our findings, others 
have reported the neuroprotective effects of CR and CRM in various pathologies (Guo 
et al., 2016). Indeed, 2DG has been found to neuroprotective in the brains of animals 
subjected to a variety of insults, including enhanced Aβ proteotoxicity in a triple 
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transgenic model of AD (Yao et al., 2011), excitotoxic and oxidative injury in 
hippocampal neurons (Lee et al., 1999), chemical or electrical induction of epileptic 
seizure-induced spatial memory deficits and hippocampal neuron loss (Garriga-Canut 
et al., 2006), neurotoxin exposure (3,3′-iminodipropionitrile-induced neurobehavioral 
toxicity in mice) (Tariq et al., 1999), and has been shown to improve brain radiotherapy 
in clinical studies (Dwarakanath et al., 2009), as well as increase the chemosensitivity 
of carcinoma cell lines to doxorubicin and sorafenib treatment (Wang et al., 2015). 
Others have also shown that administration of 2DG in rodents improved 
cardiovascular stress, and up-regulated genes associated with neurogenesis and 
increased stress resistance to cold shock, Aβ, iron exposure (Guo and Mattson, 2000; 
Wan et al., 2004). In support of our findings (Fig. 5.6), Ma et al. (2016) suggests that 
long-term CR may prevent age-related cognitive impairment via suppression of 
apoptosis, as evidenced by a significant reduction in Total Caspase-3, PARP, as well 
as proapoptotic protein Bax in mice. Although it is unknown if 2DG ameliorates 
proteotoxicity in humans, our data supports the role of 2DG supplementation as an 
effective treatment intervention that can be executed immediately and safely in the 
prevention of cell death onset, particularly in AD, as this CRM has been found to 
ameliorate Aβ load by enhancing autophagic function during APP overexpression. 
Although the mechanisms of CR/CRM-induced neuroprotection are complex and not 
fully understood, our findings suggest that CRM 2DG may confer neuroprotection via 
the induction of autophagic pathways and suppression of apoptosis during APP 
overexpression. These findings raise the possibility that 2DG may be utilized to 
harness the power of enhanced autophagic activity for therapeutic intervention in AD. 
However, further studies are needed to investigate the contribution of autophagic 
pathways, MA and CMA, in the mechanism of 2DG neuroprotection. 
 
5.4. The modulation of MA and CMA activity using 3MA 
 
To fully assess the contribution of both MA and CMA to neuronal protection following 
2DG treatment with 24 hrs APP overexpression, we next assessed the time-
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dependent effects of the MA inhibitor, 3MA, on cell viability. The WST-1 results 
indicate that the reductive capacity of N2aswe cells is significantly reduced following 
6 hrs, 12 hrs, and 18 hrs 3MA treatment compared to control cells (Fig. 5.7). In line 
with our findings, studies have reported the time-dependent detrimental effects of 
inhibiting autophagosome synthesis on cell viability (Hou et al., 2012; Wu et al., 2010). 
3MA inhibits the early stages of autophagosome biogenesis, hence, the drastic 
reduction in cell viability, particularly during 12 hrs 3MA treatment, supports the role of 
MA as a cytoprotective mechanism, which triggers cell death onset when suppressed. 
In agreement, a study by Boya et al. (2005). demonstrates that cell viability is severely 
compromised in response to the complete inhibition of MA, tipping the scales towards 
cell death onset. Furthermore, the significant increase in cell recovery, following 
prolonged 3MA treatment, as noted during 24 hrs and 30 hrs 3MA treatment, clearly 
indicates that MA induction may act as pro-survival mechanism. 
 
Western blot analysis of autophagosome formation, i.e.LC3II, and p62 protein levels 
(Fig. 5.8.A) was performed to determine the most suitable time point at which 
complete MA inhibition may be achieved using 3MA treatment. Our results indicate a 
profound decrease in LC3II expression/autophagosome synthesis following 6 hrs, 12 
hrs, and 18 hrs 3MA treatment compared to control cells, while LC3II levels are 
significantly increased upon 24 hrs, and 30 hrs 3MA treatment compared to control 
cells (Fig. 5.8.B). These findings suggest that 3MA’s inhibitory effects on 
autophagosome synthesis are transient, and time dependent. When assessing the 
effects of 3MA treatment on p62 degradation, our results indicate a significant increase 
in p62 expression upon 12 hrs 3MA treatment compared to control cells (Fig. 5.8.C). 
Notably, this increase was further enhanced at the time point in which cell viability was 
previously found to be at its lowest (Fig. 5.7). In line with our findings, kinetic studies 
have reported the temporal effects of 3MA inhibition on autophagosome synthesis. In 
fact, 3MA has been shown to have short-lived inhibitory effects on VPS34 activity, 
whereas its effects on the class I PI3K is comparatively longer-lived, resulting in 
increased autophagosome synthesis following extended periods of 3MA treatment 
(Heckmann et al., 2013; Wu et al., 2010), as evidenced by the increased LC3II 
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expression at the 24 hrs, and 30 hrs 3MA treatment time points. In line with our data, 
studies have reported a self-limiting negative feedback mechanism through which 
nutrient availability regulates in MA activity (Avruch et al., 2009; Yu et al., 2010). 
Briefly, when intracellular amino acids are decreased due to inhibition of MA, mTORC1 
signalling can in turn be inhibited, thereby inducing MA activity. Conversely, an 
increase in the amino acid pool size following MA-mediated protein degradation, can 
reactivate mTORC1 signalling, thereby inhibiting MA activity (Avruch et al., 2009; Yu 
et al., 2010). This negative feedback mechanism is thought to prevent the pathologic 
overactivation of MA. 
 
5.5. The modulation of MA and CMA activity using concomitant 2DG and 3MA 
treatment 
 
WST-1 analysis reveals increased reductive capacity in the 12 hrs 2DG, [24 hrs BA + 
12 hrs 2DG], and [24 hrs BA + 12 hrs (2DG + 3MA)] treatment groups compared to 
the 24 hrs BA treatment group (Fig. 5.9). Conversely, cellular reductive capacity is 
significantly reduced following 24 hrs BA treatment and complete inhibition of 
autophagosome synthesis in the 12 hrs 3MA treatment group. This data indicates that 
cell viability is preserved and cytoprotection is conferred following 2DG treatment with 
and without 24 hrs APP overexpression. Moreover, our results suggest that 
neuroprotection may not only be dependent on MA induction alone, as enhanced cell 
viability is also indicated following concomitant 2DG and 3MA treatment with 24 hrs 
APP overexpression.  
 
Western blot analysis of concomitant 2DG, and 3MA treatment with 24 hrs APP 
overexpression was performed to further unravel the role of MA in the regulation of 
2DG mediated neuroprotection. Our results reveal a significant reduction in APP 
expression following 12 hrs 2DG, and [24 hrs BA + 12 hrs 2DG] compared to 24 hrs 
BA treatment, while a significant increase in APP expression is revealed in the 24 hrs 
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BA, 24 hrs 3MA, [24 hrs BA + 12 hrs 3MA], and [24 hrs BA + 12 hrs (2DG + 3MA)] 
compared to control cells (Fig. 5.10.B). Moreover, APP is further enhanced in the [24 
hrs BA + 12 hrs (2DG + 3MA)] treatment group compared to the [24 hrs BA + 12 hrs 
2DG] treatment group. This data suggests that (i) concomitant 2DG treatment during 
24 hrs APP overexpression attenuates APP expression, while concomitant 2DG and 
3MA treatment with 24 hrs APP overexpression is not neuroprotective in this context, 
additionally, (ii) that complete inhibition of autophagosome synthesis enhances APP 
expression, and this effect is further enhanced following concomitant 3MA treatment 
during 24 hrs APP overexpression. These findings suggest that (i) 2DG mitigates APP 
levels translating to cell protection, (ii) APP may be proteinaceous cargo for MA 
degradation, as APP levels are increased when MA induction is inhibited, and further 
augmented with increasing APP expression. In line with our findings, previous reports 
have shown increased APP levels following 24 hrs 3MA treatment in the 
neuroblastoma SH-SY5Y cell line, and APP expression was further enhanced 
following concomitant 24 hrs treatment with 3MA, and MA inducer (STF-62247) (Cai 
et al., 2015). It is reasonable to propose that inhibition of MA augments APP 
processing. Our data reveal that β-secretase activity is significantly increased in all the 
treatment groups compared to control cells, and further enhanced in the 12 hrs 3MA, 
[24 hrs BA + 12 hrs 3MA], and [24 hrs BA + 12 hrs (2DG + 3MA)] treatment groups 
compared to the 24 hrs BA treatment group (Fig. 5.10.D). This data suggests that 
amyloidogenic processing is enhanced following induction and complete inhibition of 
MA with and without 24 hrs APP overexpression. Moreover, our findings indicate that 
concomitant 2DG and 3MA treatment with 24 hrs APP overexpression also favours 
amyloidogenic processing as evidenced by the increased β-secretase activity in this 
treatment group. Indeed, we found that β-secretase activity is enhanced in the [24 hrs 
BA + 12 hrs (2DG + 3MA)] treatment group compared to the 24 hrs BA treatment group 
(Fig. 5.10.D), suggesting that simultaneous inhibition and induction of MA augments 
APP overexpression through increased β-secretase activity. Moreover, our results 
reveal that amyloidogenic processing is more pronounced following complete 
inhibition of MA. Indeed, Cai et al. (2015) reveal enhanced β-secretase activity 
following 24 hrs 3MA treatment in SH-SY5Y cells. These findings are further supported 
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in Zheng et al. (2011) SH-SY5Y cells transfected with APPwt and APPswe plasmids 
and exposed to hyperoxia or normoxia conditions for 7 days with or without 3MA 
treatment (1 mM). Consistent with enhanced APP, and β-secretase expression in 
these groups, Aβ levels are significantly increased in the 12 hrs 3MA, [24 hrs BA + 12 
hrs 3MA], and the [24 hrs BA + 12 hrs (2DG + 3MA)] treatment groups compared to 
both the control cells, and the 24 hrs BA treatment group (Fig. 5.10.F). These findings 
suggest Aβ accumulation is increased due to complete MA inhibition. Consistent with 
our results, Cai et al. (2015) reveal that the level of Aβ1–42 peptide SH-SY5Y cells was 
significantly increased by 3MA treatment compared to control cells. Our findings are 
further supported in a study by Fonseca et al. (2014)., which demonstrates an increase 
in Aβ levels of brain endothelial cells incubated with Aβ1–40 for 6 hrs. Additionally, this 
study revealed that the aggregation state of Aβ peptide was further enhanced when 
cells were simultaneously incubated with 24 hrs 3MA treatment and extracellularly 
added Aβ1–40 (Fonseca et al., 2014). Hence, it is reasonable to suggest that Aβ is 
degraded through the MA pathway, and inhibition of this pathway promotes Aβ 
accumulation. Our results also reveal that Aβ expression in the 12 hrs 2DG, and [24 
hrs BA + 12 hrs 2DG] is comparable to the control cells (Fig. 5.10.F). This data 
indicates that while 2DG with and without 24 hrs APP overexpression limits Aβ 
production translating to protection, inhibition of the MA pathway following 3MA with 
and without 24 hrs APP overexpression favours enhanced Aβ 
accumulation/proteotoxicity. Indeed, work by Yu et al. (2004) has revealed that Aβ is 
produced in AVs within the AD brain, suggesting that induction and inhibition of MA 
does indeed impact APP processing/Aβ production within this pathway. Overall, our 
data suggests that 2DG treatment is protective as it mitigates APP processing in 
favour of cell protection as evidenced by decreased Aβ production. Moreover, this data 
suggests that MA is the primary cytoprotective mechanism, as evidenced by enhanced 
APP overexpression following inhibition of this pathway (Fig. 5.10.B). In accord, Nixon 
(2007) suggests that the defective clearance of Aβ-generating AVs creates conditions 
favourable for Aβ accumulation in AD, and this is supported by data indicating that MA 
induction following rapamycin treatment reduces Aβ levels both in vivo and in vitro  
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(Cho et al., 2014; Spilman et al., 2010). Our work dissects this further, by bringing 
together clearance and proteotoxicity in the context of MA pathway proficiency.  
 
Western blot analysis of MA molecular markers was performed to assess the 
contribution of this pathway in 2DG-mediated preservation of cell viability (Fig. 5.9). 
Our results reveal a significant increase in LC3II expression for all the treatment 
groups compared to the control cells, and LC3II levels are further enhanced in the [24 
hrs BA + 12 hrs 2DG] treatment group compared to the 24 hrs BA treatment group 
(Fig. 5.11.B). Although the level of LC3II observed provides a good index of MA 
induction, it is important to note that LC3II expression is increased in all the groups for 
different reasons. Briefly, in the 12 hrs 3MA and [24 hrs BA + 12 hrs 3MA] treatment 
group LC3II levels are enhanced due to complete inhibition of autophagosome 
synthesis, hence the observed LC3II levels may be indicative of the basal MA activity 
prior to inhibition of this process. Conversely, in the 12 hrs 2DG, [24 hrs BA + 12 hrs 
2DG], and the [24 hrs BA + 12 hrs (2DG + 3MA)] treatment group, LC3II levels are 
enhanced due to enhanced MA activity above basal levels following 2DG treatment, 
while enhanced LC3II levels in the 3MA/2DG concomitant treatment group during APP 
overexpression may reflect impaired autophagosome clearance. In line with our 
findings, Chakraborty (2017) have also demonstrated that CR regimes upregulate MA 
activity above basal levels and mitigate APP expression both in vitro and in vivo. In 
support of these findings, a time-lapse imaging assessment by Chen et al. (2015) 
revealed that fasting upregulates MA activity above basal levels in neurons of AD 
mouse models. Similarly, Ni et al. (2010) also reported increased LC3II levels, with 
reduced BECN1 expression following 3MA treatment in rat cortical tissue, suggesting 
that the detected LC3II levels were due to the accumulation of autophagosomes 
formed prior to inhibition of autophagosome synthesis. Moreover, 3MA is known to 
have an MA stimulatory effect under nutrient-rich conditions based on its inhibitory 
effect on the class I PtdIns3K (Klionsky et al., 2016; Wu et al., 2010), which is 
consistent with our observations in the 12 hrs 3MA, and 24 hrs BA + 12 hrs 3MA 
treatment groups (Fig. 5.11.B). 
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Our results also reveal that p62 expression is significantly increased in the 12 hrs 3MA, 
[24 hrs BA + 12 hrs MA], [24 hrs BA + 12 hrs 2DG], and the [24 hrs BA + 12 hrs (2DG 
+ 3MA)] treatment group compared to both the control cells and the 24 hrs BA 
treatment group (Fig. 5.11.D). This data suggests that MA-mediated cargo 
degradation is impaired in response to complete of autophagosome synthesis with 
and without 24 hrs APP overexpression, with 2DG treatment in the presence of 24 hrs 
APP overexpression, and with 3MA/2DG concomitant treatment with 24 hrs APP 
overexpression, while p62 clearance in the 12 hrs 2DG is comparable to control cells. 
A mismatch is revealed, whereby increased p62 levels (Fig. 5.11.D) are not consistent 
with the indication that MA activity is increased above basal levels (Fig. 5.11.B), 
indicating that other mechanisms/cellular response may impact p62 expression. 
Indeed, studies by Jamart et al. (2013) and Sanchez et al. (2014) reveal that p62 are 
affected by both increased transcription and decreased degradation.  
 
The contribution of the CMA pathway to 2DG-mediated preservation of cell viability 
during 24 hrs APP expression (Fig. 5.9) was assessed with western blot analysis. To 
our surprise, our findings reveals no significant changes in LAMP2A (Fig. 5.12.B) and 
HSC70 (Fig. 5.12.D) protein expression for all the treatment groups compared to 
control cells. This data suggests that CMA activity is not activated above basal levels 
in the presence of complete MA pathway inhibition or induction of MA with and without 
24 hrs APP overexpression. These finding suggest that CMA has little to no role in 
amyloidogenic processing in this context. In contrast with our findings, previous 
studies have demonstrated that CMA is activated above basal levels in response to 
amino acid or glucose deprivation in lysosomes isolated from rat liver, however, MA 
was not inhibited in this context (Cuervo et al., 1995, 1997). Moreover, the authors 
also revealed that CMA is induced following ‘prolonged’ nutrient starvation, indicating 
temporal differences in the activation of MA and CMA. Our findings suggest that 12 
hrs 2DG treatment may not be sufficient to induce CMA above basal levels in this 
context. This findings LRP1 is contrast with a study by Schneider et al. (2014) which 
demonstrated an induction in MA activity in LAMP2A knockout/CMA-deficient mice. 
Similarly, Galan-Acosta et al. (2015) reported enhanced CMA activity in response to 
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nutrient-deprivation, and inhibition of the MA pathway using spautin-1 in cancer cells 
(Galan-Acosta et al., 2015). However, and most importantly, these experiments were 
performed in different experimental model systems, not under such controlled APP 
environment in the current study context. Overall, our findings suggest that inhibition 
of the MA pathway during 24 hrs APP overexpression does not promote compensatory 
CMA response. Moreover, despite suggestions of CMA’s role in APP clearance, our 
results indicate that CMA has, at least in this in vitro scenario, no role in 2DG-medaited 
cytoprotection. 
 
Finally, western blot was performed to assess the effects of 3MA/ 2DG concomitant 
treatment during 24 hrs APP overexpression on apoptosis (Fig. 5.13). Our results 
reveal significantly increased Total Caspase-3 (Fig. 5.13.B) and c-PARP (Fig. 5.13.D) 
expression for all the treatment groups compared to control cells, with Total Caspase-
3 further enhanced in the 12 hrs 3MA treatment group compared to the 24 hrs BA 
treatment group. These results indicate that the apoptotic pathway is activated 
irrespective whether MA is induced or inhibited. Although MA has previously been 
shown to impact APP processing in favour of decreased Aβ production and/or 
increased clearance (Fig. 5.10.B,F), this response appears insufficient to mediate 
complete cytoprotection following 24 hrs APP overexpression. However, Total 
Caspase-3 expression is further enhanced in response to complete MA inhibition, 
suggesting the role of MA towards creating a more favourable environment for cell 
survival. These findings raise the possibility that inducing MA activity above basal 
levels should be performed earlier in APP overexpression, i.e. 12 hrs BA treatment, or 
that the duration of 2DG exposure should be prolonged, e.g. 24 hrs 2DG treatment, 
which may also create more favourable conditions for CMA to be fully induced. 
However, the induction of MA has been described as a ‘double-edged sword’. On the 
one hand, MA is an essential neuroprotective response shown to regulate the 
clearance of cytotoxic Aβ oligomers (Nilsson and Saido, 2014; Nilsson et al., 2013, 
2015), on the other hand, excessive MA induction has been shown to be pathogenic 
due to its sustained degradation of critical cellular constituents, ultimately leading to 
cell death onset as reviewed in Levine and Yuan (2005). While the decision to further 
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enhance MA can lead to adverse effects in cells under certain pathological conditions, 
our results clearly show that the upregulation of MA above basal levels may translate 
into neuronal protection in the context of APP overexpression. It is reasonable to 
propose that therapeutic interventions with dual-functionality in both enhanced MA 
activity, and Aβ clearance may ameliorate Aβ proteotoxicity in AD, translating to 
neuroprotection.  
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CHAPTER 6 RESULTS: IN VIVO ASSESSMENT OF THE ROLE OF MA AND CMA 
IN A PARAQUAT-INDUCED BRAIN INJURY MODEL  
 
6.1. Introduction to results 
 
Paraquat (PQ)-induced neurotoxicity is a well-established model system in the field of 
neurodegeneration and proteotoxicity (Huang et al., 2016; Wang et al., 2017). PQ is a 
commonly used pesticide shown to induce mitochondrial damage and increased ROS 
production, ultimately leading to neurodegeneration (Yan et al., 2016). Oxidative 
stress is associated with increased production of ROS and reactive nitrogen species, 
including hydrogen peroxide, which have been shown to contribute to the early stages 
of AD prior to the onset of clinical symptoms (Uttara et al., 2009). Oxidative stress 
markers including high levels of lipid peroxidation have been reported in post-mortem 
brain tissue from individuals with preclinical or early stage AD (Sultana et al., 2011). 
CR regimes have consistently been shown to ameliorate age-associated pathology in 
various organisms (Mattson, 2005). Intermittent fasting (IF), a dietary intervention 
analogous to CR and involving ad libitum to food access on alternate days, has also 
been shown to attenuate brain aging through the reduction of inflammatory processes, 
including the reduction of ROS and induction of cellular stress resistance mechanisms 
(Li et al., 2017; Parikh et al., 2016). However, the effect of CR regimes on particularly 
MA, and CMA activity, but also glial fibrillary acidic protein (GFAP), a marker of brain 
injury, cytochrome c, a marker of apoptosis, and 4-hydroxynonenal (4HNE), a marker 
of lipid peroxidation, in the PQ-induced brain injury model is largely unclear. Therefore, 
the aims of this chapter were to assess (i) the contribution of MA and CMA in this 
model system in protein clearance, and (ii) the effects of 48 hrs IF on oxidative stress 
in the hippocampus, cortex, and cerebellum region. These brain regions were selected 
based on pathological studies of AD patients, which indicate that the greatest 
neurodegenerative changes, including generalised cell loss, occur in these regions at 
varying degrees in response to increased oxidative stress (Schmahmann, 2016). Mice 
were subjected twice weekly to PQ treatment of 10 mg/kg followed by 48 hrs IF for 3 
weeks. 









6.2.1. Effect of the treatment intervention on body weight 
 
As shown in Fig. 6.1, the results indicate a significant decrease in body weight in the 
48 hrs IF group [21.11 ± 0.53 (p<0.05)], and [(48 hrs IF) + PQ] group [21.27 ± 0.53 
(p<0.05)] compared to the control [25.22 ± 0.25] and PQ exposed group [26.26 ± 0.27] 
after the completion of the 21-day treatment intervention. Body weight loss reached 
significance on day 8, however, and most importantly, body weight was regained in 
response to the 24 hrs refeeding period. In Brief, body weight loss was significant: (i) 
on day 8, in the 48 hrs IF group [17.68 ± 0.47 (p<0.05)], and [(48 hrs IF) + PQ] group 
[18.38 ± 0.47 (p<0.05)] compared to the control [24.87 ± 0.47] and PQ exposed group 
[25.9 ± 0.47]; (ii) on day 11, in the 48 hrs IF group [17.45 ± 0.47 (p<0.05)], and [(48 
hrs IF) + PQ] group [18.03 ± 0.47 (p<0.05)] compared to the control [25.47 ± 0.47] and 
PQ exposed group [26.47 ± 0.47]; (iv) on day 14, in the 48 hrs IF group [17.26 ± 0.47 
(p<0.05)], and [(48 hrs IF) + PQ] group [17.79 ± 0.47 (p<0.05)] compared to the control 
[25.96 ± 0.47] and PQ exposed group [27.14 ± 0.47]; (vii) on day 17, in the 48 hrs IF 
group [18.0 ± 0.47 (p<0.05)], and [(48 hrs IF) + PQ] group [17.6 ± 0.47 (p<0.05)] 
compared to the control [26.6 ± 0.47] and PQ exposed group [27.73 ± 0.47]; and (ix) 
on day 20, in the 48 hrs IF group [18.26 ± 0.47 (p<0.05)], and [(48 hrs IF) + PQ] group 
[17.79 ± 0.47 (p<0.05)] compared to the control [26.89 ± 0.47] and PQ exposed group 
[28.05 ± 0.47] (Fig. 6.1), suggesting that the 24 hrs refeeding period was sufficient to 
counteract the loss in body weight. 
 




Figure 6.1: Body weight in response to the 21-day treatment intervention. Data 
expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs 
control, #p<0.05 vs. PQ, n = 12. Abbreviations: PQ, paraquat exposed group; 48h (IF), 48 hrs 
intermittent fasted group; [(48h IF) + PQ], 48 hrs intermittent fasted and paraquat group. 
 
6.2.2. Effect of the 21-day treatment intervention on overall food consumption and ex 
vivo brain weight 
 
As shown in Fig. 6.2.A, a significant increase in overall food consumption is indicated 
in the 48 hrs IF group [27.06 ± 0.3 (p<0.05)], and [(48 hrs IF) + PQ] group [25.77 ± 
2.35 (p<0.05)] compared to control [18.78 ± 0.71] and the PQ exposed group [19.38 ± 
0.77]. 
No significant difference in ex vivo brain weight is revealed for all groups (Fig. 6.2.B). 
A.                                                                         B. 
 
Figure 6.2: (A) food consumption and (B) ex vivo brain weight in response to treatment 
intervention. Data expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni 
correction, *p<0.05 vs control, #p<0.05 vs. PQ, n = 12.  
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6.2.3. Effect of the 21-day treatment intervention on survival  
 
Figure 6.3 reveals no significant difference in survival following the 21-day treatment 
intervention. Three mice were censored in the [(48 hrs IF) + PQ] group, with no effect 
on survival when compared to the control, PQ exposed group, or the 48 hrs IF group. 
 
 
Figure 6.3: Kaplan–Meier survival curves of treatment groups. Overall survival was 
quantified using the log rank test, p< 0.05, n = 12. Abbreviations: PQ, paraquat exposed group; 
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6.2.4. Assessment of the hippocampus region 
 
In order to assess the overall histology and cellular morphology of the hippocampus 
region following the 21-day treatment intervention period, Haematoxylin and Eosin (H 
& E) staining was performed. As shown in Fig. 6.4, no major abnormalities in individual 
nuclei distribution or density is observed in any of the treatment groups compared to 
the control. 
6.2.4.1. Representative H & E micrographs of the hippocampus 
 
 
Figure 6.4: Representative H & E micrographs of the hippocampus in response to the 
21-day treatment intervention. Representative micrographs indicate the control, paraquat 
exposed (PQ) group, 48 hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ)] group, n= 
6. Scale bars indicate 500 μm. Images (A) = ×4 magnification, images (B) = ×10 magnification. 
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6.2.4.2. Effect of the 21-day treatment intervention on lipid peroxidation and apoptosis 
in the hippocampus 
 
As shown in Fig. 6.5.A, 4HNE protein expression is significantly increased in the PQ 
exposed group [0.71 ± 0.02 (p<0.05)] compared to the control [0.58 ± 0.04], while 
4HNE expression is significantly decreased in the 48 hrs IF group [0.17 ± 0.03 
(p<0.05)], and importantly, the [(48 hrs IF) PQ] group [0.08 ± 0.02 (p<0.05)] compared 
to the PQ exposed group [0.71 ± 0.02] and control group (Fig. 6.5.B). 
 
Figure 6.5.C indicates that cytochrome c expression follows the same pattern as 
4HNE, i.e. cytochrome c is significantly increased in the PQ exposed group [0.56 ± 
0.02 (p<0.05)] compared to the control [0.34 ± 0.05], while a significant decrease is 
indicated in the [(48 hrs IF) + PQ] group [0.19 ± 0.02 (p<0.05)] compared to the PQ 
exposed group [0.56 ± 0.02] and the control, with a similar decrease in the 48 hrs IF 
group [0.32 ± 0.02 (p<0.05)] compared to the PQ exposed group only (Fig. 6.5.D). 
These data indicate robust protection in response to the IF regime. 
 













Figure 6.5: Effect of the 21-day treatment intervention on lipid peroxidation and 
apoptosis in the hippocampus. Representative western blot and densitometric analysis for 
(A, B) 4HNE (low and high exposure), and (C, D) cytochrome c protein expression is shown. 
Data expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni correction, * 
p<0.05 vs. control, #p<0.05 vs. PQ, n = 6, arbitrary units (a.u).  
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6.2.4.3. Representative 4HNE and cytochrome c fluorescence micrographs of the 
hippocampus 
 
In order to assess the localization and signal intensity pattern of 4HNE, and 
cytochrome c protein in the hippocampus region, immunofluorescence analysis was 
performed. As shown in Fig. 6.6, 4HNE signal (red, left panel), and cytochrome c 
signal (red, right panel) are both strongly indicted in the PQ exposed group compared 
to the control, the 48 hrs IF group and the [(48 hrs IF) PQ] group. 
 
 
Figure 6.6: Immunofluorescence micrographs indicating 4HNE and cytochrome c 
protein expression in the hippocampus. Left panel indicates 4HNE (red). Right panel 
indicates cytochrome c (red). The treatment intervention groups are defined as the control, 
paraquat exposed (PQ) group, 48 hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ)] 
group, n = 6. Nuclei counterstained with Hoechst 33342 (blue), scale bars = 100 μm, higher 
magnification micrographs = 50 μm. Arrowheads indicate regions of strong 4HNE or 
cytochrome c protein signal. 
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6.2.4.4. Effect of the 21-day treatment intervention on MA activity in the hippocampus 
 
Figure 6.7.A indicates a significant increase in LC3II protein expression in the 48 hrs 
IF group [1.39 ± 0.06 (p<0.05)], and the [(48 hrs IF) + PQ] group [0.19 ± 0.02 (p<0.05)] 
compared to the control [1.07 ± 0.01]. More importantly, LC3II expression is 
significantly increased in the [(48 hrs IF) + PQ] group [0.19 ± 0.02 (p<0.05)] compared 







Figure 6.7: Effect of the 21-day treatment intervention on MA activity in the 
hippocampus. Representative western blot (low and high exposure) and densitometric 
analysis for (A, B) LC3II protein expression is shown. Data expressed as mean ± SEM, 
statistical analysis: ANOVA and Bonferroni correction, * p<0.05 vs. control, #p<0.05 vs. PQ, n 
= 6, arbitrary units (a.u). 
 
6.2.4.5. Representative GFAP and LC3II fluorescence micrographs of the 
hippocampus 
 
As shown in Fig. 6.8, GFAP (red), and LC3II (green) protein signal is strongly 
indicated in the PQ exposed group compared to the other treatment groups. 




Figure 6.8: Immunofluorescence micrographs indicating LC3II (green) and GFAP (red) expression in the hippocampus. Representative 
micrographs indicate the control, paraquat exposed (PQ) group, 48 hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ) group. Nuclei 
counterstained with Hoechst 33342 (blue), scale bars = 100 μm, higher magnification micrographs = 50 μm. Arrowheads indicate regions of 
strong GFAP or LC3II protein signal. 
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6.2.4.6. Effect of the 21-day treatment intervention on MA cargo protein degradation 
in the hippocampus 
 
As shown in Fig. 6.9.A, p62 protein expression is significantly decreased in the 48 hrs 
IF group [0.41 ± 0.06 (p<0.05)], and [(48 hrs IF) + PQ] group [0.27 ± 0.05 (p<0.05)] 
compared to the control [0.65 ± 0.02]. Importantly, a significant decrease is indicated 
in the [(48 hrs IF) + PQ] group [0.27 ± 0.05 (p<0.05)] compared to the PQ exposed 








Figure 6.9: Effect of the 21-day treatment intervention on MA cargo protein degradation 
in the hippocampus. Representative western blot (low and high exposure) and densitometric 
analysis for (A, B) p62 protein expression is shown. Data expressed as mean ± SEM, 
statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. PQ, n 
= 6, arbitrary units (a.u). 
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6.2.4.7. Representative p62 fluorescence micrographs of the hippocampus 
 
Figure 6.10 reveals that p62 (magenta) protein signal is strongly indicated in the PQ 




Figure 6.10: Immunofluorescence micrographs indicating p62 signal (magenta) in the 
hippocampus. Representative micrographs indicate the control, paraquat exposed (PQ) 
group, 48 hrs intermittent fasting (IF) group, and the [(48 hrs IF) + PQ)] group. Nuclei 
counterstained with Hoechst 33342 (blue), scale bars = 100 μm, higher magnification 
micrographs = 50 μm. Arrowheads indicate regions of strong p62 protein signal. 
Stellenbosch University  https://scholar.sun.ac.za
217 
 
6.2.4.8. Effect of the 21-day treatment intervention on the expression of CMA exclusive 
protein in the hippocampus 
 
As shown in Fig. 6.11.A, LAMP2A protein expression is significantly increased in the 
48 hrs IF group [1.12 ± 0.07 (p<0.05)], and the [(48 hrs IF) + PQ] group [1.11 ± 0.03 
(p<0.05)] compared to the control [0.75 ± 0.12]. Importantly, LAMP2A expression is 
significantly increased in the 48 hrs IF group, and the [(48 hrs IF) + PQ] group 
compared to the PQ exposed group [0.75 ± 0.05] (Fig. 6.11.B), suggesting that the IF 











Figure 6.11: Effect of the 21-day treatment intervention on CMA activity in the 
hippocampus. Representative western blot (low and high exposure) and densitometric 
analysis for (A, B) LAMP2A protein expression is shown. Data expressed as mean ± SEM, 
statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. PQ,  
n = 6, arbitrary units (a.u). 
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6.2.4.9. Effect of the 21-day treatment intervention on APP expression in the 
hippocampus 
 
Figure 6.12.A reveals that APP expression is significantly increased in the PQ 
exposed group [1.86 ± 0.13 (p<0.05)] compared to the control [0.62 ± 0.1]. However, 
and most importantly, APP expression is significantly decreased in the 48 hrs IF group 
[0.18 ± 0.04 (p<0.05)] and [(48 hrs IF) + PQ] [0.78 ± 0.13 (p<0.05)] group compared 
to the PQ exposed group, while significantly increased APP expression is revealed in 






Figure 6.12: Effect of the 21-day treatment intervention on APP expression in the 
hippocampus. Representative western blot (low and high exposure) and densitometric 
analysis for (A, B) APP protein expression is shown. Data expressed as mean ± SEM, 
statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. PQ, 
#p<0.05 vs. 48h IF, n = 6, arbitrary units (a.u). 
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6.2.5. Assessment of the cortex region 
 
As shown in Fig. 6.13, H & E staining of the cortex reveals uniform distribution of 
individual nuclei for all the groups, with no indications of cell loss, or architectural 
abnormalities following the 21-day treatment intervention. 
 
6.2.5.1. Representative H & E micrographs of the cortex 
 
 
Figure 6.13: Representative H&E micrographs of the cortex in response to the 21-day 
treatment intervention. Representative micrographs indicate the control, paraquat exposed 
(PQ) group, 48 hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ] group, n= 6. Scale 
bars indicate 500 μm. Images (A) = ×4 magnification, images (B) = ×10 magnification. 
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6.2.5.2. Effect of the 21-day treatment intervention on lipid peroxidation and apoptosis 
in the cortex 
 
Figure 6.14.A reveals a significant increase in 4HNE protein expression in the PQ 
exposed group [0.54 ± 0.01 (p<0.05)] compared to the control [0.31 ± 0.02], while 
4HNE expression is significantly decreased in the 48 hrs IF group [0.04 ± 0.002 
(p<0.05)], and the [(48 hrs IF) + PQ] group [0.02 ± 0.006 (p<0.05)] compared to the 
PQ exposed group and the control (Fig. 6.14.B).  
 
As shown in Fig. 6.14.C, cytochrome c protein expression significantly increased in 
the PQ exposed group [0.068 ± 0.003 (p<0.05)] compared to the control [0.03 ± 0.0], 
while cytochrome c expression is significantly decreased in the 48 hrs IF group [0.03 
± 0.002 (p<0.05)], and the [(48 hrs IF) + PQ] group [0.03 ± 0.0 (p<0.05)] compared to 

















Figure 6.14: Effect of the 21-day treatment intervention on lipid peroxidation and 
apoptosis in the cortex. Representative western blot and densitometric analysis for (A, B) 
4HNE (low and high exposure), and (C, D) cytochrome c protein expression is shown. Data 
expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni correction, * p<0.05 
vs. control, #p<0.05 vs. PQ, n = 6, arbitrary units (a.u). 
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6.2.5.3. Representative 4HNE and cytochrome c fluorescence micrographs of the 
cortex 
 
Figure 6.15 indicates that 4HNE (red, left panel), and cytochrome c (red, right panel) 
protein signal is strongly revealed in the PQ exposed group while the control, 48h IF 
group and the [(48 hrs IF) + PQ] group reveal diminished 4HNE and cytochrome c 
protein signal. 
 
Figure 6.15: Immunofluorescence micrographs indicating 4HNE and cytochrome c 
signal in the cortex. Left panel indicates 4HNE (red). Right panel indicates cytochrome c 
(red). The treatment intervention is defined as the control, paraquat exposed (PQ) group, 48 
hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ)] treatment group. Nuclei 
counterstained with Hoechst 33342 (blue), scale bars = 100 μm, higher magnification 
micrographs = 50 μm. Arrowheads indicate regions of strong 4HNE or cytochrome c protein 
signal. 
Stellenbosch University  https://scholar.sun.ac.za
223 
 
6.2.5.4. Effect of the 21-day treatment intervention on MA activity in the cortex 
 
As shown in Fig. 6.16.A, LC3II protein expression is significantly increased in the 48 
hrs IF group [0.87 ± 0.06 (p<0.05)], and the [(48 hrs IF) + PQ] group [0.95 ± 0.03 
(p<0.05)] compared to the control [0.65 ± 0.005], with no significant difference in LC3II 







Figure 6.16: Effect of the 21-day treatment intervention on MA activity in the cortex. 
Representative western blot (low and high exposure) and densitometric analysis for (A, B) 
LC3II protein expression is shown. Data expressed as mean ± SEM, statistical analysis: 
ANOVA and Bonferroni correction, * p<0.05 vs. control, n = 6, arbitrary units (a.u). 
 
6.2.5.5. Representative GFAP and LC3II fluorescence micrographs of the cortex 
 
Figure 6.17 reveals relatively uniform GFAP (red) protein signal in all the groups, 
while LC3II (green) protein signal appears slightly increased in the 48h IF group and 
[(48 hrs IF) + PQ] group compared to the control. 




Figure 6.17: Immunofluorescence micrographs indicating LC3II (green) and GFAP (red) signal in the cortex. Representative micrographs 
indicate the control, paraquat exposed (PQ) group, 48 hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ)] group. Nuclei counterstained 
with Hoechst 33342 (blue), scale bars = 100 μm, higher magnification micrographs = 50 μm. Arrowheads indicate regions of strong LC3II protein 
signal.
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6.2.5.6. Effect of the 21-day treatment intervention on MA cargo degradation in the cortex 
 
Figure 6.18.A indicates that p62 protein expression is significantly decreased in the 
48 hrs IF group [0.31 ± 0.03 (p<0.05)], and [(48 hrs IF) + PQ] group [0.24 ± 0.05 
(p<0.05)] compared to the control [0.79 ± 0.03] and the PQ exposed group [0.89 ± 
0.06] (Fig. 6.18.B), suggesting increased MA degradative activity in this region in 






Figure 6.18: Effect of the 21-day treatment intervention on MA cargo protein 
degradation in the cortex. Representative western blot (low and high exposure) and 
densitometric analysis for (A, B) p62 protein expression is shown. Data expressed as mean ± 
SEM, statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 
PQ, n = 6, arbitrary units (a.u). 
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6.2.5.7. Representative p62 fluorescence micrographs of the cortex 
 
As shown in Fig. 6.19, immunofluorescence analysis indicates that p62 protein signal 
(magenta) is diminished in the 48h IF group, and the [(48 hrs IF) + PQ] group 
compared to the PQ exposed group, where p62 signal is revealed more intensely. 
 
Figure 6.19: Immunofluorescence micrographs indicating p62 signal (magenta) in the 
cortex. Representative micrographs indicate the control, paraquat exposed (PQ) group, 48 
hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ)] group. Nuclei counterstained with 
Hoechst 33342 (blue), scale bars = 100 μm, higher magnification micrographs = 50 μm. 
Arrowheads indicate regions of strong p62 protein signal. 
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6.2.5.8. Effect of the 21-day treatment intervention on the expression of CMA exclusive 
protein in the cortex 
 
As shown in Fig. 6.20.A, LAMP2A protein expression is significantly increased in the 
48 hrs IF group [1.57 ± 0.04 (p<0.05)], and [(48 hrs IF) + PQ] group [1.7 ± 0.04 












Figure 6.20: Effect of the 21-day treatment intervention on CMA activity in the cortex. 
Representative western blot (low and high exposure) and densitometric analysis for (A, B) 
LAMP2A protein expression is shown. Data expressed as mean ± SEM, statistical analysis: 
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6.2.5.9. Effect of the 21-day treatment intervention on APP expression in the cortex 
 
Figure 6.21.A indicates that APP protein expression is significantly increased in the 
PQ exposed group [0.88 ± 0.09 (p<0.05)] compared to control [0.51 ± 0.04]. Notably, 
APP expression is significantly decreased in the 48 hrs IF group [0.46 ± 0.03 (p<0.05)], 
and [(48 hrs IF) + PQ] group [0.43 ± 0.04 (p<0.05)] compared to the PQ exposed group 






Figure 6.21: Effect of the 21-day treatment intervention on APP expression in the cortex. 
Representative western blot and densitometric analysis for (A, B) APP protein expression is 
shown. Data expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni 
correction, *p<0.05 vs. control, #p<0.05 vs. PQ, n = 6, arbitrary units (a.u). 
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6.2.6. Assessment of the cerebellum region 
 
As shown in Fig. 6.22, H & E staining of the cerebellum reveals no structural 
architectural abnormalities in the density or nuclei distribution for all the groups in 
response to the 21-day treatment intervention. 
 
6.2.6.1. Representative H & E staining of the cerebellum 
 
Figure 6.22: Representative H & E micrographs of the cerebellum in response to a 21-
day treatment intervention. Representative micrographs indicate the control, paraquat 
exposed (PQ) group, 48 hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ] group. Scale 
bars indicate 500 μm. Images (A) = ×4 magnification, images (B) = ×10 magnification. 
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6.2.6.2. Effect of the 21-day treatment intervention on lipid peroxidation and apoptosis 
in the cerebellum 
 
As shown in Fig. 6.23.A, no significant difference in 4HNE protein expression is 
indicated in the 48 hrs IF group [0.92 ± 0.0], [(48 hrs IF) + PQ] group [0.91 ± 0.02], and 
the PQ exposed group [0.95 ± 0.03] compared to the control [0.84 ± 0.0] (Fig. 6.23.B). 
 
However, as shown in Fig. 6.23.C, cytochrome c protein expression is significantly 
increased in the PQ exposed group [1.1 ± 0.03 (p<0.05)] compared to the control [0.76 
± 0.05], more importantly, cytochrome c expression is significantly decreased in the 
48 hrs IF group [0.69 ± 0.03 (p<0.05)], and [(48 hrs IF) + PQ] group [0.57 ± 0.07 
(p<0.05)] compared to the PQ exposed group [1.1 ± 0.03]. No significant difference is 
indicated in the 48 hrs IF group, and [(48 hrs IF) + PQ] group compared to the control 
(Fig. 6.23.D). 
 












Figure 6.23: Effect of the 21-day treatment intervention on lipid peroxidation and 
apoptosis in the cerebellum. Representative western blot and densitometric analysis for (A, 
B) 4HNE, and (C, D) cytochrome c (low and high exposure) protein expression is shown. Data 
expressed as mean ± SEM, statistical analysis: ANOVA and Bonferroni correction, *p<0.05 
vs. control, #p<0.05 vs. PQ, n = 6, arbitrary units (a.u).
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6.2.6.3. Representative HNE and cytochrome c fluorescence micrographs of the 
cerebellum 
 
As shown in Fig. 6.24, no major differences in 4HNE (red, left panel), and cytochrome 
c (red, right panel) protein signal is observed in all the groups. However, 4HNE 




Figure 6.24: Immunofluorescence micrographs indicating 4HNE and cytochrome c 
signal in the cerebellum. Left panel indicates 4HNE (red). Right panel indicates 
cytochrome c (red). The treatment intervention is defined as the control, paraquat exposed 
(PQ) group, 48 hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ)] group. Nuclei 
counterstained with Hoechst 33342 (blue), scale bars = 100 μm, higher magnification 
micrographs = 50 μm. Arrowheads indicate regions of strong 4HNE, or cytochrome c protein 
signal. 
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6.2.6.4. Effect of the 21-day treatment intervention on MA activity in the cerebellum 
 
LC3II expression is significantly increased in the PQ exposed group [1.35 ± 0.06 
(p<0.05)], 48 hrs IF group [1.32 ± 0.05 (p<0.05)], and [(48 hrs IF) + PQ] group [1.43 ± 
0.06 (p<0.05)] compared to the control [1.07 ± 0.0] (Fig. 6.25.A), suggesting that MA 







Figure 6.25: Effect of the 21-day treatment intervention on MA activity in the cerebellum. 
Representative western blot (low and high exposure) and densitometric analysis for (A, B) 
LC3II protein expression is shown. Data expressed as mean ± SEM, statistical analysis: 
ANOVA and Bonferroni correction, *p<0.05 vs. control, n = 6, arbitrary units (a.u). 
 
6.2.6.5. Representative GFAP and LC3II fluorescence micrographs of the cerebellum 
 
Figure 6.26 reveals uniform GFAP (red) protein signal in all the treatment groups, with 
strong signal in the PQ exposed group. Stronger LC3II (green) protein signal is 
indicated in the PQ exposed group, 48h IF group, and [(48 hrs IF) + PQ] group 
compared to the control, in accordance with increased MA activity in this region. 




Figure 6.26: Immunofluorescence micrographs indicating LC3II (green) and GFAP (red) expression in the cerebellum. Representative 
micrographs indicate the control, paraquat exposed (PQ) group, 48 hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ)] group. Nuclei 
counterstained with Hoechst 33342 (blue), scale bars = 100 μm, higher magnification micrographs = 50 μm. Arrowheads indicate regions of 
strong GFAP or LC3II protein signal. 
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6.2.6.6. Effect of the 21-day treatment intervention on MA cargo degradation in the 
cerebellum 
 
Figure 6.27.A reveals a significant increase in p62 protein expression in the 48 hrs IF 
group [0.74 ± 0.05 (p<0.05)], compared to the [(48 hrs IF) + PQ] group [0.19 ± 0.04]. 
Importantly, p62 expression is significantly decreased in the 48 hrs IF group, and [(48 
hrs IF) + PQ] group compared to the control [1.29 ± 0.01] and the PQ exposed group 







Figure 6.27: Effect of the 21-day treatment intervention on MA cargo protein 
degradation in the cerebellum. Representative western blot (low and high exposure) and 
densitometric analysis for (A, B) p62 protein expression is shown. Data expressed as mean ± 
SEM, statistical analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. 
PQ, $p<0.05 vs. 48h IF, n = 6, arbitrary units (a.u). 
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6.2.6.7. Representative p62 fluorescence micrographs of the cerebellum 
 
As shown in Fig. 6.28, p62 protein signal (magenta) appears diminished in the 48h IF 
group and the [(48 hrs IF) + PQ] group compared to the control, with increased p62 
signal in the PQ exposed group compared to the 48h IF group, and the [(48 hrs IF) + 
PQ] group. 
 
Figure 6.28: Immunofluorescence micrographs indicating p62 expression (magenta) in 
the cerebellum. Representative micrographs indicate the control, paraquat exposed (PQ) 
group, 48 hrs intermittent fasting (IF) group, and [(48 hrs IF) + PQ)] group. Nuclei 
counterstained with Hoechst 33342 (blue), scale bars = 100 μm, higher magnification 
micrographs = 50 μm. Arrowheads indicate regions of strong p62 protein signal. 
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6.2.6.8. Effect of the 21-day treatment intervention on CMA exclusive protein in the 
cerebellum 
 
As indicated in Fig. 6.29.A, LAMP2A expression is significantly increased in the PQ 
exposed group [0.29 ± 0.04 (p<0.05)], 48 hrs IF group [1.02 ± 0.03 (p<0.05)], and [(48 
hrs IF) + PQ] group [1.22 ± 0.06 (p<0.05)] compared to the control [0.04 ± 0.0]. 
Moreover, LAMP2A expression significantly increased in the 48 hrs IF group, and [(48 






Figure 6.29: Effect of the 21-day treatment intervention on CMA activity in the 
cerebellum. Representative western blot (low and high exposure) and densitometric analysis 
for (A, B) LAMP2A protein expression is shown. Data expressed as mean ± SEM, statistical 
analysis: ANOVA and Bonferroni correction, *p<0.05 vs. control, #p<0.05 vs. PQ, $p<0.05 vs. 
(48h IF) + PQ, n = 6, arbitrary units (a.u). 
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6.2.6.9. Effect of the 21-day treatment intervention on APP expression in the 
cerebellum 
 
No significant difference in APP protein expression is indicated in all the treatment 







Figure 6.30: Effect of the 21-day treatment intervention on APP expression in the 
cerebellum. Representative western blot (low and high exposure) and densitometric analysis 
for (A, B) APP protein expression is shown. Data expressed as mean ± SEM, statistical 
analysis: ANOVA and Bonferroni correction, n = 6, arbitrary units (a.u). 
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CHAPTER 6 DISCUSSION: IN VIVO ASSESSMENT OF THE ROLE OF MA AND 
CMA IN A PARAQUAT-INDUCED BRAIN INJURY MODEL 
 
To date, CR is the only intervention that has consistently been found to enhance 
physiological function with advancing age, and delay the onset of age-associated 
diseases, such as neurodegeneration, cancer and diabetes mellitus type 2, across 
multiple species including nonhuman primates (Balasubramanian et al., 2017; Colman 
et al., 2014). The beneficial physiological effects of CR are thought to be mediated 
through its modulation of the cellular nutrient-sensing pathways, including mTOR 
signalling, the insulin-like growth factor 1 (IGF-1) signalling, and Sirtuin 1 (SIRT1) 
(Fontana et al., 2010; Ravussin et al., 2015). Importantly, long term CR is known to 
counteract physiological effects of aging, and recent research has provided compelling 
evidence that CR slows down brain aging and protects from age-related 
neurodegenerative diseases (Balasubramanian et al., 2017; Colman et al., 2014). 
Indeed, CR has been shown to significantly delay the onset of neurodegeneration, by 
preventing synaptic loss and preserving cognitive capacities, as observed in a mouse 
model of neurodegeneration (Gräff et al., 2013). The oxidative stress hypothesis of 
aging ascribes increased oxidative stress as the major causal factor of cell death, 
given that the amount of oxidative damage increases as an organism ages (Harman, 
1956; Stadtman, 1992, 2001). Moreover, experimental evidence suggests that 
overexpression of antioxidative enzymes may retard the age-related accumulation of 
oxidative damage and extend life-span in disease models of aging (Sun et al., 2002), 
and as shown by Stankovic et al. (2013), differences in life-span among different 
species may inversely correlate with the rate of mitochondrial generation of the 
superoxide anion radical and hydrogen peroxide. However, the potential contribution 
of nutrient signalling pathways, i.e. primarily MA and CMA, in mediating the beneficial 
physiological effects of CR on brain health remains unclear. In the previous chapters 
we assessed in great detail the relationship between MA and CMA in the context of 
APP induced neuronal toxicity. To what extent these two pathways play a role in an in 
vivo environment is largely unclear. Hence, here we investigated the potential role of 
these pathways in neuroprotection. 




We therefore investigated the effects of IF, defined as 48 hrs followed by 24 hrs 
refeeding (Collier, 2013) in GFP–LC3 expressing transgenic mice subjected to a 
robust neuronal injury associated with neurodegeneration (Niveditha et al., 2017), 
induced by paraquat exposure. GFP-LC3 mice were uniquely chosen for our 
experimental purposes, which included the assessment of MA using 
immunofluorescence microscopy as previously described (Mizushima, 2004). Brain 
injury was simulated in these mice using a well-established paraquat PQ protocol, 
previously shown to result in neurodegeneration (Chen et al., 2012). PQ is used as a 
quaternary ammonium herbicide; one of the most widely used herbicides, which is 
quick-acting, non-selective, and has been shown to be toxic to various organisms 
(Bismuth et al., 1990). The oxidation of this agent by oxygen has been shown to 
generate superoxide radicals, which result from the transfer of a single electron from 
reduced PQ to oxygen (Litteljohn et al., 2011). Due to its structural similarity to N-
methyl-4-phenyl pyridinium (MPP+), PQ exposure has been shown to induce 
dopaminergic toxicity and selective nigrostriatal degeneration in the mouse brain 
(Litteljohn et al., 2011; McCormack et al., 2002). The PQ model of neurodegeneration 
was utilized in order to examine whether CR can protect against neuronal loss in the 
context of oxidative stress, and if so, whether MA and CMA pathways play a role in 
this context. Although paraquat preferentially affects the nigrostriatal system, HAS 
been shown to accumulate in the hippocampus and cortex regions (Prasad et al., 
2009). Therefore, paraquat could potentially impair learning and memory and affect 
AD pathogenesis. The mechanism of PQ toxicity is defined as the induction oxidative 
stress and mitochondrial of oxidative damage (Drechsel and Patel, 2008). Here we 
determined the effects of PQ-induced oxidative stress in vulnerable neuronal 
populations of the hippocampus, cortex, and cerebellum brain regions using LC3II and 
p62 as markers for MA activity, LAMP2A as a marker for CMA activity, 4HNE as a 
marker for lipid peroxidation, cytochrome c as marker for mitochondrial injury and cell 
death onset, GFAP as a marker for inflammation, and APP expression as an indicator 
of amyloidogenic processing. 
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6.3. Physiological effects to the 21-day treatment intervention 
 
After 21 days of the treatment intervention, there were no significant differences in 
body weight (Fig. 6.1). However, a significant reduction in body weight is observed 
only during the second day of the IF intervention, indicated as day 8, 11, 14, 17, and 
20, in the 48 hrs IF, and [(48 hrs IF) + PQ) treatment groups compared to both the 
control and PQ exposed group. Notably, body weight in these treatment groups was 
comparable to the control and the PQ exposed group following the 24 hrs ad libitum 
refeeding, suggesting that ad libitum refeeding for this period was sufficient to 
counteract the loss of weight. The reduction in body weight was expected, and in line 
with our findings, others have shown that CR diets do not generally lead to lasting 
weight loss, instead resulting in muscle-mass reduction over time (Miller and Wolfe, 
2008). In further support of these findings, ad libitum refeeding has been shown to 
restore body weight, and the level of most CR-induced biomarker changes to baseline 
levels following moderate CR in rodents (Greene et al., 2001; Keenan et al., 1999).  
 
Our findings reveal that the average food intake of the 48 hrs IF, and [(48 hrs IF) + 
PQ] treatment groups was significantly higher than that of the control and PQ exposed 
group (Fig. 6.2.A). In line with our findings, Mahoney et al. (2006) have revealed that 
on the day of refeeding, CR mice typically ‘binge ate’, consuming approximately twice 
as much food as their unrestricted counterparts. Despite the increased food intake, 
the body weights of the 48 hrs IF, and [(48 hrs IF) + PQ) treatment groups was 
comparable to the control and PQ exposed group upon completion of the 21-day 
treatment intervention. Moreover, no differences in ex vivo brain weight were observed 
for all the groups (Fig. 6.2.B), suggesting that CR does not impact the brain structural 
integrity. In agreement, others have reported that CR also preserves structural brain 
integrity, synaptic plasticity and cognitive function in mouse models of 
neurodegeneration (Gräff et al., 2013; Guo et al., 2015). 
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Consistent with the life-prolonging effects of CR, our results indicate that the 21-day 
treatment intervention had no significant impact on survival for all the treatment groups 
(Fig. 6.3). Indeed, CR has been found to retard age-associated changes and extend 
maximum life-span by mitigation the effects of damage (Sohal and Weindruch, 1996). 
 
6.4. Analysis of the hippocampal region 
 
In order to assess the tissue for signs of injury, such as neuronal loss, inclusion body 
formation, apoptotic bodies or fibrotic lesions, Haematoxylin and Eosin (H & E) staining 
was performed. Our data reveals no major structural abnormalities or morphological 
indices for neuronal cell loss in the hippocampus region following the 21-day treatment 
intervention (Fig. 6.4). This observation suggests that neuronal injury is likely of a less 
severe nature in this context. Indeed, systemic exposure of PQ exposure has been 
shown to promote aggregate formation within neurons of the substantia nigra in in an 
in vivo model of PD (Manning-Bog et al., 2002). Immunohistochemistry staining of 
brain sections by (Chen et al., 2012) revealed pronounced inclusion body formation 
with associated Aβ plaque deposition following PQ exposure over a period of 3 weeks 
in APP transgenic mice, and these observations were further exacerbated following 
PQ exposure over a period of 5 months in the same mouse model (Chen et al., 2015a). 
These findings raise the possibility that PQ-induced oxidative stress was not sufficient 
to cause the expected neuronal loss reported in the above studies. 
 
4HNE is one of the major end products of lipid peroxidation, the production of which 
is accelerated in response to increased oxidative stress, and it also serves as a source 
of further ROS generation, making 4HNE both an inducer and mediator of oxidative 
stress (Zhong and Yin, 2015). Under physiological conditions the cellular 
concentration of 4HNE ranges from 0.1-0.3 µM and considered to play an important 
role in stimulating the expression of antioxidative enzymes during the induction of 
oxidative stress adaptive responses (Ceaser et al., 2004; Chen et al., 2005). However, 
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under conditions of excessive oxidative stress, 4HNE has been found to accumulate 
up to concentrations of 10 µM to 5 mM in various pathological states including AD, 
PD, inflammation, atherosclerosis, and cancer (Ji et al., 2016; Uchida, 2003). In these 
pathological states, lipid peroxidation has been shown to mediate changes in the 
permeability and fluidity of the membrane lipid bilayer and can drastically alter the cell 
integrity, ultimately eliciting a decrease in cell proliferation and the induction of 
apoptosis (McCracken et al., 2000; Siegel et al., 2007). Enhanced 4HNE expression 
would hence indicate ROS damage. Hence, next, 4HNE levels were assessed. Our 
western blot data reveals a significant increase in 4HNE expression in the PQ exposed 
group compared to the control, 48 hrs IF, and [(48 hrs IF) + PQ] groups (Fig. 6.5.B). 
Moreover, a significant decrease in 4HNE expression is indicated in the 48 hrs IF, and 
[(48 hrs IF) + PQ] treatment groups compared to the control. In addition, we also 
observe that 4HNE is significantly decreased in CR compared to control. In line with 
our findings, SDS-PAGE data by Sharma et al. (2012) revealed a significant increase 
in 4HNE levels following nitric oxide exposure in 9-month-old rates subjected to CR 
(food intake adjusted weekly to 60 to 65% of ad libitum intake). In a study by Dobashi 
et al. (2018), simultaneously exercise training conducted simultaneously with CR was 
found to improve the redox status, and completely suppress the exercise-induced 
elevation in both hippocampal 4HNE and brain-derived neurotrophic factor (BDNF) 
levels. BDNF is pivotal neurotrophic factor which plays crucial roles in neuronal 
survival, brain development, and has been shown to contribute substantially to the 
prevention of AD and depression through maintaining cognitive function (Alomari et 
al., 2016; Yamada et al., 2002). In support of our data, these studies reveal that CR 
regimes mitigates lipid peroxidation through the activation of neuroprotective 
mechanisms to detoxify/remove 4HNE and thereby prevent its potentially damaging 
actions.  
 
Cytochrome c plays a crucial role in apoptosis execution, at least in part, by 
complexing with other pro-apoptotic factors in the cytosol to induce apoptosis (Kagan 
et al., 2006, 2009). Indeed, cells lacking cytochrome c have been shown to have 
reduced caspase-3 activation and are resistant to the proapoptotic effects of UV 
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irradiation, nutrient starvation (Li et al., 2000). These studies confirm the role of 
cytochrome c in apoptotic signalling cascades, and hence underpin the severity of 
oxidative insult. Similar to our observations for 4HNE expression, our western blot data 
reveals a similar pattern in cytochrome c expression, which is significantly increased 
in the PQ exposed group compared to the control, 48 hrs IF, and [(48 hrs IF) + PQ] 
treatment groups, with a significant reduction also indicated in the [(48 hrs IF) + PQ] 
treatment group compared to the control (Fig. 6.5.D). These results indicate that the 
IF regime ameliorated the effects of increased oxidative stress, as evidenced by 
reduced cytochrome c expression in the IF treatment groups, in favour of protection. 
 
In line with our findings, others have shown that resveratrol, a CRM, translates to 
protection by, at least in part, preventing cytochrome c release in the hippocampal 
CA1 neurons following global cerebral ischaemia (Endo et al., 2006; Matapurkar and 
Lazebnik, 2006; Sanderson et al., 2008). Similar findings in the hippocampal region 
have been replicated by others in different in vivo models of oxidative stress damage 
(Liang et al., 2000; Zheng et al., 2011). Excessive ROS production has been shown 
to induce cytochrome c release from the mitochondrial membrane into the cytosol 
where it binds with apoptotic protease-activating factor 1, promoting the formation of 
the apoptosome (a large quaternary protein structure formed in the process of 
apoptosis), and in turn stimulating the recruitment and activation of caspases for the 
initiation of apoptosis (Sun et al., 2010; Wang, 2001). Therefore, the modulation of 
ROS levels, particularly in the brain, may represent a promising treatment strategy in 
neurodegeneration. In line with our western blot data, our immunofluorescence 
analysis mirrors the increased localization and expression of 4HNE and cytochrome c 
protein in the hippocampus of the PQ exposed group compared to the control, 48 hrs 
IF, and [(48 hrs IF) + PQ] treatment groups, with selective hotspots revealed within the 
hippocampus (Fig. 6.6). Given that 4HNE is also significantly decreased in the IF only 
group, this observation could also indicate the overall benefit of IF on ROS handling. 
The immunofluorescence images also support the notion that the hippocampus is a 
particularly sensitive region of susceptibility, as surrounding tissue is less positive for 
4HNE positive (Lumkwana et al., 2017). 




Accumulating evidence suggests that CR plays a major role in longevity, and that the 
neuroprotective effects of this dietary regime can largely be attributed to increased MA 
activity above basal levels (Bergamini et al., 2007; Knuppertz et al., 2014). Hence, in 
order to assess the role of MA in the context of PQ-induced neuronal toxicity, LC3II 
protein levels were assessed. Our western blot analysis reveals a significant increase 
in LC3II levels in the [(48 hrs IF) + PQ] treatment group compared to the PQ exposed 
group, the 48 hrs IF treatment group, and control, with LC3II levels also significantly 
increased in the 48 hrs IF treatment group compared to the control (Fig. 6.7.B). This 
data suggests that MA activity in the hippocampus region is indeed increased above 
basal levels in response to IF in this model system, and further enhanced in 
combination with PQ-induced injury, while PQ exposure alone does not appear 
sufficient to robustly induce MA. Our data is supported previous findings that show 
that CR induces AMPK activation, this molecular energy sensor in turn induced MA 
activity above basal levels to provide essential amino acids under conditions of nutrient 
deprivation (Hursting et al., 2010, 2013). Others have also shown that established 
tumours utilize the MA pathways to reduce oxidative stress and preserve mitochondrial 
bioenergetics in order to overcome /adapt to stressors, such as nutrient deprivation 
(Guo and White, 2016; White et al., 2015). Our results shed light onto the mechanism 
of CR-induced neuroprotection in this model system. These data are supported by the 
immunofluorescence analysis which reveals distinct hotspots of LC3II localization 
strongly indicated in the hippocampus of the 48 hrs IF, and [(48 hrs IF) + PQ] treatment 
groups compared to the PQ exposed group and the control (Fig. 6.7). Additionally, 
GFAP localization is indicated in the PQ exposed group compared to the control, 48 
hrs IF, and [(48 hrs IF) + PQ] treatment group, suggesting that increased oxidative 
stress elicits a strong inflammatory response in the PQ exposed group. More 
importantly, this inflammatory response is attenuated in the [(48 hrs IF) + PQ] 
treatment group, suggesting that the IF regime is protective in this context. These 
observations are supported by studies that have reported increased levels of GFAP in 
the CSF (Ishiki et al., 2016) and frontal cortices, and hippocampal tissues of AD 
patients (Kamphuis et al., 2014). Current literature suggests that inflammation, MA 
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and neurodegeneration are connected processes. Indeed, recent work by François et 
al. (2013, 2014) revealed evidence of a cross-talk between these processes. In these 
studies, increased Aβ42 expression was found to enhance oxidative stress, modulate 
the expression of selective MA proteins (p62, p70S6K) (François et al., 2013), with the 
levels of inflammatory mediators correlating with expression of key MA regulators, 
such as mTOR and BECN1 (François et al., 2014). Furthermore, findings from 
preclinical studies suggests that CR reduces inflammation (Harvey et al., 2014; Harvie 
and Howell, 2012). Notably, IF dietary regimes (from 24 hrs to 6 days) have been 
found to promote similar metabolic and anti-inflammatory changes as observed with 
chronic CR regimes (Lee and Longo, 2011). Consistent with our immunofluorescence 
observations, these studies suggest that increased oxidative stress, may induce 
inflammation, while MA induction above basal levels mitigates this stress response. 
Thus, IF/CR-mediated induction of MA may play a protective role in the context of 
increased oxidative stress. 
 
Consistent with enhanced MA activity in these groups (Fig. 6.7.B), our western blot 
data reveals a significant reduction in p62 levels in the 48 hrs IF, and [(48 hrs IF) + 
PQ)] treatment group compared to the control and PQ exposed group (Fig. 6.9.B). 
Moreover, p62 levels are significantly decreased in the [(48 hrs IF) + PQ] treatment 
group compared to the PQ exposed group. These data are supported by the 
immunofluorescence analysis which reveal that p62 protein signal is strongly indicated 
in the PQ exposed group, with minor signal in the control, 48 hrs IF, and [(48 hrs IF) + 
PQ)] treatment group (Fig. 6.10). Together, these findings suggest that cargo 
degradation is robustly induced above basal levels in the hippocampus of the 48 hrs 
IF, and [(48 hrs IF) + PQ)] treatment group, suggesting that oxidative stress, and IF 
strongly induce protein turnover. The significant decrease in p62 levels in the IF groups 
further reiterates the role of CR in MA pathway induction, which is generally associated 
with a concomitant decrease in p62 levels. In line with our findings, increased p62 
levels have been reported in vitro under CR conditions in the presence of chloroquine 
than under CR conditions without chloroquine (Ferreira-Marques et al., 2016), 
suggesting that p62 levels are enhanced following inhibition of autophagosome 
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degradation. These data suggest that indeed CR enhances protein clearance, which 
in turn will contribute towards decreasing proteotoxicity, translating to protection.  
 
Interestingly, western blot analysis CMA activity also reveals enhanced LAMP2A 
levels in the 48 hrs IF, and [(48 hrs IF) + PQ)] treatment group compared to the control 
and PQ exposed group (Fig. 6.11.B). This data suggests that prolonged IF induces 
CMA activity in addition to enhanced MA activity. These findings shed new light onto 
the interplay between MA and CMA in vivo. In the past, CMA activity has been primarily 
assessed in lysosomes isolated from rat liver (Cuervo et al., 1995b, 1998), however, 
its role in PQ-induced injury has not assessed. Findings by Wing et al. (1991) suggest 
that the CMA pathway is either not be active, or may function at constitutively low 
levels in brain, based on the absence of changes in the levels of KFERQ-containing 
proteins under starvation conditions. However, in line with our findings, studies indeed 
support the active role of the CMA pathway in lysosomes isolated from astrocytes, 
dopaminergic and cortical neurons, although these studies were not performed in the 
context of CR or oxidative stress (Cuervo, 2004; Martinez-Vicente et al., 2008). In line 
with our findings, studies by Cuervo and Dice (2000) reveal maximal activation of CMA 
activity above basal levels following 36 hrs amino acid deprivation, as evidenced by 
the increased recruitment of LAMP2A to the lysosomal membrane. In contrast with our 
findings (Fig. 6.11.B), previous findings reveal that oxidative stress exposure alone is 
sufficient to robustly induce CMA activity in vitro (Kiffin et al., 2004; Su et al., 2016). 
This discrepancy can perhaps be attributed to the model system assessed. 
Nevertheless, transgenic mice overexpressing LAMP2A have been shown to 
accumulate fewer 4HNE modified proteins compared to wild-type controls, at least in 
part, due to an enhanced CMA activity above basal levels (Zhang and Cuervo, 2008). 
Although, this finding was reported in a different tissue, it is possible that CMA 
induction may also contribute to the decreased 4HNE expression observed in the 48 
hrs IF, and [(48 hrs IF) + PQ)] treatment groups (Fig. 6.7 – 6.8), but further studies are 
warranted in this regard. 
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Our western blot analysis indicates a significant decrease in APP levels in the 48 hrs 
IF treatment group compared to the [(48 hrs IF) + PQ] treatment group (Fig. 6.12.B). 
More importantly, APP levels are significantly increased in the PQ exposed group 
compared to the 48 hrs IF, and [(48 hrs IF) + PQ] treatment group. These data suggest 
that IF is indeed modulating amyloidogenic processing, in fact clearing the 
accumulating APP. This IF-mediated APP clearance contributes towards the 
protective effect observed (Fig. 6.7 - 6.8), by decreasing APP load. In support of these 
findings, CR has been shown to prevent Aβ generation and neuritic plaque deposition 
in the neocortical and hippocampal brain regions in a mouse model of amyloidosis 
(Wang et al., 2005). Findings by Wang et al. (2005) suggest that CR impacts APP 
processing by promoting α-secretase activity through mechanisms resulting in 
reduced Aβ neurotoxicity. Indeed, this possibility is supported by evidence of 
decreased α-secretase activity in the brain of CR transgenic mice compared to 
controls (Kawarabayashi et al., 2001; Postina et al., 2004). Given the critical role of 
particularly the hippocampus in neurodegeneration and memory formation, our 
findings are of significance. 
 
6.5. Analysis of the cortex region 
 
In order to contextualize the hippocampal data, the effects of the treatment intervention 
in the cortex region was assessed in a similar manner. The cortex is usually associated 
with degeneration at later stages, such as indicated by the ‘Braak staging’ (Braak and 
Braak, 1991). Our H & E analysis reveals no obvious indications of cell loss or 
architectural abnormalities following the 21-day treatment intervention (Fig. 6.13). This 
lack of subcellular alterations may suggest that similarly to the hippocampus, the ROS 
levels in this region may not have yet exceeded the antioxidant capacity of the tissue 
in this region, as described by Kannan and Jain (2000), whereby the cells are still able 
to sufficiently counteract the deleterious effects of excessive ROS in favour of cell 
survival. 
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Western blot analysis reveals a significant increase in 4HNE expression in the PQ 
exposed group compared to the control, 48 hrs IF, and [(48 hrs IF) + PQ] treatment 
group, while 4HNE is significantly reduced in the 48 hrs IF, and [(48 hrs IF) + PQ] 
treatment group compared to the control, and, more importantly, compared to the PQ 
exposed group (Fig. 6.14.B). Similarly, cytochrome c expression is significantly 
enhanced in the PQ exposed group compared to the control, 48 hrs IF, and [(48 hrs 
IF) + PQ] treatment group (Fig. 6.14.D). More importantly, cytochrome c expression 
is significantly reduced in the [(48 hrs IF) + PQ] treatment group compared to PQ only, 
suggesting that is protection from neuronal injury via IF intervention. Indeed, 
neuroprotection in the cortex region in response to the IF is echoed by the reduced 
levels of lipid peroxidation, and apoptosis. These results are supported by work 
conducted by Lohren et al. (2015), where it was revealed that the reported decrease 
in cortical cellular populations could be associated with induction of apoptosis in the 
motor cortex of adult rats following chronic oxidative stress exposure. Work by Teixeira 
et al. (2018) also suggests that lipid peroxidation plays a major role in necrosis and 
cell death detected in the cortical tissue of in vivo models of chronic oxidative stress 
exposure. Our results suggest apoptosis onset, however, no obvious decrease in 
cortical cells was indicated and it is possible that the extent and duration of oxidative 
stress was not sufficient to induce robust neuronal loss our model system. In line with 
our findings, work by Hyun et al. (2006) revealed that age-related increases in lipid 
peroxidation, and markers of oxidative stress were significantly reduced in rat cortical 
cells incubated in medium containing serum from animals subjected to CR, compared 
to cells treated with ad libitum serum. The neuroprotective effect of CR in the context 
of oxidative stress exposure in the cortex has also been replicated in vivo, where 
several studies reveal that cortical cells isolated from AD, PD, and HD mouse models 
maintained on CR regimens were relatively more resistant to oxidative and metabolic 
stress compared with animals fed ad libitum (Bruce-Keller et al., 1999; Duan and 
Mattson, 1999; Maswood et al., 2004). Consistent with our western blot data, our 
immunofluorescence analysis reveals that 4HNE and cytochrome c protein signal is 
strongly indicated in the PQ exposed group with no particular neuronal cell layer 
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showing a distinct response, compared to the control, 48 hrs IF, and [(48 hrs IF) + PQ] 
treatment group (Fig. 6.15). 
 
Western blot analysis indicates a significant increase in LC3II expression in the 48 hrs 
IF, and [(48 hrs IF) + PQ] treatment group compared to the control (Fig. 6.16.B). This 
data suggests that MA is robustly induced in response to IF, with and without oxidative 
stress exposure, while oxidative stress alone appears to have no effect on LC3II 
protein levels compared to the control. In agreement, our western blot data indicates 
that MA cargo degradation, as evidenced by p62 expression, is significantly enhanced 
in the 48 hrs IF, and [(48 hrs IF) + PQ] treatment group compared to the control, and 
most importantly, compared to the PQ exposed group (Fig. 6.18.B). Our data suggests 
that MA activity in the cortex is increased above basal levels in the IF groups, with and 
without oxidative stress exposure, while MA activity in response to oxidative stress 
alone elicits a response comparable to that observed in the control. Indeed, previous 
studies reveal that CR mitigates the effects of oxidative damage via three major 
mechanisms: (1) increased protein turnover through MA induction above basal levels, 
(2) diminished production of mitochondrial ROS, and increased antioxidant defence 
responses (Bevilacqua et al., 2005; Gredilla and Barja, 2005). In line with our data, 
work by Arumugam et al. (2010) demonstrated that IF modulates neurotrophic and 
inflammatory pathways to protect neurons against brain injury, while this 
neuroprotection was severely compromised with age, partly, due to diminished 
proteolytic activity, resulting in progressively reduced cognitive capabilities and poorer 
functional outcome. In support of this data, others have suggested that CR may exert 
its beneficial effects on longevity through a ‘hormetic’ response that results in the 
activation of the MA above basal levels, recruitment of chaperon proteins, as well as 
the inhibition of inflammatory pathway responses in rodents (Lee and Notterpek, 2013; 
Mattson, 2008, 2010). While our immunofluorescence analysis reveals strong 
localization of LC3II protein signal in the 48 hrs IF and [(48 hrs IF) + PQ] treatment 
group compared to the PQ exposed group, and the control, the localization of GFAP 
appears uniformly diminished in all the groups, with strongest signal in the PQ group 
(Fig. 6.17). Our findings suggest that the PQ treatment did not induce such a strong 
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GFAP signal as was observed in the hippocampus (Fig. 6.8), indicating that potentially 
susceptibility to oxidative stress injury is generally lower in the cortex. Indeed, these 
findings are in line with Braak staging (Braak and Braak, 1991), and evidence from 
studies of neuronal number in the hippocampus, and cortex of species from rodents 
to primates using unbiased stereological measurements has determined that 
significant cell loss does not occur first, and most profoundly in the aging hippocampus 
(Christopher et al., 2017; Rapp and Gallagher, 1996; Vivar et al., 2013). In line with 
our findings, work by Manzanero et al. (2011) reveals that CR-mediated protection 
following stroke-induced cerebral cortex injury, in part, by through the upregulation 
anti-inflammatory cytokines, and cellular protective mechanisms such as MA. Our 
immunofluorescence analysis also reveals strong p62 protein signal in the PQ 
exposed group, consistent with reduced cargo turnover, with minor p62 signal 
observed in the 48 hrs IF treatment group, while increased cargo degradation is 
revealed in the [(48 hrs IF) + PQ] treatment group (Fig. 6.19), suggesting IF may 
confer neuroprotection through increased autophagosome degradation in this context. 
 
Western blot analysis of CMA activity reveals a significant increase in LAMP2A 
expression in the 48 hrs IF, and [(48 hrs IF) + PQ] treatment group compared to the 
control, and most importantly, compared to the PQ exposed group (Fig. 6.20.B). This 
data suggests that IF induces CMA activity above basal levels, while oxidative stress 
alone does not elicit a significant response. A similar response was indicated in the 
hippocampus (Fig. 6.11), indicating that CMA activity and its response is not distinct 
in these two brain regions. Although, to our knowledge, the CMA pathway has not 
been specifically assessed in the cortex, upregulation of pathway has been extensively 
reported in the context of mild oxidative stress, serum starvation, and proteo- and 
lipotoxicity in fibroblasts (Massey et al., 2006c, 2008), hepatocytes (Schneider et al., 
2015), lysosomes isolated from aging liver (Zhang and Cuervo, 2008). Nevertheless, 
long-term nutrient deprivation has been shown to enhance CMA activity, improve 
cellular viability in ST14A cells were transiently transfected with Htt25QP-HBH + CBP 
+ IKK-βHD (overexpressing the HD protein) (Thompson et al., 2009), by preferentially 
targeting mutant huntingtin protein to the CMA pathway in HD mouse models (Bauer 
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et al., 2010). Additionally, exogenous overexpression LAMP2A has been shown to 
preserve CMA function until late in life, reducing intracellular levels of oxidized and 
aggregated proteins, and thereby enhancing the oxidative stress response of these 
mice (Zhang and Cuervo, 2008). In line with our data, these findings support the 
protective role of CR in the activation of CMA, particularly in the context of increased 
oxidative stress. 
 
Our western blot data reveals significantly enhanced APP expression, most notably, 
in the PQ exposed group compared to the control, 48 hrs IF, and [(48 hrs IF) + PQ] 
treatment group (Fig. 6.21.B). These results suggest that IF may either enhance APP 
clearance, and/or decrease APP processing in the cortex. In line with our findings, 
Schafer et al. (2015) have demonstrated that compared to ad libitum fed Tg2576 mice 
(in vivo model of age-related neurodegeneration), significantly reduced APP levels and 
Aβ deposition was revealed within the hippocampal and the cortex of the mice 
subjected to CR, suggesting that CR mitigates APP/Aβ accumulation translating to 
neuroprotection with age. Consistent with our data, work by Muche et al. (2017) 
reveals that increased oxidative stress the cortical tissue of Tg2576 mice induces the 
amyloidogenic route of APP processing, suggesting that oxidative stress may 
represent a major risk factor for Aβ proteotoxicity. In agreement, earlier work by White 
et al. (1998) reported increased cell viability in primary cortical and cerebellar neuronal 
cultures established from APP knock-out mice compared to wild-type mice when 
exposed to oxidative stress, suggesting that oxidative stress is one of the mechanisms 
of Aβ-induced proteotoxicity. Although these studies were not performed in the context 
of CR conditions, our overall assessment of the cortex region indicates, to our 
knowledge, for the first time a protective role for both MA and CMA activity, which is 
increased above basal levels following IF-mediated induction.  
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6.6. Analysis of the cerebellum region 
 
The cerebellum has often been described as least sensitive to neurodegenerative 
processes (Lumkwana et al., 2017), on the other hand, it has been elegantly shown 
that CR enables particularly an autophagy response in the cerebellum (Alirezaei et al., 
2010). Representative H & E micrographs reveal no structural or archetypical 
abnormalities in cell distribution or density in all the groups in response to the 21-day 
treatment intervention (Fig. 6.22). In contradiction with these data, McFarland et al. 
(2007) presented evidence for sustained manganese super oxide dismutase activity 
(oxidative stress marker) with concomitant increase in Purkinje cell death in Lurcher 
transgenic mice (harbouring an autosomal dominant mutation in the d2 glutamate 
receptor (GluRd2), suggesting that oxidative stress may play a role in cerebellar cell 
death. It is possible that the dosage of PQ utilised in this context was not sufficient to 
impact the cerebellum on a cellular level. Notably, previous work using this same injury 
model was performed in APP transgenic APP mice or other AD-related pathology 
(Chen et al., 2012, 2015a), which may account for the discrepancy. 
 
To our surprise, western blot analysis reveals no significant differences in 4HNE 
expression in all the treatment groups compared to the control (Fig. 6.23.B), 
supporting the notion of the cerebellum being least impacted in protein aggregation 
and toxicity (Lumkwana et al., 2017). These findings are in contrast with work by Wang 
et al. (2009), which revealed that cerebellar granule neurons are so sensitive to 
oxidative stress that even the oxygen tension in the ambient air induced cell death. 
However, our immunofluorescence analysis reveals strong 4HNE protein signal in all 
the treatment groups, with more intense 4HNE localization indicated in the PQ 
exposed group (Fig. 6.24). Interestingly, despite the lack of major changes in 4HNE, 
our findings indicate that the execution of apoptosis may be initiated, as evidenced by 
the enhanced cytochrome c expression in the PQ exposed group compared to the 
control, 48 hrs IF, and [(48 hrs IF) + PQ] treatment group (Fig. 6.23.D). It is however 
likely that these changes are not strong enough to result in significant changes in 
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4HNE protein levels. The 4HNE data can perhaps be attributed to the vulnerability of 
cerebellar neurons to selective oxidative stress-inducing agents (Niveditha et al., 
2017). Consistent with our observations of robust cytochrome c expression in the PQ 
exposed group (Fig. 6.23.D), work by Anderson et al. (2009) found enhanced cell 
death onset in aged individuals with concomitant oxidative stress induction. It is 
therefore reasonable to propose that the reduced cytochrome c expression indicated 
in the IF groups (Fig. 6.24) may suggest that IF indeed confers neuronal protection in 
the cerebellum. 
 
Western blot analysis of MA activity reveals a significant increase in LC3II expression 
in the PQ exposed group, 48 hrs IF, and [(48 hrs IF) + PQ] treatment group (Fig. 
6.25.B). In support of this finding, a significant reduction in p62 expression is indicated 
in the 48 hrs IF, and [(48 hrs IF) + PQ] treatment group compared to the PQ exposed 
group and the control (Fig. 6.27.B). Although our immunofluorescence analysis 
reveals strong p62 hotspots in all the treatment groups, p62 localization appears 
comparatively more pronounced in the PQ exposed group, and overall weaker in the 
IF groups, further supporting neuronal protein clearance (Fig. 6.28). In support of 
these findings, work by Cunha-Santos et al. (2016) demonstrated that CR significantly 
reduced neuropathology, and neuroinflammation through robust activation of MA 
activity and SIRT1 protein expression in mice models of Machado–Joseph disease 
(MJD), a neurodegenerative disease characterised by the abnormal CAG triplet 
expansion of in the ATXN3 gene particularly in the cerebellum region. Work by Lee et 
al. (2008) reveals that increased SIRT1 expression under CR conditions in turn 
induces MA activity, by deacetylating ATG5, ATG7 and ATG8, suggesting that SIRT1 
deacetylase is an important regulator of MA during conditions of nutrient limitation. 
Indeed, Huang et al. (2015) recently demonstrated that SIRT1 plays a crucial role in 
MA induction under nutrient starvation conditions. In line with our findings, work by 
Cunha-Santos et al. (2016) reveals that MA activity is robustly induced, in turn 
mitigating Purkinje cell death onset in a CR MJD mouse model of following oxidative 
stress exposure compared with ad libitum fed MJD mice. Consistent with our western 
blot data, our immunofluorescence analysis reveals increased LC3II signal in the 48 
Stellenbosch University  https://scholar.sun.ac.za
255 
 
hrs IF, and [(48 hrs IF) + PQ] treatment group, while strong GFAP protein signal is 
only indicated in the PQ exposed group (Fig. 6.26). This observation suggests that the 
IF may indeed attenuate inflammatory pathway responses in this region. In agreement, 
Cunha-Santos et al. (2016) reported a significant decrease of gliosis markers and 
mRNA levels of neuroinflammatory markers in the cerebellum of CR MJD mouse 
models following oxidative stress exposure. 
 
Increased CMA activity is indicated by the significant increase in LAMP2A expression 
in the [(48 hrs IF) + PQ] treatment group compared to the PQ exposed group, the 48 
hrs IF treatment group, and the control (Fig. 6.28.B). Moreover, LAMP2A expression 
is significantly increased in the 48 hrs IF treatment group compared to the PQ exposed 
group. This data suggests that both oxidative stress and IF induce CMA, in favour of 
increased proteostasis. As extensively described by Xilouri and Stefanis (2016), CMA 
operates at basal conditions in most mammalian cell models, and is generally 
activated in response to nutrient deprivation, or oxidative stress, as evidenced in the 
cerebellum region of our treatment groups. 
 
To our surprise, following the 21-day treatment regime, western blot analysis revealed 
no significant changes in APP expression in all the treatment groups compared to the 
control (Fig. 6.30). This data suggests that, in contrast to the data observed in the 
hippocampus (Fig. 6.12) and cortex (Fig. 6.21) where indeed the hippocampus was 
shown to be most susceptible to APP expression profile changes in response to the 
intervention, APP processing may operate distinctively in the cerebellum. These 
findings are somewhat in contrast to reports indicating increased APP, and Aβ 
deposition in the cerebellum of APPswe/PSΔE9 double transgenic mice [i.e. 
expressing both APPswe and a mutant human presenilin 1 (PS1-dE9)] (Deng et al., 
2014), and APPSwDI transgenic mice (harbouring human APP with Swedish, Dutch 
and Iowa mutations on a C57BL/6 background) (Dhurandhar et al., 2013). Recent 
work by Cheignon et al. (2018) suggests that oxidative stress and increased APP 
processing may represent a unifying mechanism of neurotoxicity in the pathogenesis 
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of a number of neurodegenerative diseases, such as AD. Our findings indeed reveal 
region specific stress responses, as revealed by Braak and Braak (1991), that may be 
of critical importance to understanding the differences in neurodegeneration 
susceptibility.  
 
Taken together, our in vivo results strongly suggest a protective role for the IF regime 
in PQ-induced brain injury, through its induction of both MA, and CMA activity above 
basal levels, its reduction of lipid peroxidation, cytochrome c release from the 
mitochondrial membrane, and mitigation of neuroinflammation, particularly in the most 
vulnerable brain regions, the hippocampus and cortex. Our data further indicates that 
IF, is a safe and attractive intervention, to potentially harness the protective role of 
both MA and CMA activity. The experimental evidence summarized herein further 
supports the notion of regional and cellular heterogeneity. Even within subpopulations 
of hippocampal neuronal clusters, studies have shown selective vulnerability 
depending on the stressor, with the cellular response varying according to the cell 
type, stress duration and environmental factors (Cleveland and Rothstein, 2001; Floyd 
and Hensley, 2002). Therefore, in an attempt to exploit cellular mechanisms that play 
a causal or protective role in neurodegeneration, it is important to mechanistically 
understand the intrinsic characteristics of vulnerable neuronal populations and how 
they uniquely respond when challenged for example by the excessive oxidative stress, 
in neurodegenerative diseases. Our data has shed light on the role of both MA and 
CMA in this context, which deserves further study. 
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CHAPTER 7: SUMMARY AND CONCLUSIONS 
 
Firstly, our findings clearly demonstrate that Aβ clearance is impaired following the 
pharmacological inhibition of autophagosomal lysosomal fusion using BafA1, 
suggesting that MA pathway dysfunction directly regulates the production and 
clearance of Aβ, as evidenced by increased Aβ levels following inhibition of 
autophagosomal lysosomal fusion. These findings suggest that disturbances in 
autophagosome turnover can further exacerbate Aβ proteotoxicity potentially 
worsening the cellular capacity to degrade APP and other proteotoxic metabolites. 
These findings are consistent with work by Nilsson and Saido (2014), which reveals 
that MA plays a role in both the production and clearance of Aβ. Moreover, previous 
studies have contributed to the clarification of the relationship between APP and MA, 
providing evidence that an essential component of the MA pathway, such as BECN1, 
is reduced in early AD progression, which in turn promotes Aβ accumulation and 
proteotoxicity in AD models (Lee and Gao, 2008; Pickford et al., 2008). Moreover, APP 
containing vesicles, have been found to build up within cells (Jaeger et al., 2010; 
Pickford et al., 2008), as evidenced in the present study following inhibition of 
autophagosome degradation using 3MA, which led to cell death onset. Secondly, our 
global proteome analysis revealed an increase in APP protein-protein interaction 
network in response to APP overexpression over time, suggesting that enhanced 
amyloidogenic processing progressively affects more cellular response pathways with 
disease progression. Thirdly, we revealed, to our knowledge for the first time, that 
macroautophagic flux remains fully functional with increasing APP overexpression but 
was insufficient to clear the Aβ load and prevent the induction of apoptosis. Modulation 
of both MA and CMA, using CRM 2DG reduced Aβ production, relatively decreased 
the level of apoptosis induction, and to our surprise, also decreased APP processing 
in favour of cell protection. These findings dissect the molecular relationship in a clear 
manner, due to the sequential APP overexpression and the rigorous modulation of the 
autophagic pathways, assessing both MA and CMA ‘s contribution to neuroprotection.  
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7.1. FINAL CONCLUSIONS 
 
Both our in vitro and in vivo findings provide compelling evidence of the protective role 
of both MA and CMA modulation, using CRM in the in vitro AD model system, and the 
IF regime in the in vivo model of PQ-induced brain injury. While our findings suggest 
that the augmentation of MA above basal levels may be a promising therapeutic 
intervention, even with late disease progression, others have shown that MA induction 
in diseases like AD may exacerbate already impaired lysosomal clearance (Lee et al., 
2010, 2011b). These studies indicate that the combination of excessive MA induction 
with faulty clearance of Aβ producing autophagosomes may further promote 
circumstances favourable to Aβ peptide aggregation and accumulation in AD brains. 
Therefore, it is important to consider the downstream effects of intervention strategies 
targeted at each stage of the MA pathway, and how the intervention strategy might 
affect the delicate balance between autophagosome formation and lysosomal 
degradation. We propose that a non-pharmaceutical intervention such as CR, or IF 
may be a promising therapeutic strategy for the augmentation of Aβ clearance through 
the MA pathway in AD and other neurodegenerative diseases. This strategy not only 
targets CMA induction, but also later steps in the MA pathway, thus improving 
macroautophagic flux, ROS handling, protein clearance, and thereby robustly 
contributing to proteostasis and neuronal protection. Given the nutritional concerns of 
CR and fasting in patients, CRM such as metformin and resveratrol, dietary regimens 
such as low carbohydrate/ketogenic and IF regimes, may serve as attractive, 
inexpensive therapeutic interventions that can be executed safely and rapidly to mimic 
the protective effects of CR both in the prevention neurodegeneration and as adjuvant 
therapies to current therapeutics. Future work may include a categoric characterization 
of such CRM’s with regard to their potency to enhance both MA and CMA activity, the 
duration of their pathway upregulation, and the context of most efficient protein 
clearance. 
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CHAPTER 8: LIMITATIONS AND FUTURE OUTLOOK 
 
7.2.1. IN VITRO 
 
This study has shed crucial insights into the role of autophagic pathways, MA and 
CMA, in the degradation of APP and its proteotoxic metabolites and suggests that 
once autophagosomal flux and turnover is impaired, an escalating cycle of APP/Aβ 
accumulation and insufficient autophagic activity occurs. However, the contribution of 
MA modulation following 2DG treatment during APP overexpression in the absence or 
presence of BafA1 could further be evaluated to compliment the study. 
Macroautophagic flux assessment may be finer dissected as described by du Toit et 
al. (2018), using a single-cell fluorescence live-cell imaging-based approach that 
would allow for more robust assessment of autophagosome flux in the context of APP 
overexpression, and would allow to quantify the extent of flux enhancement based on 
MA pathway intermediates. This measurement of the complete autophagosomal pool 
size per cell would require the z-stack acquisition of all fluorescence images in order 
to achieve a complete measure of the intracellular autophagosome pool size, and the 
autophagosome count can then objectively be achieved using the ‘particle 
count/analysis’ function of an open source programme such as ImageJ as detailed in 
Loos et al. (2014). This assessment would enable one to better delineate the functional 
state of the macroautophagic system during APP overexpression, by providing a more 
sensitive quantitative read-out of autophagosome flux, pool sizes and transition time 
in N2aswe cells during APP overexpression. CMA assessment can also be further 
enhanced using purified CMA-positive lysosomal isolated from N2aswe cells during 
APP overexpression. To this end, a lysosome immunoprecipitation (LysoIP) technique 
has been described in recent work by Abu-Remaileh et al. (2017), who engineered 
cultured human embryonic kidney (HEK) 293T cells to produce a protein tag 
(transmembrane protein 192 (TMEM192) fused to three tandem hemagglutinin (HA) 
epitopes] on lysosomal membranes that can be used to rapidly precipitate purified 
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lysosomes on magnetic beads. These kinds of analyses would be extremely powerful 
to further contextualize the role of CMA and lysosomal function in models of AD. 
 
7.2.2. IN VIVO 
 
The in vivo brain-injury model may be improved, and better aligned with the in vitro 
model system, by assessing the role of MA and CMA during CR in the hippocampus, 
and the contribution of these pathways to neuroprotection following chronic oxidative 
stress exposure in an APP overexpressing mouse model. The functionality of the 
complete MA pathway could also be assessed in transgenic mice expressing the 
mRFP-GFP-LC3 (i.e. is a fusion protein of GFP-LC3 and RFP-LC3) probe in the whole 
organism (Castillo et al., 2013; Hariharan et al., 2011; Li et al., 2014b). These mice 
have been generated and successfully used to assess starvation-induced MA, and the 
dynamics of MA activity after ischemia–reperfusion injury in the proximal tubules 
(Castillo et al., 2013; Li et al., 2014b). In these mice, GFP/RFP ratio precisely 
quantifies the cumulative GFP-LC3 degradation by MA, with MA induction resulting in 
an increase in GFP-LC3 degradation and reduction in the GFP/RFP ratio. In a study 
by Castillo et al. (2013), the mRFP-GFP-LC3 MA probe was successfully introduced 
through intracerebroventricular injection of adeno-associated viruses in new-born 
mice, and its expression was observed throughout the nervous system; with an 
increased number of mCherry-positive and GFP-negative puncta being observed upon 
rapamycin or trehalose injection. Theoretically, an elaborate APP transgenic mouse 
model expressing the GFP-LC3-RFP-LC3∆G (Kaizuka et al., 2016) MA probe could 
be generated in the future, as this would be a powerful tool to monitor both basal and 
induced MA in the context of APP overexpression. The study of CMA in vivo is still in 
its infancy, and additional studies, for example using CMA-positive lysosomes isolated 
from the hippocampal tissues of APP mice, are needed to fully dissect the role of CMA 
in both physiological and disease conditions. To this end, further investigations 
assessing long-term CR or 2DG dietary supplementation may better elucidate the 
precise role of CMA in the progression of AD-associated amyloidosis. 





Table A.1. Routinely used solutions. 
Solution Formulation 
Ammonium persulphate (APS) 1 g APS, H2O 10 ml. Stored at 4oC 
10x Phosphate Buffered Saline (PBS) In 800 ml dH2O, dissolve: 80 g of NaCl, 2.0 g f 
KCl,14.4 g of Na2HPO4, and 2.4 g of KH2PO4. 
Volume adjusted to 1 L with additional dH2O.  
pH adjusted 7.4. Sterilize by autoclaving. 
1x PBS-T 100 ml 10x PBS, 900 ml dH2O, 1 ml Tween-20 
1% BSA in 1x PBS-T 0.1 g BSA in 10 ml 1x PBS-T. 
RIPA lysis buffer Tris-HCl 50 mM; NaCl 150 mM, EDTA 1 mM,  
NP-40 1%, Na-deoxycholate 0.25%. Stored at 4oC. 
Protease and phosphatase inhibitor 
supplementation to 1 ml RIPA lysis 
buffer 
1 mM Sodium Orthovanadate (Na3VO4), 1 mM 
Sodium Fluoride (NaF), 1mM PMSF 
(phenylmethylsulfonyl fluoride) and 1xcOmplete™ 
Protease Inhibitor Cocktail Tablets (#11873580001) 
Stripping buffer for Western blotting 0.2 M Glycine, 1% SDS and pH adjusted to 2.5  
using HCl 
10x Tris-Buffered Saline (TBS) 4.2 g Tris, 80 g NaCl, dissolved in 600 ml dH2O 
(volume adjusted to 1 L with additional dH2O,  
pH adjusted to 7.6 using HCl 
1x TBST-T 100 ml 10x TBS, 1 ml Tween-20, 900 ml dH2O 
Freezing media (for cell lines) FCS 90%, DMSO 10% 
Laemmli’s sample buffer Solution A: 38 ml dH2O, 10 ml 0.5 M Tris (pH 6.8), 8 
ml glycerol, 16 ml 10% SDS, 4 ml 0.05% 
(w/v) Bromophenol blue. 
Solution B: β-mercaptoethanol. On day of use, 850 
µl Solution A, was added to 150 µl Solution B 
Tris-acetate-EDTA (TAE) 40 mM Tris, 0.1% glacial acetic acid, 1 mM EDTA 
Stellenbosch University  https://scholar.sun.ac.za
262 
 
4% Paraformaldehyde (PFA) fixative 
solution 
For 1 L of 4% PFA, 800 ml 1x PBS is added to a 
glass beaker on a stir plate in a ventilated hood and 
heated to ~60°C while stirring. 40 g PFA is added to 
the heated PBS solution. pH slowly raised by adding 
1 N NaOH dropwise until the solution clears. Once 
the PFA is dissolved, the solution is cooled, filtered, 
and the volume of the solution is adjusted to 1 L  
with 1x PBS 
Permeabilization solution  
(1x PBS/0.2% Triton X-100) 
In 25 ml: 2.5 ml 10x PBS, and 22.5 ml dH2O is added 
and mixed well. While stirring, 50 µl Triton X-100  
is added 
5 % BSA solution 2.5 g BSA in 50 ml of 1x TBS-T. Stored at 4oC for  
10 min to dissolve (stirring causes foam, which 
is generally the denatured BSA) 
1x Tris-glycine SDS running buffer 100 ml 10x Tris-glycine running buffer (#161- 0772) 
is added to 900 ml dH2O, and mixed well 
Western blotting blocking buffer 5% fat free milk is added in 1x TBS-T 
Immunofluorescence blocking buffer 5% donkey serum is added in 1x PBS-T 
Primary antibody dilution buffer: 5% BSA is added in 1x TBS-T 
Harris haematoxylin 5 g Harris haematoxylin, 100 g Ammonium, 50 ml 
100% ethanol, and 2.5 g mercuric acid is added  
to 1 L dH2O 
Eosin stock solution 2.0 g of water-soluble eosin Y is added to 40 ml  
of dH2O, and mixed until dissolved. Then 160 ml  
of 95% ethanol is added, and mixed. Store at RT. 
Working solution 
200 ml of eosin Y stock solution is added to 600 ml 
80% ethanol and mixed well. In a fume hood, 4 ml  
of glacial acetic acid is added and mixed well.  
Store covered at RT 
Scott’s tap water 20 g MgSO4, 3.5 g NaHCO3, and 10 ml 37%  
formalin is added to 1 L dH2O 
0.85% Saline solution For 1 L: 8.5 g NaCl is dissolved in dH2O. Autoclaved 
for 25 min at 121oC and cooled at RT.  
Solution stored at -20oC 
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Table A.2: List of proteins with significantly increased expression during 24 hrs APP overexpression relative to control.  
  Protein Gene  Accession ID. P value Fold change 
1 Amyloid precursor protein APP P05067 1.4E-02 1.59 
2 60S ribosomal protein L26 Rpl26 P61255  9.8E-03 2.01 
3 Caspase-3 CASP3 P70677  9.7E-03 2.02 
4 55 kDa erythrocyte membrane protein Mpp1 P70290 9.3E-03 2.03 
5 Dihydroorotate dehydrogenase (quinone) Dhodh O35435  9.3E-03 2.03 
6 Tryptophan-tRNA ligase. cytoplasmic Wars P32921  8.7E-03 2.06 
7 Lamin-B1 Lmnb1 P14733 8.6E-03 2.07 
8 Ribosomal protein L8 RPL8 Q9Z237 8.1E-03 2.09 
9 Inositol polyphosphate 4-phosphatase type II alpha  Inpp4b Q1A6V1  7.1E-03 2.15 
10 Integrin beta-4 Itgb4 A2A863  7.0E-03 2.15 
11 CD97 antigen Cd97 Q9Z0M6  6.7E-03 2.18 
12 Nuclear factor NF-kappa-B p105 subunit Nfkb1 P25799 6.5E-03 2.19 
13 Histidine-tRNA ligase. cytoplasmic Hars Q61035 6.1E-03 2.21 
14 Paired box protein Pax-8 Pax8 Q00288  5.8E-03 2.24 
15 Pyruvate dehydrogenase E1 component subunit 
beta. mitochondrial 
Pdhb Q9D051 5.4E-03 2.26 
16  Lysosome-associated membrane glycoprotein 1 Lamp1 P11438 5.1E-03 2.29 
17 Tripeptidyl-peptidase 2 Tpp2 Q64514  4.9E-03 2.31 
18 Disintegrin and metalloproteinase domain- Adam15 O88839  4.9E-03 2.31 
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containing protein 15 
19 Synaptotagmin-1 Syt1 P46096  4.9E-03 2.31 
20 Transcriptional repressor NF-X1 Nfx1 B1AY10  4.6E-03 2.34 
21 Tyrosine-protein kinase ZAP-70 Zap70 P43404  4.2E-03 2.37 
22 Voltage-dependent calcium channel subunit beta-4 Cacnb4 Q8R0S4  4.2E-03 2.37 
23 Acyl-CoA-binding protein Dbi M0QWU8 4.0E-03 2.41 
24 Proteasome subunit beta type-9 Psmb9 P28076  3.8E-03 2.42 
25 Fatty acid-binding protein. epidermal Fabp5 Q05816  3.7E-03 2.43 
26 Serine/threonine-protein kinase Nek4 Nek4 Q9Z1J2 3.6E-03 2.44 
27 Homeobox protein Hox-D4 Hoxd4 P10628  3.2E-03 2.50 
28 Calmodulin Calm1 P62204  3.2E-03 2.50 
29 Probable allantoicase Allc Q9JHX6  3.1E-03 2.50 
30 Band 3 anion transport protein Slc4a1 P04919  3.1E-03 2.50 
31 Activated CDC42 kinase 1 Tnk2 O54967 3.1E-03 2.50 
32 Heat shock cognate 71 kDa protein Hspa8 P63017  3.1E-03 2.51 
33 Mitochondrial carnitine/acylcarnitine carrier protein Slc25a20 Q9Z2Z6  2.7E-03 2.57 
34 ATP-citrate synthase Acly Q3V117  2.5E-03 2.60 
35 Glyceraldehyde-3-phosphate dehydrogenase Gapdh P16858  2.1E-03 2.68 
36 Proteasome subunit alpha type-5  Psma5  Q9Z2U1  2.0E-03 2.69 
37 Tenascin-W Tnn  Q70HX0  1.8E-03 2.75 
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38 Catalase Cat P24270 1.6E-03 2.80 
39 Histone H3.1 Hist1h3a P68433 1.6E-03 2.80 
40 Beclin 1-  BECN1 O88597  1.6E-03 2.81 
41 Retinol dehydrogenase 11 Rdh11  Q9QYF1  1.4E-03 2.84 
42 N-acetylglutamate synthase. mitochondrial Nags Q8R4H7  1.2E-03 2.93 
43 Zinc finger protein 185 Znf185 Q62394  1.2E-03 2.93 
44 Neuromodulin Gap43 P06837 7.2E-04 3.14 
45 Beta-2-microglobulin B2m P01887 5.7E-04 3.24 
46 Integrin alpha-E Itgae Q60677  5.7E-04 3.25 
47 Ubiquitin-conjugating enzyme E2 C Ube2c UBE2C 5.5E-04 3.26 
48 LIM domain kinase 1 Limk1 P53668 4.1E-04 3.39 
49 Acetoacetyl-CoA synthetase Aacs  Q9D2R0  2.6E-04 3.58 
50 Histone H3.3 H3f3a P84244 2.0E-04 3.71 
51 Probable ATP-dependent RNA helicase Ddx5 Q61656  1.9E-04 3.72 
52 Protein disulphide-isomerase A3 Pdia3 P27773  1.8E-04 3.74 
53 Nectin-1 Nectin-1 Q9JKF6 9.6E-05 4.02 
54 26S proteasome non-ATPase regulatory subunit 12 Psmd12 Q9D8W5  5.6E-05 4.25 
55 Alpha-mannosidase 2 Man2a1 P27046  5.1E-05 4.29 
56 Eukaryotic initiation factor 4A-I Eif4a1 P60843  4.8E-06 5.31 
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Table A.3: List of proteins with significantly increased expression during 48 hrs APP overexpression relative to control.  
 
Protein Description Gene Name Accession ID P value Fold change  
1 Nuclear migration protein nudC Nudc O35685  9.9E-03 2.01 
2 Myosin-9 Myh9 Q8VDD5  9.8E-03 2.01 
3 T-box protein 22 Tbx22 Q811Z5  9.4E-03 2.02 
4 Homogentisate 1.2-dioxygenase Hgd O09173  8.6E-03 2.07 
5 Thrombopoietin receptor Mpl Q08351  2.1E-03 2.07 
6 Class I MHC receptor KLRA5 Klra5 Q548A2  4.3E-03 2.07 
7 Aspartate aminotransferase. cytoplasmic Got1 F7ALS6  8.1E-03 2.07 
8 Proteasome subunit alpha type-7 Psma7 Q9Z2U0  8.3E-03 2.08 
9 BAG family molecular chaperone regulator 3 Bag3 Q9JLV1|  8.1E-03 2.09 
10 Proteasome subunit beta type-2 Psmb2 Q9R1P3  7.9E-03 2.10 
11 Prefoldin subunit 3 Vbp1 P61759  7.3E-03 2.13 
12 Heat shock protein HSP 90-beta Hsp90ab1 P11499  7.2E-03 2.15 
13 CPN10-like protein Cpn10-rs1 Q9JI95  7.1E-03 2.15 
14 H-2 class I histocompatibility antigen. Q7 alpha chain H2-Q7 P14429  7.4E-03 2.16 
15 Glyceraldehyde-3-phosphate dehydrogenase Gapdh P16858  6.4E-03 2.17 
16 Amyloid beta A4 precursor protein-binding family A member 1 Apba1 B2RUJ5 6.2E-03 2.20 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
267 
 
17 Phospholipase D1 Pld1 Q9Z280  5.9E-03 2.20 
18 ATP-dependent RNA helicase A Dhx9 O70133 6.0E-03 2.23 
19 LIM and SH3 domain protein 1 Lasp1 Q61792  4.8E-03 2.23 
20 Tenascin-W Tnn Q70HX0 5.5E-03 2.26 
21 Chloride channel accessory 3A2 Clca3a2 Q9EQR4 4.4E-03 2.26 
22 Serum albumin Alb  P02768 5.4E-03 2.27 
23 Pyruvate dehydrogenase E1 component subunit beta Pdhb Q9D051 Pdhb 2.31 
24 D-3-phosphoglycerate dehydrogenase Phgdh Q61753  4.7E-03 2.33 
25 Msx2-interacting protein Spen Q62504  4.5E-03 2.35 
26 Pyruvate kinase PKM Pkm P52480  4.4E-03 2.35 
27 RWD domain-containing protein 1 Rwdd1 Q9CQK7  2.6E-03 2.41 
28 Adenosine deaminase Ada P03958  3.5E-03 2.43 
29 Gelsolin Gsn P13020  3.8E-03 2.43 
30 Retinoic acid receptor gamma Rarg P18911  1.0E-03 2.48 
31 Multiple PDZ domain protein Mpdz Q8VBX6 3.3E-03 2.49 
32 Caspase-3  Casp3 P70677  3.2E-03 2.49 
33 Desmocollin-1 Dsc1 P55849  3.0E-03 2.53 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
268 
 
34 Talin-2 Tln2 Q71LX4  2.9E-03 2.54 
35 Tyrosine-protein kinase JAK1 Jak1 P52332  2.6E-03 2.59 
36 Acyl-CoA-binding protein Dbi M0QWU8  2.4E-03 2.63 
37 Proteasome subunit alpha type-1 Psma1 Q9R1P4 2.1E-03 2.68 
38 Catenin delta-2 Ctnnd2 E9QKH8 2.0E-03 2.69 
39 Polycomb protein EED Eed Q921E6 2.0E-03 2.69 
40 Extracellular matrix protein 1 Ecm1 Q61508  1.9E-03 2.71 
41 Beclin1 BECN1 O88597 1.9E-03 2.75 
42 Valyl-tRNA synthetase 2 Vars Q790I0 1.9E-03 2.73 
43 Ras-related protein Rab-7a Rab7a P51150  1.8E-03 2.73 
44 Eukaryotic initiation factor 4A-I Eif4a1 P60843  1.2E-03 2.80 
45 Acetoacetyl-CoA synthetase Aacs Q9D2R0 1.4E-03 2.82 
46 Proteasome subunit alpha type-4 Psma4 Q9R1P0  1.4E-03 2.85 
47 ANK repeat and PH domain-containing protein 2 Arap2 E9QP44  1.3E-03 2.89 
48 Proteasome subunit alpha type-5 Psma5 Q9Z2U1  1.2E-03 2.92 
49 Neural Wiskott-Aldrich syndrome protein Wasl Q91YD9  9.0E-04 2.92 
50 Apoptosis regulator BAX Bax Q91YD9  1.0E-03 2.92 
51 Proteasome subunit alpha type-3 Psma3 O70435  1.1E-03 2.96 
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52 Amyloid beta A4 protein APP P05067 6.3E-04 2.99 
53 H-2 class I histocompatibility antigen. D-B alpha chain H2-D1 P01899  9.8E-04 3.02 
54 T-cell surface glycoprotein Cd4 P06332 5.0E-04 3.03 
55 Dynactin subunit 2  Dctn2 Q99KJ8 5.7E-04 3.04 
56 N-acyl-aromatic-L-amino acid amidohydrolase Acy3 Q91XE4  9.0E-04 3.07 
57 Creatine kinase B-type Ckb Q04447  8.3E-04 3.08 
58 DbpA murine homologue Ybx3 Q61478  7.8E-04 3.11 
59 26S protease regulatory subunit 8 Psmc5 P62196  7.4E-04 3.13 
60 Dihydrolipoyllysine-residue acetyltransferase  Dlat Q8BMF4  7.1E-04 3.15 
61 DNA replication licensing factor MCM3 Mcm3 P25206  6.4E-04 3.20 
62 Probable ATP-dependent RNA helicase DDX5 Ddx5 Q61656  6.3E-04 3.20 
63 Threonine-tRNA ligase. cytoplasmic Tars Q9D0R2  5.4E-04 3.27 
64 Bifunctional methylenetetrahydrofolate dehydrogenase Mthfd2 P18155  4.7E-04 3.33 
65 Plakophilin-4 Pkp4  A2AS45  3.6E-04 3.40 
66 Serum amyloid A-3 protein Saa3 P04918 3.1E-04 3.45 
67 Eukaryotic peptide chain release factor subunit 1 Etf1 Q8BWY3  2.0E-04 3.69 
68 Dihydropyrimidinase-related protein 2 Dpysl2 O08553 2.0E-04 3.70 
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69 Bifunctional glutamate/proline-tRNA ligase Eprs Q8CGC7  1.0E-04 3.98 
70 Integrin beta-1 Itgb1 P09055  9.6E-05 4.02 
71 ATP-citrate synthase Acly Q91V92  6.0E-05 4.22 
72 Superoxide dismutase [Mn]. mitochondrial Sod2 P09671  3.5E-04 4.46 
73 Tripeptidyl-peptidase 2 Tpp2 Q64514  7.7E-06 4.97 
74 mouse NK cell activating receptor Ly49H  Ly49H Q49U25 1.0E-05 5.00 
75 H-2 class I histocompatibility antigen. K-K alpha chain  H2-K1 P04223 1.2E-06 5.93 
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Table A.4: List of proteins with significantly increased expression levels between 24 hrs and 48 hrs APP overexpression. 
 
Protein  Gene  Accession ID P value Fold change 
1 Multiple PDZ domain protein  Mpdz Q8VBX6 9.1E-03 2.04 
2 Homogentisate 1.2-dioxygenase Hgd O09173  9.0E-03 2.05 
3 Proteasome subunit alpha type-6  Psma6 Q9QUM9  8.9E-03 2.05 
4 Serine/threonine-protein kinase MAK Mak Q04859 8.3E-03 2.08 
5 4F2 cell-surface antigen heavy chain Slc3a2 P10852  8.2E-03 2.08 
6 Cathepsin D   CasD P18242 7.7E-03 2.11 
7 Methylcytosine dioxygenase TET2  Tet2 Q4JK59  7.5E-03 2.12 
8 Plasminogen activator inhibitor 2. macrophage  Serpinb2 P12388  7.4E-03 2.13 
9 Adenosine deaminase  Ada  P03958  7.0E-03 2.15 
10 MHC class Ib antigen H2-M2 Q6W9J8  6.8E-03 2.17 
11 Tyrosine-protein phosphatase non-receptor type 4  Ptpn4 Q9WU22  6.2E-03 2.21 
12 Mitochondrial carnitine/acylcarnitine carrier protein  SLC25A20 Q9Z2Z6  5.9E-03 2.23 
13 Amyloid beta A4 protein  APP  P05067 5.8E-03 2.28 
14 Citron Rho-interacting kinase  Cit P49025  5.4E-03 2.27 
15 T-cell surface antigen CD2  Cd2  P08920 5.1E-03 2.29 
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16 Dihydropyrimidinase-related protein 2  Dpysl2 O08553 4.9E-03 2.31 
17 Serum albumin Alb  P02768 4.4E-03 2.36 
18 Adhesion G protein-coupled receptor B2  Adgrb2 H7BWZ2 3.8E-03 2.42 
19 Testin  Tes P47226  3.0E-03 2.52 
20 ABCG4  Abcg4 Q8K4E1  3.0E-03 2.52 
21 RNA/DNA-binding protein  Rnps1 Q62150  2.9E-03 2.53 
22 Extracellular matrix protein 1  Ecm1 Q61508 2.9E-03 2.59 
23 Nuclear factor 1  Nfib  Q6GSP7 2.3E-03 2.63 
24 B-cell lymphoma 6 protein homolog  Bcl6 P41183  2.3E-03 2.63 
25 Neural Wiskott-Aldrich syndrome protein Wasl Q91YD9  2.3E-03 2.64 
26 Heat shock protein HSC70t  HSC70t Q91ZU4 1.8E-03 2.20 
27 Polyhomeotic-like protein 1  Phc1 Q64028 1.6E-03 2.80 
28 Tyrosine-protein kinase  Btk P35991 1.5E-03 2.82 
29 Integrin beta-1  Itgb1 P09055 1.5E-03 2.83 
30 T-cell surface glycoprotein CD4  Cd4 P06332 1.3E-03 2.87 
31 EC2-V2R pheromone receptor protein Vmn2r43 Q80Z08  1.1E-03 2.96 
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32 Macrophage colony-stimulating factor 1 Csf1 P07141  1.0E-03 2.99 
33 Homeobox protein Hox-A6  Hoxa6 P09092 1.0E-03 2.99 
34 Bifunctional glutamate/proline-tRNA ligase  Eprs Q8CGC7  4.8E-04 3.32 
35 Dynactin subunit 2  Dctn2 Q99KJ8  3.8E-04 3.42 
36 Valyl-tRNA synthetase 2 Vars Q790I0 3.6E-04 3.45 
37 Zinc finger 202 m1  Zfp202 Q99PG9 1.8E-04 3.74 
38 Calcium/calmodulin-dependent protein kinase type II subunit Camk2b Q5SVI3  1.5E-04 3.81 
39 Klra21 protein Klra21 Q49U25 6.4E-05 4.20 
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Table B.1: Animal welfare monitoring sheet (6 mice housed per cage with a total of 12 mice per group). 
Experimental group   
Monitoring frequency Daily  
Date          
Weight measurements 
for: 
Baseline (g) Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Body weight % 
compared to 
baseline 
Mouse 1          
Mouse 2          
Mouse 3          
Mouse 4          
Mouse 5          
Mouse 6          
Mouse 7          
Mouse 8          
Mouse 9          
Mouse 10          
Mouse 11          
Mouse 12          
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* Mouse grimace scale: assessment of visible discomfort 
Comfort scores 
for: 
Baseline score score score score score score score score Average score per 
week 
Mouse 1          
Mouse 2          
Mouse 3          
Mouse 4          
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Table B.2: Description of behavioural or visible symptoms. 
Symptom Mild symptoms Severe symptoms 
Inactivity Fully mobile, active as 
usual 
Occasional movement, but largely 
unresponsive to prompting 
Hunched posture Small change in normal 
posture 
Noticeably hunched over without 
regaining normal posture 
Ruffled fur Some isolated ruffling of fur Obvious ruffling of fur 
Rate of breathing Slightly above, or below 
normal 
Excessive panting, or markedly 
diminished rate of breathing 
Crusty eyes Slight build-up of excretion 
in eyes 
Significant excretion in eyes, vision 
likely to be impaired 
Shivering Occasional shivering Constant prominent shivering with 
normal temperature 
Diarrhea Loose stools Stools have completely loose stools 
Inquisitive/alertness Slightly reduced response 
to stimuli 
Largely unresponsive to stimuli 
Action taken: 
0 = normal: no action   
1 = moderate changes: should be monitored daily 
2 = significant changes: monitor twice daily 
3 = euthanise  
[Welfare monitoring sheets adapted from (Animals, 2009; Langford et al., 2010; Leach et al., 
2012)] 
 




Figure B.1. Grimace scale: evaluating mouse well post-and pre-treatment monitoring. 
Coding system for assessing mouse facial expressions of pain (Langford et al., 2010). 




Figure B.2: Mouse body condition assessment scoring chart. Mandatory euthanasia is 
suggested provided there is no improvement after consecutive daily monitoring and if an 
animal is chronically emaciated (>20%) weight loss (Ullman-Culleré and Foltz, 1999). 
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